

## ***Evidence Synthesis***

---

### ***Number 95***

# **Screening for HIV: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation**

#### **Prepared for:**

Agency for Healthcare Research and Quality  
U.S. Department of Health and Human Services  
540 Gaither Road  
Rockville, MD 20850  
[www.ahrq.gov](http://www.ahrq.gov)

**Contract No. HHS-290-2007-10057-I, Task Order No. 8**

#### **Prepared by:**

Oregon Evidence-Based Practice Center  
Oregon Health & Science University  
3181 SW Sam Jackson Park Road  
Portland, OR 97239  
[www.ohsu.edu/epc](http://www.ohsu.edu/epc)

#### **Investigators:**

Roger Chou, MD  
Shelley Selph, MD, MPH  
Tracy Dana, MLS  
Christina Bougatsos, MPH  
Bernadette Zakher, MBBS  
Ian Blazina, MPH  
P. Todd Korthuis, MD, MPH

**AHRQ Publication No. 12-05173-EF-1  
November 2012**

This report is based on research conducted by the Oregon Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-02-0024). The investigators involved have declared no conflicts of interest with objectively conducting this research. The findings and conclusions in this document are those of the author(s), who are responsible for its content, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.

The information in this report is intended to help clinicians, employers, policymakers, and others make informed decisions about the provision of health care services. This report is intended as a reference and not as a substitute for clinical judgment.

This report may be used, in whole or in part, as the basis for the development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.

**Acknowledgements:** The authors acknowledge Laurie Hoyt Huffman, MS, for contributions to the report. The authors also thank the AHRQ Medical Officer, Jennifer Croswell, MD, MPH, as well as the U.S. Preventive Services Task Force leads, Susan Curry, PhD, Virginia Moyer, MD, MPH, Wanda Nicholson, MD, MPH, MBA, Timothy Wilt, MD, MPH, and Douglas Owens, MD, MS.

**Suggested Citation:** Chou R, Selph S, Dana T, Bougatsos C, Zakher B, Blazina I, Korthuis PT. Screening for HIV: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation. Evidence Synthesis No. 95. AHRQ Publication No. 12-05173-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; November 2012.

## Structured Abstract

**Background:** A 2005 U.S. Preventive Services Task Force (USPSTF) review found good evidence that HIV screening tests are accurate and that identification of undiagnosed HIV infection and treatment of immunologically advanced disease is associated with substantial clinical benefits. However, it found insufficient evidence to estimate effects of diagnosis and subsequent interventions on transmission risks, or to estimate clinical benefits of antiretroviral treatment in patients with less immunologically advanced disease.

**Purpose:** To systematically update the 2005 USPSTF review on benefits and harms of screening for HIV infection in adolescents and adults, focusing on research gaps identified in the prior review.

**Data Sources:** We searched the Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews (through the second quarter of 2012) and Ovid MEDLINE (2004 through June 2012) and manually reviewed reference lists.

**Study Selection:** We selected randomized trials and observational studies that compared different HIV screening strategies and reported clinical outcomes; the uptake, yield, or harms of screening; CD4 counts at diagnosis; or rates of linkage to care. We also selected randomized trials and observational studies that reported the effects of starting antiretroviral therapy (ART) at different CD4 count thresholds and long-term harms associated with ART, and randomized trials and observational studies that reported the effects of screening and subsequent interventions on risky behaviors and transmission risk.

**Data Extraction:** One investigator abstracted data and a second investigator checked data abstraction for accuracy. Two investigators independently assessed study quality using methods developed by the USPSTF.

**Data Synthesis (Results):** No study directly evaluated effects of screening for HIV infection versus no screening on clinical outcomes, or compared effects of repeat screening versus one-time screening. Evidence from studies comparing effects of different HIV screening strategies on the uptake or yield of screening, CD4 count at diagnosis, linkage to care, or harms associated with screening is too limited to draw reliable conclusions. New evidence provides strong evidence for effectiveness of earlier initiation of ART, including a subgroup analysis from a randomized trial that found initiation of ART at CD4 counts  $<0.250 \times 10^9$  cells/L associated with markedly increased risk of death or acquired immunodeficiency syndrome (AIDS) events compared with initiation at CD4 counts  $>0.350 \times 10^9$  cells/L after a mean of 18 months (hazard ratio, 5.3 [95% CI, 1.3 to 9.6]). Large, fair-quality cohort studies also consistently found initiation of ART at CD4 counts of  $0.350$  to  $0.500 \times 10^9$  cells/L associated with decreased risk of mortality and clinical events compared with delayed initiation. New evidence from good-quality cohort studies confirm a small increase in risk of long-term cardiovascular events associated with certain antiretroviral drugs. Although direct clinical evidence showing that changes in risky behaviors as a result of screening or subsequent interventions reduces transmission risk remains unavailable, there is now strong evidence from a randomized trial as well as consistent evidence from multiple observational studies that ART use is associated with an approximately 10- to 20-

fold reduction in risk of sexual transmission of HIV infection.

**Limitations:** Only English-language articles were included. Observational studies were included. Studies conducted in resource-poor or high-prevalence settings were included, but might be of limited applicability to general screening in the United States.

**Conclusions:** Prior studies have shown that HIV screening is accurate, targeted screening misses a substantial proportion of cases, and treatments are effective at improving clinical outcomes in patients with advanced immunodeficiency. New evidence indicates that ART reduces risk of AIDS-defining events and mortality in persons with less advanced immunodeficiency and reduces sexual transmission. More research is needed to understand effects of different screening strategies on the uptake and yield of screening, harms, CD4 count at diagnosis, and linkage to care.

# Table of Contents

<b>Chapter 1. Introduction</b> .....	1
Purpose of Review and Prior USPSTF Recommendations.....	1
Condition Definition .....	2
Prevalence and Burden of Disease .....	2
Etiology and Natural History .....	3
Risk Factors/Indicators.....	4
Rationale for Screening/Screening Strategies .....	4
Interventions/Treatment .....	4
Current Clinical Practice .....	5
Recommendations of Other Groups .....	5
<b>Chapter 2. Methods</b> .....	6
Key Questions and Analytic Framework .....	6
Key Questions .....	6
Search Strategies .....	8
Study Selection.....	8
Data Abstraction and Quality Rating .....	9
Data Synthesis .....	9
External Review .....	9
<b>Chapter 3. Results</b> .....	10
Key Question 1. What Are the Benefits of Universal or Targeted HIV Screening Versus No Screening or Each Other in Asymptomatic, Nonpregnant Adolescents and Adults on Disease Transmission, Morbidity, Mortality, and Quality of Life? .....	10
Key Question 2a. What Is the Yield (Number of New Diagnoses) of HIV Screening at Different Intervals in Nonpregnant Adolescents and Adults?.....	10
Key Question 2b. What Are the Effects of Universal Versus Targeted HIV Screening on Testing Acceptability and Uptake in Nonpregnant Adolescents and Adults? .....	10
Summary .....	10
Evidence .....	10
Key Question 2c. What Is the Effect of Opt-Out Versus Opt-In Testing or Different Pre- or Post-Test HIV Counseling Methods on Screening Uptake or Rates of Followup and Linkage to Care in Nonpregnant Adolescents and Adults? .....	11
Summary .....	11
Evidence .....	11
Key Question 2d. What Are the Adverse Effects (Including False-Positive Results and Anxiety) of Rapid Versus Standard HIV Testing in Nonpregnant Adolescents and Adults Not Known to Be at Higher Risk? .....	12
Summary .....	12
Evidence .....	12
Key Question 2e. What Are the Effects of Universal Versus Targeted HIV Screening on CD4 Counts at the Time of Diagnosis?.....	13
Summary .....	13
Evidence .....	13

Key Question 2f. What Are the Effects of Universal Versus Targeted HIV Screening on Rates of Followup and Linkage to Care in Nonpregnant Adolescents and Adults Who Screen Positive? .....	15
Summary .....	15
Evidence .....	15
Key Question 3a. To What Extent Does Knowledge of HIV-Positive Status Affect Behaviors Associated With Increased Risk of HIV Transmission in Nonpregnant Adolescents and Adults? .....	16
Summary .....	16
Evidence .....	16
Key Question 3b. To What Extent Does Use of Antiretroviral Therapy Affect Behaviors Associated With Increased Risk of HIV Transmission in Nonpregnant Adolescents and Adults? .....	17
Summary .....	17
Evidence .....	17
Key Question 4a. How Effective Is Antiretroviral Therapy in Reducing Transmission of HIV in Nonpregnant Adolescents and Adults With Chronic HIV Infection?.....	18
Summary .....	18
Evidence .....	19
Key Question 4b. How Effective Is Behavioral Counseling in Reducing Transmission of HIV in Nonpregnant Adolescents and Adults With Chronic HIV Infection?.....	20
Summary .....	20
Evidence .....	20
Key Question 4c. In Asymptomatic, Nonpregnant Adolescents and Adults With Chronic HIV Infection, What Are the Effects of Initiating Antiretroviral Therapy at Different CD4 Counts or Viral Load Thresholds on Morbidity, Mortality, and Quality of Life?....	21
Summary .....	21
Evidence .....	21
Key Question 5. What Are the Longer-Term Harms Associated With Antiretroviral Therapy in Nonpregnant Adolescents and Adults With Chronic HIV Infection? .....	23
Summary .....	23
Evidence .....	23
Key Question 6a. To What Extent Are Improvements in Viremia Associated With Reductions in HIV Transmission Rates in Nonpregnant Adolescents and Adults? .....	24
Summary .....	24
Evidence .....	25
Key Question 6b. To What Extent Are Improvements in Risky Behaviors Associated With Reductions in HIV Transmission Rates in Nonpregnant Adolescents and Adults? .....	26
Summary .....	26
Evidence .....	26
Contextual Question. What Is the Cost-Effectiveness of Universal Versus Targeted HIV Screening in Low- or Average-Prevalence Populations?.....	27
<b>Chapter 4. Discussion .....</b>	<b>29</b>
Summary of Review Findings.....	29
Limitations .....	30

Emerging Issues .....	31
Future Research.....	31
Conclusions .....	31

<b>References.....</b>	<b>32</b>
------------------------	-----------

## Figures

Figure. Analytic Framework for Screening for HIV in Nonpregnant Adolescents and Adults

## Summary Tables

Table 1. Positive Predictive Values and False-Positive Results Associated With HIV Rapid Testing
Table 2. Effect of Knowledge of HIV-Positive Status on Risky Behaviors
Table 3. Effect of Use of Antiretroviral Therapy on Risky Behaviors
Table 4. Effect of Initiating Antiretroviral Therapy at Different CD4 Counts or Viral Load Thresholds on Progression to AIDS or Mortality
Table 5. Cardiovascular Events and Antiretroviral Therapy Use
Table 6. HIV Transmission by Viral Load
Table 7. Summary of Evidence

## Appendix

### *Appendix A. Detailed Methods*

Appendix A1. Search Strategies
Appendix A2. Inclusion and Exclusion Criteria per Key Question
Appendix A3. Literature Flow Diagram
Appendix A4. Excluded Studies List
Appendix A5. U.S. Preventive Services Task Force Quality Rating Criteria
Appendix A6. Criteria for Assessing Scientific Quality of Research Reviews
Appendix A7. Expert Reviewers of the Draft Report

### *Appendix B. Evidence and Quality Tables*

Appendix B1. Key Question 2b: Evidence Table of Studies of Acceptability/Uptake of Universal or Targeted HIV Testing
Appendix B2. Key Question 2b: Quality Assessment of a Cohort Study
Appendix B3. Key Question 2c: Evidence Table of Studies of Testing Rates of Opt-Out Versus Opt-In HIV Testing
Appendix B4. Key Question 2c: Quality Assessment of Cohort Studies
Appendix B5. Key Question 2e: Evidence Table of Studies of Universal Versus Targeted HIV Screening and CD4 Counts at Time of Diagnosis
Appendix B6. Key Question 2e: Quality Assessment of Cohort Studies
Appendix B7. Key Question 2f: Evidence Table of Studies Reporting Linkage to Care Following HIV Testing
Appendix B8. Key Question 2f: Quality Assessment of a Cohort Study
Appendix B9. Key Question 3a: Evidence Table of Studies of Effect of Knowledge of HIV-Positive Status or Use of Highly Active Antiretroviral Therapy on Risky Behaviors

Appendix B10. Key Question 3a: Quality Assessment of Cohort Studies

Appendix B11. Key Question 3b: Evidence Table of Studies of Effect of Knowledge of HIV-Positive Status or Use of Highly Active Antiretroviral Therapy on Risky Behaviors

Appendix B12. Key Question 3b: Quality Assessment of Cohort Studies

Appendix B13. Key Question 4a: Evidence Table of a Systematic Review of Effect of Counseling or Antiretroviral Therapy Use on HIV Transmission

Appendix B14. Key Question 4a: Quality Assessment of a Systematic Review

Appendix B15. Key Question 4a: Evidence Table of Studies of Effect of Counseling or Antiretroviral Therapy Use on HIV Transmission

Appendix B16. Key Question 4a: Quality Assessment of a Randomized, Controlled Trial

Appendix B17. Key Question 4a: Quality Assessment of Cohort Studies

Appendix B18. Key Question 4b: Evidence Table of Studies of Effect of Counseling or Antiretroviral Therapy Use on HIV Transmission

Appendix B19. Key Question 4b: Quality Assessment of a Randomized, Controlled Trial

Appendix B20. Key Question 4b: Quality Assessment of a Cohort Study

Appendix B21. Key Question 4c: Evidence Table of Trials of Effect of Initiating Highly Active Antiretroviral Therapy at Different CD4 Counts or Viral Load Thresholds on Clinical Outcomes

Appendix B22. Key Question 4c: Quality Assessment of Randomized, Controlled Trials

Appendix B23. Key Question 4c: Evidence Tables of Cohort Studies of Effect of Initiating Highly Active Antiretroviral Therapy at Different CD4 Counts or Viral Load Thresholds on Clinical Outcomes

Appendix B24. Key Question 4c: Quality Assessment of Cohort Studies

Appendix B25. Key Question 5: Evidence Table of Studies of Longer-Term Harms of Highly Active Antiretroviral Therapy Use

Appendix B26. Key Question 5: Quality Assessment of Cohort Studies

Appendix B27. Key Question 6a: Evidence Table of Studies of Effect of Viremia on HIV Transmission Rates

Appendix B28. Key Question 6a: Quality Assessment of Cohort Studies

Appendix B29. Key Question 6b: Evidence Table of Studies of Effect of Risky Behaviors on HIV Transmission Rates

Appendix B30. Key Question 6b: Quality Assessment of Cohort Studies



# CHAPTER 1. INTRODUCTION

## Purpose of Review and Prior USPSTF Recommendations

The purpose of this report is to update a previous systematic review<sup>1-3</sup> commissioned by the U.S. Preventive Services Task Force (USPSTF) on screening for asymptomatic HIV infection in nonpregnant adults and adolescents. It will be used by the USPSTF to update its 2005 recommendation on screening for HIV in nonpregnant adolescents and adults.<sup>4</sup> A separate report updates the evidence on prenatal HIV screening.<sup>5</sup>

In 2005, based on the earlier evidence review,<sup>1-3</sup> the USPSTF recommended screening all adolescents and adults at increased risk (defined as persons reporting HIV risk factors or evaluated in settings with an HIV infection prevalence of >1%) for HIV infection (grade A recommendation).<sup>4</sup> The USPSTF based its recommendation on the high yield of screening in these patients, good evidence that standard and rapid HIV screening tests accurately detect HIV infection (sensitivity and specificity each >99%), and good evidence that identification and treatment of unsuspected HIV infection at immunologically advanced stages of disease (defined as CD4 counts <0.200 x 10<sup>9</sup> cells/L) with antiretroviral therapy (ART) and other interventions (such as prophylaxis for opportunistic infections) results in marked reduction in risk of progression to acquired immunodeficiency syndrome (AIDS) and AIDS-related clinical events and mortality. Although the USPSTF found ART associated with short-term adverse events and increased risk of long-term cardiovascular events, it determined that estimated benefits greatly outweighed harms.

The USPSTF made no recommendation for or against routinely screening for HIV in adolescents and adults not at increased risk for HIV infection (grade C recommendation\*).<sup>4</sup> Because of the lower prevalence of HIV infection in persons not at increased risk, the USPSTF determined that benefits from screening would be smaller than screening in higher-risk populations, resulting in a close balance between potential benefits and harms, including false-positive results, labeling, anxiety, and adverse events associated with ART and other interventions. Importantly, the USPSTF found insufficient evidence to estimate benefits from screening in persons at less immunologically advanced stages of disease (CD4 counts >0.200 x 10<sup>9</sup> cells/L) or effects of screening and subsequent interventions on risk of HIV transmission.

In 2006, the Centers for Disease Control and Prevention (CDC) issued its revised guideline recommending routine voluntary HIV screening of all persons ages 13 to 64 years, unless the prevalence of undiagnosed HIV infection has been documented to be <0.1 percent.<sup>6</sup> The CDC also recommended that testing be performed on an opt-out basis (screening after notifying the patient that an HIV test will be performed unless the patient declines) without a requirement for pretest prevention counseling, in order to reduce barriers to screening. A key reason for the differences

---

\* The USPSTF definition of a “C” recommendation has changed since this guideline was published. In 2005, a “C” recommendation indicated that the USPSTF “makes no recommendation for or against” routinely screening this population. Now, a “C” recommendation indicates that “clinicians may provide this service to selected patients depending on individual circumstances. However, for most individuals without signs or symptoms there is likely to be only a small benefit from this service.”

between the CDC and USPSTF recommendations is evidence showing that 20 to 26 percent of patients with HIV infection report no risk factors,<sup>7</sup> suggesting that any screening strategy based on risk factor identification will miss an important proportion of infected persons. Other reasons for the differences between the CDC and USPSTF recommendations include greater weight placed by the CDC on studies showing reductions in self-reported risky behaviors following diagnosis of HIV infection, acceptance of modeling studies to estimate effects of HIV diagnosis and reductions in risky behaviors on transmission risk, and greater weight placed on studies showing acceptable incremental cost-effectiveness ratios for screening versus no screening in very low-prevalence populations. The USPSTF subsequently commissioned a focused update of its 2005 report with the studies included in the CDC guideline,<sup>1</sup> but found insufficient evidence to change its C recommendation on screening in persons not at higher risk.<sup>4</sup> The USPSTF found methodological shortcomings in the studies showing reduced risky behaviors following HIV diagnosis, which made estimations of reductions in transmission risk unreliable. In addition, some evidence suggested that cost-effectiveness of HIV screening in low-prevalence populations is sensitive to transmission benefits, and the cost-effectiveness analyses did not compare universal with targeted screening in low-prevalence settings.<sup>8,9</sup>

This report updates the prior USPSTF review on the benefits and harms of HIV screening in nonpregnant adolescents and adults, focusing on key research gaps identified in the earlier review, including the yield and outcomes of routine versus targeted screening; periodicity of screening; effects of screening, counseling, and ART use on risky behaviors and HIV transmission risk; effectiveness of treatments in HIV-infected persons with CD4 counts  $>0.200 \times 10^9$  cells/L, and long-term harms of ART. This report also addresses areas not addressed in the prior USPSTF review, including effects of different screening methods (e.g., rapid vs. standard testing, different methods of pretest counseling, opt-out vs. opt-in testing) on uptake, CD4 count at diagnosis, linkage to followup care, and harms, in order to help inform optimal screening strategies. This report does not re-examine evidence considered to be well-established, such as the diagnostic accuracy of HIV screening tests, the effectiveness of ART in persons with CD4 counts  $<0.200 \times 10^9$  cells/L, or the effectiveness of prophylaxis for opportunistic infections.<sup>2,3</sup> The review primarily focuses on evidence from studies of low- or average-risk populations, as there is strong evidence supporting screening in high-risk populations, with consensus across guidelines.<sup>4,6</sup>

## Condition Definition

HIV is a ribonucleic acid (RNA) retrovirus that infects the immune cells of its human hosts, in particular, CD4 helper T cells, and leads to AIDS in most patients if left untreated. HIV is a communicable disease with two types: HIV-1 and HIV-2. HIV-2 infection is very uncommon in the United States, primarily affects persons from West Africa, and is less likely to progress to AIDS.<sup>10</sup> AIDS is a life-threatening disease defined by severe immune dysfunction (CD4 T cell count  $\leq 0.200 \times 10^9$  cells/L) or one or more neoplastic conditions or opportunistic infections.<sup>11</sup>

## Prevalence and Burden of Disease

Since the first cases of AIDS were reported in 1981, an estimated 1,108,611 people in the United

States have been diagnosed with AIDS and nearly 594,500 have died.<sup>12</sup> The CDC estimates that 1.2 million people in the United States were living with HIV infection in 2008, with approximately one in five infected persons unaware of their positive status.<sup>12-14</sup> The incidence of HIV in the United States is approximately 50,000 cases per year.<sup>12, 15</sup> Although incidence prior to 2006 was estimated at about 40,000 cases per year,<sup>16</sup> these data are not directly comparable with current estimates because methods for estimating incidence have changed.<sup>15</sup> Estimates of HIV incidence were relatively stable from 2006 through 2009.<sup>12, 15</sup>

The groups most affected by HIV infection in the United States are gay and bisexual men, African Americans, and Hispanics/Latinos. Between 2006 and 2009, there was a 21 percent increase in HIV incidence for people ages 13 to 29 years, driven largely by a 34 percent increase in young men who have sex with men (MSM), who were the only risk group to experience a significant increase in incidence during this period ( $p < 0.001$ ).<sup>15</sup> Approximately 75 percent of people living with HIV are men.<sup>17</sup> CDC data from 40 States in 2009 estimated prevalence at 0.02 percent (19.5 cases per 100,000 persons) for 13- to 14-year-olds and 0.04 percent (39 cases per 100,000 persons) for 15- to 19-year-olds. For 20- to 24-year-olds, the prevalence was 0.13 percent. Prevalence increases through ages 40 to 49 years (0.7%), where it then decreases to 0.2 percent in ages 60 to 64 years and to 0.07 percent at age 65 years and older.<sup>18</sup>

## Etiology and Natural History

HIV is acquired through percutaneous exposure with infected bodily fluids such as blood, semen, and genital tract secretions. Factors facilitating sexual transmission include the presence of sexually transmitted diseases (STDs), high-risk sexual practices such as unprotected penile-anal intercourse, and high viral load in the infected partner.<sup>19, 20</sup> In injection drug users, factors associated with HIV infection include increased frequency or duration of injection, sharing needles, and backloading (injecting drugs from one syringe into the back of another opened syringe).<sup>21</sup>

The primary HIV infection syndrome usually develops 2 to 4 weeks following initial exposure to HIV.<sup>22</sup> A clinical syndrome resembling infectious mononucleosis is often associated with acute infection.<sup>23, 24</sup> Very early after acute infection, there is rapid virus production that declines to a set point (which varies between individuals) as the host immune system responds, although continuous rapid virus production and clearance occurs at all stages of infection.<sup>25-30</sup>

Although a small proportion of untreated HIV-infected persons remain asymptomatic and show little evidence of progressive immune suppression after 10 or more years of infection, over 90 percent of untreated patients eventually develop AIDS.<sup>11</sup> Before the highly active antiretroviral therapy (HAART) era, the median time from seroconversion to the development of AIDS was 7.7 to 11.0 years, and median survival ranged from 7.5 to 12 years.<sup>31, 32</sup>

The primary mechanism through which chronic HIV infection causes immune deficiency is through a decrease in the level and functioning of CD4+ T lymphocytes. On average, the CD4 count declines 0.050 to 0.075 x 10<sup>9</sup> cells/L per year.<sup>33</sup> Most patients with CD4 counts >0.200 x 10<sup>9</sup> cells/L are either asymptomatic or have mild disease,<sup>34</sup> though research indicates an increased risk of AIDS or death even in patients with CD4 counts >0.500 x 10<sup>9</sup> cells/L.<sup>35</sup> Patients with CD4 counts <0.200

$\times 10^9$  cells/L have advanced immunodeficiency and are at markedly increased risk for AIDS-related opportunistic infections and other AIDS-related complications.<sup>36-38</sup>

A higher HIV viral load is a strong independent predictor of more rapid progression to AIDS.<sup>36-41</sup> Other predictors of more rapid progression include older age at the time of infection,<sup>31, 32, 36, 37, 40, 42, 43</sup> more severe symptoms at the time of primary HIV infection,<sup>44</sup> and other clinical and genetic factors. A host factor consistently associated with slow progression is the homozygous presence of the CCR5 delta32 genotype.<sup>45-49</sup>

## **Risk Factors/Indicators**

Persons considered to be at increased risk for HIV infection include MSM; men and women having unprotected vaginal or anal intercourse with more than one partner; men and women who exchange sex for drugs or money; people with a history of or current injection drug use; people seeking treatment for other sexually transmitted infections (STIs); people with a history of blood transfusion between 1978 and 1985; people whose past or present sex partners are HIV-infected, bisexual, or injection drug users; and people who do not report one of these risk factors but who request HIV testing. Settings in which the prevalence of HIV infection is often  $>1$  percent include STD clinics, correctional facilities, homeless shelters, tuberculosis clinics, clinics caring predominately for MSM, and adolescent clinics with a high prevalence of STIs.<sup>3</sup>

## **Rationale for Screening/Screening Strategies**

Identification and treatment of asymptomatic HIV-positive individuals may lead to interventions that reduce the risk of progression to AIDS, AIDS-defining clinical events, and mortality. The 2005 USPSTF review found treatment (including ART and prophylaxis for opportunistic infections) of HIV-infected persons with immunologically advanced disease (CD4 counts  $\leq 0.200 \times 10^9$  cells/L) associated with substantially improved health outcomes.<sup>3</sup> More evidence is now available on the effectiveness of treatments for patients with less immunologically advanced disease (see key question 4c). In addition, screening may help identify patients at higher CD4 counts before they develop severe immune deficiency or present with an AIDS-defining event. Earlier detection of asymptomatic HIV-positive patients may also help reduce the risk of transmission to others, through effects of knowledge of positive HIV serostatus or counseling interventions on behaviors, or through other interventions (such as use of ART) that may reduce the risk of transmission. It is estimated that approximately 20,000 infections per year are due to transmission of HIV by persons who are unaware that they are infected.<sup>50, 51</sup>

## **Interventions/Treatment**

There remains no effective vaccine to prevent HIV infection and no cure for chronic infection. Interventions for HIV-infected patients include ART, prophylaxis for opportunistic infections, immunizations, Papanicolaou testing, counseling to reduce high-risk behaviors, and routine monitoring and followup. HAART, defined as three or more antiretroviral agents used in

combination (usually from at least two drug classes), is the standard of care for ART (because all currently recommended antiretroviral regimens meet criteria for HAART, this report will primarily simply refer to “antiretroviral therapy,” in accordance with current treatment guidelines).<sup>52</sup> Of the interventions used to treat chronic HIV infection, ART has the greatest impact on clinical outcomes, including survival.<sup>53</sup> Clinical practice has generally evolved toward earlier initiation of ART in asymptomatic individuals, though decisions are more individualized at higher CD4 counts ( $>0.350 \times 10^9$  cells/L).<sup>52</sup> Detailed and regularly updated guidelines for the U.S. population regarding specifically recommended antiretroviral regimens<sup>52</sup> and chemoprophylaxis for opportunistic infections<sup>54</sup> are available.

## Current Clinical Practice

The use of repeatedly reactive enzyme immunoassay on an office-based venipuncture specimen followed by confirmatory Western blot or immunofluorescent assay for positive tests is associated with a sensitivity and specificity  $>99$  percent.<sup>55,56</sup> Rapid, point-of-care HIV antibody tests on blood or oral fluid specimens provide results in 5 to 40 minutes compared with 1 to 2 weeks for standard testing, with diagnostic accuracy comparable with standard testing.<sup>57,58</sup> However, initial positive results on a rapid test can represent false-positives and require confirmation. A revised CDC HIV testing algorithm is expected in 2012. The algorithm, which will utilize combination immunoassays that screen simultaneously for both the p24 antigen and HIV antibody and test for HIV RNA without requiring Western blot confirmation, is intended to detect acute HIV infection earlier and to differentiate HIV-2 from HIV-1 infection.<sup>59</sup>

About 45 percent of U.S. adults ages 18 to 64 years report ever being tested for HIV infection.<sup>60</sup> Screening rates for HIV vary by State, age, sex, race/ethnicity, and other factors. For example, African Americans and Latinos are more likely to report testing than whites.

## Recommendations of Other Groups

As described above, in 2006 the CDC recommended routine voluntary HIV screening of all adults ages 13 to 64 years regardless of other recognized risk factors, unless the prevalence of HIV has been documented to be  $<0.1$  percent.<sup>6</sup> The CDC also recommended “opt-out” HIV testing, meaning that all patients should be informed about testing and tested unless they specifically decline, without a requirement for prevention counseling prior to screening in order to reduce barriers to testing. In 2009, the American College of Physicians endorsed the CDC approach.<sup>61</sup> The Infectious Diseases Society of America recommends routine HIV screening for all sexually active adults,<sup>62</sup> the American Congress of Obstetricians and Gynecologists recommends routine opt-out screening in all women ages 19 to 64 years and targeted screening in women with risk factors outside of that age range,<sup>63</sup> and the American Academy of Pediatrics recommends routine HIV testing be offered to all adolescents at least once by ages 16 to 18 years when prevalence of HIV is  $>0.1$  percent in the community and testing of all sexually active adolescents and those with risk factors in low-prevalence settings.<sup>64</sup> In 2007, the American Academy of Family Physicians recommended screening for HIV in high-risk groups and in areas where the HIV prevalence is at least 1 percent.<sup>65</sup>

# CHAPTER 2. METHODS

## Key Questions and Analytic Framework

Using the methods developed by the USPSTF,<sup>66</sup> the USPSTF and the Agency for Healthcare Research and Quality (AHRQ) determined the scope and key questions for this review. Investigators created an analytic framework with the key questions and the patient populations, interventions, and outcomes reviewed (**Figure**). The target population for HIV screening was nonpregnant adolescents and adults without signs or symptoms of HIV infection. We defined “universal” testing to mean routine testing of all persons ages 13 to 64 years, unless the prevalence of HIV infection has been documented to be <0.1 percent,<sup>6</sup> and “targeted” screening to mean routine screening of persons with risk factors or in high-prevalence (>1%) settings.<sup>4</sup> We defined “opt-out” testing as screening after notifying the patient that an HIV test will be performed unless the patient declines and “opt-in” testing to mean that screening is offered but only performed if the patient actively agrees to it.<sup>6</sup>

A contextual question was also requested by the USPSTF to help inform the report. (Contextual questions are not reviewed using systematic review methodology.)

### Key Questions

**Key Question 1.** What are the benefits of universal or targeted HIV screening versus no screening or each other in asymptomatic, nonpregnant adolescents and adults on disease transmission, morbidity, mortality, and quality of life?

**Key Question 2a.** What is the yield (number of new diagnoses) of HIV screening at different intervals in nonpregnant adolescents and adults?

**Key Question 2b.** What are the effects of universal versus targeted HIV screening on testing acceptability and uptake in nonpregnant adolescents and adults?

**Key Question 2c.** What is the effect of opt-out versus opt-in testing or different pre- or post-test HIV counseling methods on screening uptake or rates of followup and linkage to care in nonpregnant adolescents and adults?

**Key Question 2d.** What are the adverse effects (including false-positive results and anxiety) of rapid versus standard HIV testing in nonpregnant adolescents and adults not known to be at higher risk?

**Key Question 2e.** What are the effects of universal versus targeted HIV screening on CD4 counts at the time of diagnosis?

**Key Question 2f.** What are the effects of universal versus targeted HIV screening on rates of followup and linkage to care in nonpregnant adolescents and adults who screen positive?

**Key Question 3a.** To what extent does knowledge of HIV-positive status affect behaviors associated with increased risk of HIV transmission in nonpregnant adolescents and adults?

**Key Question 3b.** To what extent does use of ART affect behaviors associated with increased risk of HIV transmission in nonpregnant adolescents and adults?

**Key Question 4a.** How effective is ART in reducing transmission of HIV in nonpregnant adolescents and adults with chronic HIV infection?

**Key Question 4b.** How effective is behavioral counseling in reducing transmission of HIV in nonpregnant adolescents and adults with chronic HIV infection?

**Key Question 4c.** In asymptomatic, nonpregnant adolescents and adults with chronic HIV infection, what are the effects of initiating ART at different CD4 counts or viral load thresholds on morbidity, mortality, and quality of life?

**Key Question 5.** What are the longer-term harms associated with ART in nonpregnant adolescents and adults with chronic HIV infection?

**Key Question 6a.** To what extent are improvements in viremia associated with reductions in HIV transmission rates in nonpregnant adolescents and adults?

**Key Question 6b.** To what extent are improvements in risky behaviors associated with reductions in HIV transmission rates in nonpregnant adolescents and adults?

**Contextual Question.** What is the cost-effectiveness of universal versus targeted HIV screening in low- or average-prevalence populations?

Key question 1 focuses on direct evidence on effects of screening for HIV infection versus no screening or different screening strategies on important health outcomes. Such direct evidence on the effectiveness of screening interventions may be sparse or unavailable. Therefore, the remainder of the analytic framework (key questions 2 through 6) evaluates the chain of indirect evidence needed to link screening for HIV infection with improvement in important health outcomes. Links in the chain of indirect evidence include the performance, yield, and acceptability of the screening test and different screening strategies for identifying HIV infection, the effectiveness of interventions for improving intermediate outcomes (such as reduced risky behaviors) or clinical outcomes (such as mortality, AIDS-related events, and HIV transmission), and any harms associated with screening and subsequent interventions. Implicit in the indirect chain of evidence is that to understand benefits and harms of screening, it is not sufficient to show that patients with HIV infection can be identified; it is also necessary to show that identification leads to effective treatments, and to understand how many screen-detected patients (e.g., based on CD4 count at diagnosis) are likely to benefit from treatments.

Because this review is a targeted update that focuses on research gaps identified in the 2005 USPSTF review and subsequent update,<sup>1-3</sup> it does not cover all aspects relevant to HIV screening.

The general diagnostic accuracy of HIV testing was not re-reviewed, since it is well established as a very accurate test, and direct harms of screening compared with no screening (e.g., labeling and anxiety) were not re-reviewed, given that direct harms associated with screening were estimated as minimal to small and are likely unchanged. Similarly, the general effectiveness of ART, prophylaxis for opportunistic infections, and immunizations was not re-reviewed. Instead, this report focuses on new evidence on the effectiveness of ART in patients with less immunologically advanced disease and harms of long-term ART; the yield of repeat screening and the effects of different screening strategies on uptake of screening, linkage to care, and CD4 counts at diagnosis; the effects of knowledge of positive HIV status and subsequent interventions on risky behaviors and transmission risk; and the association between changes in risky behaviors and transmission risk. This report also addresses areas not covered in the prior report on effects of different screening methods (e.g., rapid vs. standard testing, different methods of pretest counseling, opt-out vs. opt-in testing) on uptake, CD4 count at diagnosis, linkage to followup care, and harms, in order to help inform optimal screening strategies.

## Search Strategies

We searched the Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews (through the second quarter of 2012) and Ovid MEDLINE (2004 through June 2012) for relevant studies and systematic reviews. Search strategies are available in **Appendix A1**. We also reviewed reference lists of relevant articles.

## Study Selection

At least two reviewers independently evaluated each study to determine inclusion eligibility. We selected studies on the basis of inclusion and exclusion criteria developed for each key question (**Appendix A2**). Articles were selected for full review if they were about HIV infection in nonpregnant adolescents and adults, were relevant to a key question, and met the predefined inclusion criteria. We restricted inclusion to English-language articles and excluded studies only published as abstracts. Studies of nonhuman subjects were also excluded, and studies had to include original data.

For key questions related to screening, we included studies of nonpregnant adolescents and adults. Prenatal screening for HIV infection is covered in a separate review.<sup>5</sup> For key questions related to interventions and behavior changes after diagnosis, we included studies of HIV-positive persons, focusing when possible on studies not specifically performed in high-risk populations (such as MSM or injection drug users) or high-prevalence populations. We excluded studies from countries with high HIV prevalence and in which management practices differ substantially from the United States, unless evidence from settings more applicable to the United States was not available. The screening interventions were standard or rapid HIV antibody testing and screening strategies included universal or targeted screening and opt-in or opt-out testing. For treatment interventions, we focused on ART and counseling and other interventions to reduce risky behaviors. Outcomes were mortality, progression to AIDS, other morbidity and quality of life, HIV transmission risk, and harms from screening (including false-positive results and anxiety) and long-term (defined as 2 or



more years following initiation of treatment) cardiovascular harms associated with ART. We included randomized, controlled trials and cohort studies for all key questions. If such studies were not available, we also included uncontrolled screening series in low-risk populations. We also included recent (published since 2010) systematic reviews that met all predefined quality criteria.<sup>67</sup> **Appendix A3** shows the results of our literature search and selection process and **Appendix A4** lists excluded studies with reasons for exclusion.

## Data Abstraction and Quality Rating

We abstracted details about the study design, patient population, setting, screening method, interventions, analysis, followup, and results. Two investigators independently applied criteria developed by the USPSTF<sup>66</sup> to rate the quality of each study as good, fair, or poor (**Appendixes A5** and **A6**). Discrepancies were resolved through a consensus process.

## Data Synthesis

We assessed the aggregate internal validity (quality) of the body of evidence for each key question (good, fair, or poor) using methods developed by the USPSTF, based on the number, quality, and size of studies, consistency of results between studies, and directness of evidence.<sup>66</sup> Meta-analysis was not attempted due to the inability to pool data from studies.

## External Review

The draft report was reviewed by content experts, USPSTF members, AHRQ Project Officers, and collaborative partners and revised prior to finalization (**Appendix A7**).

## CHAPTER 3. RESULTS

### **Key Question 1. What Are the Benefits of Universal or Targeted HIV Screening Versus No Screening or Each Other in Asymptomatic, Nonpregnant Adolescents and Adults on Disease Transmission, Morbidity, Mortality, and Quality of Life?**

No randomized trial or observational study compared clinical outcomes between adults and adolescents screened and not screened for HIV infection.

### **Key Question 2a. What Is the Yield (Number of New Diagnoses) of HIV Screening at Different Intervals in Nonpregnant Adolescents and Adults?**

No randomized trial or observational study evaluated the yield of repeat HIV screening compared with one-time screening, or compared the yield of different strategies for repeat screening (e.g., risk-based repeat screening vs. a routine repeat test). The yield of repeated screening would depend in part on the frequency of new HIV infections. Some modeling studies have estimated the cost-effectiveness of strategies involving repeat screening (see the contextual question below).

### **Key Question 2b. What Are the Effects of Universal Versus Targeted HIV Screening on Testing Acceptability and Uptake in Nonpregnant Adolescents and Adults?**

#### **Summary**

No study directly evaluated the acceptability of universal versus targeted HIV screening. One fair-quality, nonrandomized study of emergency department (ED) patients found universal, opt-out rapid screening associated with higher likelihood of testing compared with physician-directed, targeted rapid screening (25% vs. 0.8%; relative risk [RR], 30 [95% CI, 26 to 34]), but testing uptake (the proportion of patients offered testing who accepted) was not reported. In two uncontrolled implementation studies of universal HIV screening conducted in primary care settings, 35 percent (standard test) and 60 percent (rapid test) of those offered screening underwent it.

#### **Evidence**

The prior USPSTF review found no studies that directly compared acceptance of universal versus targeted HIV screening.<sup>1-3</sup> It found that general acceptance of voluntary HIV testing in the United States varied from 11 to 91 percent, with greater uptake in higher prevalence settings, in patients

with perceived or acknowledged HIV risk factors, when confidentiality protections were present, and when providers believed testing was beneficial.<sup>1-3</sup> Other factors that appeared to increase HIV testing uptake were use of opt-out testing, anonymous testing, and for adolescents, removal of parental consent.

One nonrandomized study published since the prior USPSTF review compared testing rates during periods of universal opt-out rapid HIV screening versus physician-directed, targeted rapid screening in sequential 4-month intervals over 2 years in an ED.<sup>68</sup> Universal screening was associated with a much higher likelihood of testing (25% [6,933/28,043] vs. 0.8% [243/29,925]; RR, 30 [95% CI, 26 to 34]), but testing uptake (the proportion of patients offered testing who accepted) was not reported. One uncontrolled implementation study of universal testing in a primary care setting reported 60 percent (574/954) of patients were offered and accepted rapid HIV testing,<sup>69</sup> and another reported that 35 percent (105/300) of patients accepted standard HIV testing<sup>70</sup> (**Appendixes B1 and B2**).

## **Key Question 2c. What Is the Effect of Opt-Out Versus Opt-In Testing or Different Pre- or Post-Test HIV Counseling Methods on Screening Uptake or Rates of Followup and Linkage to Care in Nonpregnant Adolescents and Adults?**

### **Summary**

One observational study of computerized, kiosk-based screening found an opt-out approach associated with higher likelihood of testing compared with an opt-in approach (13% vs. 7%; RR, 2.1 [95% CI, 1.9 to 2.4]), but patients who underwent opt-out testing were more likely to report that they had not been informed of HIV testing. Only two patients had newly diagnosed HIV infection, precluding conclusions regarding rates of followup or linkage to care. One other study found opt-out testing associated with lower testing uptake compared with opt-in testing, but results may have been confounded by differences in who offered the testing.

No study compared effects of different pre- or post-test HIV counseling methods on screening uptake or rates of followup and linkage to care.

### **Evidence**

The prior USPSTF review included an uncontrolled implementation study that found that 35 percent (26/74) of HIV-infected persons identified through a routine voluntary screening program in an urgent care center had entered care within 4 months.<sup>71</sup> No study was found on effects of opt-out versus opt-in testing on screening uptake in nonpregnant persons, or on effects of different pre- or post-test HIV counseling methods on screening uptake or rates of followup and linkage to care.

One fair-quality, prospective observational study (n=12,827) published since the prior USPSTF review of computerized, kiosk-based screening in the ED found opt-out screening associated with a higher likelihood of testing compared with opt-in testing (13% vs. 7%; RR, 2.1 [95% CI, 1.9 to

2.4])<sup>72</sup> (**Appendixes B3 and B4**). However, patients who underwent opt-out testing were also more likely to report that they had not been informed of HIV testing compared with those who underwent opt-in testing (54% vs. 2.5%; RR, 21 [95% CI, 5.4 to 85]). Only two patients in the study were diagnosed with HIV infection (both during the opt-in period); both were successfully linked to ongoing HIV care.

One other observational study (n=8,732) in an ED setting reported lower testing uptake with opt-out screening offered by ED front desk registration staff compared with opt-in screening offered by ED triage nurses and providers (31% vs. 63%; p<0.01), but results may have been confounded by differences in who offered the testing.<sup>73</sup>

No study compared effects of different pre- or post-test HIV counseling methods on screening uptake or rates of followup and linkage to care. One randomized trial compared streamlined versus traditional pretest counseling but was excluded because of other differences between arms other than the counseling intervention, including referral for possible testing versus on-site counseling and testing, physician- versus nurse-directed testing, and use of rapid versus standard HIV testing.<sup>74</sup>

## **Key Question 2d. What Are the Adverse Effects (Including False-Positive Results and Anxiety) of Rapid Versus Standard HIV Testing in Nonpregnant Adolescents and Adults Not Known to Be at Higher Risk?**

### **Summary**

The prior USPSTF review found standard and rapid HIV testing with confirmatory Western blot associated with high sensitivities and specificities, though the positive predictive value associated with rapid testing prior to confirmatory testing decreased as the prevalence of HIV infection decreased. One randomized trial published since the prior USPSTF review directly compared rapid versus standard HIV testing but only identified one confirmed HIV infection. In large studies of rapid testing (without a comparison to standard testing), the positive predictive value was 95 percent in one study of a higher-prevalence (1.1%) setting, and varied widely (16% to 83%) in four studies of lower-prevalence (0.2% to 0.4%) settings. No study compared psychological or other harms associated with rapid versus standard HIV testing.

### **Evidence**

No study in the prior USPSTF review directly compared harms associated with rapid versus standard HIV testing. The prior USPSTF review found standard HIV testing followed by confirmatory Western blot associated with sensitivity  $\geq 99.7$  percent and specificity  $\geq 98.5$  percent, with a false-alarm rate ( $1 - \text{positive predictive value}$ ) in low-prevalence settings of about 1 in 250,000 (95% CI, 1 in 173,000 to 1 in 379,000).<sup>1-3</sup> It found rapid testing prior to confirmatory testing associated with a sensitivity  $\geq 94$  percent and specificity  $\geq 99$  percent, with positive predictive values of 25 to 50 percent (in settings with a prevalence of 0.3%), and 85 to 95 percent (in settings with a prevalence of 5%). The prior USPSTF review also identified anecdotal reports of other

harms of screening, including stigmatization (including verbal and physical abuse) and anxiety, but found insufficient evidence to estimate their magnitude.<sup>1-3</sup>

One trial published since the prior USPSTF review randomized patients in a Department of Veterans Affairs primary care setting to universal HIV screening based on one of three strategies: nurse-initiated rapid testing (n=84), nurse-initiated standard testing (n=84), or physician-initiated standard testing (n=83), but only identified one patient with a preliminary positive result.<sup>74</sup> No other study directly compared rapid versus standard testing and reported positive predictive values.

Five large (sample sizes, 2,002 to 23,900) uncontrolled observational studies published since the 2005 USPSTF review reported positive predictive values associated with rapid testing<sup>68, 73, 75-77</sup> (**Table 1**). In lower-prevalence (0.2% to 0.4%) settings, positive predictive values varied dramatically, from 16 to 83 percent.<sup>68, 73, 76, 77</sup> One study appeared to be an outlier,<sup>77</sup> reporting a positive predictive value of 16 percent compared with 77 to 83 percent in the other studies. Stratification of the low-prevalence studies according to whether they evaluated a rapid test using an oral fluid (16% and 78%)<sup>77</sup> versus finger-stick (77%)<sup>76</sup> or whole-blood specimen (83%)<sup>68</sup> did not explain the variability in positive predictive values.

One large study (n=23,900) in a higher-prevalence (1.1%) setting reported a positive predictive value following a positive rapid HIV test (oral fluid or finger-stick specimen) of 94 percent.<sup>75</sup>

No study evaluated psychological or other adverse effects associated with rapid versus standard HIV testing.

## **Key Question 2e. What Are the Effects of Universal Versus Targeted HIV Screening on CD4 Counts at the Time of Diagnosis?**

### **Summary**

One fair-quality study found universal testing associated with a higher median CD4 count and lower likelihood of CD4 count  $<0.200 \times 10^9$  cells/L at the time of diagnosis compared with targeted HIV screening, but these differences were not statistically significant. No other studies directly compared effects of universal versus targeted HIV screening, though epidemiologic data indicate temporal trends suggesting earlier diagnosis since the 2006 CDC recommendation on routine HIV screening was issued.

### **Evidence**

A high proportion of HIV-infected patients are diagnosed at late stages of disease. In 2008, about one third of patients received an AIDS diagnosis within 1 year of testing HIV-positive.<sup>13</sup> The prior USPSTF review<sup>1-3</sup> identified no studies on the effects of universal screening on the proportion of patients with HIV infection identified shortly before being diagnosed with AIDS or concurrently with their AIDS diagnosis.

One fair-quality cohort study published since the prior USPSTF review of patients in a large urban ED compared universal opt-out rapid HIV testing (n=6,702) with targeted HIV testing (n=243) (**Appendixes B5 and B6**).<sup>68</sup> The median CD4 count at the time of HIV diagnosis was  $0.069 \times 10^9$  cells/L (interquartile range,  $0.017$  to  $0.430 \times 10^9$  cells/L) for 16 confirmed infections identified during opt-out testing (prevalence, 0.24%) versus  $0.013 \times 10^9$  cells/L (interquartile range,  $0.011$  to  $0.015 \times 10^9$  cells/L) for five confirmed infections (prevalence, 2.1%) identified during diagnostic testing phases (p=0.02 for difference). Nine of 15 patients with HIV infections identified during universal opt-out testing had an initial CD4 count  $<0.200 \times 10^9$  cells/L compared with all four confirmed HIV infections identified during targeted testing (60% vs. 100%; RR, 0.66 [95% CI, 0.40 to 1.1]).

One other observational study (n=8,732) reported a mean CD4 count of  $0.415 \times 10^9$  cells/L (standard deviation [SD],  $0.237 \times 10^9$  cells/L) in eight new, confirmed HIV infections (prevalence, 0.2%) identified during universal opt-in screening offered by ED triage nurses and providers versus  $0.307 \times 10^9$  cells/L (SD,  $0.274 \times 10^9$  cells/L) in 21 infections (prevalence, 0.4%) identified during universal opt-out screening offered by ED front desk registration staff (p=0.84).<sup>73</sup> Twenty-five percent of patients diagnosed during opt-in screening had a CD4 count  $<0.200 \times 10^9$  cells/L versus 48 percent diagnosed during opt-out screening (RR, 0.52 [95% CI, 0.15 to 1.9]). Results may have been confounded by differential HIV testing acceptance rates in the two groups (31% for opt-out testing and 63% for opt-in testing), perhaps due in part to differences in who offered the testing.

No other study directly evaluated effects of universal versus targeted screening on CD4 counts at the time of diagnosis, though epidemiologic data may provide some indirect evidence. The CDC reported that the proportion of newly diagnosed patients in the United States with a late diagnosis (defined as CD4 cell count  $<0.200 \times 10^9$  cells/L or AIDS-defining illness within 12 months of HIV diagnosis) decreased from 37 percent between 2001 and 2004 to 32 percent in 2007.<sup>60</sup> Similarly, a large cohort study (n=44,491) reported a decrease over time in the proportion of HIV-positive patients initially presenting to care with a CD4 cell count  $<0.350 \times 10^9$  cells/L from 1997 to 2007 (from 62% to 54%), with an increase in median CD4 count at presentation of  $0.061 \times 10^9$  cells/L.<sup>78</sup> One study (n=4,478) in Washington, D.C., found that the median CD4 count at the time of HIV diagnosis increased from  $0.266 \times 10^9$  cells/L in 2005 to  $0.361 \times 10^9$  cells/L in 2009, though the statistical significance of the difference was not reported.<sup>79</sup> Another, smaller study (n=1,203) also reported a temporal trend for lower likelihood of late diagnosis (39% in 2000–2001 and 35% in 2008–2009), though the difference was not statistically significant.<sup>80</sup> Although these trends appear to temporally coincide with the CDC recommendations for universal opt-out HIV screening released in 2006,<sup>6</sup> it is not possible to determine causality between increased testing and earlier diagnosis based on these data.

## Key Question 2f. What Are the Effects of Universal Versus Targeted HIV Screening on Rates of Followup and Linkage to Care in Nonpregnant Adolescents and Adults Who Screen Positive?

### Summary

Three observational studies published since the prior USPSTF review reported rates of followup or linkage to care following a new HIV diagnosis found during universal testing, ranging from 75 to 100 percent. The only study that directly compared universal with targeted testing reported very high rates of followup (defined as attending at least one HIV clinic visit) with either strategy (97% to 100%). All studies were limited by small numbers of patients with newly diagnosed HIV infection.

### Evidence

In order to realize the potential clinical benefits from HIV screening, patients must be successfully linked to HIV care following diagnosis. The prior USPSTF review identified little evidence on the effect of universal versus targeted HIV screening on linkage to care following HIV diagnosis.<sup>1-3</sup> It included one uncontrolled study that found that 35 percent (26/74) of HIV-infected persons identified through a universal voluntary screening program in an urgent care center had entered care within 4 months.<sup>71</sup> Another uncontrolled study, also performed in an urgent care center, found that at least 70 percent (42/60) of newly diagnosed HIV-infected persons had one or more documented followup visits following identification through routine screening.<sup>81</sup>

Three studies<sup>68, 73, 76</sup> published since the prior USPSTF review reported linkage to care following universal HIV testing (**Appendixes B7 and B8**). One study compared universal with targeted screening and two reported rates of linkage to care after universal testing (one study<sup>73</sup> evaluated two strategies of universal testing). All studies were limited by small numbers of newly diagnosed HIV infections (17 to 36 cases).

The study that directly compared universal with targeted screening (36 new HIV cases) was a fair-quality, nonrandomized study conducted in a large urban ED that found a very high likelihood of attending at least one HIV clinic appointment in patients diagnosed with either universal or targeted testing (97% vs. 100%; RR, 1.0 [95% CI, 0.81 to 1.3]).<sup>68</sup> An uncontrolled study of universal rapid HIV testing in Federally Qualified Health Centers found 14 of 17 (82%) patients with confirmed HIV infections were linked to HIV care following diagnosis.<sup>76</sup> A pre-post evaluation of universal opt-in or opt-out rapid oral HIV screening implementation (29 new HIV cases identified) in an ED reported similar rates of linkage to care within 90 days following HIV diagnosis with either strategy (75% [6/8] vs. 77% [16/21]; RR, 0.98 [95% CI, 0.62 to 1.6]).<sup>73</sup>

# Key Question 3a. To What Extent Does Knowledge of HIV-Positive Status Affect Behaviors Associated With Increased Risk of HIV Transmission in Nonpregnant Adolescents and Adults?

## Summary

Four before-after studies not included in the prior USPSTF review addressed effects of knowledge of HIV-positive status on risk behaviors. As in the prior USPSTF review, the studies found knowledge of HIV-positive status associated with reduced self-reported risky behaviors in all populations studied.

## Evidence

The prior USPSTF evidence review<sup>1-3</sup> included two systematic reviews on the association between HIV-positive status and high-risk behaviors.<sup>82, 83</sup> Both reviews found greater self-reported reductions in unprotected intercourse in persons testing HIV positive and in serodiscordant couples compared with those testing negative or those who were untested or unaware of their status. Interpretation of these findings was difficult because the primary studies in the reviews evaluated diverse populations and frequently had methodological shortcomings, such as retrospective design, low participation rates, or high loss to followup. Although these studies relied on self-reported behavior, with its attendant shortcomings, there is no practical alternative for assessing these outcomes. Reasons for HIV testing were typically not reported in the primary studies, so the applicability of results to asymptomatic patients undergoing screening was unclear.

Four before-after studies not considered in the prior USPSTF review evaluated the association between knowledge of HIV-positive status and behaviors associated with increased risk of HIV transmission<sup>84-87</sup> (**Table 2, Appendix B9**). Sample sizes ranged from 73 to 560 and behaviors were evaluated from 1 month to 2 or more years following diagnosis. One study was rated good-quality<sup>87</sup> and three studies fair-quality<sup>84-86</sup> (**Appendix B10**). All studies relied on self-reported risky behaviors and one<sup>86</sup> relied on retrospective recall of pre-HIV diagnosis behaviors. Two studies focused on high-risk groups (MSM or injection drug users), potentially limiting applicability to individuals without these risk factors.<sup>85, 87</sup>

One retrospective before-after study of a mixed population (n=487) of HIV-positive persons (injection drug users, noninjection drug-using heterosexual individuals, and MSM) found a significantly lower likelihood of self-reported injection drug use 2 or more years following HIV diagnosis compared with prior to diagnosis (32% vs. 54%).<sup>86</sup> The study also found increased condom use after compared with before HIV diagnosis during vaginal (40% vs. 5.5%), anal (32% vs. 4.1%), or oral-genital sex (9.0% vs. 0.9%) with stable partners (p<0.0005 for all differences). Although patients were also less likely to have stable partners following an HIV diagnosis compared with before diagnosis (77% vs. 89%; p<0.0005), likelihood of condom use during intercourse with occasional partners also increased after HIV diagnosis. Patients were also less likely to report engaging in sex for money or drugs following HIV diagnosis (6.8% vs. 13%;



p<0.0005) or engaging in sex with sex workers (7.2% vs. 16%; p<0.0005). One other small (n=16) before-after study of heterosexual individuals also found reduced risky sexual behaviors 3 months following a diagnosis of HIV infection compared with before diagnosis.<sup>84</sup>

Two studies of high-risk populations also found decreases in high-risk behaviors following HIV diagnosis. A prospective before-after study of MSM with primary HIV infection (n=98) found greater self-reported condom use (proportion always using during insertive anal intercourse, 61% vs. 31%; p<0.01) and fewer sexual partners (66% reported fewer sex partners, 27% no change, and 7.1% more partners; p<0.001) 3 months following diagnosis compared with at the time of testing.<sup>87</sup> Seventy-six percent reported no high-risk behaviors at all following HIV diagnosis (high-risk behaviors defined as unprotected anal intercourse with a regular partner of unknown or HIV-negative status, unprotected anal intercourse with a casual male partner, or incident STI). Another prospective before-after study found that 26 percent (11/42) of HIV-positive injection drug users reported cessation of injection drug use 1 to 6 months following diagnosis, 73 percent (19/26) stopped lending needles, 62 percent (23/37) stopped borrowing needles, and 38 percent (27/72) increased use of needle exchange programs.<sup>85</sup> Among males, 50 percent (9/18) had ceased sexual relations over the past 3 months, and all five men previously engaged in sex work had stopped this activity.

## **Key Question 3b. To What Extent Does Use of Antiretroviral Therapy Affect Behaviors Associated With Increased Risk of HIV Transmission in Nonpregnant Adolescents and Adults?**

### **Summary**

Seven observational studies not included in the prior USPSTF review addressed the effect of ART use on HIV risk behaviors. The studies primarily used a cross-sectional design and had methodological shortcomings, including failure to report baseline differences or to adjust for potential confounders. They found no clear association between ART use and increase in self-reported risky behaviors, with some studies showing decreased risky behaviors.

### **Evidence**

The prior USPSTF review identified one good-quality meta-analysis that found no association between ART use in HIV-infected persons and increased likelihood of unprotected sex.<sup>89</sup> However, some individual studies included in the prior USPSTF review reported associations between ART use and increased risk of high-risk sexual behaviors and in MSM,<sup>90</sup> as well as associations between ART use and increased likelihood of developing an STD<sup>91</sup> and higher risk for pregnancy.<sup>92</sup>

Five cross-sectional studies,<sup>93-97</sup> one prospective cohort study,<sup>98</sup> and one before-after study<sup>99</sup> not included in the prior USPSTF review evaluated the association between ART use and high-risk behaviors (**Table 3, Appendix B11**). Sample sizes ranged from 67 to 4,016. In the prospective cohort study, duration of followup averaged 8 years.<sup>98</sup> All studies were rated fair-quality<sup>93-99</sup> (**Appendix B12**). Methodological shortcomings included group differences between those taking

and not taking ART<sup>93</sup> or insufficient information to compare groups by ART use at baseline.<sup>94-97</sup> Three studies did not adjust for or did not clearly describe statistical adjustments for potential confounders,<sup>93, 96, 98</sup> and one study did not adjust for sex.<sup>95</sup> Risky behaviors were self-reported in all studies.<sup>93-99</sup> Three studies included only high-risk groups (MSM or injection drug users).<sup>96, 98, 99</sup>

Three observational studies of women or mixed (male or female) populations of heterosexual patients found no association between ART use and increased risky sexual behaviors, with two studies showing decreased risk.<sup>93, 95, 97</sup> A cross-sectional Spanish study of 625 HIV-serodiscordant heterosexual couples found lower likelihood of self-reported unprotected sexual intercourse in the preceding 6 months in couples in which the index partner was taking ART compared with couples in which the index partner was not taking ART (46% vs. 57%;  $p=0.02$ ).<sup>93</sup> A cross-sectional U.S. study also found trends toward reduced likelihood of engaging in risky behaviors in women ( $n=1,104$ ) or heterosexual men ( $n=803$ ) taking ART compared with those not taking ART, though differences were not statistically significant.<sup>97</sup> A cross-sectional United Kingdom study found no association between ART use and unprotected intercourse in women ( $n=480$ ) or heterosexual men ( $n=224$ ).<sup>95</sup>

Six observational studies of high-risk populations (MSM or injection drug users) also found no clear increases in risky behaviors (high-risk sexual behaviors or injection drug use) after initiation of ART compared with before initiation of therapy, or in HIV-infected patients taking ART compared with those not on therapy.<sup>94-99</sup> Two of these studies found ART use associated with reduced likelihood of high-risk behaviors.<sup>94, 97</sup> One ( $n=4,016$ ) found ART use associated with decreased risk of engaging in risky sexual behaviors over the past 6 months in MSM (adjusted odds ratio [OR], 0.73 [95% CI, 0.54 to 1.0]).<sup>97</sup> The other ( $n=874$ ) found ART use associated with decreased risk of unprotected anal or vaginal intercourse (adjusted OR, 0.70 [95% CI, 0.50 to 1.0]) in a population primarily consisting of gay men and injection drug users.<sup>94</sup>

## **Key Question 4a. How Effective Is Antiretroviral Therapy in Reducing Transmission of HIV in Nonpregnant Adolescents and Adults With Chronic HIV Infection?**

### **Summary**

A good-quality systematic review found consistent evidence from one randomized, controlled trial and seven observational studies that ART use is associated with decreased risk of HIV transmission from HIV-positive persons to uninfected sexual partners. In the randomized trial, the risk of HIV seroconversion in uninfected sexual partners of patients with baseline CD4 counts of 0.350 to 0.550  $\times 10^9$  cells/L was much lower in those randomized to immediate versus delayed ART after 1.7 years of followup (HR, 0.04 [95% CI, 0.01 to 0.27] for genomically linked seroconversion), consistent with the pooled risk estimate from observational studies (HR, 0.16 [95% CI, 0.07 to 0.35]).

### **Evidence**

The prior USPSTF review<sup>1-3</sup> identified no studies that directly evaluated the association between

ART use and risk of transmission. However, ART could decrease risk of HIV transmission from infected persons by decreasing viral load.<sup>19, 104-106</sup> One pre-HAART era cohort study found zidovudine associated with lower risk of heterosexual transmission compared with no treatment in monogamous men (RR, 0.5 [95% CI, 0.1 to 0.9]).<sup>107</sup>

A recent, good-quality systematic review evaluated the association between ART use and risk of HIV transmission from HIV-positive persons to uninfected sexual partners<sup>108</sup> (**Appendixes B13 and B14**). It included one randomized, controlled trial<sup>109</sup> and seven observational studies.<sup>93, 107, 110-114</sup>

The good-quality randomized, controlled trial (HIV Prevention Trials Network [HPTN] 052) compared early ART (started at enrollment) versus delayed therapy (after a decline in CD4 count to  $<0.250 \times 10^9$  cells/L or onset of symptoms) in HIV-infected patients with baseline CD4 counts of  $0.350$  to  $0.550 \times 10^9$  cells/L and an HIV-negative partner<sup>109</sup> (**Appendixes B15 and B16**). Fifty-four percent of the 1,763 couples were from Africa, with the remainder from Brazil, India, Thailand, and the United States. Ninety-seven percent of couples were heterosexual and 94 percent were married. All couples received condoms and counseling along with quarterly HIV testing of uninfected partners. The trial was designed to follow patients for 5 years, but was terminated early after meeting prespecified criteria for efficacy in interim analyses. At a median followup of 1.7 years, there were 39 seroconversions among all participants in the trial (1.2 per 100 person-years). Risk of seroconversion in HIV-negative partners was much lower in the early compared with the delayed therapy group (0.3 vs. 2.2 per 100 person-years; HR, 0.11 [95% CI, 0.04 to 0.32]). When restricted to the 28 cases that were genomically linked to the HIV-infected patient enrolled in the trial (one transmission in the early-therapy group and 27 transmissions in the delayed-therapy group), the HR was 0.04 (95% CI, 0.01 to 0.27). All cases of linked transmission in the delayed-therapy group occurred prior to initiation of ART in the HIV-infected partner.

Results of seven observational studies<sup>93, 107, 110-114</sup> (**Appendixes B15 and B17**) included in the systematic review<sup>108</sup> were consistent with the randomized trial.<sup>109</sup> Sample sizes ranged from 93 to 3,408 couples, with typical followup between 1 and 3 years (range, 3 months to 9 years). All seven observational studies were cohort studies of HIV-serodiscordant, heterosexual couples from Africa, Italy, Spain, Brazil, or China. Six cohort studies were rated fair-quality<sup>93, 107, 110-112, 114</sup> and the seventh<sup>113</sup> was reported as a conference abstract only and could not be quality rated. Three studies adjusted for possible confounding variables such as age, sex, condom use, or frequency of sexual intercourse.<sup>107, 110, 114</sup> Four studies reported low loss to followup.<sup>107, 110, 111, 114</sup>

Six of the seven observational studies reported decreased risk of HIV transmission from persons taking ART compared with those who were untreated.<sup>93, 107, 110-113</sup> Of the 436 total HIV transmissions in the seven observational studies, 71 were in couples in which the HIV-infected individual was receiving ART and 365 transmissions were in couples in which the HIV-infected individual was not receiving ART (pooled HR, 0.34 [95% CI, 0.13 to 0.92]).<sup>108</sup> However, there was substantial statistical heterogeneity ( $I^2=73\%$ ). Excluding one study with inadequate person-time data<sup>114</sup> and one older study that included persons treated with monotherapy only<sup>107</sup> resulted in a pooled HR of 0.16 (95% CI, 0.07 to 0.35) and eliminated the statistical heterogeneity ( $I^2=0\%$ ). The treatment effect was also more pronounced when the analysis was restricted to couples in which the HIV-infected individual had a CD4 count  $<0.200 \times 10^9$  cells/L (pooled HR, 0.06 [95% CI, 0.01 to 0.54]),<sup>93, 110-112</sup> couples in which the index case was male (pooled HR, 0.02 [95% CI, 0.00 to

0.89]),<sup>93, 113</sup> or couples residing in low/middle income countries (pooled HR, 0.24 [95% CI, 0.06 to 1.03]).<sup>110-114</sup>

## Key Question 4b. How Effective Is Behavioral Counseling in Reducing Transmission of HIV in Nonpregnant Adolescents and Adults With Chronic HIV Infection?

### Summary

Two studies of counseling interventions identified too few cases of new HIV infection to reliably estimate effects of counseling on risk of transmission.

### Evidence

The prior USPSTF review<sup>1-3</sup> found no randomized trials or controlled observational studies on the effects of counseling HIV-positive persons regarding risky behaviors on HIV transmission risk. One uncontrolled prospective U.S. study of 144 serodiscordant heterosexual couples reported reduced risky behaviors and no HIV transmission following counseling after 193 couple-years of followup.<sup>115</sup>

There remains little direct evidence on effects of testing and counseling regarding risky behaviors on HIV transmission (**Appendixes B18, B19, and B20**). Trials of counseling have generally not been designed to assess the effect of counseling on HIV transmission rates and have been underpowered. A cluster-randomized, controlled trial of African American, HIV-serodiscordant, heterosexual couples (n=536 couples) from four U.S. cities who had recently engaged in unprotected sexual intercourse found an Afrocentric HIV-STD risk-reduction counseling intervention<sup>116</sup> associated with increased likelihood of condom use compared with an attention-matched, individual-focused health promotion comparison group (63% vs. 48%; RR, 1.4 [95% CI, 1.2 to 1.7]), but after 12 months, there were only two HIV transmissions out of 260 couples in the counseling group and only three HIV transmissions out of 275 couples in the comparison group.<sup>117</sup> Similarly, a before-after study of 564 serodiscordant couples who participated in couples counseling and testing in Madrid from 1989 to 2007 found an increased likelihood of 100 percent condom use following counseling compared with before counseling (69% vs. 49%; p<0.001), but there were only five seroconversions during 1,279 couple-years of followup.<sup>118</sup>

No study estimated the effects of testing and counseling HIV-positive persons on injection drug use behaviors and transmission rates.

## Key Question 4c. In Asymptomatic, Nonpregnant Adolescents and Adults With Chronic HIV Infection, What Are the Effects of Initiating Antiretroviral Therapy at Different CD4 Counts or Viral Load Thresholds on Morbidity, Mortality, and Quality of Life?

### Summary

The prior USPSTF review found good-quality evidence that ART is associated with decreased risk of AIDS events and mortality compared with placebo or less-intensive regimens in patients with CD4 counts  $<0.200 \times 10^9$  cells/L. Two randomized, controlled trials (including one subgroup analysis) published after the prior USPSTF review found initiation of ART at CD4 counts  $<0.250 \times 10^9$  cells/L associated with substantially increased risk of death or AIDS events compared with initiation at CD4 counts  $>0.350 \times 10^9$  cells/L. Recent large, observational studies incorporating data from 12 to 23 cohorts also consistently found initiation of ART at CD4 counts between  $0.350$  and  $0.500 \times 10^9$  cells/L associated with decreased risk of mortality, or a trend toward decreased risk, compared with deferred or no ART. Four studies evaluating initiation of ART at CD4 counts  $>0.500 \times 10^9$  cells/L were inconsistent, with one study showing beneficial effects on clinical outcomes and three studies finding no clear benefit.

Two studies reported inconsistent results for the association between viral load at the time of initiation of ART and subsequent mortality.

### Evidence

**CD4 count.** The prior USPSTF review included good-quality randomized, controlled trials<sup>119-121</sup> and observational studies<sup>36, 122-128</sup> that consistently found ART associated with decreased risk of AIDS events and mortality compared with placebo or less-intensive regimens in patients with CD4 counts  $<0.200 \times 10^9$  cells/L. Evidence showing benefits of starting ART at higher CD4 counts was limited. Although a Swiss cohort study found starting ART at CD4 counts  $>0.350 \times 10^9$  cells/L associated with reduced risk of mortality and progression to AIDS compared with starting at counts  $<0.350 \times 10^9$  cells/L,<sup>129</sup> three U.S. cohort studies found no difference in risk between starting ART at CD4 counts between  $0.350$  and  $0.500 \times 10^9$  cells/L versus delaying until CD4 counts were between  $0.200$  and  $0.350 \times 10^9$  cells/L.<sup>126-128</sup>

Two good-quality randomized trials<sup>109, 130</sup> published since the prior USPSTF and one subgroup analysis<sup>131</sup> from another good-quality randomized trial evaluated effects of initiating ART at different CD4 count thresholds (**Appendixes B21 and B22**). Five observational studies (reported in six publications) that each combined data from 12 to 23 U.S., European, and Australian cohorts (~9,000 to  $>60,000$  participants; duration of followup, 1 to 5 years, with substantial overlap in the cohorts included in the studies) also evaluated effects of starting ART at different CD4 count thresholds<sup>132-137</sup> (**Appendix B23**). All studies were rated fair-quality (**Appendix B24**). None reported blinding of outcome assessors or those analyzing data, and attrition rates were often not reported or unclear. Although all studies adjusted for important confounders in their analyses, most

provided insufficient information to determine baseline comparability of patients started and not started on ART in different CD4 count strata.

Three randomized, controlled trials found delayed initiation of ART associated with increased risk of the combined outcome of death or AIDS-related events (**Table 4**). A retrospective subgroup analysis of patients (n=477) in the Strategies for Management of Antiretroviral Therapy (SMART) randomized trial who were treatment-naïve or had been off therapy for at least 6 months found initiation of ART at CD4 counts  $<0.250 \times 10^9$  cells/L associated with increased risk of death or AIDS events compared with initiation at CD4 counts  $>0.350 \times 10^9$  cells/L after a mean of 18 months (HR, 5.3 [95% CI, 1.3 to 9.6]).<sup>131</sup> The SMART trial was conducted in 33 primarily nonresource-poor countries. HPTN 052, conducted in 1,763 serodiscordant partners from primarily resource-poor countries, found initiation of ART at CD4 counts  $<0.250 \times 10^9$  cells/L associated with increased risk for the combined endpoint of death or AIDS events compared with initiation at CD4 counts between 0.350 and  $0.550 \times 10^9$  cells/L (adjusted HR, 1.7 [95% CI, 1.1 to 2.5]), though these results were strongly influenced by the incidence of extrapulmonary tuberculosis (RR, 5.6 [95% CI, 1.7 to 20]).<sup>109</sup> Results for mortality or pulmonary tuberculosis were not significant when these outcomes were considered individually. The third randomized trial (n=816) found initiation of ART at CD4 counts  $<0.200 \times 10^9$  cells/L associated with increased risk of mortality compared with initiation at CD4 counts of 0.201 to  $0.350 \times 10^9$  cells/L (HR, 4.0 [95% CI, 1.6 to 9.8]; p=0.001), but is less directly applicable to the U.S. population, as it was conducted in Haiti and CD4 count thresholds for treatment in both groups were lower than those typically used in the United States.<sup>130</sup>

Four observational studies consistently found initiation of ART at CD4 counts between 0.350 and  $0.500 \times 10^9$  cells/L associated with decreased risk of mortality compared with deferred or no ART (**Table 4**).<sup>132, 134-136</sup> One other study found a reduction in risk that was not statistically significant.<sup>137</sup> The largest study, the HIV Cohorts Analyzed Using Structural Approaches to Longitudinal Data (HIV-CAUSAL) (n=62,760 from 12 cohorts), found initiation of ART at CD4 counts of 0.350 to  $0.500 \times 10^9$  cells/L associated with decreased risk of mortality compared with noninitiation within this CD4 count range after an average of 3.3 years of followup (adjusted HR, 0.55 [95% CI, 0.41 to 0.74]).<sup>134</sup> Similarly, the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) (n=17,517 from 22 cohorts) found initiation of ART at CD4 counts of 0.350 to  $0.500 \times 10^9$  cells/L associated with decreased risk of death compared with deferred treatment within these thresholds after an average of 3 years of followup (adjusted RR, 0.61 [95% CI, 0.46 to 0.83]).<sup>135</sup> Initiation of ART at CD4 counts  $>0.350 \times 10^9$  cells/L was also associated with decreased risk of the combined outcome of AIDS-defining events or death compared with deferred or no initiation of ART in two studies (**Table 4**).<sup>132, 136</sup> One other study found a reduction in risk that was not statistically significant.<sup>137</sup>

Studies on initiation of ART at CD4 counts  $>0.500 \times 10^9$  cells/L were less consistent. NA-ACCORD found initiation of ART at CD4 counts  $>0.500 \times 10^9$  cells/L associated with decreased mortality compared with deferred therapy (adjusted RR, 0.54 [95% CI, 0.35 to 0.83]),<sup>135</sup> and HIV-CAUSAL found decreased mortality risk that was not statistically significant after 3 years (adjusted HR, 0.77 [95% CI, 0.58 to 1.0]).<sup>134</sup> Another analysis from HIV-CAUSAL that directly compared initiation of ART at CD4 counts  $>0.500 \times 10^9$  cells/L versus initiation at counts  $>0.350 \times 10^9$  cells/L found no difference in mortality (HR, 0.99 [95% CI, 0.73 to 1.4]).<sup>133</sup> Two other large cohort studies found initiation of ART at CD4 counts  $>0.500 \times 10^9$  cells/L associated with no difference in risk of

mortality when compared with noninitiation after 5 years (adjusted HR, 1.0 [95% CI, 0.49 to 2.1])<sup>132</sup> or when compared with slightly delayed initiation after 3 years (adjusted HR, 0.93 [95% CI, 0.60 to 1.4] for starting at CD4 counts of 0.451 to 0.550 versus 0.351 to 0.450 x 10<sup>9</sup> cells/L).<sup>137</sup> In all four studies, absolute mortality rates were low in patients with CD4 counts >0.500 x 10<sup>9</sup> cells/L (range, 2% to 5%).

Results were also mixed for the combined outcome of mortality plus AIDS-defining events, which was not reported in NA-ACCORD.<sup>135</sup> HIV-CAUSAL found initiation above a threshold of 0.500 x 10<sup>9</sup> cells/L associated with decreased risk of AIDS-defining events or death compared with initiation above 0.350 x 10<sup>9</sup> cells/L (HR, 0.72 [95% CI, 0.59 to 0.88]).<sup>133</sup> Two other studies found no clear association between starting versus not starting ART at CD4 counts >0.500 x 10<sup>9</sup> cells/L and risk of AIDS-defining events or death (**Table 4**).<sup>132, 137</sup>

**Viral load.** Two studies reported inconsistent results for the association between viral load at time of initiation of ART and subsequent mortality (**Appendix B23**).<sup>134, 136</sup> HIV-CAUSAL (n=62,760 from 12 cohorts) found initiation of ART at higher viral loads associated with greater reduction in mortality risk (adjusted HR, 0.82 [95% CI, 0.64 to 1.0] for initiation at viral load <10,000 copies/mL vs. noninitiation; adjusted HR, 0.46 [95% CI, 0.36 to 0.60] for viral load of 10,000 to 100,000 copies/mL; and adjusted HR, 0.36 [95% CI, 0.28 to 0.45] for viral load >100,000 copies/mL).<sup>134</sup> Another study, the Antiretroviral Therapy Cohort Collaboration (n=20,379 from 12 cohorts), found initiation of ART at viral loads of 10,000 to <100,000 copies/mL and 1,000 to <10,000 copies/mL each associated with decreased risk of mortality or progression to AIDS compared with initiation at a viral load ≥100,000 copies/mL (adjusted HRs, 0.80 [95% CI, 0.73 to 0.88] and 0.80 [95% CI, 0.68 to 0.95], respectively).<sup>136</sup>

## **Key Question 5. What Are the Longer-Term Harms Associated With Antiretroviral Therapy in Nonpregnant Adolescents and Adults With Chronic HIV Infection?**

### **Summary**

The 2005 USPSTF review included results from the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study, which found longer duration of exposure to ART associated with increased risk of myocardial infarction (adjusted RR per year of exposure, 1.3 [95% CI, 1.1 to 1.4]). More recent analyses from DAD with up to 6 years of followup were consistent with earlier results in finding slightly increased risk of myocardial infarction with use of some protease inhibitors. Two studies (DAD and one other cohort study) found abacavir associated with increased risk of cardiovascular events, but two other studies found no such association. There was no clear association between use of other nucleoside reverse transcriptase inhibitors or nonnucleoside reverse transcriptase inhibitors and increased risk of adverse cardiovascular events.

### **Evidence**

The prior USPSTF review included results from the large (n=23,468), ongoing DAD study, which

found increased risk of myocardial infarction associated with longer exposure to ART (adjusted RR per year of exposure, 1.3 [95% CI, 1.1 to 1.4]), though absolute event rates were low (3.5/1,000 person-years).<sup>141</sup>

Subsequent analyses from DAD<sup>142-144</sup> and three other cohort studies reported cardiovascular harms associated with ART through up to 4 to 6 years of followup (**Appendix B25**).<sup>145-147</sup> Sample sizes ranged from 2,952 to >30,000. All of the studies were rated good-quality except for one,<sup>145</sup> which was rated fair-quality due to lack of detail about baseline patient characteristics and blinding of study personnel (**Appendix B26**).

Like the earlier DAD results, the most recent DAD analysis found longer exposure to indinavir alone (adjusted RR per year of exposure, 1.1 [95% CI, 1.1 to 1.2]), ritonavir-boosted indinavir (adjusted RR per year of exposure, 1.2 [95% CI, 1.1 to 1.3]), and ritonavir-boosted lopinavir (adjusted RR per year of exposure, 1.1 [95% CI, 1.0 to 1.2]) each associated with slightly increased risk of myocardial infarction compared with nonuse, after adjustment for age, sex, HIV infection risk group, ethnicity, calendar year, family history of cardiovascular disease, prior cardiovascular disease, smoking status, body mass index, and other factors (**Table 5**).<sup>144</sup> No other protease inhibitor was associated with increased myocardial risk.

Evidence on the association between the nucleoside reverse transcriptase inhibitor abacavir and risk of myocardial infarction is mixed. Although two studies found abacavir use associated with increased risk (adjusted RRs, 1.7 and 2.0),<sup>144, 146</sup> two others found no association (adjusted HRs, 0.6 and 1.2)<sup>145, 147</sup> after 4 to 6 years of followup (**Table 5**).

The DAD study also found recent didanosine use associated with increased myocardial infarction risk (adjusted RR, 1.4 [95% CI, 1.1 to 1.8]), but no association when analyses were based on cumulative didanosine exposure.<sup>144</sup> There was no association between use of other nucleoside reverse transcriptase inhibitors or the nonnucleoside reverse transcriptase inhibitors nevirapine or efavirenz and increased risk of cardiovascular events.<sup>144</sup>

## **Key Question 6a. To What Extent Are Improvements in Viremia Associated With Reductions in HIV Transmission Rates in Nonpregnant Adolescents and Adults?**

### **Summary**

The prior USPSTF review included seven observational studies that consistently found a strong association between lower individual viral load and decreased risk of heterosexual transmission of HIV infection. Three observational studies not included in the prior USPSTF review reported results consistent with these findings. Three other observational studies (two with overlapping populations) found lower community viral load (defined as the average viral load in a defined population) associated with decreased risk of HIV transmission.



## Evidence

The prior USPSTF report<sup>3</sup> included seven observational studies<sup>19, 106, 150-154</sup> that consistently found an association between lower individual viral load and lower risk of heterosexual transmission of HIV infection (**Table 6**). The strongest evidence was from a good-quality prospective cohort study of 415 serodiscordant couples in rural Uganda (a setting in which ART was not available), which found viral load to be the strongest predictor for heterosexual HIV transmission (male to female or female to male).<sup>19</sup> The rate of transmission in patients with HIV-1 viral load <1,500 copies/mL was zero out of 51, and increased in a dose-response fashion to 23 per 100 person-years at a viral load  $\geq 50,000$  copies/mL. The adjusted RR for transmission was 12 (95% CI, 5.0 to 35) for a viral load  $> 50,000$  copies/mL compared with  $< 3,500$  copies/mL. Another analysis of the same Ugandan cohort reported an adjusted RR of transmission per coital act of 16 (95% CI, 3.1 to 296) for a viral load of 1,700 to 12,499 copies/mL versus  $< 1,700$  copies/mL, 18 (95% CI, 3.4 to 329) for viral loads of 12,500 to 38,499 copies/mL, and 28 (95% CI, 5.4 to 507) for viral loads  $\geq 38,500$  copies/mL.<sup>20</sup>

Three observational studies not included in the prior USPSTF review evaluated the association between viral load in individual patients and risk of HIV transmission<sup>110, 155, 156</sup> (**Table 6, Appendixes B27 and B28**). Two evaluated heterosexual couples in Africa.<sup>110, 155</sup> One cohort study evaluated 3,408 HIV-discordant couples in seven African countries in which the index case was infected with both HIV and herpes simplex virus-2 and had CD4 counts  $> 0.250 \times 10^9$  cells/L.<sup>110</sup> The group at greatest risk for HIV transmission were individuals with CD4 counts of 0.200 to  $0.349 \times 10^9$  cells/L and a viral load of  $\geq 50,000$  copies/mL (incidence per 100 person-years, 4.7 [95% CI, 3.2 to 6.6]). A case-control study of heterosexual couples in Zambia (109 cases of HIV transmission to the uninfected partner and 208 control couples with no transmission) found a dose-dependent association between higher viral load and risk of transmission from females to males (RR per log viral load, 2.5 [95% CI, 1.5 to 4.0]) as well as from males to females (RR per log viral load, 1.8 [95% CI, 1.2 to 2.8]).<sup>155</sup> HIV RNA viral load was also a predictor of transmission risk in a cohort study (1,144 men, 41 cases) of MSM in the United Kingdom (RR per log viral load, 1.6 [95% CI, 1.2 to 2.3]).<sup>156</sup>

Studies that evaluated community viral load (the average viral load in a defined population) also found an association between higher viral load and increased risk of transmission<sup>157-159</sup> (**Appendixes B27 and B28**). One study found that for every 10-fold decrease in the median viral load of all HIV-infected individuals in a specific year in British Columbia, the number of new HIV cases decreased by a factor of 0.86 (95% CI, 0.75 to 0.98) after adjusting for year and number of individuals taking ART, despite increased rates of other STDs in this population.<sup>158</sup> An analysis of a subgroup of the above population, consisting of injection drug users in inner-city Vancouver, also found community viral load independently associated with time to HIV seroconversion (HR per  $\log_{10}$  increase, 3.3 [95% CI, 1.8 to 6.1]) after adjusting for other markers of risk.<sup>159</sup> Similarly, a study based on San Francisco's HIV/AIDS surveillance system found both higher mean community viral load and sum total viral load associated with increased risk of HIV incidence (unadjusted,  $p=0.003$  and  $p=0.002$ , respectively).<sup>157</sup>

## Key Question 6b. To What Extent Are Improvements in Risky Behaviors Associated With Reductions in HIV Transmission Rates in Nonpregnant Adolescents and Adults?

### Summary

The prior USPSTF review included two systematic reviews that found consistent condom use associated with substantially reduced risk of sexual transmission of HIV infection. Two observational studies not included in the prior USPSTF review were consistent with these findings.

No study evaluated effects of safer injection drug use behaviors by HIV-positive patients on risk of HIV transmission.

### Evidence

The prior USPSTF review included a systematic review<sup>1-3</sup> (11 prospective studies, two retrospective studies, and one case report) of primarily HIV-discordant heterosexual couples from the United States, Europe, Africa, and Haiti that found consistent use of condoms (defined as use of a condom for all acts of penetrative vaginal intercourse) associated with an 80 percent reduction in heterosexual transmission of HIV.<sup>160</sup> Another pooled analysis found consistent condom users were 10 to 20 times less likely to become infected when exposed to the virus than inconsistent or nonusers.<sup>161</sup>

The 2007 USPSTF update<sup>1</sup> also included a study that used a mathematical formula to estimate that transmission risk was 3.5 times higher in HIV-positive patients unaware of their status (6.9%) compared with those aware (2.0%) of their HIV infection, resulting in a projected 31 percent decline in new sexual infections per year (from 32,000 to 22,150) if all HIV-positive patients unaware of their status became aware.<sup>51</sup> However, these results were based on estimates for reduced risky behaviors from studies with methodological shortcomings, and may not have adequately accounted for other important factors that might affect transmission risk (such as type of risky behaviors, number of risky behavior episodes, number of sexual partners, viral load, use of ART, presence of other STDs, CD4 count, and time since diagnosis).<sup>162</sup>

Two observational studies published since the prior USPSTF review reported results consistent with previous findings<sup>93, 114</sup> (**Appendixes B29 and B30**). One prospective cohort study of 476 heterosexual Spanish individuals (1,355 couple-years of followup) found self-reported condom use associated with decreased risk of HIV transmission per act of intercourse compared with intercourse without a condom (unadjusted RR, 0.07 [95% CI, 0.01 to 0.58]).<sup>93</sup> A Chinese study of 1,927 serodiscordant couples found not always using condoms associated with increased risk of seroconversion (RR, 8.4 [95% CI, 4.8 to 15]) in multivariate analysis when compared with always using a condom, after adjusting for frequency of sexual intercourse, switching of ART regimen, and physical and psychological quality-of-life scores.<sup>114</sup>

No study evaluated effects of safer injection drug use behaviors by HIV-positive patients on risk of

HIV transmission.

## **Contextual Question. What Is the Cost-Effectiveness of Universal Versus Targeted HIV Screening in Low- or Average-Prevalence Populations?**

The 2005 USPSTF review included two good-quality studies<sup>8,9</sup> that estimated cost-effectiveness of HIV screening in low- or average-prevalence populations. One study by Sanders et al estimated <\$50,000 (2004 U.S. dollars) per quality-adjusted life-year (QALY) for one-time screening versus no screening at an HIV prevalence of 0.5 percent, excluding potential transmission benefits.<sup>9</sup> After incorporating potential transmission benefits, cost-effectiveness remained <\$50,000 per QALY at an HIV prevalence of 0.05 percent, or substantially lower than seen in the general population. Another study by Paltiel et al, which did not directly incorporate secondary transmission benefits, estimated incremental cost-effectiveness of one-time screening in the general population (prevalence of undiagnosed HIV infection, 0.1%; corresponding to an overall HIV prevalence of about 0.4%) of \$113,000 (2001 U.S. dollars) per QALY compared with no screening.<sup>8</sup> Neither study evaluated the incremental cost-effectiveness of a strategy of universal versus targeted screening in low-prevalence populations,<sup>163</sup> though one of the studies included assumptions about background testing rates in the no screening arm.<sup>8</sup> Long-term cardiovascular harms were not accounted for in either model. In the study that included secondary transmission benefits, cost-effectiveness in low-prevalence settings was sensitive to estimates of beneficial effects of screening on transmission.<sup>9</sup> The other cost-effectiveness analysis did not directly incorporate secondary transmission benefits when estimating cost-effectiveness,<sup>8</sup> though a subsequent analysis found that increasing rates of test notification and entry into care had a greater impact on cost-effectiveness than similar increases in rates of testing.<sup>164</sup>

The cost-effectiveness analyses included in the prior USPSTF review also evaluated screening strategies involving repeat testing.<sup>8,9</sup> They found screening every 5 years in a population with 1 percent prevalence associated with a cost-effectiveness ratio <\$50,000 per QALY when secondary transmission benefits were included and annual incidence was at least 0.09 percent. In low-prevalence (0.1% undiagnosed HIV infection) settings, one of these studies found that repeat screening at any interval cost >\$100,000 per QALY at all plausible incidences.<sup>8</sup> This study also found that in a high-risk setting (incidence, 1.2%; prevalence, 3.0%), screening every 5 years cost \$50,000 per QALY compared with one-time screening, screening every 3 years cost \$63,000 per QALY compared with screening every 5 years, and screening annually cost \$100,000 per QALY compared with screening every 3 years.

Subsequent cost-effectiveness analyses based on the models used in the above studies have been published.<sup>165-167</sup> Paltiel et al estimated cost-effectiveness ratios of <\$50,000 (2004 U.S. dollars) per QALY for one-time rapid screening compared with no screening in settings with HIV prevalence as low as 0.20 percent, when assuming moderately favorable effects of ART on transmission (decrease in the basic reproductive number [ $R_0$ ], 1.44 to 1.27).<sup>167</sup> Cost-effectiveness ratios remained <\$50,000 per QALY for screening every 5 years compared with no screening at prevalences as low as 0.45 percent and annual incidences as low as 0.0075 percent. Sanders et al estimated cost-effectiveness ratios of <\$60,000 (2007 U.S. dollars) per QALY for one-time screening with streamlined

counseling compared with no screening in persons ages 55 to 75 years with a sexual partner at risk at an HIV prevalence as low as 0.1 percent, assuming favorable effects on transmission.<sup>165</sup> Cost-effectiveness ratios were also <\$60,000 per QALY for one-time screening with streamlined counseling compared with no screening in persons ages 55 to 65 years without a sexual partner at risk at an HIV prevalence of 0.5 percent. With traditional counseling, cost-effectiveness ratios of screening compared with no screening were >\$100,000 per QALY for screening persons ages 75 years or older with a sexual partner at risk or persons ages 65 years or older without a sexual partner at risk. In a separate study, Sanders et al estimated a cost-effectiveness ratio of \$10,660 per QALY for nurse-initiated routine screening with rapid HIV testing and streamlined counseling compared with traditional HIV counseling and testing.<sup>166</sup>

One other study published since the 2005 USPSTF review estimated a cost-effectiveness ratio of \$22,382 (2009 U.S. dollars) per QALY for one-time screening of low-risk persons (HIV prevalence, 0.10% in men and 0.22% in women) plus annual screening of high-risk persons compared with current practice (annual rate of screening, 23% in high-risk persons and 10% in low-risk persons), assuming a 20 percent reduction in sexual activity after screening, with an associated reduction in risk of HIV transmission.<sup>168</sup> Assuming the same screening strategy plus an increase in ART utilization in 75 percent of infected persons resulted in a similar cost-effectiveness ratio, though more infections would be prevented. Screening low-risk persons every 3 years or more frequently was associated with cost-effectiveness ratios of >\$100,000 per QALY compared with one-time screening of low-risk persons, with annual screening of high-risk persons included as part of both strategies.

No study directly compared cost-effectiveness of universal versus targeted screening in low-prevalence populations, or explicitly included potential long-term cardiovascular harms of combination ART in models.

## CHAPTER 4. DISCUSSION

### Summary of Review Findings

As in the 2005 USPSTF review,<sup>1-3</sup> we found no direct evidence on effects of screening for HIV infection versus no screening on clinical outcomes. Other evidence reviewed in this update is summarized in **Table 7**.

The 2005 USPSTF review found good evidence that HIV screening tests are accurate and that identification of undiagnosed HIV infection and treatment of immunologically advanced disease (CD4 count  $<0.200 \times 10^9$  cells/L) are associated with substantial clinical benefits, but insufficient evidence to estimate effects of diagnosis and subsequent interventions on transmission risks or to estimate clinical benefits of ART in patients with less immunologically advanced disease. New studies included in this update provide strong evidence for effectiveness of initiation of ART at CD4 counts of  $0.350$  to  $0.500 \times 10^9$  cells/L,<sup>131, 132, 134-137</sup> though evidence is less consistent for CD4 counts  $>0.500 \times 10^9$  cells/L.<sup>132, 134, 135, 137</sup> Recent studies indicate that about 54 percent of patients presented for initial HIV care with CD4 counts  $<0.350 \times 10^9$  cells/L,<sup>78</sup> and about 75 percent were diagnosed with CD4 counts  $<0.500 \times 10^9$  cells/L,<sup>80</sup> suggesting that a large proportion of patients identified by screening could directly benefit from immediate initiation of ART. Additional research confirms previous findings of a small but statistically significant increase in risk of long-term cardiovascular harms primarily associated with use of protease inhibitors.<sup>142-144, 146</sup> Such long-term cardiovascular harms are an important consideration when initiating ART or selecting specific regimens, since patients will typically continue ART indefinitely. In the DAD study, the overall rate of myocardial infarction (fatal or nonfatal) after 5.8 years was 3.2 per 1,000 person-years (5.8 years median followup), with an increase in risk associated with protease inhibitors of about 10 percent per year of exposure, for an absolute increase of about 0.3 myocardial infarctions per 1,000 person-years.<sup>144</sup> In the largest cohort study, HIV-CAUSAL, all-cause mortality after a mean of 3.3 years ranged from 28.8 per 1,000 person-years at a CD4 count of  $<100 \times 10^9$  cells/L to 7.0 per 1,000 person-years at a CD4 count of  $0.350$  to  $<0.500 \times 10^9$  cells/L, with a decrease in risk with initiation versus noninitiation of ART of 71 and 45 percent, respectively, for an absolute decrease in mortality of about 3.2 to 20 per 1,000 person-years.<sup>134</sup> Whether current first-line protease inhibitors and other antiretrovirals are also associated with increased cardiovascular risk is not yet established. Long-term ART is also associated with other harms, including osteoporotic fractures<sup>169</sup> and lipodystrophy,<sup>170</sup> that were not addressed in this review.

Although direct clinical evidence showing that changes in risky behaviors as a result of knowledge of positive HIV status or that counseling interventions in HIV-positive persons reduces transmission risk is still not available, there is now strong evidence from a randomized trial as well as consistent evidence from multiple observational studies that ART use is associated with a 10- to 20-fold reduction in risk of sexual transmission.<sup>108, 109</sup> These findings are consistent with other evidence confirming a strong association between reduced viral load (individual or community) and transmission risk.<sup>110, 155-159</sup> The implications of these findings for reducing spread of HIV infection are substantial. Recent evidence showing that counseling interventions were relatively ineffective in reducing risky behaviors in HIV-infected persons suggest that beneficial effects of screening on transmission are likely to be driven by use of ART.<sup>171</sup>

Evidence on effects of different HIV screening strategies (such as universal vs. targeted screening, rapid vs. standard testing, opt-out vs. opt-in testing, or streamlined vs. traditional pretest counseling) on the uptake or yield of screening, CD4 count at diagnosis, linkage to care, or harms associated with screening are limited. Few studies directly compared these strategies, and in those that reported these outcomes, small numbers of HIV infection were identified, precluding reliable conclusions. Nonetheless, limited evidence suggests high rates of linkage of care following universal testing.<sup>68, 73, 76</sup> There is insufficient evidence to estimate effects of different HIV screening strategies on rates of uptake, which may also be affected by the clinical setting, the perceived risk in the individual being offered testing, and other factors. There is also insufficient evidence to determine effects of different HIV screening strategies on CD4 count at diagnosis, though epidemiologic data indicate some recent trends toward earlier diagnosis, temporally coinciding with when the CDC recommendation for routine HIV screening was issued.<sup>60, 78, 80</sup> Studies indicate that rapid testing is associated with higher false-alarm rates in lower-prevalence settings, though estimates varied widely.<sup>68, 73, 76, 77</sup> The consequences of initially false-positive rapid test results have not been evaluated, but will depend on whether patients are notified prior to confirmatory testing, and are likely to be affected by other factors, such as how patients are counseled about results. Patients are unlikely to receive ART based on a false-positive result, given routine confirmation of positive test results and because use of ART depends in part on CD4 count and presence of viremia.

Modeling studies suggest that screening is likely to be cost-effective at prevalences similar to or lower than observed in the general population.<sup>9, 167</sup> In addition, the modeling studies may underestimate cost-effectiveness, given relatively modest assumed reductions in risk of transmission (20%) relative to the results observed in the randomized trial described above.<sup>109</sup>

No clinical study has evaluated the yield of repeat HIV screening. Modeling studies suggest that repeat screening of low-risk individuals is unlikely to be associated with cost-effectiveness ratios <\$100,000 per QALY compared with one-time screening, though repeat screening in high-risk individuals may be cost-effective, depending on the frequency of testing and incidence of new infections.<sup>8, 167, 168</sup>

## Limitations

We excluded nonEnglish-language articles, which could result in language bias, though we identified no nonEnglish-language studies that would have met inclusion criteria. We did not search for studies published only as abstracts and could not formally assess for publication bias with graphical or statistical methods because of small numbers of studies for each key question, and differences in study design, populations, and outcomes assessed. We included observational studies, which are more susceptible to bias and confounding than well-conducted randomized trials, though we focused on results from studies that performed statistical adjustment for potential confounding. When evidence from settings more applicable to U.S. practice and screening in low- and average-risk populations was sparse or unavailable, we included studies conducted in resource-poor and high-prevalence settings, which could limit applicability to U.S. practice.

## Emerging Issues

ART regimens and indications for initiating long-term ART continue to evolve. Since the 2005 USPSTF review, four new antiretroviral agents have been approved by the Food and Drug Administration for use in HIV-positive patients. Two represent new drug classes: the CCR5 antagonist maraviroc and the integrase inhibitor raltegravir. The other two drugs are the nonnucleoside reverse transcriptase inhibitor etravirine and the protease inhibitor darunavir. Although these medications have primarily been approved for use in patients with resistance to first-line medications, raltegravir has been approved for treatment-naïve individuals. Regularly updated guidelines on selection of ART are available.<sup>52</sup> A new CDC HIV testing algorithm is expected in 2012. Although it is believed to be at least as accurate as the prior testing algorithm, and is designed to diagnose patients sooner in the “window” period before seroconversion, studies should be performed to confirm its accuracy in clinical practice.

## Future Research

More research is needed on the effects of different HIV screening strategies on testing uptake, CD4 count at diagnosis, linkage to care, and harms. Studies should be designed with adequate statistical power to evaluate outcomes such as CD4 count at diagnosis, linkage to care, and harms, which may require collaborative efforts like those used to assess effects of initiation of ART at different CD4 count strata. Continued followup of patients taking ART is needed to further understand effects of long-term exposure to ART, as many patients are exposed for far longer than the 6 years evaluated in the longest studies to date. The Strategic Timing of Antiretroviral Treatment randomized trial, which compares initiation of ART at CD4 counts  $>0.500 \times 10^9$  cells/L compared with deferred treatment until CD4 counts decline to  $<0.350 \times 10^9$  cells/L, is currently in its recruitment phase and should help further clarify effects of very early initiation of ART.<sup>172</sup>

## Conclusions

Prior studies have shown that HIV screening is accurate, targeted screening misses a substantial proportion of cases, and treatments are effective in patients with advanced immunodeficiency. New evidence indicates that ART reduces risk of AIDS-defining events and mortality in persons with less advanced immunodeficiency and reduces sexual transmission. More research is needed to understand effects of different screening strategies on the uptake and yield of screening, harms, CD4 count at diagnosis, and linkage to care.

## REFERENCES

1. Chou R, Huffman L. Screening for Human Immunodeficiency Virus: Focused Update of a 2005 Systematic Evidence Review for the U.S. Preventive Services Task Force. Evidence Synthesis No. 46. AHRQ Publication No. 07-0597-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; April 2007. Accessed at <http://www.ncbi.nlm.nih.gov/books/NBK33475/> on 24 October 2012.
2. Chou R, Korthuis PT, Huffman LH, Smits AK. Screening for Human Immunodeficiency Virus in Adolescents and Adults. Evidence Synthesis No. 38. Rockville, MD: Agency for Healthcare Research and Quality; July 2005. Accessed at <http://www.ahrq.gov/downloads/pub/prevent/pdfser/hivrevsyn.pdf> on 24 October 2012.
3. Chou R, Huffman LH, Fu R, Smits AK, Korthuis PT; U.S. Preventive Services Task Force. Screening for HIV: a review of the evidence for the U.S. Preventive Services Task Force. *Ann Intern Med.* 2005;143(1):55-73.
4. U.S. Preventive Services Task Force. Screening for HIV: Recommendation Statement. AHRQ Publication No. 07-0597-EF-2. Rockville, MD: Agency for Healthcare Research and Quality; July 2005 (Amended April 2007).
5. Chou R, Smits AK, Huffman LH, Korthuis PT. Screening for Human Immunodeficiency Virus in Pregnant Women. Evidence Synthesis No. 39. Rockville, MD: Agency for Healthcare Research and Quality; July 2005. Accessed at <http://www.ncbi.nlm.nih.gov/books/NBK33383/> on 24 October 2012.
6. Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB, et al; Centers for Disease Prevention and Control. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. *MMWR Recomm Rep.* 2006;55(RR-14):1-17.
7. Peterman TA, Todd KA, Mupanduki I. Opportunities for targeting publicly funded human immunodeficiency virus counseling and testing. *J Acquir Immune Defic Syndr Hum Retrovirol.* 1996;12(1):69-74.
8. Paltiel AD, Weinstein MC, Kimmel AD, Seage GR 3rd, Losina E, Zhang H, et al. Expanded screening for HIV in the United States—an analysis of cost-effectiveness. *N Engl J Med.* 2005;352(6):586-95.
9. Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, Rydzak CE, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. *N Engl J Med.* 2005;352(6):570-85.
10. Centers for Disease Control and Prevention. HIV-2 surveillance—United States, 1987–2009. *MMWR Morb Mortal Wkly Rep.* 2011;60(29):985-8.
11. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. *MMWR Recomm Rep.* 1992;41(RR-17):1-19.
12. Centers for Disease Control and Prevention. HIV in the United States: At a Glance. Atlanta: Centers for Disease Control and Prevention; 2012. Accessed at <http://www.cdc.gov/hiv/resources/factsheets/us.htm> on 24 October 2012.
13. Centers for Disease Control and Prevention. HIV surveillance—United States, 1981–2008. *MMWR Morb Mortal Wkly Rep.* 2011;60(21):689-93.



14. Campsmith ML, Rhodes PH, Hall I, Green TA. Undiagnosed HIV prevalence among adults and adolescents in the United States at the end of 2006. *J Acquir Immune Defic Syndr*. 2010;53(5):619-24.
15. Prejean J, Song R, Hernandez A, Ziebell R, Green T, Walker F, et al; HIV Incidence Surveillance Group. Estimated HIV incidence in the United States, 2006–2009. *PLoS One*. 2011;6(8):e17502.
16. Centers for Disease Control and Prevention. Increases in HIV diagnoses—29 states, 1999–2002. *MMWR Morb Mortal Wkly Rep*. 2003;52(47):1145-8.
17. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2006. Vol 18. Atlanta: Centers for Disease Control and Prevention; 2008. Accessed at <http://www.cdc.gov/hiv/topics/surveillance/resources/reports/2006report/pdf/2006SurveillanceReport.pdf> on 24 October 2012.
18. Centers for Disease Control and Prevention. Persons Living With a Diagnosis of HIV Infection, by Year and Selected Characteristics, 2006–2008: 40 States With Confidential Name-Based HIV Infection Reporting. Atlanta: Centers for Disease Control and Prevention; 2009. Accessed at <http://www.cdc.gov/hiv/surveillance/resources/reports/2009report/pdf/table15a.pdf> on 24 October 2012.
19. Quinn TC, Wawer MJ, Sewankambo NK, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. *N Engl J Med*. 2000;342(13):921-9.
20. Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, Wabwire-Mangen F, et al; Rakai Project Team. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. *Lancet*. 2001;357(9263):1149-53.
21. Doherty MC, Garfein RS, Monterroso E, Brown D, Vlahov D. Correlates of HIV infection among young adult short-term injection drug users. *AIDS*. 2000;14(6):717-26.
22. Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. *N Engl J Med*. 1998;339(1):33-9.
23. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. *Ann Intern Med*. 1996;125(4):257-64.
24. Vanhems P, Allard R, Cooper DA, Perrin L, Vizzard J, Hirschel B, et al. Acute human immunodeficiency virus type 1 disease as a mononucleosis-like illness: is the diagnosis too restrictive? *Clin Infect Dis*. 1997;24(5):965-70.
25. Daar ES, Moudgil T, Meyer RD, Ho DD. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. *N Engl J Med*. 1991;324(14):961-4.
26. Henrard DR, Phillips JF, Muenz LR, Blattner WA, Wiesner D, Eyster ME, et al. Natural history of HIV-1 cell-free viremia. *JAMA*. 1995;274(7):554-8.
27. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. *Nature*. 1995;373(6510):123-6.
28. Schacker TW, Hughes JP, Shea T, Coombs RW, Corey L. Biological and virologic characteristics of primary HIV infection. *Ann Intern Med*. 1998;128(8):613-20.
29. Touloumi G, Pantazis N, Babiker AG, Walker SA, Katsarou O, Karafoulidou A, et al; CASCADE Collaboration. Differences in HIV RNA levels before the initiation of

- antiretroviral therapy among 1864 individuals with known HIV-1 seroconversion dates. *AIDS*. 2004;18(12):1697-705.
30. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, et al. Viral dynamics in human immunodeficiency virus type 1 infection. *Nature*. 1995;373(6510):117-22.
  31. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. *Lancet*. 2000;355(9210):1131-7.
  32. Koblin B, van Benthem BH, Buchbinder SP, Ren L, Vittinghoff E, Stevens CE, et al. Long-term survival after infection with human immunodeficiency virus type 1 (HIV-1) among homosexual men in hepatitis B vaccine trial cohorts in Amsterdam, New York City, and San Francisco, 1978–1995. *Am J Epidemiol*. 1999;150(10):1026-30.
  33. Stein DS, Korvick JA, Vermund SH. CD4+ lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: a review. *J Infect Dis*. 1992;165(2):352-63.
  34. Kaslow RA, Phair JP, Friedman HB, Lyter D, Solomon RE, Dudley J, et al. Infection with the human immunodeficiency virus: clinical manifestations and their relationship to immune deficiency. A report from the Multicenter AIDS Cohort Study. *Ann Intern Med*. 1987;107(4):474-80.
  35. Phillips AN, Gazzard B, Gilson R, Easterbrook P, Johnson M, Walsh J, et al; UK Collaborative HIV Cohort Study. Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. *AIDS*. 2007;21(13):1717-21.
  36. Egger M, May M, Chêne G, Phillips AN, Ledergerber B, Dabis F, et al; ART Cohort Collaboration. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. *Lancet*. 2002;360(9327):119-29.
  37. Phillips A, Pezzotti P; CASCADE Collaboration. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. *AIDS*. 2004;18(1):51-8.
  38. Phillips AN, Lee CA, Elford J, Janossy G, Timms A, Bofill M, et al. Serial CD4 lymphocyte counts and development of AIDS. *Lancet*. 1991;337(8738):389-92.
  39. Mellors JW, Kingsley LA, Rinaldo CR Jr, Todd JA, Hoo BS, Kokka RP, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. *Ann Intern Med*. 1995;122(8):573-9.
  40. Mellors JW, Muñoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. *Ann Intern Med*. 1997;126(12):946-54.
  41. Phair JP, Mellors JW, Detels R, Margolick JB, Muñoz A. Virologic and immunologic values allowing safe deferral of antiretroviral therapy. *AIDS*. 2002;16(18):2455-9.
  42. Babiker AG, Peto T, Porter K, Walker AS, Darbyshire JH. Age as a determinant of survival in HIV infection. *J Clin Epidemiol*. 2001;54(Suppl 1):S16-21.
  43. Vella S, Giuliano M, Florida M, Chiesi A, Tomino C, Seeber A, et al. Effect of sex, age and transmission category on the progression to AIDS and survival of zidovudine-treated symptomatic patients. *AIDS*. 1995;9(1):51-6.

44. Pedersen C, Lindhardt BO, Jensen BL, Lauritzen E, Gerstoft J, Dickmeiss E, et al. Clinical course of primary HIV infection: consequences for subsequent course of infection. *BMJ*. 1989;299(6692):154-7.
45. de Roda Husman AM, Koot M, Cornelissen M, Keet IP, Brouwer M, Broersen SM, et al. Association between CCR5 genotype and the clinical course of HIV-1 infection. *Ann Intern Med*. 1997;127(10):882-90.
46. Ioannidis JP, Rosenberg PS, Goedert JJ, Ashton LJ, Benfield TL, Buchbinder SP, et al; International Meta-Analysis of HIV Host Genetics. Effects of CCR5-delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: an international meta-analysis of individual-patient data. *Ann Intern Med*. 2001;135(9):782-95.
47. Lathey JL, Tierney C, Chang SY, D'Aquila RT, Bettendorf DM, Alexander HC, et al. Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapy. *J Infect Dis*. 2001;184(11):1402-11.
48. Marmor M, Sheppard HW, Donnell D, Bozeman S, Celum C, Buchbinder S, et al; HIV Network for Prevention Trials Vaccine Preparedness Protocol Team. Homozygous and heterozygous CCR5-delta32 genotypes are associated with resistance to HIV infection. *J Acquir Immune Defic Syndr*. 2001;27(5):472-81.
49. Nolan D, Gaudieri S, John M, Mallal S. Impact of host genetics on HIV disease progression and treatment: new conflicts on an ancient battleground. *AIDS*. 2004;18(9):1231-40.
50. Centers for Disease Control and Prevention. Estimates of New HIV Infections in the United States. Atlanta: Centers for Disease Control and Prevention; 2008. Accessed at <http://www.cdc.gov/nchhstp/newsroom/docs/Fact-Sheet-on-HIV-Estimates.pdf> on 24 October 2012.
51. Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. *AIDS*. 2006;20(10):1447-50.
52. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Washington, DC: Department of Health and Human Services; 2012. Accessed at <http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf> on 24 October 2012.
53. McNaghten AD, Hanson DL, Jones JL, Dworkin MS, Ward JW; Adult/Adolescent Spectrum of Disease Group. Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. *AIDS*. 1999;13(13):1687-95.
54. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H; Centers for Disease Control and Prevention; National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. *MMWR Recomm Rep*. 2009;58(RR-4):1-207.
55. Centers for Disease Control. Interpretation and use of the western blot assay for serodiagnosis of human immunodeficiency virus type 1 infections. *JAMA*. 1989;262(24):3395-7.
56. Centers for Disease Control. Update: serologic testing for HIV-1 antibody—United States, 1988 and 1989. *MMWR Morb Mortal Wkly Rep*. 1990;39(22):380-3.
57. Lampe M, Branson B, Paul S, Burr C, Gross E, Eicher C, et al. Rapid HIV Antibody Testing During Labor and Delivery for Women of Unknown HIV Status: A Practical Guide and

- Model Protocol. Atlanta: Centers for Disease Control and Prevention; 2004. Accessed at <http://www.cdc.gov/hiv/topics/testing/resources/guidelines/rt-labor&delivery.htm> on 24 October 2012.
58. Greenwald JL, Burstein GR, Pincus J, Branson B. A rapid review of rapid HIV antibody tests. *Curr Infect Dis Rep.* 2006;8(2):125-31.
  59. Branson BM. The future of HIV testing. *J Acquir Immune Defic Syndr.* 2010;55(Suppl 2):S102-5.
  60. Centers for Disease Control and Prevention. Vital signs: HIV testing and diagnosis among adults—United States, 2001–2009. *MMWR Morb Mortal Wkly Rep.* 2010;59(47):1550-5.
  61. Qaseem A, Snow V, Shekelle P, Hopkins R Jr, Owens DK; Clinical Efficacy Assessment Subcommittee, American College of Physicians. Screening for HIV in health care settings: a guidance statement from the American College of Physicians and HIV Medicine Association. *Ann Intern Med.* 2009;150(2):125-31.
  62. Lubinski C, Aberg J, Bardeguez AD, Elion R, Emmanuel P, Kuritzkes D, et al. HIV policy: the path forward—a joint position paper of the HIV Medicine Association of the Infectious Diseases Society of America and the American College of Physicians. *Clin Infect Dis.* 2009;48(10):1335-44.
  63. American College of Obstetricians and Gynecologists. ACOG Committee Opinion: routine human immunodeficiency virus screening. *Obstet Gynecol.* 2008;112(2 Pt 1):401-3.
  64. Emmanuel PJ, Martinez J; Committee on Pediatric AIDS, American Academy of Pediatrics. Adolescents and HIV infection: the pediatrician's role in promoting routine testing. *Pediatrics.* 2011;128(5):1023-9.
  65. American Academy of Family Physicians. Human Immunodeficiency Virus. Leawood, KS: American Academy of Family Physicians; 2005. Accessed at <http://www.aafp.org/online/en/home/clinical/exam/hiv.html> on 24 October 2012.
  66. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, et al; Methods Work Group, Third U.S. Preventive Services Task Force. Current methods of the U.S. Preventive Services Task Force: a review of the process. *Am J Prev Med.* 2001;20(3 Suppl):21-35.
  67. Shea BJ, Hamel C, Wells GA, Bouter LM, Kristjansson E, Grimshaw J, et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. *J Clin Epidemiol.* 2009;62(10):1013-20.
  68. Haukoos JS, Hopkins E, Conroy AA, Silverman M, Byyny RL, Eisert S, et al; Denver Emergency Department HIV Opt-Out Study Group. Routine opt-out rapid HIV screening and detection of HIV infection in emergency department patients. *JAMA.* 2010;304(3):284-92.
  69. Weis KE, Liese AD, Hussey J, Coleman J, Powell P, Gibson JJ, et al. A routine HIV screening program in a South Carolina community health center in an area of low HIV prevalence. *AIDS Patient Care STDS.* 2009;23(4):251-8.
  70. Cunningham CO, Doran B, DeLuca J, Dyksterhouse R, Asgary R, Sacajiu G. Routine opt-out HIV testing in an urban community health center. *Aids Patient Care STDS.* 2009;23(8):619-23.
  71. Centers for Disease Control and Prevention. Routinely recommended HIV testing at an urban urgent-care clinic—Atlanta, Georgia, 2000. *MMWR Morb Mortal Wkly Rep.* 2001;50(25):538-41.
  72. Haukoos JS, Hopkins E, Bender B, Al-Tayyib A, Long J, Harvey J, et al; Denver Emergency Department HIV Testing Research Consortium. Use of kiosks and patient

- understanding of opt-out and opt-in consent for routine rapid human immunodeficiency virus screening in the emergency department. *Acad Emerg Med.* 2012;19(3):287-93.
73. White DA, Scribner AN, Vahidnia F, Dideum PJ, Gordon DM, Frazee BW, et al. HIV screening in an urban emergency department: comparison of screening using an opt-in versus an opt-out approach. *Ann Emerg Med.* 2011;58(Suppl 1):S89-95.
  74. Anaya HD, Hoang T, Golden JF, Goetz MB, Gifford A, Bowman C, et al. Improving HIV screening and receipt of results by nurse-initiated streamlined counseling and rapid testing. *J Gen Intern Med.* 2008;23(6):800-7.
  75. Bowles KE, Clark HA, Tai E, Sullivan PS, Song B, Tsang J, et al. Implementing rapid HIV testing in outreach and community settings: results from an advancing HIV prevention demonstration project conducted in seven U.S. cities. *Public Health Rep.* 2008;123(Suppl 3):78-85.
  76. Myers JJ, Modica C, Dufour MS, Bernstein C, McNamara K. Routine rapid HIV screening in six community health centers serving populations at risk. *J Gen Intern Med.* 2009;24(12):1269-74.
  77. Walensky RP, Reichmann WM, Arbelaez C, Wright E, Katz JN, Seage GR 3rd, et al. Counselor- versus provider-based HIV screening in the emergency department: results from the Universal Screening for HIV infection in the Emergency Room (USHER) randomized controlled trial. *Ann Emerg Med.* 2011;58(Suppl 1):S126-32.
  78. Althoff KN, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RJ, et al. Late presentation for human immunodeficiency virus care in the United States and Canada. *Clin Infect Dis.* 2010;50(11):1512-20.
  79. District of Columbia HIV/AIDS, Hepatitis, STD, and TB Administration. Annual Report 2010. Washington, DC: Government of the District of Columbia, Department of Health; 2010. Accessed at [http://doh.dc.gov/sites/default/files/dc/sites/doh/publication/attachments/2010\\_Annual\\_Report\\_FINAL\\_0.pdf](http://doh.dc.gov/sites/default/files/dc/sites/doh/publication/attachments/2010_Annual_Report_FINAL_0.pdf) on 24 October 2012.
  80. Buchacz K, Armon C, Palella FJ, Baker RK, Tedaldi E, Durham MD, et al. CD4 cells counts at HIV diagnosis among HIV outpatient study participants, 2000–2009. *AIDS Res Treat.* 2012;2012:869841.
  81. Centers for Disease Control and Prevention. Voluntary HIV testing as part of routine medical care—Massachusetts, 2002. *MMWR Morb Mortal Wkly Rep.* 2004;53(24):523-6.
  82. Marks G, Crepaz N, Senterfitt JW, Janssen RS. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. *J Acquir Immune Defic Syndr.* 2005;39(4):446-53.
  83. Weinhardt LS. HIV diagnosis and risk behavior. In: *Positive Prevention: Reducing HIV Transmission Among People Living With HIV/AIDS*. SC Kalichman (ed). New York: Kluwer Academic/Plenum; 2005.
  84. Amaro H, Morrill AC, Dai J, Cabral H, Raj A. Heterosexual behavioral maintenance and change following HIV counseling and testing. *J Health Psychol.* 2005;10(2):287-300.
  85. Brogly SB, Bruneau J, Lamothe F, Vincelette J, Franco EL. HIV-positive notification and behavior changes in Montreal injection drug users. *AIDS Educ Prev.* 2002;14(1):17-28.
  86. Camoni L, Regine V, Colucci A, Conte ID, Chiriotto M, Vullo V, et al. Changes in at-risk behavior for HIV infection among HIV-positive persons in Italy. *AIDS Patient Care STDS.* 2009;23(10):853-8.

87. Fox J, White PJ, Macdonald N, Weber J, McClure M, Fidler S, et al. Reductions in HIV transmission risk behaviour following diagnosis of primary HIV infection: a cohort of high-risk men who have sex with men. *HIV Med.* 2009;10(7):432-8.
88. Bruneau J, Lamothe F, Soto J, Lachance N, Vincelette J, Vassal A, et al. Sex-specific determinants of HIV infection among injection drug users in Montreal. *Can Med Assoc J.* 2001;164(6):767-73.
89. Crepaz N, Hart TA, Marks G. Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review. *JAMA.* 2004;292(2):224-36.
90. Katz MH, Schwarcz SK, Kellogg TA, Klausner JD, Dilley JW, Gibson S, et al. Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. *Am J Public Health.* 2002;92(3):388-94.
91. Scheer S, Chu PL, Klausner JD, Katz MH, Schwarcz SK. Effect of highly active antiretroviral therapy on diagnoses of sexually transmitted diseases in people with AIDS. *Lancet.* 2001;357(9254):432-5.
92. Blair JM, Hanson DL, Jones JL, Dworkin MS. Trends in pregnancy rates among women with human immunodeficiency virus. *Obstet Gynecol.* 2004;103(4):663-8.
93. Del Romero J, Castilla J, Hernando V, Rodríguez C, García S. Combined antiretroviral treatment and heterosexual transmission of HIV-1: cross sectional and prospective cohort study. *BMJ.* 2010;340:c2205.
94. Diamond C, Richardson JL, Milam J, Stoyanoff S, McCutchan JA, Kemper C, et al; California Collaborative Trials Group. Use of and adherence to antiretroviral therapy is associated with decreased sexual risk behavior in HIV clinic patients. *J Acquir Immune Defic Syndr.* 2005;39(2):211-8.
95. Elford J, Ibrahim F, Bukutu C, Anderson J. Sexual behaviour of people living with HIV in London: implications for HIV transmission. *AIDS.* 2007;21(Suppl 1):S63-70.
96. Miguez-Burbano MJ, Pineda-Medina L, Lecusay R, Page JB, Castillo G, Burbano X, et al. Continued high risk behaviors in HIV infected drug abusers. *J Addict Dis.* 2002;21(4):67-80.
97. Morin SF, Myers JJ, Shade SB, Koester K, Maiorana A, Rose CD. Predicting HIV transmission risk among HIV-infected patients seen in clinical settings. *AIDS Behav.* 2007;11(5 Suppl):S6-16.
98. Smit C, Lindenburg K, Geskus RB, Brinkman K, Coutinho RA, Prins M. Highly active antiretroviral therapy (HAART) among HIV-infected drug users: a prospective cohort study of sexual risk and injecting behaviour. *Addiction.* 2006;101(3):433-40.
99. Tun W, Gange SJ, Vlahov D, Strathdee SA, Celentano DD. Increase in sexual risk behavior associated with immunologic response to highly active antiretroviral therapy among HIV-infected injection drug users. *Clin Infect Dis.* 2004;38(8):1167-74.
100. Elford J, Anderson J, Bukutu C, Ibrahim F. HIV in East London: ethnicity, gender and risk. Design and methods. *BMC Public Health.* 2006;6(1):150.
101. van Haastrecht HJ, van den Hoek JA, Bardoux C, Leentvaar-Kuypers A, Coutinho RA. The course of the HIV epidemic among intravenous drug users in Amsterdam, The Netherlands. *Am J Public Health.* 1991;81(1):59-62.
102. Vlahov D, Anthony JC, Muñoz A, Margolick J, Nelson KE, Celentano DD, et al. The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. *J Drug Issues.* 1991;21(4):759-76.



103. Vlahov D, Safaien M, Lai S, Strathdee SA, Johnson L, Sterling T, et al. Sexual and drug risk-related behaviours after initiating highly active antiretroviral therapy among injection drug users. *AIDS*. 2001;15(17):2311-6.
104. Barroso PF, Schechter M, Gupta P, Melo MF, Vieira M, Murta FC, et al. Effect of antiretroviral therapy on HIV shedding in semen. *Ann Intern Med*. 2000;133(4):280-4.
105. Cu-Uvin S, Caliendo AM, Reinert S, Chang A, Juliano-Remollino C, Flanigan TP, et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. *AIDS*. 2000;14(4):415-21.
106. Operskalski EA, Stram DO, Busch MP, Huang W, Harris M, Dietrich SL, et al; Transfusion Safety Study Group. Role of viral load in heterosexual transmission of human immunodeficiency virus type 1 by blood transfusion recipients. *Am J Epidemiol*. 1997;146(8):655-61.
107. Musicco M, Lazzarin A, Nicolosi A, Gasparini M, Costigliola P, Arici C, et al; Italian Study Group on HIV Heterosexual Transmission. Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission. *Arch Intern Med*. 1994;154(17):1971-6.
108. Anglemyer A, Rutherford GW, Baggaley RC, Egger M, Siegfried N. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. *Cochrane Database Syst Rev*. 2011;(8):CD009153.
109. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. *N Engl J Med*. 2011;365(6):493-505.
110. Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, Cohen CR, et al; Partners in Prevention HSV/HIV Transmission Study Team. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. *Lancet*. 2010;375(9731):2092-8.
111. Melo MG, Santos BR, De Cassia Lira R, Varella IS, Turella ML, Rocha TM, et al. Sexual transmission of HIV-1 among serodiscordant couples in Porto Alegre, Southern Brazil. *Sex Transm Dis*. 2008;35(11):912-5.
112. Reynolds SJ, Makumbi F, Nakigozi G, Kagaayi J, Gray RH, Wawer M, et al. HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy. *AIDS*. 2011;25(4):473-7.
113. Sullivan P, Kayitenkore K, Chomba E, Karita E, Mwananyanda L, Vwalika C. Reduction of HIV transmission risk and high risk sex while prescribed ART: results from discordant couples in Rwanda and Zambia. Paper presented at: 16th Conference on Retroviruses and Opportunistic Infections; February 2009; Montréal, Canada.
114. Wang L, Ge Z, Luo J, Duo S, Xing G, Guo-Wei D, et al. HIV transmission risk among serodiscordant couples: a retrospective study of former plasma donors in Henan, China. *J Acquir Immune Defic Syndr*. 2010;55(2):232-8.
115. Padian NS, O'Brien TR, Chang Y, Glass S, Francis DP. Prevention of heterosexual transmission of human immunodeficiency virus through couple counseling. *J Acquir Immune Defic Syndr*. 1993;6(9):1043-8.
116. NIMH Multisite HIV/STD Prevention Trial for African American Couples Group. Eban HIV/STD risk reduction intervention: conceptual basis and procedures. *J Acquir Immune Defic Syndr*. 2008;49(Suppl 1):S15-27.

117. El-Bassel N, Jemmott JB, Landis JR, Pequegnat W, Wingood GM, Wyatt GE, et al; NIMH Multisite HIV/STD Prevention Trial for African American Couples Group. National Institute of Mental Health multisite Eban HIV/STD prevention intervention for African American HIV serodiscordant couples: a cluster randomized trial. *Arch Intern Med*. 2010;170(17):1594-601.
118. Hernando V, del Romero J, García S, Rodríguez C, del Amo J, Castilla J. Reducing sexual risk behavior among steady heterosexual serodiscordant couples in a testing and counseling program. *Sex Transm Dis*. 2009;36(10):621-8.
119. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. *N Engl J Med*. 1997;337(11):725-33.
120. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. *N Engl J Med*. 1997;337(11):734-9.
121. Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath C, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. *Lancet*. 1998;351(9102):543-9.
122. Sterling TR, Chaisson RE, Moore RD. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. *AIDS*. 2001;15(17):2251-7.
123. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. *JAMA*. 2001;286(20):2568-77.
124. Kaplan JE, Hanson DL, Cohn DL, Karon J, Buskin S, Thompson M, et al; Adult/Adolescent Spectrum of HIV Disease Project Investigators. When to begin highly active antiretroviral therapy? Evidence supporting initiation of therapy at CD4+ lymphocyte counts <350 cells/ $\mu$ L. *Clin Infect Dis*. 2003;37(7):951-8.
125. Cozzi Lepri A, Phillips AN, d'Arminio Monforte A, Castelli F, Antinori A, de Luca A, et al; ICONA Study Group. When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study. *AIDS*. 2001;15(8):983-90.
126. Palella FJ Jr, Deloria-Knoll M, Chmiel JS, Moorman AC, Wood KC, Greenberg AE, et al; HIV Outpatient Study Investigators. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. *Ann Intern Med*. 2003;138(8):620-6.
127. Ahdieh-Grant L, Yamashita TE, Phair JP, Detels R, Wolinsky SM, Margolick JB, et al. When to initiate highly active antiretroviral therapy: a cohort approach. *Am J Epidemiol*. 2003;157(8):738-46.
128. Sterling TR, Chaisson RE, Moore RD. Initiation of highly active antiretroviral therapy at CD4+ T lymphocyte counts of  $>350$  cells/mm<sup>3</sup>: disease progression, treatment durability, and drug toxicity. *Clin Infect Dis*. 2003;36(6):812-5.
129. Opravil M, Ledergerber B, Furrer H, Hirschel B, Imhof A, Gallant S, et al; Swiss HIV Cohort Study. Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count  $>350 \times 10^6/L$ . *AIDS*. 2002;16(10):1371-81.
130. Severe P, Juste MA, Ambroise A, Eliacin L, Marchand C, Apollon S, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. *New Engl J Med*. 2010;363(3):257-65.



131. Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, et al; Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Major clinical outcomes in antiretroviral therapy (ART)-naïve participants and in those not receiving ART at baseline in the SMART study. *J Infect Dis.* 2008;197(8):1133-44.
132. Writing Committee for the CASCADE Collaboration. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. *Arch Intern Med.* 2011;171(17):1560-19.
133. Cain LE, Logan R, Robins JM, Sterne JA, Sabin C, Bansi L, et al; HIV-CAUSAL Collaboration. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. *Ann Intern Med.* 2011;154(8):509-15.
134. Ray M, Logan R, Sterne JA, Hernández-Díaz S, Robins JM, Sabin C, et al; HIV-CAUSAL Collaboration. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. *AIDS.* 2010;24(1):123-37.
135. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al; NA-ACCORD Investigators. Effect of early versus deferred antiretroviral therapy for HIV on survival. *N Engl J Med.* 2009;360(18):1815-26.
136. May M, Sterne JA, Sabin C, Costagliola D, Justice AC, Thiébaud R, et al; Antiretroviral Therapy (ART) Cohort Collaboration. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. *AIDS.* 2007;21(9):1185-97.
137. Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, et al; When to Start Consortium. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. *Lancet.* 2009;373(9672):1352-63.
138. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al; Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. *N Engl J Med.* 2006;355(22):2283-96.
139. Lanoy E, May M, Mocroft A, Phillip A, Justice A, Chêne G, et al; Antiretroviral Therapy Cohort Collaboration. Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. *AIDS.* 2009;23(16):2199-208.
140. Moore DM, Harris R, Lima V, Hogg B, May M, Yip B, et al; Antiretroviral Therapy Cohort Collaboration. Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression. *J Acquir Immune Defic Syndr.* 2009;52(3):357-63.
141. Friis-Møller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al; Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. *N Engl J Med.* 2003;349(21):1993-2003.
142. Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. *N Engl J Med.* 2007;356(17):1723-35.
143. Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected

- patients enrolled in the DAD study: a multi-cohort collaboration. *Lancet*. 2008;371(9622):1417-26.
144. Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the Data Collection on Adverse Events of Anti-HIV Drugs study. *J Infect Dis*. 2010;201(3):318-30.
  145. Bedimo RJ, Westfall AO, Drechsler H, Vidiella G, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. *Clin Infect Dis*. 2011;53(1):84-91.
  146. Obel N, Farkas DK, Kronborg G, Larsen CS, Pedersen G, Riis A, et al. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. *HIV Med*. 2010;11(2):130-6.
  147. Ribaud HJ, Benson CA, Zheng Y, Koletar SL, Collier AC, Lok JJ, et al; ACTG A5001/ALLRT Protocol Team. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. *Clin Infect Dis*. 2011;52(7):929-40.
  148. Obel N, Engsig FN, Rasmussen LD, Larsen MV, Omland LH, Sørensen HT. Cohort profile: the Danish HIV cohort study. *Int J Epidemiol*. 2008;38(5):1202-6.
  149. Lohse N, Kronborg G, Gerstoft J, Larsen CS, Pedersen G, Pedersen C, et al. Virological control during the first 6–18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study. *Clin Infect Dis*. 2006;42(1):136-44.
  150. Fiore JR, Zhang YJ, Björndal A, Di Stefano M, Angarano G, Pastore G, et al. Biological correlates of HIV-1 heterosexual transmission. *AIDS*. 1997;11(9):1089-94.
  151. Lee TH, Sakahara N, Fiebig E, Busch MP, O'Brien TR, Herman SA. Correlation of HIV-1 RNA levels in plasma and heterosexual transmission of HIV-1 from infected transfusion recipients. *J Acquir Immune Defic Syndr Hum Retrovirol*. 1996;12(4):427-8.
  152. Pedraza MA, del Romero J, Roldán F, García S, Ayerbe MC, Noriega AR, et al. Heterosexual transmission of HIV-1 is associated with high plasma viral load levels and a positive viral isolation in the infected partner. *J Acquir Immune Defic Syndr*. 1999;21(2):120-5.
  153. Ragni MV, Faruki H, Kingsley LA. Heterosexual HIV-1 transmission and viral load in hemophilic patients. *J Acquir Immune Defic Syndr Hum Retrovirol*. 1998;17(1):42-5.
  154. Tovanabutra S, Robison V, Wongtrakul J, Sennum S, Suriyanon V, Kingkeow D, et al. Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. *J Acquir Immune Defic Syndr*. 2002;29(3):275-83.
  155. Fideli US, Allen SA, Musonda R, Trask S, Hahn BH, Weiss H, et al. Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. *AIDS Res Hum Retroviruses*. 2001;17(10):901-10.
  156. Fisher M, Pao D, Brown AE, Sudarshi D, Gill ON, Cane P, et al. Determinants of HIV-1 transmission in men who have sex with men: a combined clinical, epidemiological and phylogenetic approach. *AIDS*. 2010;24(11):1739-47.
  157. Das M, Chu PL, Santos GM, Scheer S, Vittinghoff E, McFarland W, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. *PLoS One*. 2010;5(6):e11068.

158. Montaner JS, Lima VD, Barrios R, Yip B, Wood E, Kerr T, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. *Lancet*. 2010;376(9740):532-9.
159. Wood E, Kerr T, Marshall BD, Li K, Zhang R, Hogg RS, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. *BMJ*. 2009;338:b1649.
160. Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. *Cochrane Database Syst Rev*. 2002;(1):CD003255.
161. Pinkerton SD, Abramson PR. Effectiveness of condoms in preventing HIV transmission. *Soc Sci Med*. 1997;44(9):1303-12.
162. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. *J Infect Dis*. 2005;191(9):1403-9.
163. Holtgrave DR. Costs and consequences of the U.S. Centers for Disease Control and Prevention's recommendations for opt-out HIV testing. *PLoS Med*. 2007;4(6):e194.
164. Walensky RP, Weinstein MC, Smith HE, Freedberg KA, Paltiel AD. Optimal allocation of testing dollars: the example of HIV counseling, testing, and referral. *Med Decis Making*. 2005;25(3):321-9.
165. Sanders GD, Bayoumi AM, Holodniy M, Owens DK. Cost-effectiveness of HIV screening in patients older than 55 years of age. *Ann Intern Med*. 2008;148(12):889-903.
166. Sanders GD, Anaya HD, Asch S, Hoang T, Golden JF, Bayoumi AM, et al. Cost-effectiveness of strategies to improve HIV testing and receipt of results: economic analysis of a randomized controlled trial. *J Gen Intern Med*. 2010;25(6):556-63.
167. Paltiel AD, Walensky RP, Schackman BR, Seage GR 3rd, Mercincavage LM, Weinstein MC, et al. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. *Ann Intern Med*. 2006;145(11):797-806.
168. Long EF, Brandeau ML, Owens DK. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. *Ann Intern Med*. 2010;153(12):778-89.
169. Bedimo R, Maalouf NM, Zhang S, Drechsler H, Tebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. *AIDS*. 2012;26(7):825-31.
170. Waters L, Nelson M. Long-term complications of antiretroviral therapy: lipoatrophy. *Int J Clin Pract*. 2007;61(6):999-1014.
171. Metsch LR, Feaster DJ, Gooden L, Matheson T, Mandler RN, Haynes L, et al. Implementing rapid HIV testing with or without risk-reduction counseling in drug treatment centers: results of a randomized trial. *Am J Public Health*. 2012;102(6):1160-7.
172. NCT00867048: Strategic Timing of Antiretroviral Treatment (START). Bethesda, MD: National Institutes of Health; 2012. Accessed at <http://clinicaltrials.gov/ct2/show/NCT00867048> on 24 October 2012.



**Table 1. Positive Predictive Values and False-Positive Results Associated With HIV Rapid Testing**

<b>Study, Year</b>	<b>Prevalence of HIV infection</b>	<b>Total N tested for HIV</b>	<b>Initial positive</b>	<b>Confirmed (true) positive</b>	<b>False positive</b>	<b>Positive predictive value*</b>	<b>Comments</b>
Bowles et al, 2008 <sup>75</sup>	1.1%	23,900	331	267	17	94%	40 declined confirmatory testing, 2 had indeterminate results, 5 had missing information
Haukoos et al, 2010 <sup>68</sup>	0.4%	7,176	36	30	6	83%	Combined groups; both opt-out and targeted used rapid screening
Myers et al, 2009 <sup>76</sup>	0.2%	10,769	39	17	5	77%	
Walensky et al, 2011 <sup>77</sup>	0.4%	2,002	54	7	36	16%	11 declined confirmatory testing
White et al, 2011 <sup>73</sup>	0.4%	8,732	49	38	11	77%	

\*Positive predictive value = true positive/(true positive + false positive).

**Table 2. Effect of Knowledge of HIV-Positive Status on Risky Behaviors**

Author, year	Setting	Sample	Type of study	Risk behavior outcomes	Quality rating
Amaro et al, 2005 <sup>84</sup>	United States HIV counseling and testing sites	560 heterosexual participants (16 HIV-positive)	Before-after observational	All HIV-positive participants adopted safer behavior with main and nonmain partners at post test (3 months after HIV testing) (statistics for this group not reported)	Fair
Brogly et al, 2002 <sup>85</sup> ; Bruneau et al, 2001 <sup>88</sup>	Canada Self-referral, hospital detoxification unit, IDU centers	73 HIV-positive IDUs	Before-after observational	<u>Behavior change in IDUs who received positive test result (at least 1 month after diagnosis)</u> 26% (11/42) stopped injecting, 73% (19/26) stopped lending needles, 62% (23/37) stopped borrowing needles, 38% (27/72) increased use of needle exchange program, 50% (9/18) of men stopped sexual relations, 100% (5/5) of men stopped sex work	Fair
Camoni et al, 2009 <sup>86</sup>	Italy Infectious diseases and sexually transmitted infections clinics	487 HIV-positive individuals diagnosed for at least 2 years (253 contributed drug use behavior data)	Retrospective before-after observational	<u>Comparing drug use, before vs. after HIV diagnosis</u> Injecting drug use: Yes; 54% (n=138) vs. 32% (n=82); p<0.0005  <u>Comparing sexual behavior, before vs. after HIV diagnosis</u> Sex for money or drugs: Yes; 13% (n=64) vs. 6.8% (n=33); p<0.0005 Sex with sex workers: Yes; 16% (n=78) vs. 7.2% (n=35); p<0.0005  <u>Comparing sexual behavior with stable partner and occasional partner, before vs. after HIV diagnosis</u> Stable partner: Yes; 89% (n=434) vs. 77% (n=377); p<0.0005 Condom use, vaginal sex: Always; 5.5% (n=24) vs. 40% (n=150); p<0.0005 Condom use, anal sex: Always; 4.1% (n=18) vs. 32% (n=120); p<0.0005 Condom use, oral-genital sex: Always; 0.9% (n=4) vs. 9.0% (n=34); p<0.0005 Occasional partners: Yes; 82% (n=400) vs. 58% (n=283); p<0.0005 Condom use, vaginal sex: Always; 10% (n=41) vs. 38% (n=107); p<0.0005 Condom use, anal sex: Always; 10% (n=42) vs. 41% (n=115); p<0.0005 Condom use, oral-genital sex: Always; 2.7% (n=11) vs. 17% (n=49); p<0.0005	Fair
Fox et al, 2009 <sup>87</sup>	United Kingdom HIV clinic	98 men who have sex with men with primary HIV infection	Before-after observational	<u>12 weeks following HIV diagnosis</u> 76% (n=74) of men posed no risk for onward transmission during that period (defined as unprotected anal intercourse with a regular partner of unknown or negative HIV status, unprotected anal intercourse with casual male partners or incident sexually transmitted infection); 66% (n=65) decreased number of partners, 27% (n=26) had no change, and 7.1% (n=7) increased number of partners, p<0.001. Proportion always using condoms during receptive anal intercourse with casual partners increased from 17% (13/76) to 64% (29/45), p<0.001; and for insertive anal intercourse from 31% (22/72) to 61% (28/46), p<0.01	Good

ART = antiretroviral therapy; IDU = injection drug user.

**Table 3. Effect of Use of Antiretroviral Therapy on Risky Behaviors**

Author, year	Setting	Sample	Type of study	Risk behavior outcomes	Quality rating
Del Romero et al, 2010 <sup>93</sup>	Spain HIV clinic	625 serodiscordant heterosexual couples engaging in sexual relationship over preceding 6 months	Cross sectional	Proportion engaging in unprotected sexual intercourse in preceding 6 months (at baseline), ART vs. no ART: 46% (69/149) vs. 57% (273/476); p=0.02	Fair
Diamond et al, 2005 <sup>94</sup>	United States HIV clinic	874 HIV-infected individuals who were sexually active in preceding 3 months	Cross sectional	Proportion engaging in unprotected sexual intercourse, ART vs. no ART: 215/689 (31%) vs. 86/185 (46%); adjusted OR, 0.70 [95% CI, 0.50–1.0]; p<0.04	Fair
Elford et al, 2007 <sup>95</sup> ; Elford et al, 2006 <sup>100</sup>	United Kingdom HIV clinic	1,687 HIV infected participants (including 758 gay men, 224 black African heterosexual men, 480 black African heterosexual women)	Cross sectional	No significant association between ART use and engaging in unprotected intercourse amongst gay men or black African heterosexual men and women; p>0.05	Fair
Miguez-Burbano et al, 2002 <sup>96</sup>	United States Community clinic	85 HIV-infected drug abusers	Cross sectional	Men receiving ART tended to have unprotected anal sex when compared with those not receiving ART; OR, 2 [95% CI, 0.47–12]; p=0.07 Contaminated needles used by 18 participants, 85% of this group was receiving ART	Fair
Morin et al, 2007 <sup>97</sup>	United States HIV clinic	4,016 HIV-infected individuals (2,109 men who have sex with men, 1,104 women, 803 men who have sex with women)	Cross sectional	ART use was negatively associated with transmission risk sex amongst men who have sex with men, women, and men who have sex with women. Association was only significant for men who have sex with men: ART use vs. no ART use, HIV transmission risk act 19% vs. 28%; adjusted OR, 0.73 [95% CI, 0.54–1.0]; p=0.05	Fair
Smit et al, 2006 <sup>98</sup> ; van Haastrecht et al, 1991 <sup>101</sup>	The Netherlands Methadone and sexually transmitted diseases clinics, word of mouth	67 HIV-infected drug users using ART matched to 130 HIV-infected drug users not using ART	Prospective cohort	Proportion of injection drug users that reported injecting drugs was significantly lower among ART users than nonART users at all visits (p<0.05), except the last two. Modeled piecewise, ART users and nonART users showed nonsignificant declines in injecting drugs over time, which did not change after ART initiation. Significant differences between ART users and nonusers were seen at every visit (p<0.05). ART users reported significantly more unprotected sex than nonART users at 3/7 visits (p<0.05). Modeled piecewise, sexual risk behavior nonsignificantly increased before ART initiation (OR, 1.67 per year [95% CI, 0.98–2.83]; p=0.06), and nonsignificantly changed after initiation (OR, 0.33 per year [95% CI, 0.10–1.08]; p=0.07). Sexual risk behavior did not change over time for nonART users	Fair
Tun et al, 2004 <sup>99</sup> ; Vlahov et al, 1991 <sup>102</sup> ; Vlahov et al, 2001 <sup>103</sup>	United States Community outreach	190 HIV-infected injection drug users	Before-after	Proportion of participants who engaged in any sexual intercourse (66% to 72%), unprotected sex (23% to 26%), any drug injection (53% to 49%), and/or needle sharing (20% to 26%) remained stable or increased slightly from before to after ART initiation, not significant. At individual level, approximately 6% to 11% discontinued any one of the behaviors, approximately 7% to 14% initiated any one of the behaviors after starting ART, and approximately 80% continued same behaviors before and after ART	Fair

ART = antiretroviral therapy; OR = odds ratio.

**Table 4. Effect of Initiating Antiretroviral Therapy at Different CD4 Counts or Viral Load Thresholds on Progression to AIDS or Mortality**

Author, year or study name	Number of patients	Duration of followup	Comparison groups (CD4 count)	Mortality	Progression to AIDS or AIDS events	Mortality or progression to AIDS or AIDS events
<b>Randomized Controlled Trials</b>						
Cohen et al, 2011 <sup>109</sup>	n=1,763 serodiscordant couples	42 months	Delayed treatment: Initiation after 2 consecutive measures of CD4 count $\leq 0.250 \times 10^9$ cells/mL or at onset of AIDS-related illness (n=877)  Early treatment: Immediate initiation of ART at CD4 count of $0.350-0.550 \times 10^9$ cells/mL (n=886)	Delayed treatment, 13/877 (2%) vs. early treatment, 10/886 (1%); HR, 1.3 (95% CI, 0.57 to 3.0)	<u>Extrapulmonary tuberculosis</u> Delayed treatment, 17/877 (2%) vs. early treatment, 3/886 (0.3%); RR, 5.7 (CI, 1.7 to 20)  <u>Pulmonary tuberculosis</u> Delayed treatment, 15/877 (2%) vs. early treatment, 13/886 (2%); RR, 1.2 (CI, 0.56 to 2.4)	Delayed treatment, 65/877 (7%) vs. early treatment, 40/886 (5%); adjusted HR, 1.7 (CI, 1.1 to 2.5)
Severe et al, 2010 <sup>130</sup>	n=816	21 months	Standard treatment (n=408): Same intervention as early treatment group, started when CD4 count $\leq 0.200 \times 10^9$ cells/L  Early treatment (n=408): Started at CD4 count of $0.201-0.350 \times 10^9$ cells/L; lamivudine 150 mg + zidovudine 300 mg bid, efavirenz 600 mg qd	Standard treatment, 23/408 (6%) vs. early treatment, 6/408 (2%); unadjusted HR, 4 (95% CI, 1.6 to 9.8)	<u>Tuberculosis</u> Standard treatment, 36/408 (9%) vs. early treatment, 18/408 (4%); unadjusted HR, 2 (95% CI, 1.2 to 3.6)	Not reported
SMART Study Group, 2008 <sup>131</sup>  Other publication: SMART Study Group, 2006 <sup>138</sup>	n=477 (249 ART-naive)	18 months	Intermittent ART/drug conservation group: CD4 count $< 0.250 \times 10^9$ cells/L or CD4 percentage $< 15\%$ or symptomatic (n=131 ART-naive)  Continuous ART/viral suppression group: CD4 count $> 0.350 \times 10^9$ cells/L (n=118 ART-naive)	Not reported	Drug conservation vs. continuous ART (fatal and nonfatal AIDS events): 3/131 (2/100 person-years) vs. 1/118 (0.5/100 person-years); HR, 4.1; p=0.22	Drug conservation vs. continuous ART: 4/131 (2.7/100 person-years) vs. 1/118 (0.5/100 person-years); HR, 5.3; p=0.13



**Table 4. Effect of Initiating Antiretroviral Therapy at Different CD4 Counts or Viral Load Thresholds on Progression to AIDS or Mortality**

Author, year or study name	Number of patients	Duration of followup	Comparison groups (CD4 count)	Mortality	Progression to AIDS or AIDS events	Mortality or progression to AIDS or AIDS events
<b>Cohort Studies</b>						
HIV-CAUSAL Collaboration, 2011 <sup>133</sup>  Other publication: HIV-CAUSAL Collaboration, 2010 <sup>134</sup>	12 cohorts n=20,971 (restricted to patients with CD4 counts >0.500 x 10 <sup>9</sup> cells/L at baseline)	Mean 1 year	0.200 x 10 <sup>9</sup> (n=8,066*) 0.250 x 10 <sup>9</sup> (n=8,078) 0.300 x 10 <sup>9</sup> (n=8,101) 0.350 x 10 <sup>9</sup> (n=8,144) 0.400 x 10 <sup>9</sup> (n=8,201) 0.450 x 10 <sup>9</sup> (n=8,281) 0.500 x 10 <sup>9</sup> (n=8,392)  *Patient-level data may cross CD4 thresholds	<u>Initiation of ART at CD4 count of 0.500 x 10<sup>9</sup> cells/L (n=65/8392) vs.:</u> 0.200 x 10 <sup>9</sup> (n=99/8066): HR, 0.83 (CI, 0.68 to 1.03) 0.250 x 10 <sup>9</sup> (n=95/8078): HR, 0.92 (CI, 0.78 to 1.09) 0.300 x 10 <sup>9</sup> (n=97/8101): HR, 0.99 (CI, 0.84 to 1.18) 0.350 x 10 <sup>9</sup> (n=94/8144): HR, 0.99 (CI, 0.82 to 1.19) 0.400 x 10 <sup>9</sup> (n=89/8201): HR, 0.95 (CI, 0.79 to 1.16) 0.450 x 10 <sup>9</sup> (n=81/8281): HR, 0.97 (CI, 0.88 to 1.09)  <u>Initiation of ART at CD4 count of 0.350 x 10<sup>9</sup> cells/L (n=94/8144) vs.:</u> 0.200 x 10 <sup>9</sup> (n=99/8066): HR, 0.85 (CI, 0.68 to 1.05) 0.250 x 10 <sup>9</sup> (n=95/8078): HR, 0.93 (CI, 0.75 to 1.16) 0.300 x 10 <sup>9</sup> (n=97/8101): HR, 1.01 (CI, 0.79 to 1.28) 0.400 x 10 <sup>9</sup> (n=89/8201): HR, 0.97 (CI, 0.85 to 1.10) 0.450 x 10 <sup>9</sup> (n=81/8281): HR, 0.99 (CI, 0.79 to 1.22) 0.500 x 10 <sup>9</sup> (n=65/8392): HR, 1.01 (CI, 0.74 to 1.41)	Not reported	<u>Initiation of ART at CD4 count of 0.500 x 10<sup>9</sup> cells/L (n=158/8392) vs.:</u> 0.200 x 10 <sup>9</sup> (n=330/8066): HR, 0.53 (CI, 0.47 to 0.60) 0.250 x 10 <sup>9</sup> (n=329/8078): HR, 0.60 (CI, 0.54 to 0.67) 0.300 x 10 <sup>9</sup> (n=317/8101): HR, 0.68 (CI, 0.61 to 0.75) 0.350 x 10 <sup>9</sup> (n=296/8144): HR, 0.72 (CI, 0.64 to 0.81) 0.400 x 10 <sup>9</sup> (n=256/8201): HR, 0.78 (CI, 0.68 to 0.87) 0.450 x 10 <sup>9</sup> (n=209/8281): HR, 0.88 (CI, 0.82 to 0.93)  <u>Initiation of ART at CD4 count of 0.350 x 10<sup>9</sup> cells/L (n=296/8144) vs.:</u> 0.200 x 10 <sup>9</sup> (n=330/8066): HR, 0.73 (CI, 0.64 to 0.83) 0.250 x 10 <sup>9</sup> (n=329/8078): HR, 0.83 (CI, 0.72 to 0.95) 0.300 x 10 <sup>9</sup> (n=317/8101): HR, 0.93 (CI, 0.81 to 1.09) 0.400 x 10 <sup>9</sup> (n=256/8201): HR, 1.06 (CI, 0.99 to 1.16) 0.450 x 10 <sup>9</sup> (n=209/8281): HR, 1.20 (CI, 1.05 to 1.39) 0.500 x 10 <sup>9</sup> (n=158/8392): HR, 1.39 (CI, 1.14 to 1.69)
HIV-CAUSAL Collaboration, 2010 <sup>134</sup>  Other publication: HIV-CAUSAL Collaboration, 2011 <sup>133</sup>	12 cohorts n=62,760	Mean 3 years	<0.100 x 10 <sup>9</sup> (n=5,319) 0.100 to <0.200 x 10 <sup>9</sup> (n=6,521) 0.200 to <0.350 x 10 <sup>9</sup> (n=14,886) 0.350 to <0.500 x 10 <sup>9</sup> (n=15,360) ≥0.500 x 10 <sup>9</sup> (n=20,674)	<u>Initiation vs. no initiation of ART, by CD4 count:</u> <0.100 x 10 <sup>9</sup> : HR, 0.29 (CI, 0.22 to 0.37) 0.100 to <0.200 x 10 <sup>9</sup> : HR, 0.33 (CI, 0.25 to 0.44) 0.200 to <0.350 x 10 <sup>9</sup> : HR, 0.38 (CI, 0.28 to 0.52) 0.350 to <0.500 x 10 <sup>9</sup> : HR, 0.55 (CI, 0.41 to 0.74) ≥0.500 x 10 <sup>9</sup> : HR, 0.77 (CI, 0.58 to 1.01)	Not reported	Not reported
Kitahata et al, 2009 <sup>135</sup>	22 cohorts n=17,517	Mean 3 years	0.351 to 0.500 x 10 <sup>9</sup> Early therapy (n=2,084) Deferred therapy (n=6,278)  >0.500 x 10 <sup>9</sup> Early therapy (n=2,220) Deferred therapy (n=6,936)	Initiation of ART at CD4 count 0.351 to 0.500 x 10 <sup>9</sup> vs. ≤0.350 x 10 <sup>9</sup> : adjusted RR, 0.61 (CI, 0.46 to 0.83)  Initiation of ART at CD4 count >0.500 x 10 <sup>9</sup> vs. ≤0.500 x 10 <sup>9</sup> : adjusted RR, 0.54 (CI, 0.35 to 0.83)	Not reported	Not reported
May et al, 2007 <sup>136</sup>  Other publications: Lanoy et al, 2009 <sup>139</sup> Moore et al, 2009 <sup>140</sup>	12 cohorts n=20,379	Mean 3 years	<0.025 x 10 <sup>9</sup> (n=2,034) 0.025 to 0.049 x 10 <sup>9</sup> (n=1,295) 0.050 to 0.099 x 10 <sup>9</sup> (n=2,059) 0.100 to 0.199 x 10 <sup>9</sup> (n=3,782) 0.200 to 0.349 x 10 <sup>9</sup> (n=5,550) ≥0.350 x 10 <sup>9</sup> (n=5,659)	<u>Initiation of ART at varying CD4 counts vs. &lt;0.025 x 10<sup>9</sup> cells/L:</u> 0.025 to 0.049 x 10 <sup>9</sup> : 111/1295 vs. 222/2034; HR, 0.82 (CI, 0.66 to 1.04) 0.050 to 0.099 x 10 <sup>9</sup> : 162/2059 vs. 222/2034; HR, 0.77 (CI, 0.63 to 0.95) 0.100 to 0.199 x 10 <sup>9</sup> : 202/3782 vs. 222/2034; HR, 0.67 (CI, 0.55 to 0.82) 0.200 to 0.349 x 10 <sup>9</sup> : 178/5550 vs. 222/2034; HR, 0.48 (CI, 0.39 to 0.60) ≥0.350 x 10 <sup>9</sup> : 130/5659 vs. 222/2034; HR, 0.34 (CI, 0.27 to 0.44)	Not reported	<u>Initiation of ART at varying CD4 counts vs. &lt;0.025 x 10<sup>9</sup> cells/L:</u> 0.025 to 0.049 x 10 <sup>9</sup> : 277/1295 vs. 519/2034; HR, 0.85 (CI, 0.73 to 0.98) 0.050 to 0.099 x 10 <sup>9</sup> : 408/2059 vs. 519/2034; HR, 0.76 (CI, 0.66 to 0.87) 0.100 to 0.199 x 10 <sup>9</sup> : 445/3782 vs. 519/2034; HR, 0.49 (CI, 0.43 to 0.56) 0.200 to 0.349 x 10 <sup>9</sup> : 361/5550 vs. 519/2034; HR, 0.29 (CI, 0.25 to 0.33) ≥0.350 x 10 <sup>9</sup> : 298/5659 vs. 519/2034; HR, 0.23 (CI, 0.19 to 0.27)

**Table 4. Effect of Initiating Antiretroviral Therapy at Different CD4 Counts or Viral Load Thresholds on Progression to AIDS or Mortality**

Author, year or study name	Number of patients	Duration of followup	Comparison groups (CD4 count)	Mortality	Progression to AIDS or AIDS events	Mortality or progression to AIDS or AIDS events
When to Start Consortium, 2009 <sup>137</sup>	18 cohorts n=45,691 (24,444 received ART)	Mean 3 years	CD4 count: <0.051 x 10 <sup>9</sup> (n=2,594) 0.051 to 0.150 x 10 <sup>9</sup> (n=4,638) 0.151 to 0.250 x 10 <sup>9</sup> (n=6,406) 0.251 to 0.350 x 10 <sup>9</sup> (n=5,753) 0.351 to 0.400 x 10 <sup>9</sup> (n=3,260) 0.451 to 0.500 x 10 <sup>9</sup> (n=1,793)	Initiation of ART at varying CD4 counts vs. 0.351 to 0.400 x 10 <sup>9</sup> cells/L: 0.451 to 550 x 10 <sup>9</sup> : HR, 0.93 (CI, 0.6 to 1.4) 0.251 to 0.350 x 10 <sup>9</sup> : HR, 0.83 (CI, 0.59 to 1.25) 0.151 to 0.250 x 10 <sup>9</sup> : HR, 0.67 (CI, 0.51 to 0.99)	Not reported	Initiation of ART at varying CD4 counts vs. 0.351 to 0.450 x 10 <sup>9</sup> cells/L: 0.451 to 550 x 10 <sup>9</sup> : HR, 0.90 (CI, 0.76 to 1.29) 0.251 to 0.350 x 10 <sup>9</sup> : HR, 0.74 (CI, 0.59 to 0.95) 0.151 to 0.250 x 10 <sup>9</sup> : HR, 0.45 (CI, 0.37 to 0.53)
Writing Committee for the CASCADE Collaboration, 2011 <sup>132</sup>	23 cohorts n=9,455	Median 5 years	Unique individuals (numbers overlap): 0 to 0.049 x 10 <sup>9</sup> (n=183) 0.050 to 0.199 x 10 <sup>9</sup> (n=1,521) 0.200 to 0.349 x 10 <sup>9</sup> (n=4,459) 0.350 to 0.499 x 10 <sup>9</sup> (n=5,527) 0.500 to 0.799 x 10 <sup>9</sup> (n=5,162)	ART vs. no ART initiation during the index month, by CD4 count: 0 to 0.049 x 10 <sup>9</sup> : HR, 0.37 (CI, 0.14 to 0.95); RD, -18.2 (CI, -32 to -4.4) 0.050 to 0.199 x 10 <sup>9</sup> : HR, 0.55 (CI, 0.28 to 1.07); RD, -7.2 (CI, -10.1 to -4.4) 0.200 to 0.349 x 10 <sup>9</sup> L: HR, 0.71 (CI, 0.44 to 1.15); RD, -1.4 (CI, -3.0 to 0.3) 0.350 to 0.499 x 10 <sup>9</sup> : HR, 0.51 (CI, 0.33 to 0.80); RD, -1.4 (CI, -2.2 to -0.6) 0.500 to 0.799 x 10 <sup>9</sup> : HR, 1.02 (CI, 0.49 to 2.12); RD, -0.4 (CI, -2 to 1.2)	Not reported	ART vs. no ART initiation during index month, by CD4 count: 0 to 0.049 x 10 <sup>9</sup> : HR, 0.32 (CI, 0.17 to 0.59); RD, -30 (CI, -45.1 to -15) 0.050 to 0.199 x 10 <sup>9</sup> : HR, 0.48 (CI, 0.31 to 0.74); RD, -15 (CI, -19.7 to -10.3) 0.200 to 0.349 x 10 <sup>9</sup> : HR, 0.59 (CI, 0.43 to 0.81); RD, -4.8 (CI, -7 to -2.6) 0.350 to 0.499 x 10 <sup>9</sup> : HR, 0.75 (CI, 0.49 to 1.14); RD, -2.9 (CI, -5 to -0.9) 0.500 to 0.799 x 10 <sup>9</sup> : HR, 1.10 (CI, 0.67 to 1.79); RD, 0.3 (CI, -3.7 to 4.2)

ART = antiretroviral therapy; HR = hazard ratio; RD = risk difference; RR = relative risk.

**Table 5. Cardiovascular Events and Antiretroviral Therapy Use**

Author, Year Title	Duration of followup	Population characteristics	Interventions	Adjusted variables for statistical analysis	Myocardial infarction	Other cardiovascular events/composite outcomes
Bedimo et al, 2011 <sup>145</sup>	Median 4 years	n=19,424 Median age, 46 years 98% male 29% smokers 13% diabetes 38% hypertension 26% hypercholesterolemia 8% chronic kidney disease 32% HCV infection	Any ART (n=14,063)	Age, diabetes, hypertension, hypercholesterolemia, smoking	<u>MI, cumulative exposure (adjusted HR [95% CI])</u> Abacavir: 1.18 (0.92 to 1.5; p=0.19) Other NRTIs: 0.99 (0.87 to 1.11; p=0.87) Mono- or dual-therapy ART: 1.29 (1.10 to 1.52; p=0.002)	Not reported
DAD Study Group, 2010 <sup>144</sup>	Median 6 years	n=33,308 Median age, 44 years 26% female Race not reported Framingham risk, total population: 53% low risk 15% moderate risk 4% high risk Framingham risk, patients with MI: 26% low risk 30% moderate risk 18% high risk Framingham risk, patients without MI: 54% low risk 15% moderate risk 4% high risk	Protease inhibitors: Nelfinavir (n=10,370) Indinavir (n=11,985) Lopinavir-ritonavir (n=9,995) Saquinavir (n=8,070) NRTIs: Zidovudine (n=25,754) Didanosine (n=13,851) Zalcitabine (n=4,951) Stavudine (n=16,840) Lamivudine (n=28,835) Abacavir (n=12,511) Tenofovir (n=13,100) NNRTIs: Nevirapine (n=12,194) Efavirenz (n=13,522)	Age, sex, HIV transmission group, race, calendar year, cohort, smoking, family history of CVD, previous CV event, BMI, exposure to other ART	<u>Cumulative PI use (adjusted relative rate [95% CI])</u> Nelfinavir: 1.04 (0.98 to 1.11) Indinavir: 1.12 (1.07 to 1.18) Lopinavir-ritonavir: 1.13 (1.05 to 1.21) Saquinavir: 1.04 (0.98 to 1.11) <u>Per year of PI exposure (adjusted relative rate [95% CI])</u> Indinavir: 1.11 (1.05 to 1.18) Indinavir + ritonavir: 1.18 (1.07 to 1.30) Saquinavir: 1.07 (0.97 to 1.20) Saquinavir + ritonavir: 1.06 (0.97 to 1.14) <u>Cumulative NRTI use (adjusted relative rate [95% CI])</u> Zidovudine: not significant (data not reported) Didanosine: 1.41 (1.09 to 1.82) Zalcitabine: not significant (data not reported) Stavudine: not significant (data not reported) Lamivudine: not significant (data not reported) Abacavir: 1.07 (1.00 to 1.14) Tenofovir: 1.04 (0.91 to 1.18) <u>Recent NRTI use (adjusted relative rate [95% CI])</u> Abacavir: 1.7 (1.17 to 2.47) Tenofovir: 1.14 (0.85 to 1.53) <u>Cumulative NNRTI use (adjusted relative rate [95% CI])</u> Nevirapine: 0.97 (0.92 to 1.03) Efavirenz: 1.02 (0.96 to 1.08)	Not reported
DAD Study Group, 2008 <sup>143</sup>	Median 5 years	n=33,347 Mean age, 43 years 26% female Framingham risk, patients with MI: 22% (113/517) low risk 26% (134/517) moderate risk 23% (120/517) high risk 29% (150/517) unknown risk	NRTIs (n not reported): Zidovudine Didanosine Stavudine Lamivudine Abacavir	Age, sex, risk group, race, cohort, BMI, family history of CVD, smoking, previous CV event, year, cumulative exposure to other ART	<u>Cumulative exposure (adjusted relative rate [95% CI])</u> Zidovudine: 1.04 (0.99 to 1.09; p=0.15) Didanosine: 1.00 (0.93 to 1.07; p=0.91) Stavudine: 1.02 (0.95 to 1.09; p=0.6) Lamivudine: 0.99 (0.93 to 1.06; p=0.8) Abacavir: 1.00 (0.92 to 1.08; p=0.91) <u>Recent exposure</u> Zidovudine: 1.22 (0.82 to 1.81) Didanosine: 1.53 (1.10 to 2.13) Stavudine: 1.22 (0.84 to 1.77) Lamivudine: 1.69 (1.02 to 2.8) Abacavir: 1.94 (1.48 to 2.55) <u>Past exposure</u> Zidovudine: 1.29 (0.89 to 1.85) Didanosine: 1.08 (0.84 to 1.39) Stavudine: 1.24 (0.93 to 1.66) Lamivudine: 1.45 (0.88 to 2.4) Abacavir: 1.29 (0.94 to 1.77)	<u>MI, CV death, or invasive CV procedure, cumulative exposure</u> Zidovudine: 1.04 (1.00 to 1.08) Didanosine: 0.99 (0.94 to 1.05) Stavudine: 1.04 (0.99 to 1.10) Lamivudine: 1.01 (0.96 to 1.06) Abacavir: 1.03 (0.96 to 1.10) <u>MI, CV death, or invasive CV procedure, any recent exposure</u> Zidovudine: 0.98 (0.79 to 1.21) Didanosine: 1.40 (1.11 to 1.77) Stavudine: 0.99 (0.78 to 1.25) Lamivudine: 1.15 (0.91 to 1.44) Abacavir: 1.63 (1.3 to 2.04)

**Table 5. Cardiovascular Events and Antiretroviral Therapy Use**

Author, Year Title	Duration of followup	Population characteristics	Interventions	Adjusted variables for statistical analysis	Myocardial infarction	Other cardiovascular events/composite outcomes
DAD Study Group, 2007 <sup>142</sup>  Other publication: Friis-Møller et al, 2003 <sup>141</sup>	Median 5 years	n=23,437 Median age, 39 years 24% female 61% current/former smokers 14% hypertension 42% dyslipidemia	Any ART use (n=21,921) Protease inhibitors (n=18,919) NNRTI (n=15,142)	Model 1: Age, sex, cohort, HIV transmission group, race, age, BMI, family history of CVD, smoking, previous CV event, calendar year Model 2: All from Model 1 plus total cholesterol, HDL, hypertension, diabetes	<u>ART use (adjusted relative rate [95% CI])</u> Incidence: 97 events/16805 person-years; 5.77/1000 person-years Model 1: 1.16 (1.09 to 1.23) <u>PI use (adjusted relative rate [95% CI])</u> Model 1: 1.16 (CI 1.10 to 1.23) Model 2: 1.10 (CI 1.04 to 1.18) Excluding patients exposed to NRTIs: 1.15 (CI 1.06 to 1.25) <u>NRTI use (adjusted relative rate, 95% CI)</u> Model 1: 1.05 (0.98 to 1.13) Model 2: 1.00 (0.93 to 1.09) Excluding patients exposed to PIs: 0.94 (0.74 to 1.19)	Not reported
Danish HIV Cohort Study, Obel et al, 2010 <sup>146</sup>  Other publication: Obel et al, 2008 <sup>148</sup> Lohse et al, 2006 <sup>149</sup>	Mean 6 years	n=2,952 Median age, 39 years 76% male CV risk factors not reported	Triple NRTI regimen including abacavir NNRTI or PI regimen including abacavir Specific drugs: Abacavir (n=1,761) Zidovudine (n=2,711) Lamivudine (n=2,867) Stavudine (n=1,031) Didanosine (n=813)	Age, gender, year of diagnosis, year of HAART initiation, CD4 count, viral load, race, injecting drug use, use of other antiretrovirals, comorbidities	<u>Abacavir use vs. nonuse</u> Any abacavir exposure: Incidence, 2.4/1000 (95% CI, 1.7 to 3.4) vs. 5.7/1000 (CI, 4.1 to 7.9); adjusted RR, 2.0 (CI, 1.1 to 3.6) Actual abacavir use: RR, 1.95 (CI, 1.05 to 3.6) Early abacavir use: RR, 2.37 (CI, 0.88 to 6.36) Abacavir as part of triple NRTI: RR, 1.91 (CI, 0.88 to 4.17) Abacavir with NNTRI or PI: RR, 2.06 (CI, 1.06 to 4.01) Abacavir initiated within 2 years of ART: RR, 1.77 (CI, 0.82 to 3.82) Abacavir initiated >2 years after starting ART: RR, 2.66 (CI, 1.31 to 5.39)	Not reported
Ribaudo et al, 2011 <sup>147</sup>	Median 3 years	n=5,056 (1,122 with 6-year data) Median age, 37 years 18% female 40% white 36% black 21% Hispanic 10% prior IV drug user 15% 2 or more CVD risk factors 5% CVD 10-year risk score ≥10	Abacavir (n=1,704) No abacavir (n=3,352)	Age, sex, race, CVD risk factors, smoking, family history of CVD	<u>Abacavir use vs. nonuse (adjusted HR [95% CI])</u> 1 year: 0.7 (0.2 to 2.6) 6 years: 0.6 (0.3 to 1.4)	<u>Serious CVD events, abacavir use vs. nonuse (adjusted HR [95% CI])</u> 1 year: 1.1 (0.5 to 2.1) 6 years: 0.9 (0.5 to 1.3)

ART = antiretroviral therapy; BMI = body mass index; CV = cardiovascular; CVD = cardiovascular disease; DAD = Data Collection on Adverse Events of Anti-HIV Drugs; HCV = hepatitis C virus; HDL = high-density lipoprotein; HR = hazard ratio; IV = intravenous; MI = myocardial infarction; NNRTI = nonnucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; RR = relative risk.

**Table 6. HIV Transmission by Viral Load\***

Study, Year, Country	Study design	Sample size	Transmission frequency/rate		Viral load	p-Value	Population
Donnell et al, 2010 <sup>110</sup> 7 African countries	Cohort	3408 HIV-discordant couples	11/1676 P-Y	656	<10,000	NR	HIV and HSV-2 with heterosexual transmission
			17/1300 P-Y	1.308	10,000–49,999	NR	
			66/1491 P-Y	4.427	≥50,000	NR	
Fideli et al, 2001 <sup>155</sup> Zambia	Case-control	109 transmitters, 208 nontransmitting controls	8/56	0.143	<10,000	NR	Heterosexual
			38/122	0.311	10,000–99,999	NR	
			58/133	0.436	≥100,000	NR	
			Median viral load for transmitters: 123,507			<0.001	
			Median viral load nontransmitters: 51,310				
Fiore et al, 1997 <sup>150</sup> Italy	Uncertain	14 couples in which male is HIV+	1/2	0.500	Not detectable	0.0039	IDU with heterosexual transmission
			0/3	0.000	<10,000		
			1/4	0.250	10,001–100,000		
			5/5	0.100	>100,000		
			Rate ratio in univariate analysis: 2.32 (95% CI, 1.79–3.01)		0.0001		
Rate ratio in multivariate analysis: 1.61 (95% CI, 1.15–2.25)		0.005					
Fisher et al, 2010 <sup>156</sup> United Kingdom	Longitudinal study	1,144 HIV+ individuals	2/3176 P-Y	0.063	<50	0.0005	MSM
			2/482 P-Y	0.415	50–1,000	0.22	
			5/427 P-Y	1.171	1001–10,000	NR	
			15/941 P-Y	1.594	10,001–100,000	0.55	
			14/611 P-Y	2.291	>100,000	0.20	
			Rate ratio in univariate analysis: 2.32 (95% CI, 1.79–3.01)		0.0001		
			Rate ratio in multivariate analysis: 1.61 (95% CI, 1.15–2.25)		0.005		
Gray et al, 2001 <sup>20</sup> Uganda	Cohort	174 monogamous, HIV-discordant couples	1/43	0.023	<1,700	NR	Heterosexual
			11/45	0.244	1,700–12,499	NR	
			11/42	0.262	12,500–38,499	NR	
			15/44	0.341	≥38,500	NR	
			Transmission probabilities increased from 0.0001 per sex act at viral loads <1700 to 0.0023 per sex act at 38,500 copies		0.02		
Operskalski et al, 1997 <sup>106</sup> United States	Cohort	18 HIV+ persons with 19 long-term sexual partners	0/6	0.000	<5,623	NR	Transfusion recipients with heterosexual transmission
			5/12	0.417	≥5,623	NR	
			Mean viral load for transmitters: 4.3 log <sub>10</sub>		0.05		
		Mean viral load for nontransmitters: 3.6 log <sub>10</sub>					
Pedraza et al, 1999 <sup>152</sup> Spain	Cohort	38 highly exposed couples with at least one member HIV+	10/38	0.26	Median viral load in transmitters: 21,139 Median viral load in nontransmitters: 5,484	0.03	Heterosexual transmission with frequent unprotected sex
Ragni et al, 1998 <sup>153</sup> United States	Cross-sectional	39 couples, all males HIV+	0/1	0.000	<1000	NS	Hemophiliacs-heterosexual transmission
			1/15	0.067	1,000–9,999	NS	
			1/17	0.059	10,000–99,999	NS	
			3/6	0.500	>100,000	0.027	
			In multivariate analysis, each log <sub>10</sub> increment of HIV RNA in the man was associated with an 81% increased rate of HIV transmission to his wife (OR, 1.81 [95% CI, 1.33–2.48])		<0.05		
Tovanabutra et al, 2002 <sup>154</sup> Thailand	Cross-sectional	493 married couples, all males HIV+	0/3	0.000	<500	0.047	Heterosexual
			1/14	0.071	500–1,580		
			15/39	0.385	1,581–4,999		
			32/95	0.337	5,000–15,810		
			70/141	0.496	15,811–49,999		
			67/138	0.486	50,000–158,110		
			30/58	0.517	158,114–499,999		
			3/5	0.600	500,000+		
			In multivariate analysis, each log <sub>10</sub> increment of HIV RNA in the man was associated with an 81% increased rate of HIV transmission to his wife (OR, 1.81 [95% CI, 1.33–2.48])		<0.05		

\*Studies from prior and current USPSTF reports.

HSV-2 = herpes simplex virus 2; IDU = intravenous drug users; MSM = men who have sex with men; NR = not reported; NS = not significant; OR = odds ratio; P-Y = person-years.

**Table 7. Summary of Evidence**

Main findings from 2005 USPSTF review	Number and type of studies identified for update <i>Overall quality*</i>	Limitations	Consistency	Applicability	Summary of findings
<b>KQ 1. What are the benefits of universal or targeted HIV screening vs. no screening or each other in asymptomatic, nonpregnant adolescents and adults on disease transmission, morbidity, mortality, and quality of life?</b>					
No evidence	No studies	No studies	No studies	No studies	No study directly compared clinical outcomes between adults and adolescents screened and not screened for HIV infection.
<b>KQ 2a. What is the yield (number of new diagnoses) of HIV screening at different intervals in nonpregnant adolescents and adults?</b>					
No evidence	No studies	No studies	No studies	No studies	No study evaluated the yield of repeat HIV screening compared with one-time screening.†
<b>KQ 2b. What are the effects of universal vs. targeted HIV screening on testing acceptability and uptake in nonpregnant adolescents and adults?</b>					
No evidence	1 cohort study and 2 uncontrolled screening series  <i>Overall quality: Poor</i>	No study of universal vs. targeted screening reported testing acceptability and uptake	Some inconsistency	No major issues	No study directly compared the acceptability of universal vs. targeted HIV screening strategies. One fair-quality, nonrandomized study of emergency department patients found universal, opt-out rapid screening associated with higher likelihood of testing compared with physician-directed, targeted rapid screening (25% vs. 0.8%; RR, 30 [95% CI, 26 to 34]), but testing uptake (the proportion of patients offered testing who accepted) was not reported. In 2 uncontrolled implementation studies of universal HIV screening conducted in primary care settings, 35% (standard test) and 60% (rapid test) of those offered screening underwent screening.
<b>KQ 2c. What is the effect of opt-out vs. opt-in testing or different pre- or post-test HIV counseling methods on screening uptake or rates of followup and linkage to care in nonpregnant adolescents and adults?</b>					
1 uncontrolled implementation study found 35% of patients with HIV infection identified through routine screening in an urgent care setting entered care within 4 months	2 cohort studies  <i>Overall quality: Poor</i>	No RCTs; no data on rates of followup and linkage to care; no evidence on different counseling methods	Some inconsistency	Studies conducted in emergency department setting	One cohort study found an opt-out approach associated with higher likelihood of testing compared with an opt-in approach (13% vs. 7%; RR, 2.1 [95% CI, 1.9 to 2.4]), but patients who underwent opt-out testing were more likely to report that they had not been informed of HIV testing. One other study found opt-in testing associated with lower testing uptake compared with opt-out testing, but results may have been confounded by differences in who offered the testing. No study compared effects of different pre- or post-test HIV counseling methods on screening uptake or rates of followup and linkage to care.
<b>KQ 2d. What are the adverse effects (including false-positive results and anxiety) of rapid vs. standard HIV testing in nonpregnant adolescents and adults not known to be at higher risk?</b>					
Good evidence that standard and rapid HIV testing with confirmatory Western blot are associated with high sensitivities and specificities	5 uncontrolled screening series‡  <i>Overall quality: Poor</i>	No comparative studies	Moderate inconsistency	Prevalence of HIV infection varied	In 5 large studies of rapid testing (without a comparison with standard testing), positive predictive value was 94% in 1 study of a higher-prevalence (1.1%) setting, and varied widely (16% to 83%) in 4 studies of lower-prevalence (0.2% to 0.4%) settings. No study evaluated psychological or other harms associated with rapid vs. standard HIV testing.
<b>KQ 2e. What are the effects of universal vs. targeted HIV screening on CD4 counts at the time of diagnosis?</b>					
No evidence	2 cohort studies  <i>Overall quality: Poor</i>	No RCTs; potential confounding based on who was offering testing	Consistent	Studies conducted in emergency department settings	One fair-quality study found universal testing associated with a higher median CD4 count and lower likelihood of CD4 count <0.200 x 10 <sup>9</sup> cells/L at the time of diagnosis compared with targeted HIV screening, but these differences were not statistically significant. No other studies directly compared effects of universal vs. targeted HIV screening, though epidemiologic data indicate temporal trends suggesting earlier diagnosis since the 2006 CDC recommendation on routine HIV screening was issued.

**Table 7. Summary of Evidence**

Main findings from 2005 USPSTF review	Number and type of studies identified for update <i>Overall quality*</i>	Limitations	Consistency	Applicability	Summary of findings
<b>KQ 2f. What are the effects of universal vs. targeted HIV screening on rates of followup and linkage to care in nonpregnant adolescents and adults who screen positive?</b>					
2 uncontrolled studies found 35% to 70% of HIV-positive patients identified through universal screening in urgent care centers were linked to care.	1 cohort study and 2 uncontrolled screening series  <i>Overall quality: Poor</i>	Small numbers of patients diagnosed with HIV infection, only 1 controlled study	Moderate	Cohort study was conducted in an emergency department setting	The only study that directly compared universal with targeted testing reported very high rates of followup (defined as attending at least 1 HIV clinic visit) with either strategy (97% to 100%). Two other observational studies reported rates of followup or linkage to care of 75% to 82% following a new HIV diagnosis found during universal testing.
<b>KQ 3a. To what extent does knowledge of HIV-positive status affect behaviors associated with increased risk for HIV transmission in nonpregnant adolescent and adults?</b>					
Systematic reviews found knowledge of HIV status associated with reductions in self-reported sexual risk behaviors, but the studies included in the systematic reviews had methodological shortcomings.	4 before-after or cross-sectional studies  <i>Overall quality: Fair</i>	Reliance on self-reported behaviors, sometimes based on retrospective recall	Consistent	2 studies focused on high-risk populations	Four before-after studies found knowledge of HIV-positive status associated with reduced risky behaviors.
<b>KQ 3b. To what extent does use of antiretroviral therapy affect behaviors associated with increased risk for HIV transmission in nonpregnant adolescent and adults?</b>					
1 meta-analysis found no association between use of HAART and increased likelihood of high-risk sexual behaviors, though some individual studies reported associations between HAART use and increased high-risk behaviors in some populations.	7 observational studies  <i>Overall quality: Fair</i>	Some studies did not adjust for confounders or had important baseline differences between groups	Some inconsistency	3 studies focused on high-risk populations	Seven observational studies found no clear association between antiretroviral use and increase in risky behaviors, with some studies showing decreased risky behaviors.
<b>KQ 4a. How effective is antiretroviral therapy in reducing transmission of HIV in nonpregnant adolescents and adults with chronic HIV infection?</b>					
No studies	1 systematic review (1 RCT and 7 observational studies)  <i>Overall quality: Good</i>	Only 1 RCT	Consistent	Some studies conducted in resource-poor settings	An RCT found immediate antiretroviral therapy in persons with a baseline CD4 count of 0.350 to 0.550 x 10 <sup>9</sup> cells/L associated with substantially reduced risk for transmission compared with delayed therapy (HR, 0.04 [95% CI, 0.01 to 0.27]). Observational studies were consistent with the RCT (pooled HR, 0.16 [95% CI, 0.07 to 0.35]).
<b>KQ 4b. How effective is behavioral counseling in reducing transmission of HIV in nonpregnant adolescents and adults with chronic HIV infection?</b>					
No RCTs or controlled observational studies	1 RCT and 1 before-after study  <i>Overall quality: Poor</i>	Underpowered to evaluate effects on transmission	Unable to determine	No major issues	Studies identified too few cases of new HIV infection to adequately evaluate effects of counseling interventions on transmission risk.
<b>KQ 4c. In asymptomatic, nonpregnant adolescents and adults with chronic HIV infection, what are the effects of initiating antiretroviral therapy at different CD4 counts or viral load thresholds on morbidity, mortality, and quality of life?</b>					
1 cohort study found initiation of HAART at CD4 counts >0.350 x 10 <sup>9</sup> cells/L associated with decreased risk for AIDS events and mortality compared with delayed initiation, but 3 others found no difference in risk	3 RCTs and 5 large collaborative cohort studies  <i>Overall quality: Good</i>	1 RCT reported a subgroup analysis, some overlap in patients evaluated in the cohort studies	Some inconsistency for CD4 counts >0.500 x 10 <sup>9</sup> cells/L	1 RCT evaluated CD4 count thresholds not applicable to U.S. practice in a resource-poor setting	One RCT and one subgroup analysis from an RCT found initiation of antiretroviral therapy at CD4 counts <0.250 x 10 <sup>9</sup> cells/L associated with substantially increased risk for death or AIDS events compared with initiation at CD4 counts >0.350 x 10 <sup>9</sup> cells/L. Five large observational studies also found initiation of antiretroviral therapy at CD4 counts of 0.350 to 0.500 x 10 <sup>9</sup> cells/L associated with decreased risk for mortality compared with deferred or no antiretroviral therapy. Four studies on initiation of antiretroviral therapy at CD4 counts >0.500 x 10 <sup>9</sup> cells/L did not consistently demonstrate clinical benefits.

**Table 7. Summary of Evidence**

Main findings from 2005 USPSTF review	Number and type of studies identified for update <i>Overall quality*</i>	Limitations	Consistency	Applicability	Summary of findings
<b>KQ 5. What are the longer-term harms associated with antiretroviral therapy in nonpregnant adolescents and adults with chronic HIV infection?</b>					
1 large cohort study found longer duration of exposure to HAART associated with increased risk of myocardial infarction (RR, 1.3 per year of exposure [95% CI, 1.1 to 1.4])	4 cohort studies (reported in 6 publications)  <i>Overall quality: Good</i>	No major limitations	Consistent	Duration of followup about 6 years	Additional followup from a large cohort study included in the prior USPSTF review found some protease inhibitors associated with increased risk for myocardial infarction (RR, 1.1 to 1.2 per year of exposure). Evidence on abacavir was mixed from four cohort studies, and there was no clear association between other antiretrovirals and increased risk for cardiovascular events.
<b>KQ 6a. To what extent are improvements in viremia associated with reductions in HIV transmission rates in nonpregnant adolescents and adults?</b>					
7 observational studies consistently found an association between lower individual viral load and lower risk for heterosexual transmission of HIV infection	6 observational studies  <i>Overall quality: Good</i>	No major limitations	Consistent	Some studies conducted in resource-poor settings	Observational studies consistently found a dose-dependent association between higher viral load and risk for transmission in various settings and populations.
<b>KQ 6b. To what extent are improvements in risky behaviors associated with reductions in HIV transmission rates in nonpregnant adolescents and adults?</b>					
2 systematic reviews of primarily heterosexual couples found consistent use of condoms associated with substantially lower (80% to 95%) risk of HIV transmission.	2 cohort studies  <i>Overall quality: Good</i>	No major limitations	Consistent	No study evaluated drug use behaviors; studies focused on condom use	Observational studies consistently found self-reported condom use associated with decreased risk for HIV transmission.

\* "Overall quality" is based on new evidence identified for this update plus previously reviewed evidence.

† Cost-effectiveness modeling studies are not included in this summary table.

‡ One RCT compared rapid versus standard testing, but it only identified one new infection.

CDC = Centers for Disease Control and Prevention; KQ = key question; RCT = randomized, controlled trial; USPSTF = U.S. Preventive Services Task Force.



## Appendix A1. Search Strategies

### All Key Questions

Database: EBM Reviews - Cochrane Database of Systematic Reviews

- 1 hiv.ti.
- 2 limit 1 to full systematic reviews
- 3 antiretroviral.mp. [mp=title, short title, abstract, full text, keywords, caption text]
- 4 haart.mp. [mp=title, short title, abstract, full text, keywords, caption text]
- 5 3 or 4
- 6 2 and 5
- 7 screen\$.mp. [mp=title, short title, abstract, full text, keywords, caption text]
- 8 2 and 7
- 9 test\$.mp. [mp=title, short title, abstract, full text, keywords, caption text]
- 10 2 and 9
- 11 6 or 8 or 10
- 12 limit 11 to last 8 years
- 13 pregnan\$.mp. [mp=title, short title, abstract, full text, keywords, caption text]
- 14 12 not 13

### Key Questions 1 and 2a-2f

Database: Ovid MEDLINE(R) without Revisions

- 1 exp AIDS Serodiagnosis/
- 2 exp HIV Seronegativity/
- 3 exp HIV Antigens/
- 4 exp HIV/
- 5 exp HIV Seroprevalence/
- 6 exp HIV Seropositivity/
- 7 exp HIV Antibodies/
- 8 or/2-7
- 9 exp Mass Screening/
- 10 8 and 9
- 11 1 or 10
- 12 (hiv adj1 screen\$.mp. [mp=protocol supplementary concept, rare disease supplementary concept, title, original title, abstract, name of substance word, subject heading word, unique identifier])
- 13 11 or 12
- 14 13 and (200406\$ or 200407\$ or 200408\$ or 200409\$ or 20041\$ or 2005\$ or 2006\$ or 2007\$ or 2008\$ or 2009\$ or 2010\$ or 2011\$.ed.
- 15 limit 14 to English language
- 16 limit 14 to abstracts
- 17 15 or 16
- 18 limit 17 to humans
- 19 universal.mp.
- 20 rapid.mp.
- 21 19 and 20
- 22 or/1-8
- 23 21 and 22
- 24 9 and 21

## Appendix A1. Search Strategies

- 25 23 or 24
- 26 18 or 25

Database: EBM Reviews - Cochrane Central Register of Controlled Trials

- 1 exp AIDS Serodiagnosis/
- 2 exp HIV Seronegativity/
- 3 exp HIV Antigens/
- 4 exp HIV/
- 5 exp HIV Seroprevalence/
- 6 exp HIV Seropositivity/
- 7 exp HIV Antibodies/
- 8 or/2-7
- 9 exp Mass Screening/
- 10 8 and 9
- 11 1 or 10
- 12 (hiv adj1 screen\$).mp. [mp=title, original title, abstract, mesh headings, heading words, keyword]
- 13 11 or 12
- 14 limit 13 to yr="2004 -Current"
- 15 Pregnancy/
- 16 14 not 15

### Key Questions 3a, 3b

Database: Ovid MEDLINE(R) without Revisions

- 1 HIV Seropositivity/
- 2 (hiv adj1 positive).mp. [mp=protocol supplementary concept, rare disease supplementary concept, title, original title, abstract, name of substance word, subject heading word, unique identifier]
- 3 1 or 2
- 4 exp Anti-HIV Agents/
- 5 exp Antiretroviral Therapy, Highly Active/
- 6 haart.mp.
- 7 5 or 6
- 8 or/3-5,7
- 9 Sexual Behavior/
- 10 Unsafe Sex/
- 11 Safe Sex/
- 12 Risk-Taking/
- 13 Needle Sharing/
- 14 or/9-13
- 15 8 and 14
- 16 Pregnancy/
- 17 15 not 16
- 18 limit 17 to English language
- 19 limit 17 to abstracts
- 20 18 or 19
- 21 limit 20 to humans

## Appendix A1. Search Strategies

Database: EBM Reviews - Cochrane Central Register of Controlled Trials

- 1 HIV Seropositivity/
- 2 (hiv adj1 positive).mp. [mp=title, original title, abstract, mesh headings, heading words, keyword]
- 3 1 or 2
- 4 exp Anti-HIV Agents/
- 5 exp Antiretroviral Therapy, Highly Active/
- 6 haart.mp.
- 7 5 or 6
- 8 or/3-5,7
- 9 Sexual Behavior/
- 10 Unsafe Sex/
- 11 Safe Sex/
- 12 Risk-Taking/
- 13 Needle Sharing/
- 14 or/9-13
- 15 8 and 14
- 16 Pregnancy/
- 17 15 not 16
- 18 limit 17 to yr="2004 -Current"

### Key Questions 4a, 4b

Database: Ovid MEDLINE(R) without Revisions

- 1 exp HIV Infections/dh, dt, pc, th [Diet Therapy, Drug Therapy, Prevention & Control, Therapy]
- 2 exp HIV Infections/tm [Transmission]
- 3 1 and 2
- 4 (hiv adj2 (transmission or transmit)).mp. [mp=protocol supplementary concept, rare disease supplementary concept, title, original title, abstract, name of substance word, subject heading word, unique identifier]
- 5 3 or 4
- 6 exp Anti-HIV Agents/tu [Therapeutic Use]
- 7 haart.mp. or Antiretroviral Therapy, Highly Active/
- 8 6 or 7
- 9 8 and (2 or 4)
- 10 Counseling/
- 11 Patient Education as Topic/
- 12 10 or 11
- 13 12 and (2 or 4)
- 14 5 or 9 or 13
- 15 Pregnancy/
- 16 14 not 15
- 17 limit 16 to English language
- 18 limit 16 to abstracts
- 19 17 or 18
- 20 limit 19 to ("all adult (19 plus years)" or "adolescent (13 to 18 years)")
- 21 limit 20 to yr="2004 - Current"

## Appendix A1. Search Strategies

Database: EBM Reviews - Cochrane Central Register of Controlled Trials

- 1 exp HIV Infections/dh, dt, pc, th [Diet Therapy, Drug Therapy, Prevention & Control, Therapy]
- 2 exp HIV Infections/tm [Transmission]
- 3 1 and 2
- 4 (hiv adj2 (transmission or transmit)).mp. [mp=title, original title, abstract, mesh headings, heading words, keyword]
- 5 3 or 4
- 6 exp Anti-HIV Agents/tu [Therapeutic Use]
- 7 haart.mp. or Antiretroviral Therapy, Highly Active/
- 8 6 or 7
- 9 8 and (2 or 4)
- 10 Counseling/
- 11 Patient Education as Topic/
- 12 10 or 11
- 13 12 and (2 or 4)
- 14 5 or 9 or 13
- 15 Pregnancy/
- 16 14 not 15
- 17 limit 16 to yr="2004 -Current"

### Key Question 4c

Database: Ovid MEDLINE(R) without Revisions

- 1 exp HIV Infections/dt, th [Drug Therapy, Therapy]
- 2 haart.mp. or Antiretroviral Therapy, Highly Active/
- 3 Anti-HIV Agents/ad, tu [Administration & Dosage, Therapeutic Use]
- 4 Anti-Retroviral Agents/ad, tu [Administration & Dosage, Therapeutic Use]
- 5 or/1-4
- 6 Viral Load/
- 7 CD4 Lymphocyte Count/
- 8 or/6-7
- 9 5 and 8
- 10 Drug Administration Schedule/
- 11 (treatment adj1 (tim\$ or administration)).mp. [mp=protocol supplementary concept, rare disease supplementary concept, title, original title, abstract, name of substance word, subject heading word, unique identifier]
- 12 10 or 11
- 13 9 and 12
- 14 Pregnancy/
- 15 13 not 14
- 16 limit 15 to ("all adult (19 plus years)" or "adolescent (13 to 18 years)")
- 17 limit 16 to English language
- 18 limit 16 to abstracts
- 19 17 or 18
- 20 limit 19 to yr="2004 - Current"

## Appendix A1. Search Strategies

Database: EBM Reviews - Cochrane Central Register of Controlled Trials

- 1 exp HIV Infections/dt, th [Drug Therapy, Therapy]
- 2 haart.mp. or Antiretroviral Therapy, Highly Active/
- 3 Anti-HIV Agents/ad, tu [Administration & Dosage, Therapeutic Use]
- 4 Anti-Retroviral Agents/ad, tu [Administration & Dosage, Therapeutic Use]
- 5 or/1-4
- 6 Viral Load/
- 7 CD4 Lymphocyte Count/
- 8 or/6-7
- 9 5 and 8
- 10 Drug Administration Schedule/
- 11 (treatment adj1 (tim\$ or administration)).mp. [mp=title, original title, abstract, mesh headings, heading words, keyword]
- 12 10 or 11
- 13 9 and 12
- 14 Pregnancy/
- 15 13 not 14
- 16 limit 15 to yr="2004 -Current"

### Key Question 4c Supplement

Database: Ovid MEDLINE(R) without Revisions

- 1 exp HIV Infections/dt, th [Drug Therapy, Therapy]
- 2 haart.mp. or Antiretroviral Therapy, Highly Active/
- 3 Anti-HIV Agents/ad, tu [Administration & Dosage, Therapeutic Use]
- 4 Anti-Retroviral Agents/ad, tu [Administration & Dosage, Therapeutic Use]
- 5 or/1-4
- 6 Viral Load/
- 7 CD4 Lymphocyte Count/
- 8 or/6-7
- 9 5 and 8
- 10 Drug Administration Schedule/
- 11 (treatment adj1 (tim\$ or administration)).mp. [mp=protocol supplementary concept, rare disease supplementary concept, title, original title, abstract, name of substance word, subject heading word, unique identifier]
- 12 10 or 11
- 13 9 and 12
- 14 Pregnancy/
- 15 13 not 14
- 16 limit 15 to ("all adult (19 plus years)" or "adolescent (13 to 18 years)")
- 17 limit 16 to English language
- 18 limit 16 to abstracts
- 19 17 or 18
- 20 (treatment adj5 (tim\$ or administration or initiation)).mp.
- 21 9 and 20
- 22 21 not 19
- 23 limit 22 to English language
- 24 23 not 14

## Appendix A1. Search Strategies

- 25 limit 24 to ("all adult (19 plus years)" or "adolescent (13 to 18 years)")
- 26 Prognosis/
- 27 9 and 26
- 28 27 not (19 or 22)
- 29 limit 28 to English language
- 30 limit 29 to ("all adult (19 plus years)" or "adolescent (13 to 18 years)")
- 31 25 or 30

### Key Question 5

Database: Ovid MEDLINE(R) without Revisions

- 1 haart.mp. or Antiretroviral Therapy, Highly Active/
- 2 (ae or co or de or mo).fs.
- 3 1 and 2
- 4 (harm\$ or safe\$ or adverse).mp. [mp=protocol supplementary concept, rare disease supplementary concept, title, original title, abstract, name of substance word, subject heading word, unique identifier]
- 5 1 and 4
- 6 3 or 5
- 7 Pregnancy/
- 8 6 not 7
- 9 limit 8 to ("all adult (19 plus years)" or "adolescent (13 to 18 years)")
- 10 limit 9 to English language
- 11 limit 9 to abstracts
- 12 10 or 11
- 13 limit 12 to yr="2004 - Current"
- 14 13 not (letter or editorial or case reports).pt.

Database: EBM Reviews - Cochrane Central Register of Controlled Trials

- 1 haart.mp. or Antiretroviral Therapy, Highly Active/
- 2 (ae or co or de or mo).fs.
- 3 1 and 2
- 4 (harm\$ or safe\$ or adverse).mp. [mp=title, original title, abstract, mesh headings, heading words, keyword]
- 5 1 and 4
- 6 3 or 5
- 7 Pregnancy/
- 8 6 not 7
- 9 limit 8 to yr="2004 -Current"

### Key Questions 6a, 6b

Database: Ovid MEDLINE(R) without Revisions

- 1 HIV Infections/tm [Transmission]
- 2 viremia.mp.
- 3 1 and 2
- 4 Risk-Taking/
- 5 Sexual Behavior/

## Appendix A1. Search Strategies

- 6 Unsafe Sex/
- 7 Safe Sex/
- 8 or/4-7
- 9 1 and 8
- 10 risk reduction behavior/
- 11 (risk\$ adj1 reduc\$).mp. [mp=protocol supplementary concept, rare disease supplementary concept, title, original title, abstract, name of substance word, subject heading word, unique identifier]
- 12 10 or 11
- 13 9 and 12
- 14 3 or 13
- 15 Pregnancy/
- 16 14 not 15
- 17 limit 16 to yr="2004 - Current"

### Database: EBM Reviews - Cochrane Central Register of Controlled Trials

- 1 HIV Infections/tm [Transmission]
- 2 viremia.mp.
- 3 1 and 2
- 4 Risk-Taking/
- 5 Sexual Behavior/
- 6 Unsafe Sex/
- 7 Safe Sex/
- 8 or/4-7
- 9 1 and 8
- 10 risk reduction behavior/
- 11 (risk\$ adj1 reduc\$).mp. [mp=title, original title, abstract, mesh headings, heading words, keyword]
- 12 10 or 11
- 13 9 and 12
- 14 3 or 13
- 15 Pregnancy/
- 16 14 not 15
- 17 limit 16 to yr="2004 -Current"

## Appendix A2. Inclusion and Exclusion Criteria per Key Question

	Include	Exclude
<b>All Key Questions (KQs)</b>		
Settings	Primary care or other settings generalizable to primary care (e.g., family planning clinics, school-based health clinics), other health care settings in which screening is commonly performed (e.g., emergency room or urgent care). Focus on studies conducted in the United States and other developed countries, unless studies are not available in those settings.	Developing countries, unless fair- or good-quality trials and studies in the United States are lacking
<b>KQ 1. What are the benefits of universal or targeted HIV screening vs. no screening or each other in asymptomatic, nonpregnant adolescents and adults on disease transmission, morbidity, mortality, and quality of life?</b>		
Populations	Asymptomatic adolescents and adults	Known HIV infection, on dialysis, post-transplant, occupational exposure
Interventions	Rapid or standard HIV testing	
Outcomes	Reduction in transmission rates of HIV; morbidity and mortality related to HIV infection and quality of life	
Comparisons	Universal or targeted HIV screening vs. no screening, or vs. one another	
Study designs	Randomized, controlled trials and controlled observational studies	Uncontrolled observational studies
<b>KQ 2a. What is the yield (number of new diagnoses) of HIV screening at different intervals in nonpregnant adolescents and adults?</b>		
Populations	Asymptomatic adolescents and adults	Known HIV infection, on dialysis, post-transplant, occupational exposure
Interventions	Rapid or standard HIV testing	
Outcomes	Number of positive test results	
Comparisons	Repeat HIV screening vs. one-time screening, or screening at one interval vs. another interval	
Study designs	Randomized, controlled trials and controlled observational studies	
<b>KQ 2b. What are the effects of universal vs. targeted HIV screening on testing acceptability and uptake in nonpregnant adolescents and adults?</b>		
Populations	Asymptomatic adolescents and adults	Known HIV infection, on dialysis, post-transplant, occupational exposure
Interventions	Rapid or standard HIV testing	
Outcomes	Testing acceptability and uptake	
Comparisons	Universal vs. targeted HIV screening	
Study designs	Any	
<b>KQ 2c. What is the effect of opt-out vs. opt-in testing or different pre- or post-test HIV counseling methods on screening uptake or rates of followup and linkage to care in nonpregnant adolescents and adults?</b>		
Populations	Asymptomatic adolescents and adults	Known HIV infection, on dialysis, post-transplant, occupational exposure
Interventions	Rapid or standard HIV testing	
Outcomes	Testing acceptability and uptake or rates of followup	
Comparisons	Opt-out vs. opt-in testing, or comparisons of different pre- or post-test HIV counseling methods	
Study designs	Any	
<b>KQ 2d. What are the adverse effects (including false-positive results and anxiety) of rapid vs. standard HIV testing in nonpregnant adolescents and adults not known to be at higher risk?</b>		
Populations	Asymptomatic adolescents and adults	High-risk; known HIV infection, on dialysis, post-transplant, occupational exposure
Interventions	Rapid or standard HIV testing	
Outcomes	False-positive results, anxiety, and effects of labeling; partner discord, abuse, or violence	
Comparisons	Rapid vs. standard HIV testing	
Study designs	Any	




## Appendix A2. Inclusion and Exclusion Criteria per Key Question

	Include	Exclude
<b>KQ 2e. What are the effects of universal vs. targeted HIV screening on CD4 counts at the time of diagnosis?</b>		
Populations	Asymptomatic adolescents and adults	Known HIV infection, on dialysis, post-transplant, occupational exposure
Interventions	Rapid or standard HIV testing	
Outcomes	CD4 count	
Comparisons	Universal or targeted HIV screening vs. no screening, or vs. one another	
Study designs	Randomized, controlled trials or controlled observational studies	
<b>KQ 2f. What are the effects of universal vs. targeted HIV screening on rates of followup and linkage to care in nonpregnant adolescents and adults who screen positive?</b>		
Populations	Asymptomatic adolescents and adults	Known HIV infection, on dialysis, post-transplant, occupational exposure
Interventions	Rapid or standard HIV testing	
Outcomes	Rates of followup and linkage to care	
Comparisons	Universal or targeted HIV screening	
Study designs	Randomized, controlled trials or controlled observational studies	
<b>KQ 3a. To what extent does knowledge of HIV-positive status affect behaviors associated with increased risk for HIV transmission in nonpregnant adolescent and adults?</b>		
Populations	Asymptomatic persons newly diagnosed with HIV infection	Already or previously taking antiretroviral therapy; acute HIV or subtypes
Comparisons	Knowledge of HIV-positive status vs. not aware	
Outcomes	Risky behaviors	
Study designs	Randomized, controlled trials or controlled observational studies	
<b>KQ 3b. To what extent does use of antiretroviral therapy affect behaviors associated with increased risk for HIV transmission in nonpregnant adolescent and adults?</b>		
Populations	Asymptomatic persons newly diagnosed with HIV infection	Already or previously taking antiretroviral therapy; acute HIV or subtypes
Comparisons	Use of antiretroviral therapy vs. no use of antiretroviral therapy	
Outcomes	Risky behaviors	
Study designs	Randomized, controlled trials or controlled observational studies	
<b>KQ 4a. How effective is antiretroviral therapy in reducing transmission of HIV in nonpregnant adolescents and adults with chronic HIV infection?</b>		
Populations	HIV-positive adolescents and adults	Acute HIV infection
Interventions	Use of antiretroviral therapy	
Comparisons	Use of antiretroviral therapy vs. no use of antiretroviral therapy	
Outcomes	Transmission rates	
Study designs	Randomized, controlled trials or controlled observational studies	
<b>KQ 4b. How effective is behavioral counseling in reducing transmission of HIV in nonpregnant adolescents and adults with chronic HIV infection?</b>		
Populations	HIV-positive adolescents and adults	Acute HIV infection
Interventions	Behavioral counseling interventions (pre- and post-test) to reduce risky sexual behaviors or enhance protective sexual behaviors for those who are asymptomatic and identified through screening	
Comparisons	Counseling vs. usual care	
Outcomes	Transmission rates	
Study designs	Randomized, controlled trials or controlled observational studies	
<b>KQ 4c. In asymptomatic, nonpregnant adolescents and adults with chronic HIV infection, what are the effects of initiating antiretroviral therapy at different CD4 counts or viral load thresholds on morbidity, mortality, and quality of life?</b>		
Populations	HIV-positive adolescents and adults	Acute HIV infection
Interventions	Antiretroviral regimens	
Comparisons	Initiation of antiretroviral therapy earlier vs. initiation later	
Outcomes	Morbidity and mortality related to HIV infection and quality of life	
Study designs	Randomized, controlled trials or controlled observational studies	

## Appendix A2. Inclusion and Exclusion Criteria per Key Question

	Include	Exclude
<b>KQ 5. What are the longer-term harms associated with antiretroviral therapy in nonpregnant adolescents and adults with chronic HIV infection?</b>		
Populations	HIV-positive adolescents and adults	Already or previously taking antiretroviral therapy; acute HIV infection
Interventions	Antiretroviral regimens	
Outcomes	Cardiovascular harms	
Study designs	Any	
Timing	Long-term followup defined as $\geq 2$ years	
<b>KQ 6a. To what extent are improvements in viremia associated with reductions in HIV transmission rates in nonpregnant adolescents and adults?</b>		
Populations	HIV-positive adolescents and adults	Acute HIV or subtypes
Comparisons	Differences in improvements in viral load	
Outcomes	HIV transmission rates	Risk perception
Study designs	Randomized, controlled trials or controlled observational studies	
<b>KQ 6b. To what extent are improvements in risky behaviors associated with reductions in HIV transmission rates in nonpregnant adolescents and adults?</b>		
Populations	HIV-positive adolescents and adults	Acute HIV or subtypes
Comparisons	Differences in self-reported risky behaviors	
Outcomes	HIV transmission rates	Risk perception
Study designs	Randomized, controlled trials or controlled observational studies	

**Appendix A3. Literature Flow Diagram**



\*Cochrane databases include the Cochrane Central Register of Controlled Trials and the Cochrane Database of Systematic Reviews.

†Other sources include reference lists, suggested by peer reviewers, etc.

‡ Some articles are included for more than one key question.

**Abbreviations:** RCT = randomized, controlled trial; SR = systematic review.

## Appendix A4. Excluded Studies List

### Wrong population

Antiretroviral Therapy Cohort Collaboration. Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients. *J Acquir Immune Defic Syndr*. 2007;15;46(5):607-15. PMID: 18043315.

Beckwith CG, Bazerman L, Cornwall AH, Patry E, Poshkus M, Fu J, et al. An evaluation of a routine opt-out rapid HIV testing program in a Rhode Island jail. *AIDS Educ Prev*. 2011;23(3 Suppl):96-109. PMID: 21689040.

Beckwith CG, Liu T, Bazerman LB, DeLong AK, Desjardins SF, Poshkus MM, et al. HIV risk behavior before and after HIV counseling and testing in jail: a pilot study. *J Acquir Immune Defic Syndr*. 2010;53(4):485-90. PMID: 20035232.

Bini EJ, Currie SL, Shen H, Brau N, Schmidt W, Anand BS, et al. National multicenter study of HIV testing and HIV seropositivity in patients with chronic hepatitis C virus infection. *J Clin Gastroenterol*. 2006;40(8):732-9. PMID: 16940888.

Bower M, Weir J, Francis N, Newsom-Davis T, Powles S, Crook T, et al. The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's sarcoma. *AIDS*. 2009;23(13):1701-6. PMID: 19550283.

Brady MT, Oleske JM, Williams PL, Elgie C, Mofenson LM, Dankner WM, et al. Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era. *J Acquir Immune Defic Syndr*. 2010;53(1):86-94. PMID: 20035164.

Branson BM, Peterman TA, Cannon RO, Ransom R, Zaidi AA. Group counseling to prevent sexually transmitted disease and HIV: a randomized controlled trial. *Sex Transm Dis*. 1998;25(10):553-60. PMID: 9858353.

Buckle C, Castillo M. Use of diffusion-weighted imaging to evaluate the initial response of progressive multifocal leukoencephalopathy to

highly active antiretroviral therapy: early experience. *Am J Neuroradiol*. 2010;31(6):1031-5. PMID: 20360338.

Cabie A, Bissuel F, Abel S, Huc P, Paturel L, Pierre-Francois S. Use of HIV rapid tests in free and anonymous screening consultations in the French West Indies. *Med Mal Infect*. 2009;39(6):370-4. PMID: 19346089.

Castelnuovo B, Kiragga A, Kanya MR, Manabe Y. Stavudine toxicity in women is the main reason for treatment change in a 3-year prospective cohort of adult patients started on first-line antiretroviral treatment in Uganda. *J Acquir Immune Defic Syndr*. 2011;56(1):59-63. PMID: 20861741.

Casula M, Bosboom-Dobbelaer I, Smolders K, Otto S, Bakker M, de Baar MP, et al. Infection with HIV-1 induces a decrease in mtDNA. *J Infect Dis*. 2005;191(9):1468-71. PMID: 15809905.

Casula M, Weverling GJ, Wit FW, Timmermans EC, Stek M, Lange JM, et al. Mitochondrial DNA and RNA increase in peripheral blood mononuclear cells from HIV-1-infected patients randomized to receive stavudine-containing or stavudine-sparing combination therapy. *J Infect Dis*. 2005;192(10):1794-800. PMID: 16235179.

Cave J, Edwards SG, Miller RF, Ardeshta KM, Lee SM. Should we implement "opt-out" HIV testing for patients with lymphoma? *Clinical Medicine*. 2009;9(4):320-2. PMID: 19728502.

Celum CL, Buchbinder SP, Donnell D, Douglas JM Jr, Mayer K, Koblin B, et al. Early human immunodeficiency virus (HIV) infection in the HIV Network for Prevention Trials Vaccine Preparedness Cohort: risk behaviors, symptoms, and early plasma and genital tract virus load. *J Infect Dis*. 2001;183(1):23-35. PMID: 11106536.

Centers for Disease Control and Prevention. Rapid HIV testing in emergency departments—three U.S. sites, January 2005–March 2006. *MMWR Morb Mortal Wkly Rep*. 2007;56(24):597-601. PMID: 17585288.

## Appendix A4. Excluded Studies List

- Chen SC, Wang ST, Chen KT, Yan TR, Tang LH, Lin CC, et al. Analysis of the influence of therapy and viral suppression on high-risk sexual behaviour and sexually transmitted infections among patients infected with human immunodeficiency virus in Taiwan. *Clin Microbiol Infect.* 2006;12(7):660-5. PMID: 16774563.
- Claassen M, van Zyl GU, Korsman SN, Smit L, Cotton MF, Preiser W. Pitfalls with rapid HIV antibody testing in HIV-infected children in the Western Cape, South Africa. *J Clin Virol.* 2006;37(1):68-71. PMID: 16875874.
- Clements-Nolle K, Marx R, Pendo M, Loughran E, Estes M, Katz M. Highly active antiretroviral therapy use and HIV transmission risk behaviors among individuals who are HIV infected and were recently released from jail. *Am J Public Health.* 2008;98(4):661-6. PMID: 18309132.
- Clotet B, Capetti A, Soto-Ramirez LE, Gatell JM, Rowell L, Salgo M, et al. A randomized, controlled study evaluating an induction treatment strategy in which enfuvirtide was added to an oral, highly active antiretroviral therapy regimen in treatment-experienced patients: the INTENSE study. *J Antimicrob Chemother.* 2008;62(6):1374-8. PMID: 18782780.
- Coenen T, Lundgren J, Lazarus JV, Matic S. Optimal HIV testing and earlier care: the way forward in Europe. *HIV Med.* 2008;2:1-5. PMID: 18557862.
- Cohall AT, Dini S, Senathirajah Y, Nye A, Neu N, Powell D, et al. Feasibility of using computer-assisted interviewing to enhance HIV test counseling in community settings. *Public Health Rep.* 2008;3:70-7. PMID: 19166091.
- Collaboration of Observational HIV Epidemiological Research Europe Study Group; Bohlius J, Schmidlin K, Costagliola D, Fatkenheuer G, May M, et al. Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. *AIDS.* 2009;23(15):2029-37. PMID: 19531926.
- Copenhaver M, Chowdhury S, Altice FL. Adaptation of an evidence-based intervention targeting HIV-infected prisoners transitioning to the community: the process and outcome of formative research for the Positive Living Using Safety (PLUS) intervention. *AIDS Patient Care STDs.* 2009;23(4):277-87. PMID: 19260773.
- Copenhaver MM, Lee IC. Examining the decay of HIV risk reduction outcomes following a community-friendly intervention targeting injection drug users in treatment. *J Psychoactive Drugs.* 2007;39(3):223-9. PMID: 18159775.
- Cosio D, Heckman TG, Anderson T, Heckman BD, Garske J, McCarthy J. Telephone-administered motivational interviewing to reduce risky sexual behavior in HIV-infected rural persons: a pilot randomized clinical trial. *Sex Transm Dis.* 2010;37(3):140-6. PMID: 20118830.
- Crepaz N, Marks G. Serostatus disclosure, sexual communication and safer sex in HIV-positive men. *AIDS Care.* 2003;15(3):379-87. PMID: 12745398.
- Dalal S, Lee CW, Farirai T, Schilsky A, Goldman T, Moore J, et al. Provider-initiated HIV testing and counseling: increased uptake in two public community health centers in South Africa and implications for scale-up. *PLoS One.* 2011;6(11):e27293. PMID: 22114668.
- Dancy BL, Crittenden KS, Talashek ML. Mothers' effectiveness as HIV risk reduction educators for adolescent daughters. *J Health Care Poor Underserved.* 2006;17(1):218-39. PMID: 16520528.
- De Luca A, Di Giambenedetto S, Cingolani A, Bacarelli A, Ammassari A, Cauda R. Three-year clinical outcomes of resistance genotyping and expert advice: extended follow-up of the Argenta trial. *Antivir Ther.* 2006;11(3):321-7. PMID: 16759048.
- Demeter LM, Jiang H, Mukherjee AL, Morse GD, DiFrancesco R, DiCenzo R, et al. A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-

## Appendix A4. Excluded Studies List

- experienced, HIV-1-infected patients. *AIDS*. 2009;23(3):357-68. PMID: 19114860.
- Desai MM, Rosenheck RA. HIV testing and receipt of test results among homeless persons with serious mental illness. *Am J Psychiatry*. 2004;161(12):2287-94. PMID: 15569902.
- Dias SF, Matos MG, Goncalves AC. AIDS-related stigma and attitudes towards AIDS-infected people among adolescents. *AIDS Care*. 2006;18(3):208-14. PMID: 16546780.
- Dzwonek AB, Lawson MS, Cole TJ, Novelli V. Body fat changes and lipodystrophy in HIV-infected children: impact of highly active antiretroviral therapy. *J Acquir Immune Defic Syndr*. 2006;43(1):121-3. PMID: 16936560.
- El-Bassel N, Gilbert L, Wu E, Witte SS, Chang M, Hill J, et al. Couple-based HIV prevention for low-income drug users from New York City: a randomized controlled trial to reduce dual risks. *J Acquir Immune Defic Syndr*. 2011;58(2):198-206. PMID: 21725249.
- El-Bassel N, Witte SS, Gilbert L, Wu E, Chang M, Hill J, et al. Long-term effects of an HIV/STI sexual risk reduction intervention for heterosexual couples. *AIDS Behav*. 2005;9(1):1-13. PMID: 15812609.
- Engsig FN, Gerstoft J, Kronborg G, Larsen CS, Pedersen G, Roge B, et al. Long-term mortality in HIV patients virally suppressed for more than three years with incomplete CD4 recovery: a cohort study. *BMC Infect Dis*. 2010;10:318. PMID: 21044307.
- Explore Study Group. Effects of a behavioural intervention to reduce acquisition of HIV among men who have sex with men: the Explore randomised controlled study. *Lancet*. 2004;364:41-50. PMID: 15234855.
- Flaks RC, Burman WJ, Gourley PJ, Rietmeijer CA, Cohn DL. HIV transmission risk behavior and its relation to antiretroviral treatment adherence. *Sex Transm Dis*. 2003;30(5):399-404. PMID: 12916130.
- Fregonese F, Collins IJ, Jourdain G, Lecoer S, Cressey TR, Ngo-Giang-Huong N, et al. Predictors of 5-year mortality in HIV-infected adults starting highly active antiretroviral therapy in Thailand. *J Acquir Immune Defic Syndr*. 2012;60(1):91-8. PMID: 22293548.
- Grund B, Peng G, Gibert CL, Hoy JF, Isaksson RL, Shlay JC, et al. Continuous antiretroviral therapy decreases bone mineral density. *AIDS*. 2009;23(12):1519-29. PMID: 19531929.
- Guaraldi G, Cocchi S, Motta A, Ciaffi S, Codeluppi M, Bonora S, et al. Efficacy and safety of atazanavir in patients with end-stage liver disease. *Infection*. 2009;37(3):250-5. PMID: 19471855.
- Herman JS, Easterbrook PJ. The metabolic toxicities of antiretroviral therapy. *Int J STD AIDS*. 2001;12(9):555-64. PMID: 11516363.
- Ickovics JR, Druley JA, Grigorenko EL, Morrill AC, Beren SE, Rodin J. Long-term effects of HIV counseling and testing for women: behavioral and psychological consequences are limited at 18 months posttest. *Health Psychol*. 1998;17(5):395-402. PMID: 9775997.
- Katlama C, Haubrich R, Lalezari J, Lazzarin A, Madruga JV, Molina JM, et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. *AIDS*. 2009;23(17):2289-300. PMID: 19710593.
- Kavasery R, Maru DS, Cornman-Homonoff J, Sylla LN, Smith D, Altice FL. Routine opt-out HIV testing strategies in a female jail setting: a prospective controlled trial. *PLoS One*. 2009;4(11):e7648. PMID: 19946370.
- Kavasery R, Maru DS, Sylla LN, Smith D, Altice FL. A prospective controlled trial of routine opt-out HIV testing in a men's jail. *PLoS One*. 2009;4(11):e8056. PMID: 19946371.
- Kawichai S, Celentano DD, Vongchak T, Beyrer C, Suriyanon V, Razak MH, et al. HIV voluntary counseling and testing and HIV incidence in male injecting drug users in northern Thailand: evidence of an urgent need for HIV prevention. *J Acquir Immune Defic Syndr*. 2006;41(2):186-93. PMID: 16394851.

## Appendix A4. Excluded Studies List

Kawichai S, Nelson KE, Natpratan C, Celentano DD, Khamboonruang C, Natpratan P, et al. Personal history of voluntary HIV counseling and testing (VCT) among adults aged 19–35 years living in peri-urban communities, Chiang Mai, northern Thailand. *AIDS Behav.* 2005;9(2):233-42. PMID: 15933842.

Kerndt PR, Dubrow R, Aynalem G, Mayer KH, Beckwith C, Remien RH, et al. Strategies used in the detection of acute/early HIV infections: the NIMH Multisite Acute HIV Infection Study, I. *AIDS Behav.* 2009;13(6):1037-45. PMID: 19495954.

Kiene SM, Bateganya M, Wanyenze R, Lule H, Nantaba H, Stein MD. Initial outcomes of provider-initiated routine HIV testing and counseling during outpatient care at a rural Ugandan hospital: risky sexual behavior, partner HIV testing, disclosure, and HIV care seeking. *AIDS Patient Care STDs.* 2010;24(2):117-26. PMID: 20059356.

Kim JY, Zaoutis T, Chu J, Zhao H, Rutstein R. Effects of highly active antiretroviral therapy (HAART) on cholesterol in HIV-1 infected children: a retrospective cohort study. *Pharmacoepidemiol Drug Saf.* 2009;18(7):589-94. PMID: 19402031.

Koblin B, Chesney M, Coates T, Team ES. Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: the EXPLORE randomised controlled study. *Lancet.* 2004;364(9428):41-50. PMID: 15234855.

Koenig LJ, Pals SL, Chandwani S, Hodge K, Abramowitz S, Barnes W, et al. Sexual transmission risk behavior of adolescents with HIV acquired perinatally or through risky behaviors. *J Acquir Immune Defic Syndr.* 2010;55(3):380-90. PMID: 20802343.

Kouliniska IN, Villamor E, Chaplin B, Msamanga G, Fawzi W, Renjifo B, et al. Transmission of cell-free and cell-associated HIV-1 through breast-feeding. *J Acquir Immune Defic Syndr.* 2006;41(1):93-9. PMID: 16340480.

Kuhn L, Aldrovandi GM, Sinkala M, Kankasa C, Semrau K, Kasonde P, et al. Differential effects of early weaning for HIV-free survival of children born to HIV-infected mothers by severity of maternal disease. *PLoS One.* 2009;4(6):e6059. PMID: 19557167.

Kuhn L, Aldrovandi GM, Sinkala M, Kankasa C, Semrau K, Mwiya M, et al. Effects of early, abrupt weaning on HIV-free survival of children in Zambia. *N Engl J Med.* 2008;359(2):130-41. PMID: 18525036.

Kuhn L, Sinkala M, Semrau K, Kankasa C, Kasonde P, Mwiya M, et al. Elevations in mortality associated with weaning persist into the second year of life among uninfected children born to HIV-infected mothers. *Clin Infect Dis.* 2010;50(3):437-44. PMID: 20047479.

Kuhn L, Trabattoni D, Kankasa C, Semrau K, Kasonde P, Lissoni F, et al. Alpha-defensins in the prevention of HIV transmission among breastfed infants. *J Acquir Immune Defic Syndr.* 2005;39(2):138-42. PMID: 15905728.

Kuhn L, Trabattoni D, Kankasa C, Sinkala M, Lissoni F, Ghosh M, et al. HIV-specific secretory IgA in breast milk of HIV-positive mothers is not associated with protection against HIV transmission among breast-fed infants. *J Pediatr.* 2006;149(5):611-6. PMID: 17095329.

Kumar A, Kilaru KR, Forde S, Waterman I. Uptake of health care services and health status of HIV-infected women diagnosed through antenatal HIV screening in Barbados, 1996–2004. *Rev Panam Salud Publica.* 2007;22(6):376-82. PMID: 18291056.

Kumar A, Rocheste E, Gibson M, Gibson T, Robinson H, Forde S. Antenatal voluntary counseling and testing for HIV in Barbados. Success and barriers to implementation. *Rev Panam Salud Publica.* 2004;15(4):242-8. PMID: 15193179.

Kumar A, St White H, Carter AO. Trends in the uptake of antenatal voluntary counselling and testing for HIV and HIV prevalence among childbearing women in Barbados, 1993–2004:

## Appendix A4. Excluded Studies List

evidence to gauge the effectiveness of HIV prevention measures. *West Indian Med J*. 2007;56(1):60-5. PMID: 17621846.

Kumwenda NI, Hoover DR, Mofenson LM, Thigpen MC, Kafulafula G, Li Q, et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. *N Engl J Med*. 2008;359(2):119-29. PMID: 18525035.

Labarga P, Barreiro P, Martin-Carbonero L, Rodriguez-Novoa S, Solera C, Medrano J, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. *AIDS*. 2009;23(6):689-96. PMID: 19262355.

Lindsell CJ, Hart KW, Lyons MS. A simple method for estimating the prevalence of undiagnosed HIV infection in an emergency department. *Ann Emerg Med*. 2011;58(Suppl 1):S23-7. PMID: 21684403.

Lindsey JC, Hughes MD, McKinney RE, Cowles MK, Englund JA, Baker CJ, et al. Treatment-mediated changes in human immunodeficiency virus (HIV) type 1 RNA and CD4 cell counts as predictors of weight growth failure, cognitive decline, and survival in HIV-infected children. *J Infect Dis*. 2000;182(5):1385-93. PMID: 11010839.

Lo J, Abbara S, Shturman L, Soni A, Wei J, Rocha-Filho JA, et al. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. *AIDS*. 2010;24(2):243-53. PMID: 19996940.

Lyons MS, Lindsell CJ, Wayne DB, Ruffner AH, Hart KW, Fichtenbaum CJ, et al. Comparison of missed opportunities for earlier HIV diagnosis in 3 geographically proximate emergency departments. *Ann Emerg Med*. 2011;58(Suppl 1):S17-22. PMID: 21684399.

Lyons MS, Raab DL, Lindsell CJ, Trott AT, Fichtenbaum CJ. A novel emergency department based prevention intervention program for people living with HIV: evaluation of early experiences. *BMC Health Serv Res*. 2007;7:164. PMID: 17937817.

Maggiolo F, Ripamonti D, Callegaro A, Gregis G, Quinzan G, Suter F. Quadruple-drug induction HAART in advanced HIV infection. *HIV Clinical Trials*. 2005;6(1):1-4. PMID: 15765306.

Mallolas J, Podzamczar D, Milinkovic A, Domingo P, Clotet B, Ribera E, et al. Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study. *J Acquir Immune Defic Syndr*. 2009;51(1):29-36. PMID: 19390327

Martinez E, Visnegarwala F, Grund B, Thomas A, Gibert C, Shlay J, et al. The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters. *AIDS*. 2010;24(3):353-63. PMID: 20057309.

Merchant RC, Clark MA, Langan TJ, Mayer KH, Seage GR 3rd, Degruittola VG. Can computer-based feedback improve emergency department patient uptake of rapid HIV screening? *Ann Emerg Med*. 2011;58(Suppl 1):S114-9. PMID: 21684389.

Miguez-Burbano MJ, de Pool I, Hadrihan S, Jackson J Jr, Angarita I, Then EP, et al. HIV knowledge and risk behaviors among women in law enforcement in Bogota, Colombia: potential role as community educators. *J Urban Health*. 2005;82(3 Suppl 4):iv43-57. PMID: 16107439.

Miranda AE, Soares RA, Prado BC, Monteiro RB, Figueiredo NC. Mother to child transmission of HIV in Vitoria, Brazil: factors associated with lack of HIV prevention. *AIDS Care*. 2005;17(6):721-8. PMID: 16036258.

Mirkuzie AH, Hinderaker SG, Morkve O. Promising outcomes of a national programme for the prevention of mother-to-child HIV transmission in Addis Ababa: a retrospective study. *BMC Health Serv Res*. 2010;10:267. PMID: 20828384.

Miura T, Goto M, Hosoya N, Odawara T, Kitamura Y, Nakamura T, et al. Depletion of mitochondrial DNA in HIV-1-infected patients and its amelioration by antiretroviral therapy. *J*



## Appendix A4. Excluded Studies List

*Med Virol.* 2003;70(4):497-505. PMID: 12794710.

Mizuno Y, Purcell D, Borkowski TM, Knight K, et al. The life priorities of HIV-seropositive injection drug users: findings from a community-based sample. *AIDS Behav.* 2003;7(4):395-403. PMID: 14707536.

Moatti JP, Prudhomme J, Traore DC, Juillet-Amari A, Akribi HA, Msellati P, et al. Access to antiretroviral treatment and sexual behaviours of HIV-infected patients aware of their serostatus in Cote d'Ivoire. *AIDS.* 2003;17:3. PMID: 14565612.

Molina JM, Cohen C, Katlama C, Grinsztejn B, Timmerman A, Pedro Rde J, et al. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3. *J Acquir Immune Defic Syndr.* 2007;46(1):24-31. PMID: 17621237.

Monpoux F, Pugliese P, Berthier F, Cottalorda J, Pradier C. Bridging the gap between adult and paediatric outcomes in HIV-1 vertically infected children: a single-centre comparison with adult data. *Acta Paediatr.* 2009;98(11):1787-92. PMID: 19681795.

Moodie EE, Pant Pai N, Klein MB. Is antiretroviral therapy causing long-term liver damage? A comparative analysis of HIV-mono-infected and HIV/hepatitis C co-infected cohorts. *PLoS One.* 2009;4(2):e4517. PMID: 19223976.

Moodley D, Esterhuizen TM, Pather T, Chetty V, Ngaleka L. High HIV incidence during pregnancy: compelling reason for repeat HIV testing. *AIDS.* 2009;23(10):1255-9. PMID: 19455017.

Morisky DE, Nguyen C, Ang A, Tiglaio TV. HIV/AIDS prevention among the male population: results of a peer education program for taxicab and tricycle drivers in the Philippines. *Health Educ Behav.* 2005;32(1):57-68. PMID: 15642754.

Mpairwe H, Muhangi L, Namujju PB, Kisitu A, Tumusiime A, Muwanga M, et al. HIV risk perception and prevalence in a program for prevention of mother-to-child HIV transmission: comparison of women who accept voluntary counseling and testing and those tested anonymously. *J Acquir Immune Defic Syndr.* 2005;39(3):354-8. PMID: 15980698.

Mustikawati DE, Morineau G, Nurhayati, Irmaningrum Y, Riono P, Priohutomo S, et al. Sexual risk taking, sexually transmitted infections and HIV prevalence among four "high-risk" occupational groups of Indonesian men. *Sex Transm Infect.* 2009;85(5):391-6. PMID: 19273478.

Muyingo SK, Walker AS, Reid A, Munderi P, Gibb DM, Ssali F, et al. Patterns of individual and population-level adherence to antiretroviral therapy and risk factors for poor adherence in the first year of the DART trial in Uganda and Zimbabwe. *J Acquir Immune Defic Syndr.* 2008;48(4):468-75. PMID: 18614918.

Mzileni MO, Longo-Mbenza B, Chephe TJ. Mortality and causes of death in HIV-positive patients receiving antiretroviral therapy at Tshepang Clinic in Doctor George Mukhari Hospital. *Pol Arch Med Wewn.* 2008;118(10):548-54. PMID: 19112815.

Nakamoto BK, McMurtray A, Davis J, Valcour V, Watters MR, Shiramizu B, et al. Incident neuropathy in HIV-infected patients on HAART. *AIDS Res Hum Retroviruses.* 2010;26(7):759-65. PMID: 20624077.

Nunes EP, Santini de Oliveira M, Mercon M, Zajdenverg R, Faulhaber JC, Pilotto JH, et al. Monotherapy with lopinavir/ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study). *HIV Clinical Trials.* 2009;10(6):368-74. PMID: 20133267.

Omer SB; Six Week Extended Dose Nevirapine (SWEN) Study Team. Twelve-month follow-up of Six Week Extended Dose Nevirapine randomized controlled trials: differential impact of extended-dose nevirapine on mother-to-child

## Appendix A4. Excluded Studies List

transmission and infant death by maternal CD4 cell count. *AIDS*. 2011;25(6):767-76. PMID: 21330912.

Orlando G, Meraviglia P, Cordier L, Meroni L, Landonio S, Giorgi R, et al. Antiretroviral treatment and age-related comorbidities in a cohort of older HIV-infected patients. *HIV Med*. 2006;7(8):549-57. PMID: 17105515.

Osih RB, Taffe P, Rickenbach M, Gayet-Ageron A, Elzi L, Fux C, et al. Outcomes of patients on dual-boosted PI regimens: experience of the Swiss HIV cohort study. *AIDS Res Hum Retroviruses*. 2010;26(11):1239-46. PMID: 20929393.

Palumbo PE, Raskino C, Fiscus S, Pahwa S, Fowler MG, Spector SA, et al. Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children. *JAMA*. 1998;279(10):756-61. PMID: 9508151.

Parsons JT, Schrimshaw EW, Wolitski RJ, Halkitis PN, Purcell DW, Hoff CC, et al. Sexual harm reduction practices of HIV-seropositive gay and bisexual men: serosorting, strategic positioning, and withdrawal before ejaculation. *AIDS*. 2005;19:1. PMID: 15838191.

Pechansky F, Bassani DG, Diemen L, Kessler F, Leukefeld CG, Surratt HL, et al. Using thought mapping and structured stories to decrease HIV risk behaviors among cocaine injectors and crack smokers in the South of Brazil. *Rev Bras Psiquiatr*. 2007;29(3):233-40. PMID: 17713693.

Puthanakit T, Oberdorfer A, Akarathum N, Kanjanavanit S, Wannarit P, Sirisanthana T, et al. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program. *Clin Infect Dis*. 2005;41(1):100-7. PMID: 15937769.

Quijano G, Drut R. Atherosclerosis and central adiposity in a pediatric patient with AIDS treated with HAART: autopsy findings. *Pediatr Dev Pathol*. 2006;9(6):474-9. PMID: 17163794.

Reliquet V, Allavena C, Morineau-Le Houssine P, Mounoury O, Raffi F. Twelve-year experience of nevirapine use: benefits and convenience for long-term management in a French cohort of HIV-1-infected patients. *HIV Clinical Trials*. 2010;11(2):110-7. PMID: 20542847.

Rosso R, Bernardini C, Bruzzone B, Secondo G, Icardi G, Viscoli C, et al. Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection. *Eur J Med Res*. 2009;14(3):136-8. PMID: 19380285.

Salazar JC, Cahn P, Yogev R, Negra MD, Castelli-Gattinara G, Fortuny C, et al. Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents. *AIDS*. 2008;22(14):1789-98. PMID: 18753862.

Samaras K, Gan SK, Peake PW, Carr A, Campbell LV. Proinflammatory markers, insulin sensitivity, and cardiometabolic risk factors in treated HIV infection. *Obesity*. 2009;17(1):53-9. PMID: 19008869.

Shet A, Berry L, Mohri H, Mehandru S, Chung C, Kim A, et al. Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. *J Acquir Immune Defic Syndr*. 2006;41(4):439-46. PMID: 16652051.

Simpson WM, Johnstone FD, Goldberg DJ, Gormley SM, Hart GJ. Antenatal HIV testing: assessment of a routine voluntary approach. *BMJ*. 1999;318(7199):1660-1. PMID: 10373168.

Sobrino-Vegas P, Garcia-San Miguel L, Caro-Murillo AM, Miro JM, Viciano P, Tural C, et al. Delayed diagnosis of HIV infection in a multicenter cohort: prevalence, risk factors, response to HAART and impact on mortality. *Curr HIV Res*. 2009;7(2):224-30. PMID: 19275591.

Spielberg F, Kurth AE, Severynen A, Yu-Hsiang H, Moring-Parris D, MacKenzie S, et al. Computer-facilitated rapid HIV testing in emergency care settings: provider and patient

## Appendix A4. Excluded Studies List

usability and acceptability. *AIDS Educ Prev*. 2011;23(3):206-21. PMID: 21696240.

Sprinz E, Neto AJ, Bargman E, Green SL, Luo MP, Sylte JR, et al. Substitution with lopinavir/ritonavir improves patient-reported outcomes including quality of life in patients who were intolerant to their antiretroviral therapy. *HIV Clinical Trials*. 2006;7(6):291-308. PMID: 17197377.

Stokes SH, McMaster P, Ismail KM. Acceptability of perinatal rapid point-of-care HIV testing in an area of low HIV prevalence in the UK. *Arch Dis Child*. 2007;92(6):505-8. PMID: 17293365.

Sturtevant D, Preiksaitis J, Singh A, Houston S, Gill J, Predy G, et al. The feasibility of using an “opt-out” approach to achieve universal HIV testing of tuberculosis patients in Alberta. *Can J Public Health*. 2009;100(2):116-20. PMID: 19839287.

Tepper NK, Farr SL, Danner SP, Maupin R, Nesheim SR, Cohen MH, et al. Rapid human immunodeficiency virus testing in obstetric outpatient settings: the MIRIAD study. *Am J Obstet Gynecol*. 2009;201:1. PMID: 19398094.

Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. *J Infect Dis*. 2005;191(9):1403-9. PMID: 15809897.

Williams BG, Lloyd-Smith JO, Gouws E, Hankins C, Getz WM, Hargrove J, et al. The potential impact of male circumcision on HIV in Sub-Saharan Africa. *PLoS Med*. 2006;3(7):e262. PMID: 16822094.

### Wrong intervention

Almeda J, Casabona J, Matas L, Gonzalez V, Muga R, Sanz B, et al. Evaluation of a commercial enzyme immunoassay for HIV screening in urine. *Eur J Clin Microbiol Infect Dis*. 2004;23(11):831-5. PMID: 15480885.

Anaya HD, Hoang T, Golden JF, Goetz MB, Gifford A, Bowman C, et al. Improving HIV screening and receipt of results by nurse-

initiated streamlined counseling and rapid testing. *J Gen Intern Med*. 2008;23(6):800-7. PMID: 18421508.

Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. *PLoS Med*. 2005;2(11):e298. PMID: 16231970.

Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. *Lancet*. 2007;369(9562):643-56. PMID: 17321310.

Barin F, Meyer L, Lancar R, Deveau C, Gharib M, Laporte A, et al. Development and validation of an immunoassay for identification of recent human immunodeficiency virus type 1 infections and its use on dried serum spots. *J Clin Microbiol*. 2005;43(9):4441-7. PMID: 16145089.

Barretina J, Blanco J, Bonjoch A, Llano A, Clotet B, Este JA. Immunological and virological study of enfuvirtide-treated HIV-positive patients. *AIDS*. 2004;18(12):1673-82. PMID: 15280778.

Bedimo R, Westfall AO, Mugavero M, Drechsler H, Khanna N, Saag M. Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. *HIV Med*. 2010;11(7):462-8. PMID: 20163481.

Beelaert G, Fransen K. Evaluation of a rapid and simple fourth-generation HIV screening assay for qualitative detection of HIV p24 antigen and/or antibodies to HIV-1 and HIV-2. *J Virol Methods*. 2010;168(1-2):218-22. PMID: 20561542.

Bourlet T, Pretis C, Pillet S, Lesenechal M, Piche J, Pozzetto B. Comparative evaluation of the VIDAS HIV DUO Ultra assay for combined detection of HIV-1 antigen and antibodies to HIV. *J Virol Methods*. 2005;127(2):165-7. PMID: 15967238.

## Appendix A4. Excluded Studies List

- Brown NC, Taylor ED, Mulatu MS, Scott W. Demographic correlates of HIV testing, high-risk behaviors, and condom/STD consultation among a multi-ethnic sample of women. *Women Health*. 2007;46(2-3):59-76. PMID: 18160370.
- Byakwaga H, Zhou J, Petoumenos K, Law MG, Boyd MA, Emery S, et al. Effect of nucleoside reverse transcriptase inhibitors on CD4 T-cell recovery in HIV-1-infected individuals receiving long-term fully suppressive combination antiretroviral therapy. *HIV Med*. 2009;10(3):143-51. PMID: 19207595.
- Carpenter KM, Stoner SA, Mikko AN, Dhanak LP, Parsons JT. Efficacy of a web-based intervention to reduce sexual risk in men who have sex with men. *AIDS Behav*. 2010;14(3):549-57. PMID: 19499321.
- Carpenter LM, Kamali A, Ruberantwari A, Malamba SS, Whitworth JA. Rates of HIV-1 transmission within marriage in rural Uganda in relation to the HIV sero-status of the partners. *AIDS*. 1999;13(9):1083-9. PMID: 10397539.
- Castro P, Plana M, Gonzalez R, Lopez A, Vilella A, Argelich R, et al. Influence of a vaccination schedule on viral load rebound and immune responses in successfully treated HIV-1-infected patients. *AIDS Res Hum Retroviruses*. 2009;25(12):1249-59. PMID: 19943787.
- Collier AC, Ribaudo H, Mukherjee AL, Feinberg J, Fischl MA, Chesney M, et al. A randomized study of serial telephone call support to increase adherence and thereby improve virologic outcome in persons initiating antiretroviral therapy. *J Infect Dis*. 2005;192(8):1398-406. PMID: 16170757.
- Colon HM, Robles RR, Marrero CA, Reyes JC, Sahai H. Behavioral effects of receiving HIV test results among injecting drug users in Puerto Rico. *AIDS*. 1996;10(10):1163-8. PMID: 8874635.
- Darbes LA, Chakravarty D, Beougher SC, Neilands TB, Hoff CC. Partner-provided social support influences choice of risk reduction strategies in gay male couples. *AIDS Behav*. 2012;16(1):159-67. PMID: 21221756.
- Davey RT, Pertel PE, Benson A, Cassell DJ, Gazzard BG, Holodniy M, et al. Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy. *J Interferon Cytokine Res*. 2008;28(2):89-100. PMID: 18279104.
- Durier C, Capitant C, Lascaux AS, Goujard C, Oksenhendler E, Poizot-Martin I, et al. Long-term effects of intermittent interleukin-2 therapy in chronic HIV-1-infected patients. *AIDS*. 2007;21(14):1887-97. PMID: 17721096.
- Fang CT, Hsu HM, Twu SJ, Chen MY, Chang YY, Hwang JS, et al. Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. *J Infect Dis*. 2004;190(5):879-85. PMID: 15295691.
- Fisac C, Fumero E, Crespo M, Roson B, Ferrer E, Virgili N, et al. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. *AIDS*. 2005;19(9):917-25. PMID: 15905672.
- Fisher M, Pao D, Murphy G, Dean G, McElborough D, Homer G, et al. Serological testing algorithm shows rising HIV incidence in a UK cohort of men who have sex with men: 10 years application. *AIDS*. 2007;21(17):2309-14. PMID: 18090279.
- Fontas E, Kousignian I, Pradier C, Poizot-Martin I, Durier C, Weiss L, et al. IL-2 therapy: potential impact of the CD4 cell count at initiation on clinical efficacy—results from the ANRS CO4 cohort. *J Antimicrob Chemother*. 2010;65(10):2215-23. PMID: 20702463.
- Freeman AE, Sattin RW, Miller KM, Dias JK, Wilde JA. Acceptance of rapid HIV screening in a southeastern emergency department. *Acad Emerg Med*. 2009;16(11):1156-64. PMID: 20053236.
- Gaydos CA, Hsieh YH, Harvey L, Burah A, Won H, Jett-Goheen M, et al. Will patients “opt in” to perform their own rapid HIV test in the emergency department? *Ann Emerg Med*. 2011;58(Suppl 1):S74-8. PMID: 21684413.

## Appendix A4. Excluded Studies List

Gibson DR, Flynn NM, Perales D. Effectiveness of syringe exchange programs in reducing HIV risk behavior and HIV seroconversion among injecting drug users. *AIDS*. 2001;15(11):1329-41. PMID: 11504954.

Golden MR, Dombrowski JC, Wood RW, Fleming M, Harrington RD. A controlled study of the effectiveness of public health HIV partner notification services. *AIDS*. 2009;23(1):133-5. PMID: 19050396.

Golden MR, Wood RW, Buskin SE, Fleming M, Harrington RD. Ongoing risk behavior among persons with HIV in medical care. *AIDS Behav*. 2007;11(5):726-35. PMID: 17497217.

Gonzalez R, Vassileva J, Bechara A, Grbesic S, Sworowski L, Novak RM, et al. The influence of executive functions, sensation seeking, and HIV serostatus on the risky sexual practices of substance-dependent individuals. *J Int Neuropsychol Soc*. 2005;11(2):121-31. PMID: 15962700.

Greenberg J, Lifshay J, Van Devanter N, Gonzales V, Celentano D. Preventing HIV infection: the effects of community linkages, time, and money on recruiting and retaining women in intervention groups. *J Womens Health*. 1998;7(5):587-96. PMID: 9650160.

Hamlyn E, Jones V, Porter K, Fidler S. Antiretroviral treatment of primary HIV infection to reduce onward transmission. *Curr Opin HIV AIDS*. 2010;5(4):283-90. PMID: 20543602.

Jackson JB, Barnett S, Piwowar-Manning E, Apuzzo L, Raines C, Hendrix C, et al. A phase I/II study of nevirapine for pre-exposure prophylaxis of HIV-1 transmission in uninfected subjects at high risk. *AIDS*. 2003;17(4):547-53. PMID: 12598775.

Jewkes R, Nduna M, Levin J, Jama N, Dunkle K, Khuzwayo N, et al. A cluster randomized-controlled trial to determine the effectiveness of Stepping Stones in preventing HIV infections and promoting safer sexual behaviour amongst youth in the rural Eastern Cape, South Africa: trial design, methods and baseline findings. *Trop*

*Med Int Health*. 2006;11(1):3-16. PMID: 16398750.

Jin F, Crawford J, Prestage GP, Zablotska I, Imrie J, Kippax SC, et al. Unprotected anal intercourse, risk reduction behaviours, and subsequent HIV infection in a cohort of homosexual men. *AIDS*. 2009;23(2):243-52. PMID: 19098494.

Johnson DF, Sorvillo FJ, Wohl AR, Bunch G, Harawa NT, Carruth A, et al. Frequent failed early HIV detection in a high prevalence area: implications for prevention. *AIDS Patient Care STDs*. 2003;17(6):277-82. PMID: 12880491.

Joseph HA, Flores SA, Parsons JT, Purcell DW. Beliefs about transmission risk and vulnerability, treatment adherence, and sexual risk behavior among a sample of HIV-positive men who have sex with men. *AIDS Care*. 2010;22(1):29-39. PMID: 20390478.

Koch O, De Silva S, Edwards S, Peake T, George B, Brough G, et al. Does using self-completed sexual history questionnaires in HIV-positive men who have sex with men affect clinical outcomes? *Int J STD AIDS*. 2008;19(3):203-5. PMID: 18397564.

Mansergh G, Marks G, Rader M, Colfax GN, Buchbinder S. Rectal use of nonoxynol-9 among men who have sex with men. *AIDS*. 2003;17(6):905-9. PMID: 12660538.

Martin JN, Roland ME, Neilands TB, Krone MR, Bamberger JD, Kohn RP, et al. Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior. *AIDS*. 2004;18(5):787-92. PMID: 15075514.

Michel L, Giorgi R, Villes V, Poizot-Martin I, Dellamonica P, Spire B, et al. Withdrawal symptoms as a predictor of mortality in patients HIV-infected through drug use and receiving highly active antiretroviral therapy (HAART). *Drug Alcohol Depend*. 2009;99(1-3):96-104. PMID: 18774237.

Mohanan P, Kamath A. Family support for reducing morbidity and mortality in people with

## Appendix A4. Excluded Studies List

HIV/AIDS. *Cochrane Database Syst Rev.* 2009;(3):CD006046. PMID: 19588378.

Molto J, Ruiz L, Romeu J, Martinez-Picado J, Negredo E, Tural C, et al. Influence of prior structured treatment interruptions on the length of time without antiretroviral treatment in chronically HIV-infected subjects. *AIDS Res Hum Retroviruses.* 2004;20(12):1283-8. PMID: 15650419.

Montes de Oca Arjona M, Perez Cano R, Orozco MJ, Martin Aspas A, Guerrero F, Fernandez Gutierrez Del Alamo C, et al. Absence of favourable changes in circulating levels of interleukin-16 or beta-chemokine concentration following structured intermittent interruption treatment of chronic human immunodeficiency virus infection. *Clin Microbiol Infect.* 2005;11(1):57-62. PMID: 15649305.

Morgenstern J, Bux DA, Parsons J, Hagman BT, Wainberg M, Irwin T. Randomized trial to reduce club drug use and HIV risk behaviors among men who have sex with men. *J Consult Clin Psychol.* 2009;77(4):645-56. PMID: 19634958.

Munoz-Moreno JA, Fumaz CR, Prats A, Ferrer MJ, Negredo E, Perez-Alvarez N, et al. Interruptions of antiretroviral therapy in human immunodeficiency virus infection: are they detrimental to neurocognitive functioning? *J Neurovirol.* 2010;16(3):208-18. PMID: 20450380.

Murri R, Guaraldi G, Lupoli P, Crisafulli R, Marcotullio S, von Schloesser F, et al. Rate and predictors of self-chosen drug discontinuations in highly active antiretroviral therapy-treated HIV-positive individuals. *AIDS Patient Care STDs.* 2009;23(1):35-9. PMID: 19183079.

Mussini C, Bedini A, Borghi V, Guaraldi G, Esposito R, Barchi E, et al. CD4 cell-monitored treatment interruption in patients with a CD4 cell count >500 x 106 cells/L. *AIDS.* 2005;19(3):287-94. PMID: 15718839.

Mussini C, Pinti M, Bugarini R, Borghi V, Nasi M, Nemes E, et al. Effect of treatment

interruption monitored by CD4 cell count on mitochondrial DNA content in HIV-infected patients: a prospective study. *AIDS.* 2005;19(15):1627-33. PMID: 16184032.

Outlaw AY, Naar-King S, Parsons JT, Green-Jones M, Janisse H, Secord E. Using motivational interviewing in HIV field outreach with young African American men who have sex with men: a randomized clinical trial. *Am J Public Health.* 2010;100:1. PMID: 20147689.

Oyugi JH, Byakika-Tusiime J, Ragland K, Laeyendecker O, Mugerwa R, Kityo C, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. *AIDS.* 2007;21(8):965-71. PMID: 17457090.

Papasavvas E, Kostman JR, Mounzer K, Grant RM, Gross R, Gallo C, et al. Randomized, controlled trial of therapy interruption in chronic HIV-1 infection. *PLoS Med.* 2004;1(3):e64. PMID: 15630469.

Phillips AN, Carr A, Neuhaus J, Visnegarwala F, Prineas R, Burman WJ, et al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. *Antivir Ther.* 2008;13(2):177-87. PMID: 18505169.

Pogany K, van Valkengoed IG, Prins JM, Nieuwkerk PT, van der Ende I, Kauffmann RH, et al. Effects of active treatment discontinuation in patients with a CD4+ T-cell nadir greater than 350 cells/mm<sup>3</sup>: 48-week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN). *J Acquir Immune Defic Syndr.* 2007;44(4):395-400. PMID: 17195761.

Powers AE, Marden SF, McConnell R, Leidy NK, Campbell CM, Soeken KL, et al. Effect of long-cycle structured intermittent versus continuous HAART on quality of life in patients with chronic HIV infection. *AIDS.* 2006;20(6):837-45. PMID: 16549967.

Rieg G, Lewis RJ, Miller LG, Witt MD, Guerrero M, Daar ES. Asymptomatic sexually

## Appendix A4. Excluded Studies List

transmitted infections in HIV-infected men who have sex with men: prevalence, incidence, predictors, and screening strategies. *AIDS Patient Care STDs*. 2008;22(12):947-54. PMID: 19072101.

Sakarovitch C, Rouet F, Murphy G, Minga AK, Alioum A, Dabis F, et al. Do tests devised to detect recent HIV-1 infection provide reliable estimates of incidence in Africa? *J Acquir Immune Defic Syndr*. 2007;45(1):115-22. PMID: 17460475.

Samet JH, Freedberg KA, Stein MD, Lewis R, Savetsky J, Sullivan L, et al. Trillion virion delay: time from testing positive for HIV to presentation for primary care. *Arch Intern Med*. 1998;158(7):734-40. PMID: 9554679.

Schechter M, do Lago RF, Mendelsohn AB, Moreira RI, Moulton LH, Harrison LH, et al. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. *J Acquir Immune Defic Syndr*. 2004;35(5):519-25. PMID: 15021317.

Schmidt M, Pichl L, Jork C, Hourfar MK, Schottstedt V, Wagner FF, et al. Blood donor screening with cobas s 201/cobas TaqScreen MPX under routine conditions at German Red Cross institutes. *Vox Sang*. 2010;98(1):37-46. PMID: 19682348.

Sena AC, Hammer JP, Wilson K, Zeveloff A, Gamble J. Feasibility and acceptability of door-to-door rapid HIV testing among Latino immigrants and their HIV risk factors in North Carolina. *AIDS Patient Care STDs*. 2010;24(3):165-73. PMID: 20214484.

Smith RJ, Bodine EN, Wilson DP, Blower SM. Evaluating the potential impact of vaginal microbicides to reduce the risk of acquiring HIV in female sex workers. *AIDS*. 2005;19(4):413-21. PMID: 15750395.

Stein JA, Nyamathi A, Ullman JB, Bentler PM. Impact of marriage on HIV/AIDS risk behaviors among impoverished, at-risk couples: a multilevel latent variable approach. *AIDS Behav*. 2007;11(1):87-98. PMID: 16456729.

Steingrover R, Pogany K, Fernandez Garcia E, Jurriaans S, Brinkman K, Schuitemaker H, et al. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. *AIDS*. 2008;22(13):1583-8. PMID: 18670217.

Tesoriero JM, Battles HB, Heavner K, Leung SY, Nemeth C, Pulver W, et al. The effect of name-based reporting and partner notification on HIV testing in New York State. *Am J Public Health*. 2008;98(4):728-35. PMID: 18356570.

Vidanapathirana J, Abramson MJ, Forbes A, Fairley C. Mass media interventions for promoting HIV testing: Cochrane systematic review. *Int J Epidemiol*. 2006;35(2):233-4. PMID: 16464935.

Weis SE, Foresman B, Cook PE, Matty KJ. Universal HIV screening at a major metropolitan TB clinic: HIV prevalence and high-risk behaviors among TB patients. *Am J Public Health*. 1999;89(1):73-5. PMID: 9987468.

White DA, Scribner AN, Huang JV. A comparison of patient acceptance of fingerstick whole blood and oral fluid rapid HIV screening in an emergency department. *J Acquir Immune Defic Syndr*. 2009;52(1):75-8. PMID: 19590430.

Wurcel A, Zaman T, Zhen S, Stone D. Acceptance of HIV antibody testing among inpatients and outpatients at a public health hospital: a study of rapid versus standard testing. *AIDS Patient Care STDs*. 2005;19(8):499-505. PMID: 16124844.

Zhang S, van Sighem A, Gras L, Reiss P, Smit C, Kroon F, et al. Clinical significance of transient HIV type-1 viraemia and treatment interruptions during suppressive antiretroviral treatment. *Antivir Ther*. 2010;15(4):555-62. PMID: 20587848.

### Wrong Outcomes

Adeyemi O, Rezai K, Bahk M, Badri S, Thomas-Gossain N. Metabolic syndrome in older HIV-infected patients: data from the CORE50 cohort. *AIDS Patient Care STDs*. 2008;22(12):941-5. PMID: 19072100.

## Appendix A4. Excluded Studies List

Akers A, Bernstein L, Henderson S, Doyle J, Corbie-Smith G. Factors associated with lack of interest in HIV testing in older at-risk women. *J Womens Health*. 2007;16(6):842-58. PMID: 17678455.

Akers AY, Bernstein L, Doyle J, Corbie-Smith G. Older women and HIV testing: examining the relationship between HIV testing history, age, and lifetime HIV risk behaviors. *Sex Transm Dis*. 2008(4):420-3. PMID: 18362866.

Allen S, Meizen-Derr J, Kautzman M, Zulu I, Trask S, Fideli U, et al. Sexual behavior of HIV discordant couples after HIV counseling and testing. *AIDS*. 2003;17(5):733-40. PMID: 12646797.

Althoff KN, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RJ, et al. Late presentation for human immunodeficiency virus care in the United States and Canada. *Clin Infect Dis*. 2010;50(11):1512-20. PMID: 20415573.

Ananworanich J, Gayet-Ageron A, Le Braz M, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, et al. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. *Lancet*. 2006;368(9534):459-65. PMID: 16890832.

Ananworanich J, Gayet-Ageron A, Ruxrungtham K, Chetchotisakd P, Prasithsirikul W, Kiertiburanakul S, et al. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir. *Antivir Ther*. 2008;13(3):375-80. PMID: 18572750.

Annan NT, Nelson M, Mandalia S, Bower M, Gazzard BG, Stebbing J. The nucleoside backbone affects durability of efavirenz- or nevirapine-based highly active antiretroviral therapy in antiretroviral-naïve individuals. *J Acquir Immune Defic Syndr*. 2009;51(2):140-6. PMID: 19352201.

Antiretroviral Therapy Cohort Collaboration; Mocroft A, Sterne JA, Egger M, May M, Grabar S, et al. Variable impact on mortality of AIDS-defining events diagnosed during combination

antiretroviral therapy: not all AIDS-defining conditions are created equal. *Clin Infect Dis*. 2009;48(8):1138-51. PMID: 19275498.

Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. *Clin Infect Dis*. 2010;50(10):1387-96. PMID: 20380565.

Apondi R, Bunnell R, Ekwaru JP, Moore D, Bechange S, Khana K, et al. Sexual behavior and HIV transmission risk of Ugandan adults taking antiretroviral therapy: 3 year follow-up. *AIDS*. 2011;25(10):1317-27. PMID: 21522005.

Apuzzo LG, Vaida F, Gallant JE, Ernstrom KB, Little SJ, Routy JP, et al. Tolerability and efficacy of PI versus NNRTI-based regimens in subjects receiving HAART during acute or early HIV infection. *J Acquir Immune Defic Syndr*. 2009;50(3):267-75. PMID: 19194317.

Arasteh K, Des Jarlais DC. HIV testing and treatment among at-risk drinking injection drug users. *J Int Assoc Physicians AIDS Care*. 2009;8(3):196-201. PMID: 19414827.

Arribas JR, Horban A, Gerstoft J, Fatkenheuer G, Nelson M, Clumeck N, et al. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/mL. *AIDS*. 2010;24(2):223-30. PMID: 20010070.

Avants SK, Warburton LA, Margolin A. How injection drug users coped with testing HIV-seropositive: implications for subsequent health-related behaviors. *AIDS Educ Prev*. 2001;13(3):207-18. PMID: 11459357.

Awad GH, Sagrestano LM, Kittleson MJ, Sarvela PD. Development of a measure of barriers to HIV testing among individuals at high risk. *AIDS Educ Prev*. 2004;16(2):115-25. PMID: 15134120.

Bachmann LH, Grimley DM, Waithaka Y, Desmond R, Saag MS, Hook EW 3rd. Sexually transmitted disease/HIV transmission risk behaviors and sexually transmitted disease



## Appendix A4. Excluded Studies List

prevalence among HIV-positive men receiving continuing care. *Sex Transm Dis.* 2005;32(1):20-6. PMID: 15614117.

Baggaley RF, White RG, Boily MC. HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. *Int J Epidemiol.* 2010;39(4):1048-63. PMID: 20406794.

Batterham P, Rice E, Rotheram-Borus MJ. Predictors of serostatus disclosure to partners among young people living with HIV in the pre- and post-HAART eras. *AIDS Behav.* 2005;9(3):281-7. PMID: 16088367.

Beckwith CG, Atunah-Jay S, Cohen J, Macalino G, Poshkus M, Rich JD, et al. Feasibility and acceptability of rapid HIV testing in jail. *AIDS Patient Care STDs.* 2007;21(1):41-7. PMID: 17263656.

Bedimo RJ, McGinnis KA, Dunlap M, Rodriguez-Barradas MC, Justice AC. Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression. *J Acquir Immune Defic Syndr.* 2009;52(2):203-8. PMID: 19617846.

Bell DN, Martinez J, Botwinick G, Shaw K, Walker LE, Dodds S, et al. Case finding for HIV-positive youth: a special type of hidden population. *J Adolesc Health.* 2003;33(2 Suppl):10-22. PMID: 12888283.

Bennett M, Strachan E, Uldall K. Development and initial validation of a brief screener for focused HIV prevention efforts. *HIV Med.* 2010;11(5):318-25. PMID: 20002502.

Berenguer J, Gonzalez J, Ribera E, Domingo P, Santos J, Miralles P, et al. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903. *Clin Infect Dis.* 2008;47(8):1083-92. PMID: 18781872.

Bernstein KT, Begier E, Burke R, Karpati A, Hogben M. HIV screening among U.S. physicians, 1999-2000. *AIDS Patient Care STDs.* 2008;22(8):649-56. PMID: 18627282.

Bernstein KT, Liu KL, Begier EM, Koblin B, Karpati A, Murrill C. Same-sex attraction disclosure to health care providers among New York City men who have sex with men: implications for HIV testing approaches. *Arch Intern Med.* 2008;168(13):1458-64. PMID: 18625927.

Binson D, Woods WJ, Pollack L, Sheon N. Bringing HIV/STI testing programmes to high-risk men. *Int J STD AIDS.* 2005;16(9):600-4. PMID: 16176625.

Blair CR, Gill CE, Taylor HM, McGowan CC, Charles PD. Testing for HIV-1 infection in a public developmental center. *Tenn Med.* 2009;102(9):51-3. PMID: 19791542.

Blanckenberg DH, Wood R, Horban A, Beniowski M, Boron-Kaczmarek A, Trocha H, et al. Evaluation of nevirapine and/or hydroxyurea with nucleoside reverse transcriptase inhibitors in treatment-naive HIV-1-infected subjects. *AIDS.* 2004;18(4):631-40. PMID: 15090768.

Bogart LM, Howerton D, Lange J, Setodji CM, Becker K, Klein DJ, et al. Provider-related barriers to rapid HIV testing in U.S. urban non-profit community clinics, community-based organizations (CBOs) and hospitals. *AIDS Behav.* 2010;14(3):697-707. PMID: 18770022.

Boily MC, Baggaley RF, Wang L, Masse B, White RG, Hayes RJ, et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. *Lancet Infect Dis.* 2009;9(2):118-29. PMID: 19179227.

Boily MC, Bastos FI, Desai K, Masse B. Changes in the transmission dynamics of the HIV epidemic after the wide-scale use of antiretroviral therapy could explain increases in sexually transmitted infections: results from mathematical models. *Sex Transm Dis.* 2004;31(2):100-13. PMID: 14743073.

## Appendix A4. Excluded Studies List

- Bond L, Lauby J, Batson H. HIV testing and the role of individual- and structural-level barriers and facilitators. *AIDS Care*. 2005;17(2):125-40. PMID: 15763709.
- Bonney EA, Crosby R, Odenat L. Repeat HIV testing among low-income minority women: a descriptive analysis of factors influencing decisional balance. *Ethn Dis*. 2004;14(3):330-5. PMID: 15328933.
- Boschi A, Tinelli C, Ortolani P, Arlotti M. Safety and factors predicting the duration of first and second treatment interruptions guided by CD4+ cell counts in patients with chronic HIV infection. *J Antimicrob Chemother*. 2006;57(3):520-6. PMID: 16387747.
- Bouhnik AD, Preau M, Schiltz MA, Lert F, Obadia Y, Spire B, et al. Unprotected sex in regular partnerships among homosexual men living with HIV: a comparison between sero-nonconcordant and seroconcordant couples (ANRS-EN12-VESPA Study). *AIDS*. 2007;21(Suppl 1):S43-8. PMID: 17159586.
- Bouldouyre MA, Charreau I, Marchou B, Tangre P, Katlama C, Morlat P, et al. Incidence and risk factors of thrombocytopenia in patients receiving intermittent antiretroviral therapy: a substudy of the ANRS 106-window trial. *J Acquir Immune Defic Syndr*. 2009;52(5):531-7. PMID: 19855285.
- Bower M, Fisher M, Hill T, Reeves I, Walsh J, Orkin C, et al. CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK. *Haematologica*. 2009;94(6):875-80. PMID: 19336735.
- Braithwaite RS, Kozal MJ, Chang CC, Roberts MS, Fultz SL, Goetz MB, et al. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies. *AIDS*. 2007;21(12):1579-89. PMID: 17630553.
- Brewer DD, Golden MR, Handsfield HH. Unsafe sexual behavior and correlates of risk in a probability sample of men who have sex with men in the era of highly active antiretroviral therapy. *Sex Transm Dis*. 2006;33(4):250-5. PMID: 16505748.
- Brown J, Kuo I, Bellows J, Barry R, Bui P, Wohlgenuth J, et al. Patient perceptions and acceptance of routine emergency department HIV testing. *Public Health Rep*. 2008;3:21-6. PMID: 19172703.
- Brown J, Shesser R, Simon G, Bahn M, Czarnogorski M, Kuo I, et al. Routine HIV screening in the emergency department using the new US Centers for Disease Control and Prevention guidelines: results from a high-prevalence area. *J Acquir Immune Defic Syndr*. 2007;46(4):395-401. PMID: 18077831.
- Burchell AN, Calzavara LM, Myers T, Schlossberg J, Millson M, Escobar M, et al. Voluntary HIV testing among inmates: sociodemographic, behavioral risk, and attitudinal correlates. *J Acquir Immune Defic Syndr*. 2003;32(5):534-41. PMID: 12679706.
- Butler DM, Smith DM, Cachay ER, Hightower GK, Nugent CT, Richman DD, et al. Herpes simplex virus 2 serostatus and viral loads of HIV-1 in blood and semen as risk factors for HIV transmission among men who have sex with men. *AIDS*. 2008;22(13):1667-71. PMID: 18670228.
- Byakwaga H, Murray JM, Petoumenos K, Kelleher AD, Law MG, Boyd MA, et al. Evolution of CD4+ T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression. *AIDS Res Hum Retroviruses*. 2009;25(6):756-76. PMID: 19500017.
- Bygrave H, Ford N, van Cutsem G, Hilderbrand K, Jouquet G, Goemaere E, et al. Implementing a tenofovir-based first-line regimen in rural Lesotho: clinical outcomes and toxicities after two years. *J Acquir Immune Defic Syndr*. 2011;56(3):e75-8. PMID: 21164354.
- Cabrero E, Griffa L, Burgos A; HIV Body Physical Changes Study Group. Prevalence and impact of body physical changes in HIV patients treated with highly active antiretroviral therapy: results from a study on patient and physician

## Appendix A4. Excluded Studies List

perceptions. *AIDS Patient Care STDs*. 2010;24(1):5-13. PMID: 20095903.

Cade WT, Reeds DN, Mittendorfer B, Patterson BW, Powderly WG, Klein S, et al. Blunted lipolysis and fatty acid oxidation during moderate exercise in HIV-infected subjects taking HAART. *Am J Physiol*. 2007;292(3):e812-9. PMID: 17106066.

Calderon Y, Leider J, Hailpern S, Haughey M, Ghosh R, Lombardi P, et al. A randomized control trial evaluating the educational effectiveness of a rapid HIV post-test counseling video. *Sex Transm Dis*. 2009;36(4):207-10. PMID: 19265735.

Callegari L, Harper CC, van der Straten A, Kamba M, Chipato T, Padian NS. Consistent condom use in married Zimbabwean women after a condom intervention. *Sex Transm Dis*. 2008;35(6):624-30. PMID: 18545141.

Candiani TM, Pinto J, Cardoso CA, Carvalho IR, Dias AC, Carneiro M, et al. Impact of highly active antiretroviral therapy (HAART) on the incidence of opportunistic infections, hospitalizations and mortality among children and adolescents living with HIV/AIDS in Belo Horizonte, Minas Gerais State, Brazil. *Cad Saude Publica*. 2007;23(Suppl 3):S414-23. PMID: 17992347.

Carballo-Diéguez A, O'Sullivan L, Lin P, Dolezal C, Pollack L, Catania J. Awareness and attitudes regarding microbicides and nonoxynol-9 use in a probability sample of gay men. *AIDS Behav*. 2007;11(2):271-6. PMID: 16775772.

Cardoso SW, Grinsztejn B, Velasque L, Veloso VG, Luz PM, Friedman RK, et al. Incidence of modifying or discontinuing first HAART regimen and its determinants in a cohort of HIV-infected patients from Rio de Janeiro, Brazil. *AIDS Res Hum Retroviruses*. 2010;26(8):865-74. PMID: 20672997.

Carnicer-Pont D, de Olalla PG, Cayla JA; AIDS Working Group. HIV infection late detection in AIDS patients of an European city with increased immigration since mid 1990s. *Curr HIV Res*. 2009;7(2):237-43. PMID: 19275593.

Carr A, Amin J. Efficacy and tolerability of initial antiretroviral therapy: a systematic review *AIDS*. 2009;23(3):343-53. PMID: 19114855.

Carr A, Ritzhaupt A, Zhang W, Zajdenverg R, Workman C, Gatell JM, et al. Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naïve adults. *AIDS*. 2008;22(17):2313-21. PMID: 18981770.

Carrico AW, Antoni MH, Duran RE, Ironson G, Penedo F, Fletcher MA, et al. Reductions in depressed mood and denial coping during cognitive behavioral stress management with HIV-positive gay men treated with HAART. *Ann Behavioral Med*. 2006;31(2):155-64. PMID: 16542130.

Carrico AW, Antoni MH, Weaver KE, Lechner SC, Schneiderman N. Cognitive-behavioural stress management with HIV-positive homosexual men: mechanisms of sustained reductions in depressive symptoms. *Chronic Illn*. 2005;1(3):207-15. PMID: 17152183.

Carvalho FT, Goncalves TR, Faria ER, Shoveller JA, Piccinini CA, Ramos MC, et al. Behavioral interventions to promote condom use among women living with HIV. *Cochrane Database of Syst Rev*. 2011;(9):CD007844. PMID: 21901711.

Casado A, Badia X, Consiglio E. Health-related quality of life in HIV-infected naïve patients treated with nelfinavir or nevirapine associated with ZDV/3TC (the COMBINE-QoL Substudy). *HIV Clinical Trials*. 2004;5(3):132-9. PMID: 15248137.

Catz SL, Meredith KL, Mundy LM. Women's HIV transmission risk perceptions and behaviors in the era of potent antiretroviral therapies. *AIDS Educ Prev*. 2001;13(3):239-51. PMID: 11459360.

Cesar C, Shepherd BE, Krolewiecki AJ, Fink VI, Schechter M, Tuboi SH, et al. Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America. *PLoS One*. 2010;5(6):e10490. PMID: 20531956.

## Appendix A4. Excluded Studies List

- Chandwani S, Abramowitz S, Koenig LJ, Barnes W, D'Angelo L. A multimodal behavioral intervention to impact adherence and risk behavior among perinatally and behaviorally HIV-infected youth: description, delivery, and receptivity of adolescent impact. *AIDS Educ Prev*. 2011;23(3):222-35. PMID: 21696241.
- Chan-Tack KM, Truffa MM, Struble KA, Birnkrant DB. Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's adverse event reporting system. *AIDS*. 2007;21(9):1215-8. PMID: 17502736.
- Cheng CY, Chen MY, Hsieh SM, Sheng WH, Sun HY, Lo YC, et al. Risk of pneumocystosis after early discontinuation of prophylaxis among HIV-infected patients receiving highly active antiretroviral therapy. *BMC Infect Dis*. 2010;10:126. PMID: 20492660.
- Cherry CL, Skolasky RL, Lal L, Creighton J, Hauer P, Raman SP, et al. Antiretroviral use and other risks for HIV-associated neuropathies in an international cohort. *Neurology*. 2006;66(6):867-73. PMID: 16567704.
- Chowers M, Gottesman BS, Leibovici L, Schapiro JM, Paul M. Nucleoside reverse transcriptase inhibitors in combination therapy for HIV patients: systematic review and meta-analysis. *Eur J Clin Microbiol Infect Dis*. 2010;29(7):779-86. PMID: 20449621.
- Chu H, Gange SJ, Li X, Hoover DR, Liu C, Chmiel JS, et al. The effect of HAART on HIV RNA trajectory among treatment-naïve men and women: a segmental Bernoulli/lognormal random effects model with left censoring. *Epidemiology*. 2010;21(Suppl 4):S25-34. PMID: 20386106.
- Clark A, Mayben JK, Hartman C, Kallen MA, Giordano TP. Conspiracy beliefs about HIV infection are common but not associated with delayed diagnosis or adherence to care. *AIDS Patient Care STDs*. 2008;22(9):753-9. PMID: 18754706.
- Collaboration of HIV Cohorts. Nucleoside analogue use before and during highly active antiretroviral therapy and virus load rebound. *J Infect Dis*. 2004;190(4):675-87. PMID: 15272393.
- Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group; Sabin CA, Smith CJ, d'Arminio Monforte A, Battegay M, Gabiano C, et al. Response to combination antiretroviral therapy: variation by age. *AIDS*. 2008;22(12):1463-73. PMID: 18614870.
- Collazos J, Asensi V, Carton JA; Grupo Español Para El Estudio Multifactorial De La Adherencia (GEEMA). Factors associated with poor immunologic responses despite viral suppression in markedly immunosuppressed patients. *AIDS Patient Care STDs*. 2007;21(6):378-84. PMID: 17594246.
- Copenhaver MM, Lee IC, Margolin A, Bruce RD, Altice FL. Testing an optimized community-based human immunodeficiency virus (HIV) risk reduction and antiretroviral adherence intervention for HIV-infected injection drug users. *Subst Abuse*. 2011;32(1):16-26. PMID: 21302180.
- Corral I, Quereda C, Moreno A, Perez-Elias MJ, Dronda F, Casado JL, et al. Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors. *Cerebrovasc Dis*. 2009;27(6):559-63. PMID: 19390181.
- Crawford KW, Spritzler J, Kalayjian RC, Parsons T, Landay A, Pollard R, et al. Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir. *AIDS Res Hum Retroviruses*. 2010;26(6):635-43. PMID: 20560793.
- Crum-Cianflone N, Hullsiek KH, Satter E, Marconi V, Weintrob A, Ganesan A, et al. Cutaneous malignancies among HIV-infected persons. *Arch Intern Med*. 2009;169(12):1130-8. PMID: 19546414.
- Crum-Cianflone NF, Hullsiek KH, Marconi V, Weintrob A, Ganesan A, Barthel RV, et al. The impact of nelfinavir exposure on cancer development among a large cohort of HIV-

## Appendix A4. Excluded Studies List

infected patients. *J Acquir Immune Defic Syndr*. 2009;51(3):305-9. PMID: 19412116.

Crystal HA, Weedon J, Holman S, Manly J, Valcour V, Cohen M, et al. Associations of cardiovascular variables and HAART with cognition in middle-aged HIV-infected and uninfected women. *J Neurovirol*. 2011;17(5):469-76. PMID: 22006469.

Daher EF, Cezar LC, Silva GB Jr, Lima RS, Damasceno LS, Lopes EB, et al. Metabolic acidosis in AIDS patients. *Arch Med Res*. 2009;40(2):109-13. PMID: 19237020.

d'Almeida KW, Kierzek G, de Truchis P, Le Vu S, Pateron D, Renaud B, et al. Modest public health impact of nontargeted human immunodeficiency virus screening in 29 emergency departments. *Arch Intern Med*. 2012;172(1):12-20. PMID: 22025095

Danta M, Brown D, Bhagani S, Pybus OG, Sabin CA, Nelson M, et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. *AIDS*. 2007;21(8):983-91. PMID: 17457092.

d'Arminio Monforte A, Cozzi-Lepri A, Phillips A, De Luca A, Murri R, Mussini C, et al. Interruption of highly active antiretroviral therapy in HIV clinical practice: results from the Italian Cohort of Antiretroviral-Naive Patients. *J Acquir Immune Defic Syndr*. 2005;38(4):407-16. PMID: 15764957.

Das-Douglas M, Zetola NM, Klausner JD, Colfax GN. Written informed consent and HIV testing rates: the San Francisco experience. *Am J Public Health*. 2008;98(9):1544-5. PMID: 18633069.

Dave SS, Stephenson J, Mercey DE, Panahmand N, Jungmann E. Sexual behaviour, condom use, and disclosure of HIV status in HIV infected heterosexual individuals attending an inner London HIV clinic. *Sex Transm Infect*. 2006;82(2):117-9. PMID: 16581734.

Davey RT, Pertel PE, Benson A, Cassell DJ, Gazzard BG, Holodniy M, et al. Safety,

tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy. *J Interferon Cytokine Res*. 2008;28(2):89-100. PMID: 18279104.

de Boer-van der Kolk IM, Sprangers MA, Prins JM, Smit C, de Wolf F, Nieuwkerk PT. Health-related quality of life and survival among HIV-infected patients receiving highly active antiretroviral therapy: a study of patients in the AIDS Therapy Evaluation in the Netherlands (ATHENA) Cohort. *Clin Infect Dis*. 2010;50(2):255-63. PMID: 20014949.

De Luca A, Weidler J, Di Giambenedetto S, Coakley E, Cingolani A, Bates M, et al. Association of HIV-1 replication capacity with treatment outcomes in patients with virologic treatment failure. *J Acquir Immune Defic Syndr*. 2007;45(4):411-7. PMID: 17554216.

de Souza Goncalves L, Souto R, Colombo AP. Detection of *Helicobacter pylori*, *Enterococcus faecalis*, and *Pseudomonas aeruginosa* in the subgingival biofilm of HIV-infected subjects undergoing HAART with chronic periodontitis. *Eur J Clin Microbiol Infect Dis*. 2009;28(11):1335-42. PMID: 19639349.

Debattista J, Bryson G, Roudenko N, Dwyer J, Kelly M, Hogan P, et al. Pilot of non-invasive (oral fluid) testing for HIV within a clinical setting. *Sex Health*. 2007;4(2):105-9. PMID: 17524288.

Degano B, Yaici A, Le Pavec J, Savale L, Jais X, Camara B, et al. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. *Eur Respir J*. 2009;33(1):92-8. PMID: 18799506.

DeJesus E, McCarty D, Farthing CF, Shortino DD, Grinsztejn B, Thomas DA, et al. Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial. *Clin Infect Dis*. 2004;39(3):411-8. PMID: 15307010.

Delaugerre C, Buyck JF, Peytavin G, Viard JP, Chaix ML, Zucman D, et al. Factors predictive

## Appendix A4. Excluded Studies List

of successful darunavir/ritonavir-based therapy in highly antiretroviral-experienced HIV-1-infected patients (the DARWEST study). *J Clin Virol.* 2010;47(3):248-52. PMID: 20097121.

Delaugerre C, Peytavin G, Dominguez S, Marcelin AG, Duvivier C, Gourelain K, et al. Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097). *J Med Virol.* 2005;77(3):345-50. PMID: 16173015.

Des Jarlais DC, Friedmann P, Hagan H, Friedman SR. The protective effect of AIDS-related behavioral change among injection drug users: a cross-national study. *Am J Public Health.* 1996;86(12):1780-5. PMID: 9003137.

Desquilbet L, Margolick JB, Fried LP, Phair JP, Jamieson BD, Holloway M, et al. Relationship between a frailty-related phenotype and progressive deterioration of the immune system in HIV-infected men. *J Acquir Immune Defic Syndr.* 2009;50(3):299-306. PMID: 19194312.

Di Giambenedetto S, Torti C, Prosperi M, Manca N, Lapadula G, Parainfo G, et al. Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study. *Infection.* 2009;37(5):438-44. PMID: 19669091.

Di Giambenedetto S, Zazzi M, Corsi P, Gonnelli A, Di Pietro M, Giacometti A, et al. Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy. *Antivir Ther.* 2009;14(3):359-69. PMID: 19474470.

Di Rocco A, Werner P, Bottiglieri T, Godbold J, Liu M, Tagliati M, et al. Treatment of AIDS-associated myelopathy with L-methionine: a placebo-controlled study. *Neurology.* 2004;63(7):1270-5. PMID: 15477550.

Diallo DD, Moore TW, Ngalame PM, White LD, Herbst JH, Painter TM. Efficacy of a single-session HIV prevention intervention for black

women: a group randomized controlled trial. *AIDS Behav.* 2010;14(3):518-29. PMID: 20135214.

DiClemente RJ, Wingood GM, Del Rio C, Crosby RA. Prevention interventions for HIV positive individuals. *Sex Transm Infect.* 2002;78(6):393-5. PMID: 12473796.

Dietz E, Clum GA, Chung SE, Leonard L, Murphy DA, Perez LV, et al. Adherence to scheduled appointments among HIV-infected female youth in five U.S. cities. *J Adolesc Health.* 2010;46(3):278-83. PMID: 20159506.

Dilley JW, Woods WJ, Loeb L, Nelson K, Sheon N, Mullan J, et al. Brief cognitive counseling with HIV testing to reduce sexual risk among men who have sex with men: results from a randomized controlled trial using paraprofessional counselors. *J Acquir Immune Defic Syndr.* 2007;44(5):569-77. PMID: 17310937.

Dilley JW, Woods WJ, Sabatino J, Lihatsch T, Adler B, Casey S, et al. Changing sexual behavior among gay male repeat testers for HIV: a randomized, controlled trial of a single-session intervention. *J Acquir Immune Defic Syndr.* 2002;30(2):177-86. PMID: 12045680.

DiScenza S, Nies M, Jordan C. Effectiveness of counseling in the health promotion of HIV-positive clients in the community. *Public Health Nurs.* 1996;13(3):209-16. PMID: 8677237.

Dodds JP, Mercey DE, Parry JV, Johnson AM. Increasing risk behaviour and high levels of undiagnosed HIV infection in a community sample of homosexual men. *Sex Transm Infect.* 2004;80(3):236-40. PMID: 15170012.

D'Offizi G, Gioia C, Corpolongo A, Martini F, Paganelli R, Volpi I, et al. An IL-15 dependent CD8 T cell response to selected HIV epitopes is related to viral control in early-treated HIV-infected subjects. *Int J Immunopathol Pharmacol.* 2007;20(3):473-85. PMID: 17880761.

Dolezal C, Meyer-Bahlburg HF, Liu X, Ehrhardt AA, Exner TM, Rabkin JG, et al. Longitudinal

## Appendix A4. Excluded Studies List

changes in sexual risk behavior among HIV+ and HIV- male injecting drug users. *Am J Drug Alcohol Abuse*. 1999;25(2):281-303. PMID: 10395161.

Domingo P, Cabeza MC, Pruvost A, Salazar J, Gutierrez Mdel M, Mateo MG, et al. Relationship between HIV/highly active antiretroviral therapy (HAART)-associated lipodystrophy syndrome and stavudine-triphosphate intracellular levels in patients with stavudine-based antiretroviral regimens. *Clin Infect Dis*. 2010;50(7):1033-40. PMID: 20192724.

Domingo P, Suarez-Lozano I, Torres F, Pomar V, Ribera E, Galindo MJ, et al. Bacterial meningitis in HIV-1-infected patients in the era of highly active antiretroviral therapy. *J Acquir Immune Defic Syndr*. 2009;51(5):582-7. PMID: 19512939.

Donnell-Fink L, Reichmann WM, Arbelaez C, Case AL, Katz JN, Losina E, et al. Patient satisfaction with rapid HIV testing in the emergency department. *Ann Emerg Med*. 2011;58(Suppl 1):S49-52. PMID: 21684408.

Dorrucchi M, Phillips AN, Longo B, Rezza G; Italian Seroconversion Study. Changes over time in post-seroconversion CD4 cell counts in the Italian HIV-Seroconversion Study: 1985-2002. *AIDS*. 2005;19(3):331-5. PMID: 15718844.

Drylewicz J, Matheron S, Lazaro E, Damond F, Bonnet F, Simon F, et al. Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France. *AIDS*. 2008;22(4):457-68. PMID: 18301058.

D'Souza G, Wiley DJ, Li X, Chmiel JS, Margolick JB, Cranston RD, et al. Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study. *J Acquir Immune Defic Syndr*. 2008;48(4):491-9. PMID: 18614927.

Dukers NH, Stolte IG, Albrecht N, Coutinho RA, de Wit JB. The impact of experiencing lipodystrophy on the sexual behaviour and well-being among HIV-infected homosexual men. *AIDS*. 2001;15(6):812-3. PMID: 11371704.

Dunic I, Vesic S, Jevtovic DJ. Oral candidiasis and seborrheic dermatitis in HIV-infected patients on highly active antiretroviral therapy. *HIV Med*. 2004;5(1):50-4. PMID: 14731170.

Duval X, Mentre F, Rey E, Auleley S, Peytavin G, Biour M, et al. Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen—ANRS 111 trial. *Fundam Clin Pharmacol*. 2009;23(4):491-500. PMID: 19709326.

Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, Murphy RL, et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. *AIDS*. 2009;23(7):817-24. PMID: 19363330.

Ehrenkranz PD, Ahn CJ, Metlay JP, Camargo CA Jr, Holmes WC, Rothman R. Availability of rapid human immunodeficiency virus testing in academic emergency departments. *Acad Emerg Med*. 2008;15(2):144-50. PMID: 18275444.

Einsiedel L, Cherry CL, Sheeran FL, Friedhuber A, Wesselingh SL, Pepe S. Mitochondrial dysfunction in CD4+ lymphocytes from stavudine-treated HIV patients. *Mitochondrion*. 2010;10(5):534-9. PMID: 20685321.

Elford J. HIV treatment optimism and high-risk sexual behaviour among gay men: the attributable population risk. *AIDS*. 2004;18(16):2216-7. PMID: 15577662.

Ellis RJ, Marquie-Beck J, Delaney P, Alexander T, Clifford DB, McArthur JC, et al. Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. *Ann Neurol*. 2008;64(5):566-72. PMID: 19067367.

El-Sadr WM, Mayer KH, Maslankowski L, Hoesley C, Justman J, Gai F, et al. Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women. *AIDS*. 2006;20(8):1109-16. PMID: 16691061.

Ena J, Leach A, Nguyen P. Switching from suppressive protease inhibitor-based regimens to

## Appendix A4. Excluded Studies List

nevirapine-based regimens: a meta-analysis of randomized controlled trials. *HIV Med.* 2008;9(9):747-56. PMID: 18651856.

Eron JJ, Feinberg J, Kessler HA, Horowitz HW, Witt MD, Carpio FF, et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial. *J Infect Dis.* 2004;189(2):265-72. PMID: 14722892.

European Partner Notification Study Group. Recently diagnosed sexually HIV-infected patients: seroconversion interval, partner notification period and a high yield of HIV diagnoses among partners. *QJM.* 2001;94(7):379-90. PMID: 11435634.

Evans WJ, Kotler DP, Staszewski S, Griffin GE, Isgaard J, Gertner JM, et al. Effect of recombinant human growth hormone on exercise capacity in patients with HIV-associated wasting on HAART. *AIDS Read.* 2005;15(6):301-3. PMID: 15962453.

Fabbiani M, Di Giambenedetto S, Ragazzoni E, Colafigli M, Prosperi M, Cauda R, et al. Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection. *HIV Med.* 2010;11(5):326-33. PMID: 20070407.

Falasca K, Ucciferri C, Mancino P, Di Iorio A, Vignale F, Pizzigallo E, et al. Cystatin C, adipokines and cardiovascular risk in HIV infected patients. *Curr HIV Res.* 2010;8(5):405-10. PMID: 20426756.

Fang CT, Chang YY, Hsu HM, Twu SJ, Chen KT, Lin CC, et al. Life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy. *QJM.* 2007;100(2):97-105. PMID: 17277317.

Farquhar C, Kiarie JN, Richardson BA, Kabura MN, John FN, Nduati RW, et al. Antenatal couple counseling increases uptake of interventions to prevent HIV-1 transmission. *J Acquir Immune Defic Syndr.* 2004;37(5):1620-6. PMID: 15577420.

Fielden SJ, Rusch ML, Yip B, Wood E, Shannon K, Levy AR, et al. Nonadherence increases the risk of hospitalization among HIV-infected antiretroviral naive patients started on HAART. *J Int Assoc Physicians AIDS Care.* 2008;7(5):238-44. PMID: 18812590.

Fischl MA, Collier AC, Mukherjee AL, Feinberg JE, Demeter LM, Tebas P, et al. Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen. *AIDS.* 2007;21(3):325-33. PMID: 17255739.

Fisher JD, Fisher WA, Cornman DH, Amico RK, Bryan A, Friedland GH. Clinician-delivered intervention during routine clinical care reduces unprotected sexual behavior among HIV-infected patients. *J Acquir Immune Defic Syndr.* 2006;41(1):44-52. PMID: 16340472.

Fitch KV, Anderson EJ, Hubbard JL, Carpenter SJ, Waddell WR, Caliendo AM, et al. Effects of a lifestyle modification program in HIV-infected patients with the metabolic syndrome. *AIDS.* 2006;20(14):1843-50. PMID: 16954725.

Flexner C, Tierney C, Gross R, Andrade A, Lalama C, Eshleman SH, et al. Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS Clinical Trials Group (ACTG) A5073, a 48-week randomized controlled trial. *Clin Infect Dis.* 2010;50(7):1041-52. PMID: 20192725.

Florence E, De Wit S, Castagna A, Ribera E, Hill A, Vanaken H, et al. HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme. *Int J STD AIDS.* 2010;21(3):224-5. PMID: 20071441.

Florence E, Garcia F, Plana M, Fumero E, Castro P, Lopez A, et al. Long-term clinical follow-up, without antiretroviral therapy, of patients with chronic HIV-1 infection with good virological response to structured treatment interruption. *Clin Infect Dis.* 2004;39(4):569-74. PMID: 15356824.



## Appendix A4. Excluded Studies List

- Florida M, Bucciardini R, Fragola V, Galluzzo CM, Giannini G, Pirillo MF, et al. Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/ $\mu$ L). *HIV Med.* 2004;5(1):1-10. PMID: 14731162.
- Fogarty LA, Heilig CM, Armstrong K, Cabral R, Galavotti C, Gielen AC, et al. Long-term effectiveness of a peer-based intervention to promote condom and contraceptive use among HIV-positive and at-risk women. *Public Health Rep.* 2001;116(Suppl 1):103-19. PMID: 11889279.
- Foglia G, Royster G, Wasunna KM, Kibaya R, Malia JA, Calero EK, et al. Use of rapid and conventional testing technologies for human immunodeficiency virus type 1 serologic screening in a rural Kenyan reference laboratory. *J Clin Microbiol.* 2004;42(8):3850-2. PMID: 15297547.
- Foley K, Duran B, Morris P, Lucero J, Jiang Y, Baxter B, et al. Using motivational interviewing to promote HIV testing at an American Indian substance abuse treatment facility. *J Psychoactive Drugs.* 2005;37(3):321-9. PMID: 16295016.
- Foli A, Maserati R, Barasolo G, Castelli F, Tomasoni L, Migliorino M, et al. Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatment interruptions. *Antivir Ther.* 2004;9(1):123-32. PMID: 15040544.
- Ford N, Darder M, Spelman T, Maclean E, Mills E, Boule A. Early adherence to antiretroviral medication as a predictor of long-term HIV virological suppression: five-year follow up of an observational cohort. *PLoS One.* 2010;5(5):e10460. PMID: 20485480.
- Fox Z, Phillips A, Cohen C, Neuhaus J, Baxter J, Emery S, et al. Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen. *AIDS.* 2008;22(17):2279-89. PMID: 18981767.
- Franceschi S, Lise M, Clifford GM, Rickenbach M, Levi F, Maspoli M, et al. Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. *Br J Cancer.* 2010;103(3):416-22. PMID: 20588274.
- Francis SA, Lam WK, Cance JD, Hogan VK. What's the 411? Assessing the feasibility of providing African American adolescents with HIV/AIDS prevention education in a faith-based setting. *J Relig Health.* 2009;48(2):164-77. PMID: 19421867.
- Francisci D, Giannini S, Baldelli F, Leone M, Belfiori B, Guglielmini G, et al. HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction. *AIDS.* 2009;23(5):589-96. PMID: 19177019.
- Frost DM, Stirratt MJ, Ouellette SC. Understanding why gay men seek HIV-seroconcordant partners: intimacy and risk reduction motivations. *Cult Health Sex.* 2008;10(5):513-27. PMID: 18568873
- Fumaz CR, Munoz-Moreno JA, Molto J, Negredo E, Ferrer MJ, Sirera G, et al. Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychological issues, and adherence. *J Acquir Immune Defic Syndr.* 2005;38(5):560-5. PMID: 15793366.
- Gagnon H, Godin G, Alary M, Bruneau J, Otis J. A randomized trial to evaluate the efficacy of a computer-tailored intervention to promote safer injection practices among drug users. *AIDS Behav.* 2010;14(3):538-48. PMID: 20033276.
- Gaitan-Cepeda LA, Dominguez-Sanchez A, Pavia-Ruz N, Munoz-Hernandez R, Verdugo-Diaz R, Valles-Medina AM, et al. Oral lesions in HIV+/AIDS adolescents perinatally infected undergoing HAART. *Med Oral Patol Oral Cir Bucal.* 2010;15(4):e545-50. PMID: 20173726.
- Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine,

## Appendix A4. Excluded Studies List

lamivudine, and efavirenz for HIV. *N Engl J Med*. 2006;354(3):251-60. PMID: 16421366.

Gallant JE, Moore RD. Renal function with use of a tenofovir-containing initial antiretroviral regimen. *AIDS*. 2009;23(15):1971-5. PMID: 19696652.

Gallant JE, Winston JA, DeJesus E, Pozniak AL, Chen SS, Cheng AK, et al. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naïve patients. *AIDS*. 2008;22(16):2155-63. PMID: 18832879.

Garcia F, Plana M, Arnedo M, Brunet M, Castro P, Gil C, et al. Effect of mycophenolate mofetil on immune response and plasma and lymphatic tissue viral load during and after interruption of highly active antiretroviral therapy for patients with chronic HIV infection: a randomized pilot study. *J Acquir Immune Defic Syndr*. 2004;36(3):823-30. PMID: 15213566.

Gardner EM, Sharma S, Peng G, Hullsiek KH, Burman WJ, Macarthur RD, et al. Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. *AIDS*. 2008;22(1):75-82. PMID: 18090394.

Gardner LI, Marks G, O'Daniels CM, Wilson TE, Golin C, Wright J, et al. Implementation and evaluation of a clinic-based behavioral intervention: positive steps for patients with HIV. *AIDS Patient Care STDs*. 2008;22(8):627-35. PMID: 18627280.

Garrabou G, Moren C, Gallego-Escuredo JM, Milinkovic A, Villarroya F, Negro E, et al. Genetic and functional mitochondrial assessment of HIV-infected patients developing HAART-related hyperlactatemia. *J Acquir Immune Defic Syndr*. 2009;52(4):443-51. PMID: 19779356.

Gasiorowicz M, Llanas MR, DiFranceisco W, Benotsch EG, Brondino MJ, Catz SL, et al. Reductions in transmission risk behaviors in HIV-positive clients receiving prevention case management services: findings from a community demonstration project. *AIDS Educ*

*Prev*. 2005;17(1 Suppl A):40-52. PMID: 15838199.

Gaur AH, Belzer M, Britto P, Garvie PA, Hu C, Graham B, et al. Directly observed therapy (DOT) for nonadherent HIV-infected youth: lessons learned, challenges ahead. *AIDS Res Hum Retroviruses*. 2010;26(9):947-53. PMID: 20707731.

Ghosn J, Flandre P, Cohen-Codar I, Girard PM, Chaix ML, Raffi F, et al. Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial. *HIV Med*. 2010;11(2):137-42. PMID: 19682100.

Gilbert P, Ciccarone D, Gansky SA, Bangsberg DR, Clanon K, McPhee SJ, et al. Interactive "Video Doctor" counseling reduces drug and sexual risk behaviors among HIV-positive patients in diverse outpatient settings. *PLoS One*. 2008;3(4):e1988. PMID: 18431475.

Giuntini R, Martinelli C, Ricci E, Vichi F, Gianelli E, Madeddu G, et al. Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study. *HIV Med*. 2010;11(1):40-5. PMID: 19686438.

Golin CE, Davis RA, Przybyla SM, Fowler B, Parker S, Earp JA, et al. SafeTalk, a multicomponent, motivational interviewing-based, safer sex counseling program for people living with HIV/AIDS: a qualitative assessment of patients' views. *AIDS Patient Care STDs*. 2010;24(4):237-45. PMID: 20377435.

Golub ET, Benning L, Sharma A, Gandhi M, Cohen MH, Young M, et al. Patterns, predictors, and consequences of initial regimen type among HIV-infected women receiving highly active antiretroviral therapy. *Clin Infect Dis*. 2008;46(2):305-12. PMID: 18171267.

Greenbaum AH, Wilson LE, Keruly JC, Moore RD, Gebo KA. Effect of age and HAART regimen on clinical response in an urban cohort of HIV-infected individuals. *AIDS*. 2008;22(17):2331-9. PMID: 18981772.

## Appendix A4. Excluded Studies List

- Griffith DM, Pichon LC, Campbell B, Allen JO. YOUR Blessed Health: a faith-based CBPR approach to addressing HIV/AIDS among African Americans. *AIDS Educ Prev*. 2010;22(3):203-17. PMID: 20528129.
- Grigoryan A, Hall HI, Durant T, Wei X. Late HIV diagnosis and determinants of progression to AIDS or death after HIV diagnosis among injection drug users, 33 US states, 1996–2004. *PLoS One*. 2009;4(2):e4445. PMID: 19214229.
- DART Virology Group and Trial Team. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. *AIDS*. 2006;20(10):1391-9. PMID: 16791013.
- Grusky O, Roberts KJ, Swanson AN. Failure to return for HIV test results: a pilot study of three community testing sites. *J Int Assoc Physicians AIDS Care*. 2007;6(1):47-55. PMID: 17329504.
- Gulick RM, Ribaldo HJ, Shikuma CM, Lalama C, Schackman BR, Meyer WA, et al. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. *JAMA*. 2006;296(7):769-81. PMID: 16905783.
- Gupta RK, Hill A, Sawyer AW, Cozzi-Lepri A, von Wyl V, Yerly S, et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. *Lancet Infect Dis*. 2009;9(7):409-17. PMID: 19555900.
- Gupta SK, Parker RA, Robbins GK, Dube MP. The effects of highly active antiretroviral therapy on albuminuria in HIV-infected persons: results from a randomized trial. *Nephrol Dial Transplant*. 2005;20(10):2237-42. PMID: 16105869.
- Gutierrez-Valencia A, Viciano P, Palacios R, Ruiz-Valderas R, Lozano F, Terron A, et al. Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial. *Ann Intern Med*. 2009;151(3):149-56. PMID: 19581631.
- Guy RJ, Prybylski D, Fairley CK, Hellard ME, Kaldor JM. Can data from HIV voluntary counselling and testing be used to assess the impact of public health interventions? A literature review. *Int J STD AIDS*. 2009;20(6):378-83. PMID: 19451320.
- Gwadz MV, Cleland CM, Quiles R, Nish D, Welch J, Michaels LS, et al. CDC HIV testing guidelines and the rapid and conventional testing practices of homeless youth. *AIDS Educ Prev*. 2010;22(4):312-27. PMID: 20707692.
- Halkitis PN, Zade DD, Shrem M, Marmor M. Beliefs about HIV non-infection and risky sexual behavior among MSM. *AIDS Educ Prev*. 2004;16(5):448-58. PMID: 15491956.
- Hallett TB, Gregson S, Lewis JJ, Lopman BA, Garnett GP. Behaviour change in generalised HIV epidemics: impact of reducing cross-generational sex and delaying age at sexual debut. *Sex Transm Infect*. 2007;83(Suppl 1):i50-4. PMID: 17314125.
- Harding R, Bensley J, Corrigan N, Franks L, Stratman J, Waller Z, et al. Outcomes and lessons from a pilot RCT of a community-based HIV prevention multi-session group intervention for gay men. *AIDS Care*. 2004;16(5):581-5. PMID: 15223527.
- Harris SK, Samples CL, Keenan PM, Fox DJ, Melchiono MW, Woods ER, et al. Outreach, mental health, and case management services: can they help to retain HIV-positive and at-risk youth and young adults in care? *Maternal Child Health J*. 2003;7(4):205-18. PMID: 14682498.
- Healthy Living Project Team. Effects of a behavioral intervention to reduce risk of transmission among people living with HIV: the Healthy Living Project randomized controlled study. *J Acquir Immune Defic Syndr*. 2007;44(2):213-21. PMID: 17146375.
- Heijman T, Geskus RB, Davidovich U, Coutinho RA, Prins M, Stolte IG. Less decrease in risk behaviour from pre-HIV to post-HIV seroconversion among MSM in the combination antiretroviral therapy era compared with the pre-

## Appendix A4. Excluded Studies List

combination antiretroviral therapy era. *AIDS*. 2012;26(4):489-95. PMID: 22156971.

Hellinger J, Cohen C, Morris A, Sheble-Hall S, Gordon D, Foy C, et al. Pilot study of saquinavir and lopinavir/ritonavir twice daily in protease inhibitor-naive HIV-positive patients. *HIV Clinical Trials*. 2005;6(2):107-17. PMID: 15983895.

Henry K, Kitch D, Dube M, Zackin R, Parker RA, Sprecher D, et al. C-reactive protein levels over time and cardiovascular risk in HIV-infected individuals suppressed on an indinavir-based regimen: AIDS Clinical Trials Group 5056s. *AIDS*. 2004;18(18):2434-7. PMID: 15622323.

Herbst JH, Sherba RT, Crepaz N, Deluca JB, Zohrabyan L, Stall RD, et al. A meta-analytic review of HIV behavioral interventions for reducing sexual risk behavior of men who have sex with men. *J Acquir Immune Defic Syndr*. 2005;39(2):228-41. PMID: 15905741.

Hicks C, King MS, Gulick RM, White AC, Eron JJ, Kessler HA, et al. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. *AIDS*. 2004;18(5):775-9. PMID: 15075512.

Hightow-Weidman LB, Jones K, Wohl AR, Futterman D, Outlaw A, Phillips G 2nd, et al. Early linkage and retention in care: findings from the outreach, linkage, and retention in care initiative among young men of color who have sex with men. *AIDS Patient Care STDs*. 2011;25(Suppl 1):S31-8. PMID: 21711141.

Hoffmann CJ, Fielding KL, Johnston V, Charalambous S, Innes C, Moore RD, et al. Changing predictors of mortality over time from cART start: implications for care. *J Acquir Immune Defic Syndr*. 2011;58(3):269-76. PMID: 21876447.

Howe CJ, Cole SR, Napravnik S, Eron JJ. Enrollment, retention, and visit attendance in the University of North Carolina Center for AIDS Research HIV clinical cohort, 2001-2007. *AIDS*

*Res Hum Retroviruses*. 2010;26(8):875-81. PMID: 20672995.

Huebner DM, Binson D, Dilworth SE, Neilands TB, Grinstead O, Woods WJ. Rapid vs. standard HIV testing in bathhouses: what is gained and lost? *AIDS Behav*. 2010;14(3):688-96. PMID: 18726682.

Huebner DM, Binson D, Woods WJ, Dilworth SE, Neilands TB, Grinstead O. Bathhouse-based voluntary counseling and testing is feasible and shows preliminary evidence of effectiveness. *J Acquir Immune Defic Syndr*. 2006;43(2):239-46. PMID: 16951645.

Jauffret-Roustide M, Emmanuelli J, Quaglia M, Barin F, Arduin P, Laporte A, et al. Impact of a harm-reduction policy on HIV and hepatitis C virus transmission among drug users: recent French data—the ANRS-Coquelicot Study. *Subst Use Misuse*. 2006;41(10-12):1603-21. PMID: 17002994.

Jayaweera DT, Kolber MA, Brill M, Tanner T, Campo R, Rodriguez A, et al. Effectiveness and tolerability of a once-daily amprenavir/ritonavir-containing highly active antiretroviral therapy regimen in antiretroviral-naive patients at risk for nonadherence: 48-week results after 24 weeks of directly observed therapy. *HIV Med*. 2004;5(5):364-70. PMID: 15369512.

Jevtovic D, Vanovac V, Veselinovic M, Salemovic D, Ranin J, Stefanova E. The incidence of and risk factors for HIV-associated cognitive-motor complex among patients on HAART. *Biomed Pharmacother*. 2009;63(8):561-5. PMID: 19026516.

Jevtovic DJ, Dragovic G, Salemovic D, Ranin J, Djurkovic-Djakovic O. The metabolic syndrome, an epidemic among HIV-infected patients on HAART. *Biomed Pharmacother*. 2009;63(5):337-42. PMID: 18996676.

Jin F, Prestage GP, Ellard J, Kippax SC, Kaldor JM, Grulich AE. How homosexual men believe they became infected with HIV: the role of risk-reduction behaviors. *J Acquir Immune Defic Syndr*. 2007;46(2):245-7. PMID: 17721400.

## Appendix A4. Excluded Studies List

Johnson MO, Charlebois E, Morin SF, Remien RH, Chesney MA; National Institute of Mental Health Healthy Living Project Team. Effects of a behavioral intervention on antiretroviral medication adherence among people living with HIV: the Healthy Living Project randomized controlled study. *J Acquir Immune Defic Syndr*. 2007;46(5):574-80. PMID: 18193499.

Johnson MO, Dilworth SE, Neilands TB, Chesney MA, Rotheram-Borus MJ, Remien RH, et al. Predictors of attrition among high risk HIV-infected participants enrolled in a multi-site prevention trial. *AIDS Behav*. 2008;12(6):974-7. PMID: 18202908.

Johnston L, O’Bra H, Chopra M, Mathews C, Townsend L, Sabin K, et al. The associations of voluntary counseling and testing acceptance and the perceived likelihood of being HIV-infected among men with multiple sex partners in a South African township. *AIDS Behav*. 2010;14(4):922-31. PMID: 18270809.

Kalayjian RC, Franceschini N, Gupta SK, Szczech LA, Mupere E, Bosch RJ, et al. Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease. *AIDS*. 2008;22(4):481-7. PMID: 18301060.

Kalichman SC, Cain D. Repeat HIV testing and HIV transmission risk behaviors among sexually transmitted infection clinic patients. *J Clin Psychol Med Settings*. 2008;15(2):127-33. PMID: 19104976.

Kalichman SC, Cherry C, Kalichman MO, Amaral CM, White D, Pope H, et al. Integrated behavioral intervention to improve HIV/AIDS treatment adherence and reduce HIV transmission. *Am J Public Health*. 2011;101(3):531-8. PMID: 21233431.

Kalichman SC, Cherry C, White D, Pope H, Cain D, Kalichman M. Altering key characteristics of a disseminated effective behavioral intervention for HIV positive adults: the “healthy relationships” experience. *J Prim Prev*. 2007;28(2):145-53. PMID: 17333382.

Kamb ML, Fishbein M, Douglas JM, Rhodes F, Rogers J, Bolan G, et al. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases. *JAMA*. 1998;280(13):1161-7. PMID: 9777816.

Kassutto S, Johnston MN, Rosenberg ES. Incomplete HIV type 1 antibody evolution and seroreversion in acutely infected individuals treated with early antiretroviral therapy. *Clin Infect Dis*. 2005;40(6):868-73. PMID: 15736021.

Kaufmann GR, Khanna N, Weber R, Perrin L, Furrer H, Cavassini M, et al. Long-term virological response to multiple sequential regimens of highly active antiretroviral therapy for HIV infection. *Antivir Ther*. 2004;9(2):263-74. PMID: 15134189.

Keane V, Hammond G, Keane H, Hewitt J. Quantitative evaluation of counseling associated with HIV testing. *Southeast Asian J Trop Med Public Health*. 2005;36(1):228-32. PMID: 15906674.

Keiser O, Spoerri A, Brinkhof MW, Hasse B, Gayet-Ageron A, Tissot F, et al. Suicide in HIV-infected individuals and the general population in Switzerland, 1988-2008. *Am J Psychiatry*. 2010;167(2):143-50. PMID: 20008942.

Keruly JC, Moore RD. Immune status at presentation to care did not improve among antiretroviral-naive persons from 1990 to 2006. *Clin Infect Dis*. 2007;45(10):1369-74. PMID: 17968837.

Kesselring AM, Gras L, Wit FW, Smit C, Geerlings SE, Mulder JW, et al. Immune restoration and onset of new AIDS-defining events with combination antiretroviral therapy in HIV type-1-infected immigrants in the Netherlands. *Antivir Ther*. 2010;15(6):871-9. PMID: 20834099.

Kesselring AM, Wit FW, Sabin CA, Lundgren JD, Gill MJ, Gatell JM, et al. Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. *AIDS*. 2009;23(13):1689-99. PMID: 19487907.

## Appendix A4. Excluded Studies List

Klein H, Elifson KW, Sterk CE. Partner communication and HIV risk behaviors among “at risk” women. *Soz Praventivmed*. 2004;49(6):363-74. PMID: 15669436.

Koegl C, Wolf E, Hanhoff N, Jessen H, Schewe K, Rausch M, et al. Treatment during primary HIV infection does not lower viral set point but improves CD4 lymphocytes in an observational cohort. *Eur J Med Res*. 2009;14(7):277-83. PMID: 19661009.

Kohli R, Lo Y, Homel P, Flanigan TP, Gardner LI, Howard AA, et al. Bacterial pneumonia, HIV therapy, and disease progression among HIV-infected women in the HIV Epidemiologic Research (HER) study. *Clin Infect Dis*. 2006;43(1):90-8. PMID: 16758423.

Korac M, Brmbolic B, Salemovic D, Ranin J, Stojic Z, Jevtovic D, et al. Diagnostic esophago-gastro-duodenoscopy (EGD) in patients with AIDS-related upper gastrointestinal abnormalities. *Hepato Gastroenterology*. 2009;56(96):1675-8. PMID: 20214216.

Korthuis PT, Asch SM, Anaya HD, Morgenstern H, Goetz MB, Yano EM, et al. Lipid screening in HIV-infected veterans. *J Acquir Immune Defic Syndr*. 2004;35(3):253-60. PMID: 15076239.

Kourtis AP, Ellington S, Bansil P, Jamieson DJ, Posner SF. Hospitalizations for invasive pneumococcal disease among HIV-1-infected adolescents and adults in the United States in the era of highly active antiretroviral therapy and the conjugate pneumococcal vaccine. *J Acquir Immune Defic Syndr*. 2010;55(1):128-31. PMID: 20622675.

Kourtis AP, Ellington S, Bansil P, Jamieson DJ, Posner SF. Hospitalizations for invasive pneumococcal disease among HIV-1-infected adolescents and adults in the United States in the era of highly active antiretroviral therapy and the conjugate pneumococcal vaccine. *J Acquir Immune Defic Syndr*. 2010;55(1):128-31. PMID: 20622675.

Kousignian I, Launay O, Mayaud C, Rabaud C, Costagliola D, Abgrall S, et al. Does enfuvirtide increase the risk of bacterial pneumonia in patients receiving combination antiretroviral therapy? *J Antimicrob Chemother*. 2010;65(1):138-44. PMID: 19903719.

Kovari H, Ledergerber B, Peter U, Flepp M, Jost J, Schmid P, et al. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. *Clin Infect Dis*. 2009;49(4):626-35. PMID: 19589079.

Kozal MJ, Amico KR, Chiarella J, Schreiber T, Cornman D, Fisher W, et al. Antiretroviral resistance and high-risk transmission behavior among HIV-positive patients in clinical care. *AIDS*. 2004;18(16):2185-9. PMID: 15577652.

Kravicik S, Victor G, Houston S, Sutherland D, Garber GE, Hawley-Foss N, et al. Effect of antiretroviral therapy and viral load on the perceived risk of HIV transmission and the need for safer sexual practices. *J Acquir Immune Defic Syndr Hum Retrovirol*. 1998;19(2):124-9. PMID: 9768620.

Kreuter A, Brockmeyer NH, Weissenborn SJ, Gambichler T, Stucker M, Altmeyer P, et al. Penile intraepithelial neoplasia is frequent in HIV-positive men with anal dysplasia. *J Invest Dermatol*. 2008;128(9):2316-24. PMID: 18385760.

Krishnan S, Schouten JT, Jacobson DL, Benson CA, Collier AC, Koletar SL, et al. Incidence of non-AIDS-defining cancer in antiretroviral treatment-naive subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis. *Oncology*. 2011;80(1-2):42-9. PMID: 21606663.

Kumar PN, Rodriguez-French A, Thompson MA, Tashima KT, Averitt D, Wannamaker PG, et al. A prospective, 96-week study of the impact of trizivir, combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity. *HIV Med*. 2006;7(2):85-98. PMID: 16420253.

## Appendix A4. Excluded Studies List

- Kunavisarut P, Bijlsma WR, Pathanapitoon K, Patikulasila D, Choovuthayakorn J, Rothova A. Proliferative vitreoretinopathy in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. *Am J Ophthalmol.* 2010;150(2):218-22. PMID: 20525529.
- Lai S, Bartlett J, Lai H, Moore R, Cofrancesco J Jr, Pannu H, et al. Long-term combination antiretroviral therapy is associated with the risk of coronary plaques in African Americans with HIV infection. *AIDS Patient Care STDs.* 2009;23(10):815-24. PMID: 19803679.
- Lifson AR, Neuhaus J, Arribas JR, van den Berg-Wolf M, Labriola AM, Read TR, et al. Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial. *Am J Public Health.* 2010;100(10):1896-903. PMID: 20724677.
- Lightfoot M, Rotheram-Borus MJ, Comulada WS, Reddy VS, Duan N. Efficacy of brief interventions in clinical care settings for persons living with HIV. *J Acquir Immune Defic Syndr.* 2010;53(3):348-56. PMID: 19996978.
- Logan TK, Cole J, Leukefeld C. Women, sex, and HIV: social and contextual factors, meta-analysis of published interventions, and implications for practice and research. *Psychol Bull.* 2002;128(6):851-85. PMID: 12405135.
- Lorello G, la Porte C, Pilon R, Zhang G, Karnauchow T, MacPherson P. Discordance in HIV-1 viral loads and antiretroviral drug concentrations comparing semen and blood plasma. *HIV Med.* 2009;10(9):548-54. PMID: 19515092.
- Louie B, Wong E, Klausner JD, Liska S, Hecht F, Dowling T, et al. Assessment of rapid tests for detection of human immunodeficiency virus-specific antibodies in recently infected individuals. *J Clin Microbiol.* 2008;46(4):1494-7. PMID: 18234875.
- Lowe SH, Hassink EA, van Eck-Smit BL, Borleffs JC, Lange JM, Reiss P. Stavudine but not didanosine as part of HAART contributes to peripheral lipoatrophy: a substudy from the Antiretroviral Regimen Evaluation Study (ARES). *HIV Clinical Trials.* 2007;8(5):337-44. PMID: 17956835.
- Lubelchek R, Kroc K, Hota B, Sharief R, Muppudi U, Pulvirenti J, et al. The role of rapid vs conventional human immunodeficiency virus testing for inpatients: effects on quality of care. *Arch Intern Med.* 2005;165(17):1956-60. PMID: 16186464.
- Lyons MS, Lindsell CJ, Hawkins DA, Raab DL, Trott AT, Fichtenbaum CJ. Contributions to early HIV diagnosis among patients linked to care vary by testing venue. *BMC Public Health.* 2008;8:220. PMID: 18578881.
- Lyons MS, Lindsell CJ, Ruffner AH, Trott AT, Fichtenbaum CJ. Relationship of self-reported prior testing history to undiagnosed HIV positivity and HIV risk. *Curr HIV Res.* 2009;7(6):580-8. PMID: 19929792.
- MacArthur RD, Novak RM, Peng G, Chen L, Xiang Y, Hullsiek KH, et al. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial. *Lancet.* 2006;368(9553):2125-35. PMID: 17174704.
- Maggiolo F, Ravasio L, Ripamonti D, Gregis G, Quinzan G, Arici C, et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. *Clin Infect Dis.* 2005;40(1):158-63. PMID: 15614706.
- Maggiolo F, Roat E, Pinti M, Nasi M, Gibellini L, De Biasi S, et al. Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatment-naive patients. *Antivir Ther.* 2010;15(1):51-9. PMID: 20167991.
- Malan DR, Krantz E, David N, Rong Y, Mathew M, Iloeje UH, et al. 96-week efficacy and safety of atazanavir, with and without ritonavir, in a HAART regimen in treatment-naive patients. *J*

## Appendix A4. Excluded Studies List

*Int Assoc Physicians AIDS Care.* 2010;9(1):34-42. PMID: 20071596.

Malan N, Su J, Mancini M, Yang R, Wirtz V, Absalon J, et al. Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study. *AIDS Care.* 2010;22(6):677-86. PMID: 20467943.

Mallolas J, Blanco JL, Pich J, Arnaiz JA, Pena JM, Dalmau D, et al. A randomized trial comparing the efficacy and tolerability of two HAART strategies at two years in antiretroviral naive patients. *Rev Clin Esp.* 2007;207(9):427-32. PMID: 17915162.

Margolin A, Avants SK, Warburton LA, Hawkins KA, Shi J. A randomized clinical trial of a manual-guided risk reduction intervention for HIV-positive injection drug users. *Health Psychol.* 2003;22(2):223-8. PMID: 12683743

Margot NA, Enejosa J, Cheng AK, Miller MD, McColl DJ; Study 934 Team. Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naive subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934. *J Acquir Immune Defic Syndr.* 2009;52(2):209-21. PMID: 19644384.

Markham CM, Shegog R, Leonard AD, Bui TC, Paul ME. +CLICK: harnessing web-based training to reduce secondary transmission among HIV-positive youth. *AIDS Care.* 2009;21(5):622-31. PMID: 19444671.

Markowitz M, Hill-Zabala C, Lang J, DeJesus E, Liao Q, Lanier ER, et al. Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients. *J Acquir Immune Defic Syndr.* 2005;39(3):257-64. PMID: 15980684.

Martin DJ, Riopelle D, Steckart MJ, Geshke N, Lin S. Support group participation, HIV viral load and sexual-risk behavior. *Am J Health Behav.* 2001;25(6):513-27. PMID: 11720299.

Masciotra S, McDougal JS, Feldman J, Sprinkle P, Wesolowski L, Owen SM. Evaluation of an alternative HIV diagnostic algorithm using specimens from seroconversion panels and persons with established HIV infections. *J Clin Virol.* 2011;52(Suppl 1):S17-22. PMID: 21981983.

Mausbach BT, Semple SJ, Strathdee SA, Zians J, Patterson TL. Efficacy of a behavioral intervention for increasing safer sex behaviors in HIV-positive MSM methamphetamine users: results from the EDGE study. *Drug Alcohol Depend.* 2007;87(2-3):249-57. PMID: 17182196.

May M, Gompels M, Delpech V, Porter K, Post F, Johnson M, et al. Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) study. *BMJ.* 2011;343:d6016. PMID: 21990260.

May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, Justice AC, et al. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. *Lancet.* 2006;368(9534):451-8. PMID: 16890831.

McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202. *J Infect Dis.* 2011;203(12):1791-801. PMID: 21606537.

Meador N, Li R, Des Jarlais CD, Pilling S. Psychosocial interventions for reducing injection and sexual risk behaviour for preventing HIV in drug users. *Cochrane Database Syst Rev.* 2010;(1):CD007192. PMID: 20091623.

Metsch LR, Feaster DJ, Gooden L, Matheson T, Mandler RN, Haynes L, et al. Implementing rapid HIV testing with or without risk-reduction counseling in drug treatment centers: results of a



## Appendix A4. Excluded Studies List

- randomized trial. *Am J Public Health*. 2012;102(6):1160-7. PMID: 22515871.
- Metsch LR, Pereyra M, Messinger S, Del Rio C, Strathdee SA, Anderson-Mahoney P, et al. HIV transmission risk behaviors among HIV-infected persons who are successfully linked to care. *Clin Infect Dis*. 2008;47(4):577-84. PMID: 18624629.
- Miguez-Burbano MJ, Espinoza L, Lewis JE. HIV treatment adherence and sexual functioning. *AIDS Behav*. 2008;12(1):78-85. PMID: 17295075.
- Mikl J, Sudar Z, Smith PF, Bruckova M, Jedlicka J, Kastankova V, et al. HIV infection and high risk behavior among patients attending an STD referral clinic in Prague, Czech Republic. *Sex Transm Infect*. 1998;74(2):128-30. PMID: 9634325.
- Milam J, Richardson JL, McCutchan A, Stoyanoff S, Weiss J, Kemper C, et al. Effect of a brief antiretroviral adherence intervention delivered by HIV care providers. *J Acquir Immune Defic Syndr*. 2005;40(3):356-63. PMID: 16249712.
- Mimiaga MJ, Case P, Johnson CV, Safren SA, Mayer KH. Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. *J Acquir Immune Defic Syndr*. 2009;50(1):77-83. PMID: 19295337.
- Mimiaga MJ, Reisner SL, Tetu AM, Bonafide KE, Cranston K, Bertrand T, et al. Partner notification after STD and HIV exposures and infections: knowledge, attitudes, and experiences of Massachusetts men who have sex with men. *Public Health Rep*. 2009;124(1):111-9. PMID: 19413033.
- Mimiaga MJ, Skeer M, Mayer KH, Safren SA. Study participation as a social group influencing sexual behaviours in an HIV-prevention trial for men who have sex with men. *AIDS Care*. 2008;20(3):346-55. PMID: 18351483.
- Mira JA, Lozano F, Santos J, Ramayo E, Terron A, Palacios R, et al. Gynaecomastia in HIV-infected men on highly active antiretroviral therapy: association with efavirenz and didanosine treatment. *Antivir Ther*. 2004;9(4):511-7. PMID: 15456082.
- Mitchell CG, Freels S, Creticos CM, Oltean A, Douglas R. Preliminary findings of an intervention integrating modified directly observed therapy and risk reduction counseling. *AIDS Care*. 2007;19(4):561-4. PMID: 17453598.
- Mitchell MM, Latimer WW. Unprotected casual sex and perceived risk of contracting HIV among drug users in Baltimore, Maryland: evaluating the influence of non-injection versus injection drug user status. *AIDS Care*. 2009;21(2):221-30. PMID: 19229692.
- Mitha K, Yirsalign M, Cherner M, McCutchan A, Langford TD. Risk perception and beliefs regarding HIV infection among Ethiopian immigrants. *AIDS Educ Prev*. 2009;21(5):484-94. PMID: 19842831.
- Mmbaga EJ, Leyna GH, Mnyika KS, Hussain A, Klepp KI. Prevalence and predictors of failure to return for HIV-1 post-test counseling in the era of antiretroviral therapy in rural Kilimanjaro, Tanzania: challenges and opportunities. *AIDS Care*. 2009;21(2):160-7. PMID: 19229684.
- Mmbaga EJ, Leyna GH, Mnyika KS, Klepp KI. Sexually transmitted infections knowledge and its impact in the practice of risky sexual behaviours and HIV serostatus: results from rural Kilimanjaro, Tanzania. *Sex Transm Infect*. 2008;84(3):224-6. PMID: 18283095.
- Mocroft A, Ledergerber B, Viard JP, Staszewski S, Murphy M, Chiesi A, et al. Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group. *J Infect Dis*. 2004;190(11):1947-56. PMID: 15529259.
- Molina JM, Journot V, Furco A, Palmer P, De Castro N, Raffi F, et al. Five-year follow up of once-daily therapy with emtricitabine,

## Appendix A4. Excluded Studies List

didanosine and efavirenz (Montana ANRS 091 trial). *Antivir Ther.* 2007;12(3):417-22. PMID: 17591032.

Molina JM, Levy Y, Fournier I, Hamonic S, Bentata M, Beck-Wirth G, et al. Interleukin-2 before antiretroviral therapy in patients with HIV infection: a randomized trial (ANRS 119). *J Infect Dis.* 2009;200(2):206-15. PMID: 19508157.

Molina JM, Podsadecki TJ, Johnson MA, Wilkin A, Domingo P, Myers R, et al. A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks. *AIDS Res Hum Retroviruses.* 2007;23(12):1505-14. PMID: 18160008

Molitor F, Facer M, Ruiz JD. Safer sex communication and unsafe sexual behavior among young men who have sex with men in California. *Arch Sex Behav.* 1999;28(4):335-43. PMID: 10553494.

Mondy KE, Gottdiener J, Overton ET, Henry K, Bush T, Conley L, et al. High prevalence of echocardiographic abnormalities among HIV-infected persons in the era of highly active antiretroviral therapy. *Clin Infect Dis.* 2011;52(5):378-86. PMID: 21217185.

Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. *Clin Infect Dis.* 2007;44(3):441-6. PMID: 17205456.

Mootsikapun P, Chetchotisakd P, Anunnatsiri S, Boonyaprawit P. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naïve HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm<sup>3</sup>: 96-week outcomes. *Antivir Ther.* 2005;10(8):911-6. PMID: 16430196.

Morin SF, Shade SB, Steward WT, Carrico AW, Remien RH, Rotheram-Borus MJ, et al. A behavioral intervention reduces HIV transmission risk by promoting sustained serosorting practices among HIV-infected men

who have sex with men. *J Acquir Immune Defic Syndr.* 2008;49(5):544-51. PMID: 18989221.

Mugavero MJ, Raper JL, Reif S, Whetten K, Leserman J, Thielman NM, et al. Overload: impact of incident stressful events on antiretroviral medication adherence and virologic failure in a longitudinal, multisite human immunodeficiency virus cohort study. *Psychosom Med.* 2009;71(9):920-6. PMID: 19875634.

Munoz-Laboy M, Castellanos D, Westacott R. Sexual risk behaviour, viral load, and perceptions of HIV transmission among homosexually active Latino men: an exploratory study. *AIDS Care.* 2005;17(1):33-45. PMID: 15832832.

Myers JJ, Shade SB, Rose CD, Koester K, Maiorana A, Malitz FE, et al. Interventions delivered in clinical settings are effective in reducing risk of HIV transmission among people living with HIV: results from the Health Resources and Services Administration (HRSA)'s Special Projects of National Significance initiative. *AIDS Behav.* 2010;14(3):483-92. PMID: 20229132.

Naar-King S, Parsons JT, Murphy DA, Chen X, Harris DR, Belzer ME. Improving health outcomes for youth living with the human immunodeficiency virus: a multisite randomized trial of a motivational intervention targeting multiple risk behaviors. *Arch Pediatr Adolesc Med.* 2009;163(12):1092-8. PMID: 19996045.

Nachega JB, Chaisson RE, Goliath R, Efron A, Chaudhary MA, Ram M, et al. Randomized controlled trial of trained patient-nominated treatment supporters providing partial directly observed antiretroviral therapy. *AIDS.* 2010;24(9):1273-80. PMID: 20453627.

Napravnik S, Keys JR, Quinlivan EB, Wohl DA, Mikeal OV, Eron JJ Jr. Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients. *AIDS.* 2007;21(7):825-34. PMID: 17415037.

Navazesh M, Mulligan R, Karim R, Mack WJ, Ram S, Seirawan H, et al. Effect of HAART on

## Appendix A4. Excluded Studies List

salivary gland function in the Women's Interagency HIV Study (WIHS). *Oral Dis.* 2009;15(1):52-60. PMID: 19017280.

Navazesh M, Mulligan R, Pogoda J, Greenspan D, Alves M, Phelan J, et al. The effect of HAART on salivary microbiota in the Women's Interagency HIV Study (WIHS). *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 2005;100(6):701-8. PMID: 16301151.

Nittayananta W, Talungchit S, Jaruratanasirikul S, Silpapojakul K, Chayakul P, Nilmanat A, et al. Effects of long-term use of HAART on oral health status of HIV-infected subjects. *J Oral Pathol Med.* 2010;39(5):397-406. PMID: 20202089.

Nugent NR, Brown LK, Belzer M, Harper GW, Nachman S, Naar-King S, et al. Youth living with HIV and problem substance use: elevated distress is associated with nonadherence and sexual risk. *J Int Assoc Physicians AIDS Care.* 2010;9(2):113-5. PMID: 20133498.

Nyamathi A, Suhadev M, Swaminathan S, Fahey J. Perceptions of a community sample about participation in future HIV vaccine trials in South India. *AIDS Behav.* 2007;11(4):619-27. PMID: 17016758.

Obermeyer CM, Rajkumar R. HAART and sexual risk behavior. *JAMA.* 2004;292(19):17. PMID: 15547154.

Ojo O, Verbeek JH, Rasanen K, Heikkinen J, Isotalo LK, Mngoma N, et al. Interventions to reduce risky sexual behaviour for preventing HIV infection in workers in occupational settings. *Cochrane Database Syst Rev.* 2011;(12):CD005274. PMID: 22161391.

Onen NF, Shacham E, Stamm KE, Overton ET. Comparisons of sexual behaviors and STD prevalence among older and younger individuals with HIV infection. *AIDS Care.* 2010;22(6):711-7. PMID: 20467941.

Orrell C, Harling G, Lawn SD, Kaplan R, McNally M, Bekker LG, et al. Conservation of first-line antiretroviral treatment regimen where

therapeutic options are limited. *Antivir Ther.* 2007;12(1):83-8. PMID: 17503751.

Osei-Sekyere B, Karstaedt AS. Immune reconstitution inflammatory syndrome involving the skin. *Clin Exp Dermatol.* 2010;35(5):477-81. PMID: 19874370.

Ostrow DG, Silverberg MJ, Cook RL, Chmiel JS, Johnson L, Li X, et al. Prospective study of attitudinal and relationship predictors of sexual risk in the multicenter AIDS cohort study. *AIDS Behav.* 2008;12(1):127-38. PMID: 17410419.

Overton ET, Nurutdinova D, Freeman J, Seyfried W, Mondy KE. Factors associated with renal dysfunction within an urban HIV-infected cohort in the era of highly active antiretroviral therapy. *HIV Med.* 2009;10(6):343-50. PMID: 19490182.

Parker RD, Ruutel K. Associations of high-risk behaviour and HIV status with HIV knowledge among persons in Tallinn, Estonia. *Scand J Public Health.* 2010;38(7):748-55. PMID: 20823046.

Parveen Z, Acheampong E, Pomerantz RJ, Jacobson JM, Wigdahl B, Mukhtar M. Effects of highly active antiretroviral therapy on HIV-1-associated oral complications. *Curr HIV Res.* 2007;5(3):281-92. PMID: 17504170.

Patel K, Hernan MA, Williams PL, Seeger JD, McIntosh K, Dyke RB, et al. Long-term effects of highly active antiretroviral therapy on CD4+ cell evolution among children and adolescents infected with HIV: 5 years and counting. *Clin Infect Dis.* 2008;46(11):1751-60. PMID: 18426371.

Patel P, Taylor MM, Montoya JA, Hamburger ME, Kerndt PR, Holmberg SD. Circuit parties: sexual behaviors and HIV disclosure practices among men who have sex with men at the White Party, Palm Springs, California, 2003. *AIDS Care.* 2006;18(8):1046-9. PMID: 17012098.

Patterson T, Shaw W, Semple S. Reducing the sexual risk behaviors of HIV+ individuals: outcome of a randomized controlled trial. *Ann*

## Appendix A4. Excluded Studies List

*Behav Med.* 2003;25(2):137-45. PMID: 12704016.

Perez-Elias MJ, Moreno A, Casado JL, Drona F, Antela A, Lopez D, et al. Observational study to evaluate clinical outcomes after first-line efavirenz-or lopinavir-ritonavir-based HAART in treatment-naive patients. *J Int Assoc Physicians AIDS Care.* 2009;8(5):308-13. PMID: 19721095.

Powles T, Robinson D, Stebbing J, Shamash J, Nelson M, Gazzard B, et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. *J Clin Oncol.* 2009;27(6):884-90. PMID: 19114688.

Prestage G, Mao L, Kippax S, Jin F, Hurley M, Grulich A, et al. Use of viral load to negotiate condom use among gay men in Sydney, Australia. *AIDS Behav.* 2009;13(4):645-51. PMID: 19199021.

Centers for Disease Control and Prevention. Disparities in diagnoses of HIV infection between blacks/African Americans and other racial/ethnic populations—37 states, 2005-2008. *MMWR Morb Mortal Wkly Rep.* 2011;60(4):93-102. PMID: 21293323.

Prost A, Griffiths CJ, Anderson J, Wight D, Hart GJ. Feasibility and acceptability of offering rapid HIV tests to patients registering with primary care in London (UK): a pilot study. *Sex Transm Infect.* 2009;85(5):326-9. PMID: 19487214.

Purcell DW, Latka MH, Metsch LR, Latkin CA, Gomez CA, Mizuno Y, et al. Results from a randomized controlled trial of a peer-mentoring intervention to reduce HIV transmission and increase access to care and adherence to HIV medications among HIV-seropositive injection drug users. *J Acquir Immune Defic Syndr.* 2007;46(2):1. PMID: 18089983.

Purcell DW, Metsch LR, Latka M, Santibanez S, Gomez CA, Eldred L, et al. Interventions for seropositive injectors—research and evaluation: an integrated behavioral intervention with HIV-positive injection drug users to address medical

care, adherence, and risk reduction. *J Acquir Immune Defic Syndr.* 2004;37(2):1. PMID: 15385907.

Ramos RL, Ferreira-Pinto JB, Rusch ML, Ramos ME. Pasa la voz (spread the word): using women's social networks for HIV education and testing. *Public Health Rep.* 2010;125(4):528-33. PMID: 20597452.

Remien RH, Halkitis PN, O'Leary A, Wolitski RJ, Gomez CA. Risk perception and sexual risk behaviors among HIV-positive men on antiretroviral therapy. *AIDS Behav.* 2005;9(2):167-76. PMID: 15933836.

Reza-Paul S, Beattie T, Syed HU, Venukumar KT, Venugopal MS, Fathima MP, et al. Declines in risk behaviour and sexually transmitted infection prevalence following a community-led HIV preventive intervention among female sex workers in Mysore, India. *AIDS.* 2008;22(Suppl 5):S91-100. PMID: 19098483.

Romero EG, Teplin LA, McClelland GM, Abram KM, Welty LJ, Washburn JJ. A longitudinal study of the prevalence, development, and persistence of HIV/sexually transmitted infection risk behaviors in delinquent youth: implications for health care in the community. *Pediatrics.* 2007;119(5):e1126-41. PMID: 17473083.

Ross MW, Timpson SC, Williams ML, Amos C, McCurdy S, Bowen AM, et al. Responsibility as a dimension of HIV prevention normative beliefs: measurement in three drug-using samples. *AIDS Care.* 2007;19(3):403-9. PMID: 17453576.

Rosser BR, Hatfield LA, Miner MH, Ghiselli ME, Lee BR, Welles SL, et al. Effects of a behavioral intervention to reduce serodiscordant unsafe sex among HIV positive men who have sex with men: the Positive Connections randomized controlled trial study. *J Behav Med.* 2010;33(2):147-58. PMID: 20101454.

Rotheram-Borus M, Lee M, Murphy D, Futterman D, Duan N, Birnbaum J, et al. Efficacy of a preventive intervention for youths

## Appendix A4. Excluded Studies List

living with HIV. *Am J Public Health*. 2001;91(3):400-5. PMID: 11236404.

Rotheram-Borus MJ, Desmond K, Comulada WS, Arnold EM, Johnson M; Healthy Living Trial Group. Reducing risky sexual behavior and substance use among currently and formerly homeless adults living with HIV. *Am J Public Health*. 2009;99(6):1100-7. PMID: 18799777.

Rutherford G, Feldman KA, Kennedy GE. Three- or four- versus two-drug antiretroviral maintenance regimens for HIV infection. *Cochrane Database Syst Rev*. 2000;(2):CD002037. PMID: 10796850.

Safren SA, O'Cleirigh C, Skeer MR, Driskell J, Goshe BM, Covahey C, et al. Demonstration and evaluation of a peer-delivered, individually-tailored, HIV prevention intervention for HIV-infected MSM in their primary care setting. *AIDS Behav*. 2011;15(5):949-58. PMID: 20853023.

Salami AK, Akande AA, Olokoba AB. Serum lipids and glucose abnormalities in HIV/AIDS patients on antiretroviral therapies. *West Afr J Med*. 2009;28(1):300-5. PMID: 19662738.

Salawu FK, Bwala SA, Wakil MA, Bani B, Bukbuk DN, Kida I. Cognitive function in HIV-seropositive Nigerians without AIDS. *J Neurol Sci*. 2008;267(1-2):142-6. PMID: 18001772.

Samaranayake A, Chen MY, McNeil J, Read TR, Hocking JS, Bradshaw CS, et al. Definitions of antiretroviral treatment failure for measuring quality outcomes. *HIV Med*. 2010;11(7):427-31. PMID: 20136659.

Samet JH, Winter MR, Grant L, Hingson R. Factors associated with HIV testing among sexually active adolescents: a Massachusetts survey. *Pediatrics*. 1997;100(3 Pt 1):371-7. PMID: 9282708.

San Antonio-Gaddy M, Richardson-Moore A, Burstein GR, Newman DR, Branson BM, Birkhead GS. Rapid HIV antibody testing in the New York State Anonymous HIV Counseling and Testing Program: experience from the field.

*J Acquir Immune Defic Syndr*. 2006;43(4):446-50. PMID: 16980908.

Sanchez-Conde M, Palacios R, Sanz J, Rodriguez-Novoa S, Rivas P, Santos J, et al. Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV infection: the ELADI study. *AIDS Res Hum Retroviruses*. 2007;23(10):1237-41. PMID: 17961110.

Sayana S, Prosser P, Ricaurte JC, Sanchez S, Hamwi G, Hershey-Weber J, et al. Analysis of a switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and quality of life at 24 weeks. *J Int Assoc Physicians AIDS Care*. 2009;8(2):85-6. PMID: 19369697.

Schappert J, Wians FH Jr, Schiff E, Smalley D, Gambardella R, Lee WM, et al. Multicenter evaluation of the Bayer ADVIA Centaur HIV 1/O/2 enhanced (EHIV) assay. *Clin Chim Acta*. 2006;372(1-2):158-66. PMID: 16769045.

Scheer S, Chu PL, Klausner JD, Katz MH, Schwarcz SK. Effect of highly active antiretroviral therapy on diagnoses of sexually transmitted diseases in people with AIDS. *Lancet*. 2001;357(9254):432-5. PMID: 11273063.

Schiller DS, Youssef-Bessler M. Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV. *Clin Ther*. 2009;31(4):692-704. PMID: 19446143.

Scott VF, Sitapati A, Martin S, Summers P, Washington M, Daniels F, et al. The Howard University Hospital experience with routineized HIV screening: a progress report. *Trans Am Clin Climatol Assoc*. 2009;120:429-34. PMID: 19768195.

Semaille C, Barin F, Cazein F, Pillonel J, Lot F, Brand D, et al. Monitoring the dynamics of the HIV epidemic using assays for recent infection and serotyping among new HIV diagnoses: experience after 2 years in France. *J Infect Dis*. 2007;196(3):377-83. PMID: 17597452.

## Appendix A4. Excluded Studies List

Shamos SJ, Mettenbrink CJ, Subiadur JA, Mitchell BL, Rietmeijer CA. Evaluation of a testing-only “express” visit option to enhance efficiency in a busy STI clinic. *Sex Transm Dis*. 2008;35(4):336-40. PMID: 18277943.

Sherman KE, Shire NJ, Cernohous P, Rouster SD, Omachi JH, Brun S, et al. Liver injury and changes in hepatitis C virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naïve HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir. *Clin Infect Dis*. 2005;41(8):1186-95. PMID: 16163639.

Shey M, Kongnyuy EJ, Shang J, Wiysonge CS. A combination drug of abacavir-lamivudine-zidovudine (trizivir) for treating HIV infection and AIDS. *Cochrane Database Syst Rev*. 2009;(3):CD005481. PMID: 19588374.

Shiels MS, Cole SR, Wegner S, Armenian H, Chmiel JS, Ganesan A, et al. Effect of HAART on incident cancer and noncancer AIDS events among male HIV seroconverters. *J Acquir Immune Defic Syndr*. 2008;48(4):485-90. PMID: 18614916.

Sikkema KJ, Wilson PA, Hansen NB, Kochman A, Neufeld S, Ghebremichael MS, et al. Effects of a coping intervention on transmission risk behavior among people living with HIV/AIDS and a history of childhood sexual abuse. *J Acquir Immune Defic Syndr*. 2008;47(4):506-13. PMID: 18176319.

Silva A, Glick NR, Lyss SB, Hutchinson AB, Gift TL, Pealer LN, et al. Implementing an HIV and sexually transmitted disease screening program in an emergency department. *Ann Emerg Med*. 2007;49(5):564-72. PMID: 17113684.

Silverman M, LaPerriere K, Haukoos JS. Rapid HIV testing in an urban emergency department: using social workers to affect risk behaviors and overcome barriers. *Health Soc Work*. 2009;34(4):305-8. PMID: 19927480.

Silvestri DM, Modjarrad K, Blevins ML, Halale E, Vermund SH, McKinzie JP. A comparison of HIV detection rates using routine opt-out

provider-initiated HIV testing and counseling versus a standard of care approach in a rural African setting. *J Acquir Immune Defic Syndr*. 2011;56(1):e9-32. PMID: 21189483.

Smith KY, Patel P, Fine D, Bellos N, Sloan L, Lackey P, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. *AIDS*. 2009;23(12):1547-56. PMID: 19542866.

Smith LV, Rudy ET, Javanbakht M, Uniyal A, Sy LS, Horton T, et al. Client satisfaction with rapid HIV testing: comparison between an urban sexually transmitted disease clinic and a community-based testing center. *AIDS Patient Care STDs*. 2006;20(10):693-700. PMID: 17052139.

Spaulding A, Rutherford GW, Siegfried N. Stavudine or zidovudine in three-drug combination therapy for initial treatment of HIV infection in antiretroviral-naïve individuals. *Cochrane Database Syst Rev*. 2010;(8):CD008651. PMID: 20687097.

Spaulding A, Rutherford GW, Siegfried N. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals. *Cochrane Database Syst Rev*. 2010;(10):CD008740. PMID: 20927777.

Spielberg F, Branson BM, Goldbaum GM, Lockhart D, Kurth A, Rossini A, et al. Choosing HIV counseling and testing strategies for outreach settings: a randomized trial. *J Acquir Immune Defic Syndr*. 2005;38(3):348-55. PMID: 15735456.

Squires KE, Young B, DeJesus E, Bellos N, Murphy D, Sutherland-Phillips DH, et al. Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients. *HIV Clin Trials*. 2010;11(2):69-79. PMID: 20542844.

## Appendix A4. Excluded Studies List

Stefan MS, Blackwell JM, Crawford KM, Martinez J, Wu Sung S, Holliday SA, et al. Patients' attitudes toward and factors predictive of human immunodeficiency virus testing of academic medical clinics. *Am J Med Sci*. 2010;340(4):264-7. PMID: 20881755.

Stein JA, Rotheram-Borus MJ, Swendeman D, Milburn NG. Predictors of sexual transmission risk behaviors among HIV-positive young men. *AIDS Care*. 2005;17(4):433-42. PMID: 16036228.

Steingrover R, Garcia EF, van Valkengoed IG, Bekker V, Bezemer D, Kroon FP, et al. Transient lowering of the viral set point after temporary antiretroviral therapy of primary HIV type 1 infection. *AIDS Res Hum Retroviruses*. 2010;26(4):379-87. PMID: 20377419.

Stolte IG, de Wit JB, van Eeden A, Coutinho RA, Dukers NH. Perceived viral load, but not actual HIV-1-RNA load, is associated with sexual risk behaviour among HIV-infected homosexual men. *AIDS*. 2004;18(14):1943-9. PMID: 15353980.

Strategies for Management of Antiretroviral Therapy Study Group; Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, et al. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ cell counts and HIV RNA levels during follow-up. *J Infect Dis*. 2008;197(8):1145-55. PMID: 18476293.

Suarez TP, Kelly JA, Pinkerton SD, Stevenson YL, Hayat M, Smith MD, et al. Influence of a partner's HIV serostatus, use of highly active antiretroviral therapy, and viral load on perceptions of sexual risk behavior in a community sample of men who have sex with men. *J Acquir Immune Defic Syndr*. 2001;28(5):471-7. PMID: 11744837.

Sued O, Miro JM, Alquezar A, Claramonte X, Garcia F, Plana M, et al. Primary human immunodeficiency virus type 1 infection: clinical, virological and immunological characteristics of 75 patients (1997-2003). *Enferm Infecc Microbiol Clin*. 2006;24(4):238-44. PMID: 16725083.

Sullivan PS, Drake AJ, Sanchez TH. Prevalence of treatment optimism-related risk behavior and associated factors among men who have sex with men in 11 states, 2000-2001. *AIDS Behav*. 2007;11(1):123-9. PMID: 16767506.

Sundaram V, Lazzeroni LC, Douglass LR, Sanders GD, Tempio P, Owens DK. A randomized trial of computer-based reminders and audit and feedback to improve HIV screening in a primary care setting. *Int J STD AIDS*. 2009;20(8):527-33. PMID: 19625582.

Sundstrom A, Mortimer O, Akerlund B, Karlsson A, Flamholz L, Hakangard C, et al. Increased risk of abdominal wall hernia associated with combination anti-retroviral therapy in HIV-infected patients: results from a Swedish cohort-study. *Pharmacoepidemiol Drug Saf*. 2010;19(5):465-73. PMID: 20186997.

Taiwo BO, Idoko JA, Marcelin AG, Otoh I, Reddy S, Iyaji PG, et al. Patient-selected treatment partners did not protect against drug resistance during first-line NNRTI-based HAART in a randomized trial. *J Acquir Immune Defic Syndr*. 2010;54(5):563-5. PMID: 20647829.

Taiwo BO, Li X, Palella F, Jacobson LP, Margolick JB, Detels R, et al. Higher risk of AIDS or death in patients with lower CD4 cell counts after virally suppressive HAART. *HIV Med*. 2009;10(10):657-60. PMID: 19601997.

Tedaldi EM, Absalon J, Thomas AJ, Shlay JC, van den Berg-Wolf M. Ethnicity, race, and gender: differences in serious adverse events among participants in an antiretroviral initiation trial—results of CPCRA 058 (FIRST Study). *J Acquir Immune Defic Syndr*. 2008;47(4):441-8. PMID: 18176329.

Tenorio AR, Jiang H, Zheng Y, Bastow B, Kuritzkes DR, Bartlett JA, et al. Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115. *AIDS Res Hum Retroviruses*. 2009;25(2):135-9. PMID: 19239354.

## Appendix A4. Excluded Studies List

Thomas BE, Ramachandran R, Anitha S, Swaminathan S. Feasibility of routine HIV testing among TB patients through a voluntary counselling and testing centre. *Int J Tuberc Lung Dis.* 2007;11(12):1296-301. PMID: 18034949.

Tien PC, Schneider MF, Cole SR, Levine AM, Cohen M, DeHovitz J, et al. Antiretroviral therapy exposure and insulin resistance in the Women's Interagency HIV Study. *J Acquir Immune Defic Syndr.* 2008;49(4):369-76. PMID: 19186350.

Tipnis SR, Fox EF. Uptake of HIV testing in a busy South London GU medicine clinic—will we reach targets set in the National Strategy and are we testing those at risk? *Int J STD AIDS.* 2006;17(7):484-5. PMID: 16820081.

Torti C, Lapadula G, Antinori A, Quirino T, Maserati R, Castelnovo F, et al. Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER cohorts. *Infection.* 2009;37(3):244-9. PMID: 19471856.

Tsu RC, Burm ML, Gilhooly JA, Sells CW. Telephone vs. face-to-face notification of HIV results in high-risk youth. *J Adolesc Health.* 2002;30(3):154-60. PMID: 11869921.

Ulett KB, Willig JH, Lin HY, Routman JS, Abrams S, Allison J, et al. The therapeutic implications of timely linkage and early retention in HIV care. *AIDS Patient Care STDs.* 2009;23(1):41-9. PMID: 19055408.

Van de Ven P, Kippax S, Knox S, Prestage G, Crawford J. HIV treatments optimism and sexual behaviour among gay men in Sydney and Melbourne. *AIDS.* 1999;13(16):2289-94. PMID: 10563714.

Van de Ven P, Mao L, Fogarty A, Rawstorne P, Crawford J, Prestage G, et al. Undetectable viral load is associated with sexual risk taking in HIV serodiscordant gay couples in Sydney. *AIDS.* 2005;19(2):179-84. PMID: 15668543.

Van de Ven P, Prestage G, Crawford J, Grulich A, Kippax S. Sexual risk behaviour increases

and is associated with HIV optimism among HIV-negative and HIV-positive gay men in Sydney over the 4 year period to February 2000. *AIDS.* 2000;14(18):2951-3. PMID: 11153682.

Van de Ven P, Rawstorne P, Nakamura T, Crawford J, Kippax S. HIV treatments optimism is associated with unprotected anal intercourse with regular and with casual partners among Australian gay and homosexually active men. *Int J STD AIDS.* 2002;13(3):181-3. PMID: 11860696.

Van Den Bout-Van Den Beukel CJ, Fievez L, Michels M, Sweep FC, Hermus AR, Bosch ME, et al. Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. *AIDS Res Hum Retroviruses.* 2008;24(11):1375-82. PMID: 18928396.

van der Snoek EM, de Wit JB, Mulder PG, van der Meijden WI. Incidence of sexually transmitted diseases and HIV infection related to perceived HIV/AIDS threat since highly active antiretroviral therapy availability in men who have sex with men. *Sex Transm Dis.* 2005;32(3):170-5. PMID: 15729154.

van der Straten A, Gomez CA, Saul J, Quan J, Padian N. Sexual risk behaviors among heterosexual HIV serodiscordant couples in the era of post-exposure prevention and viral suppressive therapy. *AIDS.* 2000;14(4):10. PMID: 10770532.

van Lelyveld SFL, Gras L, Kesselring A, Zhang S, De Wolf F, Wensing AMJ, et al. Long-term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort. *AIDS.* 2012;26(4):465-74. PMID: 22112603.

van Leth F, Andrews S, Grinsztejn B, Wilkins E, Lazanas MK, Lange JM, et al. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. *AIDS.* 2005;19(5):463-71. PMID: 15764851.

Vanable PA, Carey MP, Blair DC, Littlewood RA. Impact of HIV-related stigma on health



## Appendix A4. Excluded Studies List

behaviors and psychological adjustment among HIV-positive men and women. *AIDS Behav.* 2006;10(5):473-82. PMID: 16604295.

Vanable PA, Ostrow DG, McKirnan DJ, Taywaditep KJ, Hope BA. Impact of combination therapies on HIV risk perceptions and sexual risk among HIV-positive and HIV-negative gay and bisexual men. *Health Psychol.* 2000;19(2):134-45. PMID: 10762097.

Vanable PA, Ostrow DG, McKirnan DJ. Viral load and HIV treatment attitudes as correlates of sexual risk behavior among HIV-positive gay men. *J Psychosom Res.* 2003;54(3):263-9. PMID: 12614836.

Walensky RP, Arbelaez C, Reichmann WM, Walls RM, Katz JN, Block BL, et al. Revising expectations from rapid HIV tests in the emergency department. *Ann Intern Med.* 2008;149(3):153-60. PMID: 18678842.

Walensky RP, Losina E, Malatesta L, Barton GE, O'Connor CA, Skolnik PR, et al. Effective HIV case identification through routine HIV screening at urgent care centers in Massachusetts. *Am J Public Health.* 2005;95(1):71-3. PMID: 15623861.

Wand H, Calmy A, Carey DL, Samaras K, Carr A, Law MG, et al. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. *AIDS.* 2007;21(18):2445-53. PMID: 18025881.

Weber R, Huber M, Rickenbach M, Furrer H, Elzi L, Hirschel B, et al. Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study. *HIV Med.* 2009;10(7):407-16. PMID: 19490174.

Wenger NS, Greenberg JM, Hilborne LH, Kusseling F, Mangotich M, Shapiro MF. Effect of HIV antibody testing and AIDS education on communication about HIV risk and sexual behavior. *Ann Intern Med.* 1992;117(11):905-11. PMID: 1443951.

Wenger NS, Linn LS, Epstein M, Shapiro MF. Reduction of high-risk sexual behavior among heterosexuals undergoing HIV antibody testing: a randomized clinical trial. *Am J Public Health.* 1991;81(12):1580-5. PMID: 1746653.

Whetten K, Reif S, Whetten R, Murphy-McMillan LK. Trauma, mental health, distrust, and stigma among HIV-positive persons: implications for effective care. *Psychosom Med.* 2008;70(5):531-8. PMID: 18541904.

White DA, Scribner AN, Schulden JD, Branson BM, Heffelfinger JD. Results of a rapid HIV screening and diagnostic testing program in an urban emergency department. *Ann Emerg Med.* 2009;54(1):56-64. PMID: 18990468.

Whyte JT, Dawson SB. The sexual behaviors of African American women living with HIV disease: is perceived HIV status altering sexual behavior? *J Assoc Nurses AIDS Care.* 2001;12(2):56-65. PMID: 11296731.

Whyte JT, Standing T, Madigan E. The relationship between HIV-related knowledge and safe sexual behavior in African American women dwelling in the rural southeast. *J Assoc Nurses AIDS Care.* 2004;15(2):51-8. PMID: 15090133.

Wilson TE, Gore ME, Greenblatt R, Cohen M, Minkoff H, Silver S, et al. Changes in sexual behavior among HIV-infected women after initiation of HAART. *Am J Public Health.* 2004;94(7):1141-6. PMID: 15226134.

Wilson TE, Minkoff H. Condom use consistency associated with beliefs regarding HIV disease transmission among women receiving HIV antiretroviral therapy. *J Acquir Immune Defic.* 2001;27(3):289-91. PMID: 11464150.

Wohl AR, Garland WH, Valencia R, Squires K, Witt MD, Kovacs A, et al. A randomized trial of directly administered antiretroviral therapy and adherence case management intervention. *Clin Infect Dis.* 2006;42(11):1619-27. PMID: 16652320.

Wolitski RJ, Gomez CA, Parsons JT. Effects of a peer-led behavioral intervention to reduce HIV

## Appendix A4. Excluded Studies List

transmission and promote serostatus disclosure among HIV-seropositive gay and bisexual men. *AIDS*. 2005;19(Suppl 1):S99-109. PMID: 15838199.

Zapka JG, Stoddard A, Zorn M, McCusker J, Mayer KH. HIV antibody test result knowledge, risk perceptions and behavior among homosexually active men. *Patient Educ Couns*. 1991;18(1):9-17. PMID: N/A.

Zaric GS, Bayoumi AM, Brandeau ML, Owens DK. The cost-effectiveness of counseling strategies to improve adherence to highly active antiretroviral therapy among men who have sex with men. *Med Decis Making*. 2008;28(3):359-76. PMID: 18349433.

Zhou J, Phanupak P, Kiertiburanakul S, Ditangco R, Kamarulzaman A, Pujary S, et al. Highly active antiretroviral treatment containing efavirenz or nevirapine and related toxicity in the TREAT Asia HIV Observational Database. *J Infect Dis*. 2006;43(4):501-3. PMID: 17099317.

Zuniga ML, Baldwin H, Uhler D, Brennan J, Olshefsky AM, Oliver E, et al. Supporting Positive Living and Sexual Health (SPLASH): a clinician and behavioral counselor risk-reduction intervention in a university-based HIV clinic. *AIDS Behav*. 2007;11(5 Suppl):S58-71. PMID: 17587172.

### Wrong study design for key question

Acar A, Kemahli S, Altunay H, Kosan E, Oncul O, Gorenek L, et al. The significance of repeat testing in Turkish blood donors screened with HBV, HCV and HIV immunoassays and the importance of S/CO ratios in the interpretation of HCV/HIV screening test results and as a determinant for further confirmatory testing. *Transfus Med*. 2010;20(3):152-9. PMID: 20059750.

Adeyemi OM, Vibhakar S, Evans AT. Obesity and lymphocyte subsets in virologically suppressed HIV-infected patients. *Metabolism*. 2009;58(9):1285-7. PMID: 19497596.

Andersson S, Asjo B, Jenum PA, Manner I, Njolstad G, Ragnhildstveit E, et al. Relevance of

a combined HIV antigen/antibody assay to detect early HIV infections in a low prevalence population: case reports. *Clin Lab*. 2004;50(7-8):409-13. PMID: 15330508.

Antiretroviral Therapy Cohort Collaboration; Zwahlen M, Harris R, May M, Hogg R, Costagliola D, et al. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. *Int J Epidemiol*. 2009;38(6):1624-33. PMID: 19820106.

Baker JV, Peng G, Rapkin J, Krason D, Reilly C, Cavert WP, et al. Poor initial CD4+ recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases. *J Acquir Immune Defic Syndr*. 2008;48(5):541-6. PMID: 18645520.

Bansi L, Sabin C, Delpech V, Hill T, Fisher M, Walsh J, et al. Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations. *HIV Med*. 2010;11(7):432-8. PMID: 20146736.

Bechange S, Bunnell R, Awor A, Moore D, King R, Mermin J, et al. Two-year follow-up of sexual behavior among HIV-uninfected household members of adults taking antiretroviral therapy in Uganda: no evidence of disinhibition. *AIDS Behav*. 2010;14(4):816-23. PMID: 18949550.

Berkley-Patton J, Bowe-Thompson C, Bradley-Ewing A, Hawes S, Moore E, Williams E, et al. Taking It to the Pews: a CBPR-guided HIV awareness and screening project with black churches. *AIDS Educ Prev*. 2010;22(3):218-37. PMID: 20528130.

Bogart LM, Howerton D, Lange J, Becker K, Setodji CM, Asch SM. Scope of rapid HIV testing in urban U.S. hospitals. *Public Health Rep*. 2008;123(4):494-503. PMID: 18763412.

Bogart LM, Howerton D, Lange J, Becker K, Setodji CM, Asch SM. Scope of rapid HIV testing in private nonprofit urban community health settings in the United States. *Am J Public Health*. 2008;98(4):736-42. PMID: 18309135.

## Appendix A4. Excluded Studies List

- Boily MC, Godin G, Hogben M, Sherr L, Bastos FI. The impact of the transmission dynamics of the HIV/AIDS epidemic on sexual behaviour: a new hypothesis to explain recent increases in risk taking-behaviour among men who have sex with men. *Med Hypotheses*. 2005;65(2):215-26. PMID: 15922091.
- Bokhour BG, Solomon JL, Knapp H, Asch SM, Gifford AL. Barriers and facilitators to routine HIV testing in VA primary care. *J Gen Intern Med*. 2009;24(10):1109-14. PMID: 19690923.
- Boodram B, Plankey MW, Cox C, Tien PC, Cohen MH, Anastos K, et al. Prevalence and correlates of elevated body mass index among HIV-positive and HIV-negative women in the Women's Interagency HIV Study. *AIDS Patient Care STDs*. 2009;23(12):1009-16. PMID: 19909168.
- Braithwaite RS, Roberts MS, Chang CC, Goetz MB, Gibert CL, Rodriguez-Barradas MC, et al. Influence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: a decision model. *Ann Intern Med*. 2008;148(3):178-85. PMID: 18252681.
- Brogly SB, Bruneau J, Vincelette J, Lamothe F, Franco EL. Risk behaviour change and HIV infection among injection drug users in Montreal. *AIDS*. 2000;14(16):2575-82. PMID: 11101070.
- Brooks RA, Landovitz RJ, Kaplan RL, Lieber E, Lee SJ, Barkley TW. Sexual risk behaviors and acceptability of HIV pre-exposure prophylaxis among HIV-negative gay and bisexual men in serodiscordant relationships: a mixed methods study. *AIDS Patient Care STDs*. 2012;26(2):87-94. PMID: 22149764.
- Bunnell R, Ekwaru JP, Solberg P, Wamai N, Bikaako-Kajura W, Were W, et al. Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. *AIDS*. 2006;20(1):85-92. PMID: 16327323.
- Butler DM, Smith DM. Serosorting can potentially increase HIV transmissions. *AIDS*. 2007;21(9):1218-20. PMID: 17502737.
- Calderon Y, Leider J, Hailpern S, Chin R, Ghosh R, Fetting J, et al. High-volume rapid HIV testing in an urban emergency department. *AIDS Patient Care STDs*. 2009;23(9):749-55. PMID: 19698029.
- Campos-Outcalt D, Mickey T, Weisbuch J, Jones R. Integrating routine HIV testing into a public health STD clinic. *Public Health Rep*. 2006;121(2):175-80. PMID: 16528951.
- Cassels S, Menza TW, Goodreau SM, Golden MR. HIV serosorting as a harm reduction strategy: evidence from Seattle, Washington. *AIDS*. 2009;23(18):2497-506. PMID: 19834319.
- Cecchi E, Imazio M, Pomari F, Dal Conte I, Preziosi C, Lipani F, et al. A clinical approach for cardiovascular monitoring of HIV-infected patients: results from an observational cohort study. *Ital Heart J*. 2005;6(12):972-6. PMID: 16502712.
- Celentano DD, Latimore AD, Mehta SH. Variations in sexual risks in drug users: emerging themes in a behavioral context. *Curr HIV/AIDS Rep*. 2008;5(4):212-8. PMID: 18838061.
- Centers for Disease Control and Prevention. Acute HIV infection—New York City, 2008. *MMWR Morb Mortal Wkly Rep*. 2009;58(46):1296-9. PMID: 19940835.
- Centers for Disease Control and Prevention. Rapid HIV testing in outreach and other community settings—United States, 2004-2006. *MMWR Morb Mortal Wkly Rep*. 2007;56(47):1233-7. PMID: 18046300.
- Chen SY, Moss WJ, Pipkin SS, McFarland W. A novel use of AIDS surveillance data to assess the impact of initial treatment regimen on survival. *Int J STD AIDS*. 2009;20(5):330-5. PMID: 19386970.
- Coffie PA, Tonwe-Gold B, Tanon AK, Amani-Bosse C, Bedikou G, Abrams EJ, et al. Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women: MTCT-Plus

## Appendix A4. Excluded Studies List

- program, Abidjan, Cote d'Ivoire. *BMC Inf Dis*. 2010;10:188. PMID: 20576111.
- Cohall A, Dini S, Nye A, Dye B, Neu N, Hyden C. HIV testing preferences among young men of color who have sex with men. *Am J Public Health*. 1961;100(10):1961-6. PMID: 20075330.
- Collins CB Jr, Hearn KD, Whittier DN, Freeman A, Stallworth JD, Phields M. Implementing packaged HIV-prevention interventions for HIV-positive individuals: considerations for clinic-based and community-based interventions. *Public Health Rep*. 2010;1:55-63. PMID: 20408388.
- Crum-Cianflone N, Tejidor R, Medina S, Barahona I, Ganesan A. Obesity among patients with HIV: the latest epidemic. *AIDS Patient Care STDs*. 2008;22(12):925-30. PMID: 19072098.
- Dalton P, McCord A. HIV sexual transmission under HAART: Project Inform comments on 2008 Swiss Statement. *Proj Inf Perspect*. 2008;46:26-8. PMID: 19048681.
- Das S, Ghanem M, Huengsberg M. Experience with efavirenz in end-stage renal disease. *Int J STD AIDS*. 2004;15(2):143. PMID: 15006080.
- Day S, Lakhani D, Hankins M, Rodgers CA. Improving uptake of HIV testing in patients with a confirmed STI. *Int J STD AIDS*. 2004;15(9):626-8. PMID: 15339373.
- De Cock KM, Gilks CF, Lo YR, Guerma T. Can antiretroviral therapy eliminate HIV transmission? *Lancet*. 2009;373(9657):7-9. PMID: 19038440.
- de Wit JB, Adam PC. To test or not to test: psychosocial barriers to HIV testing in high-income countries. *HIV Med*. 2008;2:20-2. PMID: 18557865.
- Del Romero J, Hernando V, Castilla J, Garcia S, Gil S, Rodriguez C. Lack of HIV heterosexual transmission attributable to HAART in serodiscordant couples. Paper presented at: XVII International AIDS Conference; August 2008; Mexico City. PMID: N/A.
- Desai MM, Rosenheck RA, Desai RA. Prevalence and correlates of human immunodeficiency virus testing and posttest counseling among outpatients with serious mental illness. *J Nerv Ment Dis*. 2007;195(9):776-80. PMID: 17984780.
- Diamond C. HAART and sexual risk behavior. *JAMA*. 2004;292(19):17. PMID: 15547155.
- Dietz CA, Ablah E, Reznik D, Robbins DK. Patients' attitudes about rapid oral HIV screening in an urban, free dental clinic. *AIDS Patient Care STDs*. 2008;22(3):205-12. PMID: 18290751.
- Ehrenkranz PD, Pagan JA, Begier EM, Linas BP, Madison K, Armstrong K. Written informed-consent statutes and HIV testing. *Am J Prev Med*. 2009;37(1):57-63. PMID: 19423271.
- Erausquin JT, Duan N, Grusky O, Swanson AN, Kerrone D, Rudy ET. Increasing the reach of HIV testing to young Latino MSM: results of a pilot study integrating outreach and services. *J Health Care Poor Underserved*. 2009;20(3):756-65. PMID: 19648703.
- Fidler S, Fraser C, Fox J, Tamm N, Griffin JT, Weber J. Comparative potency of three antiretroviral therapy regimens in primary HIV infection. *AIDS*. 2006;20(2):247-52. PMID: 16511418.
- Forsyth SF, Agogo EA, Lau L, Jungmann E, Man S, Edwards SG, et al. Would offering rapid point-of-care testing or non-invasive methods improve uptake of HIV testing among high-risk genitourinary medicine clinic attendees? A patient perspective. *Int J STD AIDS*. 2008;19(8):550-2. PMID: 18663043.
- Freedman E, Dhaliwal K, Estcourt C, Baily G. Symptomatic HIV viraemia during a drug holiday: an argument against treatment interruption? *Int J STD AIDS*. 2004;15(8):564-5. PMID: 15307970.
- Galatowitsch P, Rodriguez E. New emphasis in HIV prevention: interventions targeting HIV-positive men. *Body Posit*. 2001;14(4):47-8. PMID: 11569954.

## Appendix A4. Excluded Studies List

Gasiorowicz M, Stodola J. HIV prevalence estimates and alignment among recent diagnoses, targeted tests, and prevention services by demographic and racial/ethnic group in Wisconsin. *AIDS Educ Prev*. 2011;23(3 Suppl):7-16. PMID: 21689033.

Goetz MB, Hoang T, Bowman C, Knapp H, Rossman B, Smith R, et al. A system-wide intervention to improve HIV testing in the Veterans Health Administration. *J Gen Intern Med*. 2008;28(8):1200-7. PMID: 18452045.

Grover SA, Coupal L, Gilmore N, Mukherjee J. Impact of dyslipidemia associated with highly active antiretroviral therapy (HAART) on cardiovascular risk and life expectancy. *Am J Cardiol*. 2005;95(5):586-91. PMID: 15721096.

Haukoos JS, Hopkins E, Hull A, Dean C, Donahoe K, Ruzas CM, et al. HIV testing in emergency departments in the United States: a national survey. *Ann Emerg Med*. 2011;58(Suppl 1):S10-6. PMID: 21684387.

Haukoos JS, White DA, Lyons MS, Hopkins E, Calderon Y, Kalish B, et al. Operational methods of HIV testing in emergency departments: a systematic review. *Ann Emerg Med*. 2011;58(Suppl 1):S96-103. PMID: 21684417.

Holstad MM. Adherence, sexual risk, and viral load in HIV-infected women prescribed antiretroviral therapy. *AIDS Patient Care STDs*. 2011;25(7):431-8. PMID: 21663541.

Hoxhaj S, Davila JA, Modi P, Kachalia N, Malone K, Ruggerio MC, et al. Using nonrapid HIV technology for routine, opt-out HIV screening in a high-volume urban emergency department. *Ann Emerg Med*. 2011;58(Suppl 1):S79-84. PMID: 21684414.

Hsieh YH, Jung JJ, Shahan JB, Pollack HA, Hairston HS, Moring-Parris D, et al. Outcomes and cost analysis of 3 operational models for rapid HIV testing services in an academic inner-city emergency department. *Ann Emerg Med*. 2011;58(Suppl 1):S133-9. PMID: 21684392.

Jaroszewicz J, Wiercinska-Drapalo A, Lapinski TW, Prokopowicz D, Rogalska M, Parfieniuk A. Does HAART improve renal function? An association between serum cystatin C concentration, HIV viral load and HAART duration. *Antivir Ther*. 2006;11(5):641-5. PMID: 16964834.

Johnson MD, Decker CF. Osteonecrosis in HIV-infected persons: radiographic findings delay clinical diagnosis. *AIDS Read*. 2008;18(3):124-6. PMID: 18398979.

Kanuha VK, Mueller CW, Sullivan KM, Glancey P, Matsumoto P, Martel LD. HIV and women in Hawaii: risk and protective factors in HIV/AIDS prevention. *Hawaii Med J*. 2003;62(9):187-92. PMID: 14593657.

Kapadia F, Latka MH, Hudson SM, Golub ET, Campbell JV, Bailey S, et al. Correlates of consistent condom use with main partners by partnership patterns among young adult male injection drug users from five US cities. *Drug Alcohol Depend*. 2007;91(Suppl 1):S56-63. PMID: 17329041.

Keiser O, Taffe P, Zwahlen M, Battegay M, Bernasconi E, Weber R, et al. All cause mortality in the Swiss HIV Cohort Study from 1990 to 2001 in comparison with the Swiss population. *AIDS*. 2004;18(13):1835-43. PMID: 15316345.

Kenagy GP, Linsk NL, Bruce D, Warnecke R, Gordon A, Wagaw F, et al. Service utilization, service barriers, and gender among HIV-positive consumers in primary care. *AIDS Patient Care STDs*. 2003;17(5):235-44. PMID: 12816617.

Kendrick SR, Kroc KA, Withum D, Rydman RJ, Branson BM, Weinstein RA. Outcomes of offering rapid point-of-care HIV testing in a sexually transmitted disease clinic. *J Acquir Immune Defic Syndr*. 2005;38(2):142-6. PMID: 15671798.

Kennedy CE, Medley AM, Sweat MD, O'Reilly KR. Behavioural interventions for HIV positive prevention in developing countries: a systematic review and meta-analysis. *Bull World Health Organ*. 2010 1;88(8):615-23. PMID: 20680127.

## Appendix A4. Excluded Studies List

- Kennedy LA, Gordin FM, Kan VL. Assessing targeted screening and low rates of HIV testing. *Am J Public Health*. 2010;100(9):1765-8. PMID: 20634454.
- Kirk JB, Goetz MB. Human immunodeficiency virus in an aging population, a complication of success. *J Am Geriatr Soc*. 2009;57(11):2129-38. PMID: 19793157.
- Klarkowski DB, Wazome JM, Lokuge KM, Shanks L, Mills CF, O'Brien DP. The evaluation of a rapid in situ HIV confirmation test in a programme with a high failure rate of the WHO HIV two-test diagnostic algorithm. *PLoS One*. 2009;4(2):e4351. PMID: 19197370.
- Klevens RM, Fleming PL, Neal JJ, Li J. Knowledge of partner risk and secondary transmission of HIV. *Am J Prev Med*. 2001;20(4):277-81. PMID: 11331116.
- Kohli R, Klein RS, Schoenbaum EE, Anastos K, Minkoff H, Sacks HS. Aging and HIV infection. *J Urban Health*. 2006;83(1):31-42. PMID: 16736353.
- Law MG, Prestage G, Grulich A, Van de Ven P, Kippax S. Modelling the effect of combination antiretroviral treatments on HIV incidence. *AIDS*. 2001;15(10):1287-94. PMID: 11426074.
- Lee MB, Leibowitz A, Rotheram-Borus MJ. Cost-effectiveness of a behavioral intervention for seropositive youth. *AIDS Educ Prev*. 2005;17(2):105-18. PMID: 15899749.
- Lekakis J, Ikonomidis I, Palios J, Tsiodras S, Karatzis E, Poulakou G, et al. Association of highly active antiretroviral therapy with increased arterial stiffness in patients infected with human immunodeficiency virus. *Am J Hypertens*. 2009;22(8):828-34. PMID: 19556973.
- Liu H, Miller LG, Hays RD, Golin CE, Wu T, Wenger NS, et al. Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors. *J Acquir Immune Defic Syndr*. 2006;41(3):315-22. PMID: 16540932.
- Lubelchek RJ, Kroc KA, Levine DL, Beavis KG, Roberts RR. Routine, rapid HIV testing of medicine service admissions in the emergency department. *Ann Emerg Med*. 2011;58(Suppl 1):S65-70. PMID: 21684411.
- Ly TD, Laperche S, Brennan C, Vallari A, Ebel A, Hunt J, et al. Evaluation of the sensitivity and specificity of six HIV combined p24 antigen and antibody assays. *J Virol Method*. 2004;122(2):185-94. PMID: 15542143.
- Lyons MS, Lindsell CJ, Ledyard HK, Frame PT, Trott AT. Emergency department HIV testing and counseling: an ongoing experience in a low-prevalence area. *Ann Emerg Med*. 2005;46(1):22-8. PMID: 15988422.
- Lyss SB, Branson BM, Kroc KA, Couture EF, Newman DR, Weinstein RA. Detecting unsuspected HIV infection with a rapid whole-blood HIV test in an urban emergency department. *J Acquir Immune Defic Syndr*. 2007;44(4):435-42. PMID: 17224850.
- Magnani R, Sabin K, Saidel T, Heckathorn D. Review of sampling hard-to-reach and hidden populations for HIV surveillance. *AIDS*. 2005;19(Suppl 2):S67-72. PMID: 15930843.
- Malm K, von Sydow M, Andersson S. Performance of three automated fourth-generation combined HIV antigen/antibody assays in large-scale screening of blood donors and clinical samples. *Transfus Med*. 2009;19(2):78-88. PMID: 19320855.
- Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. *AIDS*. 2006;20(10):1447-50. PMID: 16791020.
- McCormick AW, Walensky RP, Lipsitch M, Losina E, Hsu H, Weinstein MC, et al. The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men. *Clin Infect Dis*. 2007;44(8):1115-22. PMID: 17366461.
- McKellar MS, Jongthavorn P, Khanlou H. False-positivity of HIV-2 immunoblots in a

## Appendix A4. Excluded Studies List

cohort of elite suppressors infected with HIV-1. *J Acquir Immune Defic Syndr*. 2008;47(5):15. PMID: 18362696.

Mehta SD, Hall J, Lyss SB, Skolnik PR, Pealer LN, Kharasch S. Adult and pediatric emergency department sexually transmitted disease and HIV screening: programmatic overview and outcomes. *Acad Emerg Med*. 2007;14(3):250-8. PMID: 17331918.

Menezes BF, Williams P, Ramtahal J, Boggild M. The significance of early HIV testing. *Clin Med*. 2008;8(5):550-1. PMID: 18975493.

Merchant RC, Catanzaro BM, Seage GR, Mayer KH, Clark MA, Degruittola VG, et al. Demographic variations in HIV testing history among emergency department patients: implications for HIV screening in US emergency departments. *J Med Screen*. 2009;16(2):60-6. PMID: 19564517.

Merchant RC, Clark MA, Seage GR 3rd, Mayer KH, Degruittola VG, Becker BM. Emergency department patient perceptions and preferences on opt-in rapid HIV screening program components. *AIDS Care*. 2009;21(4):490-500. PMID: 19283644.

Merchant RC, Seage GR, Mayer KH, Clark MA, DeGruttola VG, Becker BM. Emergency department patient acceptance of opt-in, universal, rapid HIV screening. *Public Health Rep*. 2008;3:27-40. PMID: 19172704.

Miller WC, Leone PA, McCoy S, Nguyen TQ, Williams DE, Pilcher CD. Targeted testing for acute HIV infection in North Carolina. *AIDS*. 2009;23(7):835-43. PMID: 19318909.

Mollen C, Lavelle J, Hawkins L, Ambrose C, Ruby B. Description of a novel pediatric emergency department-based HIV screening program for adolescents. *AIDS Patient Care STDs*. 2008;22(6):505-12. PMID: 18462077.

Mugavero MJ, Pence BW, Whetten K, Leserman J, Swartz M, Stangl D, et al. Childhood abuse and initial presentation for HIV care: an opportunity for early intervention. *AIDS Care*. 2007;19(9):1083-7. PMID: 18058391.

Mullins TL, Kollar LM, Lehmann C, Kahn JA. Changes in human immunodeficiency virus testing rates among urban adolescents after introduction of routine and rapid testing. *Arch Pediatr Adolesc Med*. 2010;164(9):870-4. PMID: 20819970.

Mumma BE, Suffoletto BP. Less encouraging lessons from the front lines: barriers to implementation of an emergency department-based HIV screening program. *Ann Emerg Med*. 2011;58(Suppl 1):S44-8. PMID: 21684407.

Murphy DA, Mitchell R, Vermund SH, Futterman D; Adolescent Medicine HIV/AIDS Research Network. Factors associated with HIV testing among HIV-positive and HIV-negative high-risk adolescents: the REACH Study. *Pediatrics*. 2002;110(3)e36. PMID: 12205286.

Myers HF, Satz P, Miller BE, Bing EG, Evans G, Richardson MA, et al. The African-American Health Project (AAHP): study overview and select findings on high risk behaviors and psychiatric disorders in African American men. *Ethn Health*. 1997;2(3):183-96. PMID: 9426983.

Myers HF, Wyatt GE, Loeb TB, Carmona JV, Warda U, Longshore D, et al. Severity of child sexual abuse, post-traumatic stress and risky sexual behaviors among HIV-positive women. *AIDS Behav*. 2006;10(2):191-9. PMID: 16479413.

Myers JJ, Steward WT, Charlebois E, Koester KA, Maiorana A, Morin SF. Written clinic procedures enhance delivery of HIV "prevention with positives" counseling in primary health care settings. *J Acquir Immune Defic Syndr*. 2004;37(Suppl 2):S95-100. PMID: 15385905.

Nacher M, El Guedj M, Vaz T, Nasser V, Randrianjohany A, Alvarez F, et al. Risk factors for late HIV diagnosis in French Guiana. *AIDS*. 2005;19(7):727-9. PMID: 15821399.

Nash D, Bennani Y, Ramaswamy C, Torian L. Estimates of HIV incidence among persons testing for HIV using the sensitive/less sensitive enzyme immunoassay, New York City, 2001. *J*

## Appendix A4. Excluded Studies List

- Acquir Immune Defic Syndr.* 2005;39(1):102-11. PMID: 15851920.
- Oette M, Kroidl A, Gobels K, Stabbert A, Menge M, Sagir A, et al. Predictors of short-term success of antiretroviral therapy in HIV infection. *J Antimicrob Chemother.* 2006;58(1):147-53. PMID: 16687458.
- Ortega-Larrocea G, Espinosa E, Reyes-Teran G. Lower incidence and severity of cytomegalovirus-associated immune recovery uveitis in HIV-infected patients with delayed highly active antiretroviral therapy. *AIDS.* 2005;19(7):735-8. PMID: 15821403.
- Ostrow DE, Fox KJ, Chmiel JS, Silvestre A, Visscher BR, Vanable PA, et al. Attitudes towards highly active antiretroviral therapy are associated with sexual risk taking among HIV-infected and uninfected homosexual men. *AIDS.* 2002;16(5):775-80. PMID: 11964534.
- Otto-Salaj LL, Stevenson LY. Influence of psychiatric diagnoses and symptoms on HIV risk behavior in adults with serious mental illness. *AIDS Read.* 2001;11(4):197-204. PMID: 11392677.
- Paci P, Carello R, Bernaschi M, D'Offizi G, Castiglione F. Immune control of HIV-1 infection after therapy interruption: immediate versus deferred antiretroviral therapy. *BMC Infect Dis.* 2009;9:172. PMID: 19840392.
- Pantazis N, Touloumi G, Vanhems P, Gill J, Bucher HC, Porter K, et al. The effect of antiretroviral treatment of different durations in primary HIV infection. *AIDS.* 2008;22(18):2441-50. PMID: 19005267.
- Pao D, Fisher M, Hue S, Dean G, Murphy G, Cane PA, et al. Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infections. *AIDS.* 2005;19(1):85-90. PMID: 15627037.
- Patterson KB, Cohn SE, Uyanik J, Hughes M, Smurzynski M, Eron JJ. Treatment responses in antiretroviral treatment-naïve premenopausal and postmenopausal HIV-1-infected women: an analysis from AIDS Clinical Trials Group Studies. *Clin Infect Dis.* 2009;49(3):473-6. PMID: 19555288.
- Picciano JF, Roffman RA, Kalichman SC, Walker DD. Lowering obstacles to HIV prevention services: effects of a brief, telephone-based intervention using motivational enhancement therapy. *Ann Behav Med.* 2007;34(2):177-87. PMID: 17927556.
- Pinto Neto LF, Vieira NF, Soprani M, Cunha CB, Cabral VP, Dietze R, et al. Longitudinal comparison between plasma and seminal HIV-1 viral loads during antiretroviral treatment. *Rev Soc Bras Med Trop.* 2003;36:689-94. PMID: 15049108.
- Pittrof R, McLellan J. Test Not Talk screening for asymptomatic men. *Int J STD AIDS.* 2007;18(4):274-5. PMID: 17509179.
- Plantier JC, Lemee V, Nabias R, Sire JM, Simon F. Generic screening test for HIV infection. *AIDS.* 2006;20(9):1345-7. PMID: 16816572.
- Plowden KO, Fletcher A, Miller JL. Factors influencing HIV-risk behaviors among HIV-positive urban African Americans. *J Assoc Nurses AIDS Care.* 2005;16(1):21-8. PMID: 15903275.
- Prado G, Schwartz SJ, Pattatucci-Aragon A, Clatts M, Pantin H, Fernandez MI, et al. The prevention of HIV transmission in Hispanic adolescents. *Drug Alcohol Depend.* 2006;84(Suppl 1):S43-53. PMID: 16764997.
- Prestage G, Mao L, Jin F, Grulich A, Kaldor J, Kippax S. Sex work and risk behaviour among HIV-negative gay men. *AIDS Care.* 2007;19(7):931-4. PMID: 17712698.
- Prestage G, Mao L, McGuigan D, Crawford J, Kippax S, Kaldor J, et al. HIV risk and communication between regular partners in a cohort of HIV-negative gay men. *AIDS Care.* 2006;18(2):166-72. PMID: 16338775.
- Puhan MA, Van Natta ML, Palella FJ, Addressi A, Meinert C; Ocular Complications of AIDS Research Group. Excess mortality in patients with AIDS in the era of highly active antiretroviral therapy: temporal changes and risk



## Appendix A4. Excluded Studies List

factors. *Clin Infect Dis*. 2010;51(8):947-56. PMID: 20825306.

Purcell DW, Parsons JT, Halkitis PN, Mizuno Y, Woods WJ. Substance use and sexual transmission risk behavior of HIV-positive men who have sex with men. *J Subst Abuse*. 2001;13(1-2):185-200. PMID: 11547619.

Pyne JM. The psychiatry of AIDS: a guide to diagnosis and treatment. *J Acquir Immune Defic Syndr*. 2006;43(1):119-20. PMID: N/A.

Rakhmanina NY, Capparelli EV, van den Anker JN. Personalized therapeutics: HIV treatment in adolescents. *Clin Pharmacol Ther*. 2008;84(6):734-40. PMID: 18830226.

Ramos CG, Barcelos NT. Does episodic antiretroviral therapy increase HIV transmission risk compared with continuous therapy? *J Acquir Immune Defic Syndr*. 2009;51(4):1. PMID: 19590291.

Rathbun RC, Farmer KC, Stephens JR, Lockhart SM. Impact of an adherence clinic on behavioral outcomes and virologic response in treatment of HIV infection: a prospective, randomized, controlled pilot study. *Clin Ther*. 2005;27(2):199-209. PMID: 15811483.

Reilly T, Woo G. Social support and maintenance of safer sex practices among people living with HIV/AIDS. *Health Soc Work*. 2004;29(2):97-105. PMID: 15156842.

Reilly T, Woodruff SI, Smith L, Clapp JD, Cade J. Unsafe sex among HIV positive individuals: cross-sectional and prospective predictors. *J Comm Health*. 2010;35(2):115-23. PMID: 20012476.

Roehr B. HIV programmes reduce deaths and new infections, UNAIDS report shows. *BMJ*. 1099;337:a1099. PMID: 18676440.

Romanowski B, Campbell PJ, Preiksaitis JK, Fonseca K. Human immunodeficiency virus seroprevalence and risk behaviors in patients attending sexually transmitted disease clinics in Alberta. *Sex Transm Dis*. 1997;24(8):487-94. PMID: 9293613.

Ross MW, Rosser BR, Neumaier ER; Positive Connections Team. The relationship of internalized homonegativity to unsafe sexual behavior in HIV-seropositive men who have sex with men. *AIDS Educ Prev*. 2008;20(6):547-57. PMID: 19072529.

Rotheram-Borus MJ, Swendeman D, Comulada WS, Weiss RE, Lee M, Lightfoot M. Prevention for substance-using HIV-positive young people: telephone and in-person delivery. *J Acquir Immune Defic Syndr*. 2004;37:S68-77. PMID: 15385902.

Rutledge SE. Single-session motivational enhancement counseling to support change toward reduction of HIV transmission by HIV positive persons. *Arch Sex Behav*. 2007;36(2):313-9. PMID: 17109234.

Ryder K, Haubrich DJ, Calla D, Myers T, Burchell AN, Calzavara L. Psychosocial impact of repeat HIV-negative testing: a follow-up study. *AIDS Behav*. 2005;9(4):459-64. PMID: 16328711.

Sabine C; Antiretroviral Therapy Cohort Collaboration. AIDS events among individuals initiating HAART: do some patients experience a greater benefit from HAART than others? *AIDS*. 2005;19(17):1995-2000. PMID: 16260906.

Sattin RW, Wilde JA, Freeman AE, Miller KM, Dias JK. Rapid HIV testing in a southeastern emergency department serving a semiurban-semirural adolescent and adult population. *Ann Emerg Med*. 2011;58(Suppl 1):S60-4. PMID: 21684410.

Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. *N Engl J Med*. 2009;361(23):2230-40. PMID: 19952143.

Schrantz SJ, Babcock CA, Theodosios C, Brown S, Mercer S, Pillow MT, et al. A targeted, conventional assay, emergency department HIV testing program integrated with existing clinical procedures. *Ann Emerg Med*. 2011;58(Suppl 1):S85-8. PMID: 21684415.

## Appendix A4. Excluded Studies List

- Scott J, Bansi L, Ivens D. HIV test uptake after introducing an opt-out screening system. *Int J STD AIDS*. 2006;17(3):213. PMID: 16510018.
- Semaille C, Cazein F, Pillonel J, Lot F, Le Vu S, Pinget R, et al. Four years of surveillance of recent HIV infections at country level, France, mid 2003-2006: experience and perspectives. *Euro Surveill*. 2008;13(7-9):17-22. PMID: 18775291.
- Semple SJ, Patterson TL, Grant I. Binge use of methamphetamine among HIV-positive men who have sex with men: pilot data and HIV prevention implications. *AIDS Educ Prev*. 2003;15(2):133-47. PMID: 12739790.
- Shagufta Z, Mahto M. Uptake of HIV testing in a genitourinary medicine clinic following opt-out screening method and uptake rate by individual clinicians. *Int J STD AIDS*. 2007;18(9):650-1. PMID: 17785017.
- Shima T, Isshiki M, Kondo M, Tsukada M, Shiomi S, Imai M. Introduction of rapid HIV tests to a public health center in Japan and evaluation of its effects [Japanese]. *Nihon Koshu Eisei Zasshi*. 2006;53(3):167-77. PMID: 16689271.
- Shima T, Sudo K, Kondo M, Kurai H, Sagara H, Imai M. Evaluation of new fourth-generation human immunodeficiency virus antigen and antibody detection assay with enzyme-linked fluorescent immunoassay. *Kansenshogaku Zasshi*. 2007;81(5):562-72. PMID: 17966638.
- Sitlinger AP, Lindsell CJ, Ruffner AH, Wayne DB, Hart KW, Trott AT, et al. Preliminary program evaluation of emergency department HIV prevention counseling. *Ann Emerg Med*. 2011;58(Suppl 1):S120-5. PMID: 21684390
- Sorensen JL, Dilley J, London J, Okin RL, Delucchi KL, Phibbs CS. Case management for substance abusers with HIV/AIDS: a randomized clinical trial. *Am J Drug Alcohol Abuse*. 2003;29(1):133-50. PMID: 12731685.
- Spielberg F, Kurth A, Reidy W, McKnight T, Dikobe W, Wilson C. Iterative evaluation in a mobile counseling and testing program to reach people of color at risk for HIV—new strategies improve program acceptability, effectiveness, and evaluation capabilities. *AIDS Educ Prev*. 2011;23(3 Suppl):110-6. PMID: 21689041.
- Stekler J, Swenson PD, Wood RW, Handsfield HH, Golden MR. Targeted screening for primary HIV infection through pooled HIV-RNA testing in men who have sex with men. *AIDS*. 2005;19(12):1323-5. PMID: 16052089.
- Tanner AE, Muvva R, Miazad R, Johnson S, Burnett P, Olthoff G, et al. Integration of HIV testing and linkage to care by the Baltimore City Health Department. *Sex Transm Dis*. 2010;37(2):129-30. PMID: 20038866.
- Torres GW, Heffelfinger JD, Pollack HA, Barrera SG, Rothman RE. HIV screening programs in US emergency departments: a cross-site comparison of structure, process, and outcomes. *Ann Emerg Med*. 2011;58(Suppl 1):S104-13. PMID: 21684388.
- Torres GW, Yonek J, Pickreign J, Whitmore H, Hasnain-Wynia R. HIV testing and referral to care in U.S. hospitals prior to 2006: results from a national survey. *Public Health Rep*. 2009;124(3):400-8. PMID: 19445416.
- Walensky RP, Paltiel AD, Losina E, Morris BL, Scott CA, Rhode ER, et al. Test and Treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. *Clin Infect Dis*. 2010;51(4):392-400. PMID: 20617921.
- White DA, Tran T, Dideum PJ, Vahidnia F, Gordon DM, Ng V, et al. Physician-initiated rapid HIV testing in an urban emergency department: comparison of testing using a point-of-care versus a laboratory model. *Ann Emerg Med*. 2011;58(Suppl 1):S53-9. PMID: 21684409.
- Wilbur L, Huffman G, Lofton S, Finnell JT. The use of a computer reminder system in an emergency department universal HIV screening program. *Ann Emerg Med*. 2011;58(Suppl 1):S71-3. PMID: 21684412.
- Wilkinson MJ, Bain BJ, Phelan L, Benzie A. Increased haemoglobin A2 percentage in HIV

## Appendix A4. Excluded Studies List

infection: disease or treatment? *AIDS*. 2007;21(9):1207-8. PMID: 17502732.

Williamson LM, Dodds JP, Mercey DE, Hart GJ, Johnson AM. Sexual risk behaviour and knowledge of HIV status among community samples of gay men in the UK. *AIDS*. 2008;22(9):1063-70. PMID: 18520350.

Wilson DP, Hoare A, Regan DG, Law MG. Importance of promoting HIV testing for preventing secondary transmissions: modelling the Australian HIV epidemic among men who have sex with men. *Sex Health*. 2009;6(1):19-33. PMID: 19254488.

Xia Q, Molitor F, Osmond DH, Tholandi M, Pollack LM, Ruiz JD, et al. Knowledge of sexual partner's HIV serostatus and serosorting practices in a California population-based sample of men who have sex with men. *AIDS*. 2006;20(16):2081-9. PMID: 17053354.

### **No original data (review article, letter, editorial, results reported elsewhere)**

Attia S, Egger M, Muller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. *AIDS*. 2009;23(11):1397-404. PMID: 19381076.

Baggaley R, Ferguson N, Garnett G. The epidemiological impact of antiretroviral use predicted by mathematical models: a review. *Emerg Themes Epidemiol*. 2005;2(1):9. PMID: 16153307.

Bassett IV, Walensky RP. Integrating HIV screening into routine health care in resource-limited settings. *Clin Infect Dis*. 2010;50(3):15. PMID: 20397960.

Bhattacharya R, Barton S, Catalan J. When good news is bad news: psychological impact of false positive diagnosis of HIV. *AIDS Care*. 2008;20(5):560-4. PMID: 18484325.

Branson BM. State of the art for diagnosis of HIV infection. *Clin Infect Dis*. 2007;45(4 Suppl):S221-5. PMID: 18190290.

Brill IK, Macaluso M, et al. A SAS program for the computation of seroconversion rates in a prospective study of HIV discordant couples in Lusaka, Zambia. Paper presented at: 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment; July 2003; Paris. PMID: N/A.

Bunnell R, Ekwaru J, King R, Bechange S, Moore D, Khana K, et al. 3-year follow-up of sexual behavior and HIV transmission risk of persons taking art in rural Uganda. Paper presented at: 15th Conference on Retroviruses and Opportunistic Infections; February 2008; Boston. PMID: N/A.

Camoni L, Dal Conte I, Regine V, Colucci A, Chiriotto M, Vullo V, et al. Sexual behaviour reported by a sample of Italian MSM before and after HIV diagnosis. *Ann Ist Super Sanita*. 2011;47(2):214-9. PMID: 21709392.

Cohen MS. Thomas Parran Award Lecture: transmission and prevention of transmission of HIV-1. *Sex Transm Dis*. 2006;33(6):338-41. PMID: 16721328.

Cossarizza A, Moyle G. Antiretroviral nucleoside and nucleotide analogues and mitochondria. *AIDS*. 2004;18(2):137-51. PMID: 15075530.

de Vincenzi I, Mertens T. Male circumcision: a role in HIV prevention? *AIDS*. 1994;8(2):153. PMID: 8043224.

del Rio C. Report from the 13th Retrovirus Conference: more on false-positive results in rapid HIV testing. *AIDS Clin Care*. 2006;18(4):39. PMID: 16718885.

Des Jarlais DC, Padian N. Strategies for universalistic and targeted HIV prevention. *J Acquir Immune Defic Syndr Hum Retrovirol*. 1997;16(2):127-36. PMID: 9358108.

Dewsnap CH, McOwan A. A review of HIV point-of-care tests. *Int J STD AIDS*. 2006;17(6):357-9. PMID: 16734952.

Dhawan D, Mayer KH. Microbicides to prevent HIV transmission: overcoming obstacles to

## Appendix A4. Excluded Studies List

chemical barrier protection. *J Infect Dis.* 2006;193(1):36-44. PMID: 16323129.

Dibosa-Osadolor O, Roberts T. Economic evaluation, human immunodeficiency virus infection and screening: a review and critical appraisal of economic studies. *Int J Technol Assess Health Care.* 2010;26(3):301-8. PMID: 20584359.

Dosekun O, Fox J. An overview of the relative risks of different sexual behaviours on HIV transmission. *Curr Opin HIV AIDS.* 2010;5(4):291-7. PMID: 20543603.

Eaton LA, Kalichman SC, O'Connell DA, Karchner WD. A strategy for selecting sexual partners believed to pose little/no risks for HIV: serosorting and its implications for HIV transmission. *AIDS Care.* 2009;21(10):1279-88. PMID: 20024704.

Elford J, Hart G. HAART, viral load and sexual risk behaviour. *AIDS.* 2005;19(2):205-7. PMID: 15668547.

Fink A. A possible explanation for heterosexual male infection with AIDS. *N Engl J Med.* 1986;315(18):1167. PMID: 3762636.

Franco-Paredes C, Tellez I, del Rio C. Rapid HIV testing: a review of the literature and implications for the clinician. *Curr HIV/AIDS Rep.* 2006;3(4):169-75. PMID: 17032576.

Galvan FH, Brooks RA, Leibowitz AA. Rapid HIV testing: issues in implementation. *AIDS Patient Care STDs.* 2004;18(1):15-8. PMID: 15006190.

Ganczak M. HIV/AIDS education as a supportive tool for premarital HIV screening. *J Infect Public Health.* 2009;2(3):153-4. PMID: 20701876.

Garland PM, Valverde EE, Fagan J, Beer L, Sanders C, Hillman D, et al. HIV counseling, testing and referral experiences of persons diagnosed with HIV who have never entered HIV medical care. *AIDS Educ Prev.* 2011(3):117-27. PMID: 21689042.

Gerbert B, Danley DW, Herzig K, Clanon K, Ciccarone D, Gilbert P, et al. Reframing "prevention with positives": incorporating counseling techniques that improve the health of HIV-positive patients. *AIDS Patient Care STDs.* 2006;20(1):19-29. PMID: 16426152.

Guinn D. HIV screening and false-positive results. *JAMA.* 2007;297(9):947. PMID: 17341704.

Hankins C. From a vicious circle to a virtuous circle: reinforcing strategies of risk, vulnerability, and impact reduction for HIV prevention. *Lancet.* 2004;364(9449):1915-6. PMID: 15566990.

Haukoos JS, Hopkins E, Byyny RL, Conroy AA, Silverman M, Eisert S, et al. Design and implementation of a controlled clinical trial to evaluate the effectiveness and efficiency of routine opt-out rapid human immunodeficiency virus screening in the emergency department. *Acad Emerg Med.* 2009;16(8):800-8. PMID: 19673717.

Haukoos JS. Rethinking how we perform HIV testing in the emergency department. *Ann Emerg Med.* 2011;58(Suppl 1):S160-3. PMID: 21684396.

Holstad MM, DiIorio C, Magowe MK. Motivating HIV positive women to adhere to antiretroviral therapy and risk reduction behavior: the KHARMA Project. *Online J Issues Nurs.* 2006;11(1):5. PMID: 16629499.

Holtgrave D, McGuire J. Impact of counseling in voluntary counseling and testing programs for persons at risk for or living with HIV infection. *Clin Infect Dis.* 2007;45(4):15. PMID: 18190293.

Howe BE, Clutterbuck D. Targeting of HIV pretest discussion and risk-reduction interventions in a low-prevalence setting. *Int J STD AIDS.* 2009;20(7):470-2. PMID: 19541888.

Johnson BT, Carey MP, Chaudoir SR, Reid AE. Sexual risk reduction for persons living with HIV: research synthesis of randomized controlled trials, 1993 to 2004. *J Acquir Immune*

## Appendix A4. Excluded Studies List

*Defic Syndr.* 2006;41(5):642-50. PMID: 16652039.

Johnson BT, Scott-Sheldon LA, Smoak ND, Lacroix JM, Anderson JR, Carey MP. Behavioral interventions for African Americans to reduce sexual risk of HIV: a meta-analysis of randomized controlled trials. *J Acquir Immune Defic Syndr.* 2009;51(4):492-501. PMID: 19436218.

Johnson WD, Diaz RM, Flanders WD, Goodman M, Hill AN, Holtgrave D, et al. Behavioral interventions to reduce risk for sexual transmission of HIV among men who have sex with men. *Cochrane Database Syst Rev.* 2008;(3):CD001230. PMID: 18646068.

Kalichman S, Carey M, Johnson B. Prevention of sexually transmitted HIV infection: a meta-analytic review of the behavioral outcome literature. *Ann Behav Med.* 1996;18(1):6-15. PMID: N/A.

Kayitenkore K, Bekan B, Rufagari J, Marion-Landais S, Karita E, Allen S, et al. The impact of art on HIV transmission among HIV serodiscordant couples. Paper presented at: XVI International AIDS Conference; August 2006; Toronto. PMID: N/A.

Kennedy C, O'Reilly K, Medley A, Sweat M. The impact of HIV treatment on risk behaviour in developing countries: a systematic review. *AIDS Care.* 2007;19(6):707-20. PMID: 17573590.

Klitzman R, Exner T, Correale J, Kirshenbaum SB, Remien R, Ehrhardt AA, et al. It's not just what you say: relationships of HIV disclosure and risk reduction among MSM in the post-HAART era. *AIDS Care.* 2007;19(6):749-56. PMID: 17573594.

Lalani T, Hicks C. Does antiretroviral therapy prevent HIV transmission to sexual partners? *Curr HIV/AIDS Rep.* 2007;4(2):80-5. PMID: 17547829.

Lazarus JV, Sihvonen-Riemenschneider H, Laukamm-Josten U, Wong F, Liljestrand J. Systematic review of interventions to prevent

the spread of sexually transmitted infections, including HIV, among young people in Europe. *Croat Med J.* 2010;51(1):74-84. PMID: 20162748.

Lundgren JD, Phillips AN, Neaton J. Uncertainty as to whether the use of antiretroviral therapy for persons recently infected with HIV has a favorable risk-to-benefit ratio. *Clin Infect Dis.* 2009;48(8):1162. PMID: 19292638.

Lyles CM, Kay LS, Crepaz N, Herbst JH, Passin WF, Kim AS, et al. Best-evidence interventions: findings from a systematic review of HIV behavioral interventions for US populations at high risk, 2000-2004. *Am J Public Health.* 2007;97(1):133-43. PMID: 17138920.

Mehendale SM, Kishore KB, Ghate MV, Sahay S, Gamble T, Godbole SV, et al. Low HIV incidence in HIV sero-discordant couples in Pune, India. *J Acquir Immune Defic Syndr.* 2006;41(3):371-3. PMID: 16540940.

Munar DE. Funding and implementing routine testing for HIV. *Clin Infect Dis.* 2007;45(4):15. PMID: 18190294.

Munderi P. When to start antiretroviral therapy in adults in low- and middle-income countries: science and practice. *Curr Opin HIV/AIDS.* 2010;5(1):6-11. PMID: 20046142.

Naftalin CM, Poulton M. The significance of early HIV testing. *Clin Med.* 2009;9(1):91-2. PMID: 19274818.

Neaton JD, Grund B. Earlier initiation of antiretroviral therapy in treatment-naïve patients: implications of results of treatment interruption trials. *Curr Opin HIV/AIDS.* 2008;3(2):112-7. PMID: 19372951.

Ota E, Wariki MV, Mori R, Hori N, Shibuya K. Behavioral interventions to reduce the transmission of HIV infection among sex workers and their clients in high-income countries. *Cochrane Database Syst Rev.* 2011;(12):CD006045. PMID: 22161397.

## Appendix A4. Excluded Studies List

Pedlow CT, Carey MP. HIV sexual risk-reduction interventions for youth: a review and methodological critique of randomized controlled trials. *Behav Modif.* 2003;27(2):135-90. PMID: 12705104.

Remien RH, Berkman A, Myer L, Bastos FI, Kagee A, El-Sadr WM. Integrating HIV care and HIV prevention: legal, policy and programmatic recommendations. *AIDS.* 2008;22(Suppl 2):S57-65. PMID: 18641470.

Reynolds S, Makumbi F, Kagaayi J, Nakigozi G, Galiwongo R. ART reduced the rate of sexual transmission of HIV among HIV-discordant couples in rural Rakai, Uganda. Paper presented at: 16th Conference on Retroviruses and Opportunistic Infections; February 2009; Montreal. PMID: N/A.

Rueda S, Park-Wyllie LY, Bayoumi A, Tynan AM, Antoniou T, Rourke S, et al. Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. *Cochrane Database Syst Rev.* 2006;(3):CD001442. PMID: 16855968.

Siegfried N, Uthman OA, Rutherford GW. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naïve adults. *Cochrane Database Syst Rev.* 2010;(3):CD008272. PMID: 20238364.

Simoni JM, Pantalone DW. Secrets and safety in the age of AIDS: does HIV disclosure lead to safer sex? *Topics HIV Med.* 2004;12(4):109-18., PMID: 15516708.

Stein R, Grimes TS, Malow R, Stratford D, Spielberg F, Holtgrave DR. Introduction to special supplement: monitoring and evaluation of HIV counseling, testing and referral (CTR) and HIV testing services. *AIDS Educ Prev.* 2011;23(3 Suppl):1-6. PMID: 21689032.

Stolte G, Dukers NH, de Wit JB, Fennema H, Coutinho RA. A summary report from Amsterdam: increase in sexually transmitted diseases and risky sexual behaviour among homosexual men in relation to the introduction of new anti-HIV drugs. *Euro Surveill.* 2002;7(2):19-22. PMID: 12631950.

Strathdee SA, Magis-Rodriguez C. Mexico's evolving HIV epidemic. *JAMA.* 2008;300(5):571-3. PMID: 18677029.

Tipranavir favored in RESIST-2. *AIDS Patient Care STDs.* 2005;19(1):59. PMID: 15700396.

Tolou-Shams M, Payne N, Houck C, Pugatch D, Beausoleil N, Brown LK, et al. HIV testing among at-risk adolescents and young adults: a prospective analysis of a community sample. *J Adolesc Health Care.* 2007;41(6):586-93. PMID: 18023788.

Trotter AB, Bhayani N, Florsheim R, Novak RM. Implementing universal oral HIV screening in an urban emergency department: do demographic characteristics impact acceptance of testing? *Clin Infect Dis.* 2010;50(2):283. PMID: 20034354.

Truong HM, Klausner JD. Diagnostic assays for HIV-1 infection. *MLO Med Lab Obs.* 2004;36(7):12-3. PMID: 15318787.

Valdiserri RO, Holtgrave DR, West GR. Promoting early HIV diagnosis and entry into care. *AIDS.* 1999;13(17):2317-30. PMID: 10597773.

van Griensven F. Non-condom use risk-reduction behaviours: can they help to contain the spread of HIV infection among men who have sex with men? *AIDS.* 2009;23(2):253-5. PMID: 19098495.

Weiss HA, Thomas SL, Munabi SK, Hayes RJ. Male circumcision and risk of syphilis, chancroid, and genital herpes: a systematic review and meta-analysis. *Sex Transm Infect.* 2006;82(2):101-10. PMID: 16581731.

Wilkin TJ, Gulick RM. Antiretroviral therapy: when and what to start—an American perspective. *Curr HIV/AIDS Rep.* 2004;1(2):59-67. PMID: 16091224.

Zdeb MS. HIV screening and false-positive results. *JAMA.* 2007;297(9):947-8. PMID: 17341703.

Zenilman JM. Behavioral interventions: rationale, measurement, and effectiveness. *Infect*

## Appendix A4. Excluded Studies List

*Dis Clin North Am.* 2005;19(2):541-62. PMID: 15963887.

### Inadequate duration

Canestri A, Sow PS, Vray M, Ngom F, M'Boup S, Kane CT, et al. Poor efficacy and tolerability of stavudine, didanosine, and efavirenz-based regimen in treatment-naïve patients in Senegal. *MedGenMed.* 2007;9(4):7. PMID: 18311357.

Chu KM, Boulle AM, Ford N, Goemaere E, Asselman V, Van Cutsem G. Nevirapine-associated early hepatotoxicity: incidence, risk factors, and associated mortality in a primary care ART programme in South Africa. *PLoS One.* 2010;5(2):e9183. PMID: 20174653.

Cohen CJ, Kubota M, Brachman PS, Harley WB, Schneider S, Williams VC, et al. Short-term safety and tolerability of a once-daily fixed-dose abacavir-lamivudine combination versus twice-daily dosing of abacavir and lamivudine as separate components: findings from the ALOHA study. *Pharmacotherapy.* 2008;28(3):314-22. PMID: 18294111.

Johnson MA, Gathe JC, Podzamczar D, Molina JM, Naylor CT, Chiu YL, et al. A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. *J Acquir Immune Defic Syndr.* 2006;43(2):153-60. PMID: 16951643.

Landman R, Capitant C, Descamps D, Chazallon C, Peytavin G, Katlama C, et al. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naïve HIV-1-infected patients: the 2IP ANRS 127 study. *J Antimicrob Chemother.* 2009;64(1):118-25. PMID: 19420019.

Malan DR, Krantz E, David N, Wirtz V, Hammond J, McGrath D, et al. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naïve patients. *J Acquir Immune Defic Syndr.* 2008;47(2):161-7. PMID: 17971713.

Martin A, Bloch M, Amin J, Baker D, Cooper DA, Emery S, et al. Simplification of

antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: a randomized, 96-week trial. *Clin Infect Dis.* 2009;49(10):1591-601. PMID: 19842973.

McComsey G, Rightmire A, Wirtz V, Yang R, Mathew M, McGrath D. Changes in body composition with ritonavir-boosted and unboosted atazanavir treatment in combination with lamivudine and stavudine: a 96-week randomized, controlled study. *Clin Infect Dis.* 2009;48(9):1323-6. PMID: 19302017.

Miiró G, Todd J, Mpendo J, Watera C, Munderi P, Nakubulwa S, et al. Reduced morbidity and mortality in the first year after initiating highly active anti-retroviral therapy (HAART) among Ugandan adults. *Trop Med Int Health.* 2009;14(5):556-63. PMID: 19320871.

Mitsuyasu R, Gelman R, Cherng DW, Landay A, Fahey J, Reichman R, et al. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial—AIDS Clinical Trials Group 328. *Arch Intern Med.* 2007;167(6):597-605. PMID: 17389292.

Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naïve HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. *Lancet.* 2008;372(9639):646-55. PMID: 18722869.

Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naïve HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. *J Acquir Immune Defic Syndr.* 2010;53(3):323-32. PMID: 20032785.

## Appendix A4. Excluded Studies List

Moyle GJ, DeJesus E, Cahn P, Castillo SA, Zhao H, Gordon DN, et al. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study. *J Acquir Immune Defic Syndr*. 2005;38(4):417-25. PMID: 15764958.

Olawumi HO, Olatunji PO, Salami AK, Odeigah L, Iseniyi JO. Effect of highly active antiretroviral therapy on CD4 count and weight in AIDS patients seen at the UITH, Ilorin. *Niger J Clin Pract*. 2008;11(4):312-5. PMID: 19320401.

Orkin C, Stebbing J, Nelson M, Bower M, Johnson M, Mandalia S, et al. A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study). *J Antimicrob Chemother*. 2005;55(2):246-51. PMID: 15608053.

Ortiz R, Dejesus E, Khanlou H, Voronin E, van Lunzen J, Andrade-Villanueva J, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. *AIDS*. 2008;22(12):1389-97. PMID: 18614861.

Palacios R, Hidalgo C, Rios MJ, Rivero A, Munoz L, Lozano F, et al. Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (truvada) in virologically suppressed HIV-infected patients on HAART. *Eur J Clin Microbiol Infect Dis*. 2009;28(4):399-402. PMID: 18841401.

Puls RL, Srasuebkul P, Petoumenos K, Boesecke C, Duncombe C, Belloso WH, et al. Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study. *Clin Infect Dis*. 2010;51(7):855-64. PMID: 20735258.

Puoti M, Cozzi-Lepri A, Parainfo G, Arici C, Moller NF, Lundgren JD, et al. Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals:

results from an inter-cohort analysis. *Antivir Ther*. 2006;11(5):567-74. PMID: 16964824.

Ribera E, Rodriguez-Pardo D, Rubio M, Soler A, Pedrol E, Blanco JL, et al. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients. *Antivir Ther*. 2005;10(5):605-14. PMID: 16152754.

Ruane PJ, Richmond GJ, DeJesus E, Hill-Zabala CE, Danehower SC, Liao Q, et al. Pharmacodynamic effects of zidovudine 600 mg once/day versus 300 mg twice/day in therapy-naive patients infected with human immunodeficiency virus. *Pharmacotherapy*. 2004;24(3):307-12. PMID: 15040643.

Saag MS, Cahn P, Raffi F, Wolff M, Pearce D, Molina JM, et al. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. *JAMA*. 2004;292(2):180-9. PMID: 15249567.

Schurmann D, Fatkenheuer G, Reynes J, Michelet C, Raffi F, van Lier J, et al. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. *AIDS*. 2007;21(10):1293-9. PMID: 17545705

Shikuma CM, Zackin R, Sattler F, Mildvan D, Nyangweso P, Alston B, et al. Changes in weight and lean body mass during highly active antiretroviral therapy. *Clin Infect Dis*. 2004;39(8):1223-30. PMID: 15486848.

van Vonderen MG, Lips P, van Agtmael MA, Hassink EA, Brinkman K, Geerlings SE, et al. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. *AIDS*. 2009;23(11):1367-76. PMID: 19424051.

### Sample size too small

Couzigou C, Semaille C, Le Strat Y, Pinget R, Pillonel J, Lot F, et al. Differential improvement in survival among patients with AIDS after the



#### Appendix A4. Excluded Studies List

introduction of HAART. *AIDS Care*. 2007;19(4):523-31. PMID: 17453593.

INITIO Trial International Coordinating Committee; Yeni P, Cooper DA, Aboulker JP, Babiker AG, Carey D, et al. Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial. *Lancet*. 2006;368(9532):287-98. PMID: 16860698.

Jaen A, Esteve A, Miro JM, Tural C, Montoliu A, Ferrer E, et al. Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain). *J Acquir Immune Defic Syndr*. 2008;47(2):212-20. PMID: 18297762.

Shepherd BE, Jenkins CA, Rebeiro PF, Stinnette SE, Bebawy SS, McGowan CC, et al. Estimating the optimal CD4 count for HIV-infected persons to start antiretroviral therapy. *Epidemiology*. 2010;21(5):698-705. PMID: 20585252.

## Randomized Controlled Trials (RCTs) and Cohort Studies

### *Criteria:*

- Initial assembly of comparable groups: RCTs—adequate randomization, including concealment and whether potential confounders were distributed equally among groups; cohort studies—consideration of potential confounders with either restriction or measurement for adjustment in the analysis; consideration of inception cohorts
- Maintenance of comparable groups (includes attrition, cross-overs, adherence, contamination)
- Important differential loss to followup or overall high loss to followup
- Measurements: equal, reliable, and valid (includes masking of outcome assessment)
- Clear definition of interventions
- Important outcomes considered
- Analysis: adjustment for potential confounders for cohort studies, or intention-to-treat analysis for RCTs; for cluster RCTs, correction for correlation coefficient

### *Definition of ratings based on above criteria:*

**Good:** Meets all criteria: comparable groups are assembled initially and maintained throughout the study (followup at least 80%); reliable and valid measurement instruments are used and applied equally to the groups; interventions are spelled out clearly; important outcomes are considered; and appropriate attention to confounders in analysis.

**Fair:** Studies will be graded “fair” if any or all of the following problems occur, without the important limitations noted in the “poor” category below: generally comparable groups are assembled initially but some question remains whether some (although not major) differences occurred in followup; measurement instruments are acceptable (although not the best) and generally applied equally; some but not all important outcomes are considered; and some but not all potential confounders are accounted for.

**Poor:** Studies will be graded “poor” if any of the following major limitations exists: groups assembled initially are not close to being comparable or maintained throughout the study; unreliable or invalid measurement instruments are used or not applied at all equally among groups (including not masking outcome assessment); and key confounders are given little or no attention.

**Source:** Harris et al, 2001<sup>66</sup>

## Appendix A6. Criteria for Assessing Scientific Quality of Research Reviews

**Each criterion was given an assessment of yes, no, unclear, or not applicable:**

1. *Was an a priori design provided?* The research question and inclusion criteria should be established before the conduct of the review.
2. *Was there duplicate study selection and data extraction?* There should be at least two independent data extractors and a consensus procedure for disagreements should be in place.
3. *Was a comprehensive literature search performed?* At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and, where feasible, the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found.
4. *Was the status of publication (i.e., gray literature) used as an inclusion criterion?* The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language, etc.
5. *Was a list of studies (included and excluded) provided?* A list of included and excluded studies should be provided.
6. *Were the characteristics of the included studies provided?* In an aggregated form, such as a table, data from the original studies should be provided on the participants, interventions, and outcomes. The ranges of characteristics in the studies analyzed, such as age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases, should be reported.
7. *Was the scientific quality of the included studies assessed and documented?* A priori methods of assessment should be provided (e.g., for effectiveness studies if the authors chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies, alternative items will be relevant.
8. *Was the scientific quality of the included studies used appropriately in formulating conclusions?* The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating the recommendations.
9. *Were the methods used to combine the findings of studies appropriate?* Reviews should not combine or pool dissimilar studies. If studies are pooled using a fixed effects model, there should be a clear rationale for doing so. A test should be done to assess for statistical heterogeneity (i.e., chi-square test for homogeneity,  $I^2$ ).
10. *Was the likelihood of publication bias assessed?* An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test). If assessment of publication bias is not possible, the review should provide justification (e.g., small numbers of studies, too much heterogeneity, poor quality).
11. *Was the conflict of interest stated?* Potential sources of support should be clearly acknowledged in both the systematic review and the included studies.

## **Appendix A6. Criteria for Assessing Scientific Quality of Research Reviews**

### **Definition of ratings based on above criteria:**

*Good:* Recent, comprehensive review that uses explicit criteria to identify and select studies for inclusion, uses appropriate methods to assess quality of primary studies appropriately, and uses appropriate methods for synthesizing or combining results.

*Fair:* Systematic methods for identifying studies but does not meet one or more of the criteria listed above.

*Poor:* No systematic methods for identifying studies, major selection bias, or inappropriate methods for combining or pooling data.

**Source:** Harris et al, 2001<sup>66</sup>

## **Appendix A7. Expert Reviewers of the Draft Report**

### **Bernie Branson, MD**

Medical Epidemiologist  
Division of HIV/AIDS Prevention  
Centers for Disease Control and Prevention

### **Grant Colfax, MD**

Director of HIV Prevention and Research  
San Francisco Department of Public Health

### **Timothy Dondero, MD**

Division of HIV/AIDS Prevention  
Centers for Disease Control and Prevention

### **Linda Kinsinger, MD, MPH**

Chief Consultant for Preventive Medicine  
Office of Patient Care Services  
Veterans Health Administration, National Center for Health Promotion and Disease Prevention

### **Lisa Metsch, PhD**

Professor of Epidemiology and Public Health, Director of Division of Health Services Research  
and Policy  
University of Miami

**Appendix B1. Key Question 2b: Evidence Table of Studies of Acceptability/Uptake of Universal or Targeted HIV Testing**

Author, Year	Study design	Location/setting/high or low prevalence population (based on 0.1% prevalence rate)	Study time frame	Comparison groups/ intervention	Baseline population characteristics	Eligibility criteria	Exclusion criteria
Cunningham et al, 2009 <sup>70</sup>	Cross-sectional	Acceptance of opt-out standard testing implemented in an urban FQHC, New York City	July 2007 to March 2008	Characteristics of those accepting testing (n=105) compared with those not accepting testing (n=195)	Mean age, 53 years (range, 18–92); 70.2% female; 55.7% black, 37.7% Hispanic; 66.0% public insurance	Patients seeing 1 of 5 participating providers; age ≥18 years; English-speaking; not pregnant; not known to be HIV-infected	None
Haukoos et al, 2010 <sup>68</sup>	Quasi-experiment with sequential time samples (cohort study)	Large urban ED (Denver) where rapid HIV testing (Uni-Gold Recombigen) performed as opt-out x 3 months vs. diagnostic (physician-directed) testing x 4 months over 2 years (3 cycles each); local estimated HIV prevalence, 0.7%	April 15, 2007 to April 15, 2009	Opt-out vs. diagnostic (physician-directed) timeframes	During opt-out phase: mean age, 36 years; 56% male; 40% white; 37% Hispanic; 14% black During diagnostic phase: mean age, 36 years; 57% male; 41% white; 37% Hispanic; 14% black	All ED patients age ≥16 years and capable of providing consent for emergency medical care	If unable to provide consent for HIV testing; detainees/ prisoners; seeking care after sexual assault; seeking care after occupational exposure; self-identified as HIV-infected; left ED prior to being placed in treatment room
Weis et al, 2009 <sup>69</sup>	Cross-sectional	Feasibility study of rapid HIV testing (Oraquick Advance Rapid HIV-1/2 with oral fluid or Uni-Gold Recombigen with finger stick) implementation in 3 rural primary care FQHCs in Aiken County, SC; low prevalence (estimated 0.01%; actual prevalence during study 0%)	Dec 2006 to July 2007	Not relevant (descriptive report of screening acceptability)	Mean age not reported; 43% age ≥50 years; 71% female; 59% black; 36% white; 52% self-pay/no insurance; 29% public insurance	All patients age ≥13 years presenting for care at participating FQHCs during first 8 months after rapid HIV testing implementation; multiple tests allowed	Patients missing demographic data (n=36; 4% of 990 unique patients attending clinic during this period)

Author, Year	Number screened/ acceptability	Adjusted variables for statistical analysis	Clinical outcomes	Adverse events	Linkage to care	CD4 count at HIV diagnosis	Quality rating	Funding source
Cunningham et al, 2009 <sup>70</sup>	300 of 319 eligible patients approached (94%) 105/300 (35%) agreed to be HIV-tested	Age, race, HIV tester, other blood test during visit	105/300 (35%) eligible patients approached agreed to screening. In multivariate models, younger age (AOR, 0.97 [95% CI, 0.96-0.99]), Hispanic race (AOR, 1.78 [CI, 1.01-3.14]), and having other blood tests done during visit (AOR, 6.36 [CI, 3.58-11.28]) were associated with test acceptance. 0 HIV-positive tests.	Not reported	N/A (no one confirmed HIV positive)	N/A (no confirmed positives)	Uncontrolled study - not rated	RWJ, New York Academy of Medicine, NIH, Center for AIDS Research at Albert Einstein College of Medicine, Montefiore Medical Center

**Appendix B1. Key Question 2b: Evidence Table of Studies of Acceptability/Uptake of Universal or Targeted HIV Testing**

Author, Year	Number screened/ acceptability	Adjusted variables for statistical analysis	Clinical outcomes	Adverse events	Linkage to care	CD4 count at HIV diagnosis	Quality rating	Funding source
Haukoos et al, 2010 <sup>68</sup>	During opt-out phase: 6702 of 28,043 eligible patients (24%) screened; during diagnostic phase: 243 of 29,925 eligible patients (0.8%) tested	Unclear. Adjusted for "potential variation between study groups"	Universal opt-out rapid screening vs. physician-directed targeted rapid screening: Testing: 24.7% or 6933/28,043 vs. 0.8% or 243/29,925; RR, 30 [CI, 26-34] Testing uptake: not reported	Across both phases, 6/7656 tests performed were false-positive tests (0.08%). PPV: 82.4%	During opt-out phase: 30/31 (96.8%) of preliminary positives attended at least 1 appt. in HIV clinic. During diagnostic phase: 5/5 (100%) preliminary positives attended initial HIV clinic visit.	During opt-out phase: median CD4 count, 0.069 x 10 <sup>9</sup> cells/L (IQR, 0.017-0.430 x 10 <sup>9</sup> cells/L). During diagnostic phase: median CD4 count, 0.013 (IQR, 0.011-0.015 x 10 <sup>9</sup> cells/L; p=0.02). Of 15 confirmed HIV infections identified during opt-out testing, 9 (60% [CI, 32%-84%]) had an initial CD4 count <0.200 x 10 <sup>9</sup> cells/L whereas all 4 confirmed HIV infections (100% [CI, 40%-100%]) had an initial CD4 count <0.200 x 10 <sup>9</sup> cells/L.	Fair	CDC, AHRQ
Weis et al, 2009 <sup>69</sup>	954/954 (100%) eligible patients offered screening during 985 visits; 574 (58%) visits accepted HIV screening	Center, gender, race/ethnicity, age, insurance, and history of prior HIV testing	574 (58%) visits accepted screening; 411 (42%) visits declined screening; in multivariate models of test acceptance, African American race (AOR, 1.53 [CI, 1.15-2.04]), age ≥50 years (AOR, 0.28 [CI, 0.28-0.98]), and Medicare insurance (vs. self-pay) (AOR, 0.61 [CI, 0.40-0.94]) associated with acceptance of HIV testing.	3/3 (100%) preliminary HIV-positive tests were false-positive (PPV=0); all in the first month of testing.	N/A (no one confirmed HIV positive)	N/A (no one confirmed positive)	Uncontrolled study - not rated	CDC

AHRQ = Agency for Healthcare Research and Quality; AOR = adjusted odds ratio; CDC = Centers for Disease Control and Prevention; CI = confidence interval; ED = emergency department; FQHC = Federally Qualified Health Center; NIH = National Institutes of Health; PPV = positive predictive value; RWJ = Robert Wood Johnson Foundation.

**Appendix B2. Key Question 2b: Quality Assessment of a Cohort Study**

<b>Author, Year</b>	<b>Did the study attempt to enroll all (or a random sample of) patients meeting inclusion criteria, or a random sample (inception cohort)?</b>	<b>Were the groups comparable at baseline on key prognostic factors (by restriction or matching)?</b>	<b>Did the study maintain comparable groups through the study period?</b>	<b>Did the study use accurate methods for ascertaining exposures and potential confounders?</b>	<b>Were outcome assessors and/or data analysts blinded to the exposure being studied?</b>	<b>Did the article report attrition?</b>	<b>Did the study perform appropriate statistical analyses on potential confounders?</b>	<b>Is there important differential loss to followup or overall high loss to followup?</b>	<b>Were outcomes prespecified, defined, and ascertained using accurate methods?</b>	<b>Quality rating</b>
Haukoos et al, 2010 <sup>68</sup>	Yes	Yes	Not applicable	Yes	Unclear	Not applicable	Yes	Not applicable	Yes	Fair



**Appendix B3. Key Question 2c: Evidence Table of Studies of Testing Rates of Opt-Out Versus Opt-In HIV Testing**

Author, Year	Study design	Comparison groups	Location/setting/high or low prevalence population (based on 0.1% prevalence rate)	Study timeframe	Baseline population characteristics	Eligibility criteria	Exclusion criteria
Haukoos et al, 2012 <sup>72</sup>	Prospective quasi-experiment (cohort study)	A: Patients offered opt-out rapid testing B: Patients offered opt-in rapid testing	Evaluation of patient acceptance and understanding of opt-out and opt-in rapid HIV screening in the emergency department of an urban hospital in Denver/low prevalence	October to December 2009	<u>A vs. B</u> Age: 36 vs. 25 years Male sex: 45% vs. 45% Race: 52% Hispanic, 26% white, 16% black, 3% unknown/missing, 2% Asian, 1% other vs. 44% Hispanic, 29% white, 21% black, 3% unknown/missing, 2% other, 1% Asian	Ambulatory patients presenting for care who were ≥13 years and able to provide informed consent	None (reported as inverse of inclusion: younger than age 13 years, arrived by ambulance, unable to consent)
White et al, 2011 <sup>73</sup>	Cohort study	Opt-in period: screening offered by providers (Feb 1, 2007–July 31, 2007; n=23,236) vs. opt-out period: screening offered by registration staff (Aug 1, 2007–January 31, 2007; n=26,757).	Pre-post evaluation of opt-in vs. Opt-Out testing implementation on screening rates and acceptance of rapid oral HIV screening in Oakland, CA ED.	February 1, 2007 to January 31, 2008	Demographic data available only for patients offered testing: <u>Opt-in phase (n=6479)</u> : mean age, 39 (SD, 13); 53% male; 43% black, 27% Hispanic, 15% white <u>Opt-out phase</u> : mean age, 42 (SD, 14); 45% female; 45% black, 26% Hispanic, 15% white	Age ≥15 years; medically stable; able to consent for HIV testing (opt-in phase) or complete general consent (opt-in and opt-out phase)	Patients requiring immediate medical evaluation or if staff deemed patient "too ill"

Author, Year	Number screened/acceptability	Clinical outcomes	Adverse events	Linkage to care	CD4 count at HIV diagnosis	Quality rating	Funding source
Haukoos et al, 2012 <sup>72</sup>	<u>A vs. B</u> 6842 eligible/3993 agreed/886 screened vs. 5985 eligible/930 agreed/389 screened	<u>A vs. B</u> Difference in completed screening: 13% vs. 7% (6% difference [95% CI, 5 to 8]) Eligible patients agreeing to testing: 44% difference (95% CI, 43 to 46) Agreed patients completing screening: -21% difference (95% CI, -17 to -27) Screened patients newly diagnosed with HIV: 2 (0.2 [95% CI, 0.02 to 0.8]) vs. 0 (0% [95% CI, 0 to 0.9]) Self-reported not being informed about HIV test: 54% vs. 3% (absolute difference, 35% [95% CI, 44 to 59]) Agreed (or neglected to opt out) but self-report not agreeing to an HIV test: 38% vs. 3% (absolute difference, 35% [95% CI, 24 to 46%])	Not reported	Newly diagnosed patients linked to care: 2/2 (100%, both from opt-out group)	CD4 counts: 0.047 and 0.085 x 10 <sup>9</sup> cells/L Viral load: 184,272 and 206,878 copies/mL	Fair	Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, Colorado HIV/AIDS Prevention Program
White et al, 2011 <sup>73</sup>	<u>Opt-in phase</u> : 6479/23,236 eligible (62.9%) offered screening; 4061/6479 (62.7%) accepted screening. <u>Opt-out phase</u> : 20,280/26,757 (75.8%) offered screening; 6273/20,280 (30.9%) accepted screening	<u>Opt-in phase</u> : 21/4053 preliminary positive rapid tests; 10/4053 confirmed positive (0.25% prevalence). <u>Opt-out phase</u> : 28/4679 preliminary positive; 28/4679 confirmed positive (0.60%). When previously known HIV-positive subjects excluded, opt-in identified 8 new cases (0.2% of tested) and opt-out identified 21 new cases (0.4%); p=0.04	11/21 (52.4%) false-positive preliminary rapid tests; all occurred during first 2 months of study (opt-in phase); cause unknown	75% of opt-in and 77% of opt-out newly diagnosed cases linked to care within 90 days of diagnosis	Mean CD4 (opt-in): 0.415 x 10 <sup>9</sup> (SD, 0.237 x 10 <sup>9</sup> ). Mean CD4 (opt-out): 0.307 x 10 <sup>9</sup> (SD, 0.274 x 10 <sup>9</sup> ). 25% of opt-in and 48% of opt-out newly diagnosed patients had CD4 count <0.200 x 10 <sup>9</sup>	Fair	Centers for Disease Control and Prevention

**Appendix B4. Key Question 2c: Quality Assessment of Cohort Studies**

<b>Author, Year</b>	<b>Did the study attempt to enroll all (or a random sample of) patients meeting inclusion criteria, or a random sample (inception cohort)?</b>	<b>Were the groups comparable at baseline on key prognostic factors (by restriction or matching)?</b>	<b>Did the study maintain comparable groups through the study period?</b>	<b>Did the study use accurate methods for ascertaining exposures and potential confounders?</b>	<b>Were outcome assessors and/or data analysts blinded to the exposure being studied?</b>	<b>Did the article report attrition?</b>	<b>Did the study perform appropriate statistical analyses on potential confounders?</b>	<b>Is there important differential loss to followup or overall high loss to followup?</b>	<b>Were outcomes prespecified, defined, and ascertained using accurate methods?</b>	<b>Quality rating</b>
Haukoos et al, 2012 <sup>72</sup>	Yes	Yes	Not applicable	Yes	Unclear	Not applicable	No	Not applicable	Yes	Fair
White et al, 2011 <sup>73</sup>	Yes	Yes; differ only on acuity rating	Not applicable	Yes	Yes	Not applicable	Unclear; states bivariate analysis completed but not shown	Not applicable	Yes	Fair

**Appendix B5. Key Question 2e: Evidence Table of Studies of Universal Versus Targeted HIV Screening and CD4 Counts at Time of Diagnosis**

Author, Year	Study design	Location/setting/high or low prevalence population (based on 0.1% prevalence rate)	Study timeframe	Comparison groups	Baseline population characteristics	Eligibility criteria	Exclusion criteria
Haukoos et al, 2010 <sup>68</sup>	Quasi-experiment with sequential time samples (cohort study)	Large urban ED (Denver) where rapid HIV testing (Uni-Gold Recombigen) performed as opt-out x 3 months vs. diagnostic (physician-directed) testing x 4 months over 2 years (3 cycles each); local estimated HIV prevalence, 0.7%	April 15, 2007 to April 15, 2009	Opt-out vs. diagnostic (physician-directed) timeframes	During opt-out phase: mean age, 36 years; 56% male; 40% white, 37% Hispanic, 14% black During diagnostic phase: mean age, 36 years; 57% male; 41% white, 37% Hispanic, 14% black	All ED patients ages ≥16 years and capable of providing consent for emergency mediare care	If unable to provide consent for HIV testing; detainees/prisoners; seeking care after sexual assault; seeking care after occupational exposure; self-identified as HIV-infected; left ED prior to being placed in treatment room
White et al, 2011 <sup>73</sup>	Cohort study	Pre-post evaluation of opt-in vs. opt-out testing implementation on screening rates and acceptance of rapid oral HIV screening in an ED in Oakland, California	February 1, 2007 to January 31, 2008	Opt-in period: screening offered by providers (February 1, 2007–July 31, 2007; n=23,236) vs. opt-out period: screening offered by registration staff (Aug 1, 2007–January 31, 2007; n=26,757)	Demographic data available only for patients offered teting: <u>Opt-in phase (n=6479):</u> Mean age, 39 years (SD, 13); 53% male; 43% black, 27% Hispanic, 15% white <u>Opt-out phase:</u> Mean age, 42 years (SD, 14); 45% female, 45% black, 26% Hispanic, 15% white	Ages ≥15 years; medically stable; ablet to consent for HIV testing (opt-in phase) or complete general consent (opt-in and opt-out phase)	Patients requiring immediate medical evaluation or if staff deemed patient "too ill"

Author, Year	Number screened/ acceptability	Adverse events	Linkage to care	CD4 count at HIV diagnosis	Quality rating	Funding source
Haukoos et al, 2010 <sup>68</sup>	During opt-out phase: 6702/28,043 eligible patients (24%) screened During diagnostic phase: 243/29,925 eligible patients (0.8%) tested	Across both phases, 6/7656 tests performed were false-positive tests (0.08%). PPV, 82.4%	During opt-out phase: 30/31 (96.8%) of preliminary positives attended at least 1 appt in HIV clinic During diagnostic phase: 5/5 (100%) of preliminary positives attended initial HIV clinic visit	During opt-out phase: median CD4 count was 0.069 x 10 <sup>9</sup> cells/L (IQR, 0.017–0.430 x 10 <sup>9</sup> ) During diagnostic phase: median CD4 count was 0.013 x 10 <sup>9</sup> cells/L (IQR, 0.011–0.015 x 10 <sup>9</sup> ; p=0.02). Of 15 confirmed HIV infections identified during opt-out testing, 9 (60% [95% CI, 32%–84%]) had an initial CD4 count <0.200 x 10 <sup>9</sup> cells/L whereas all 4 confirmed HIV infections (100% [95% CI, 40%–100%]) has an initial CD4 count <0.200 x 10 <sup>9</sup> cells/L	Fair	CDC, AHRQ
White et al, 2011 <sup>73</sup>	<u>Opt-in phase:</u> 6479/23,236 eligible (62.9%) offered screening; 4061/6479 (62.7%) accepted screening <u>Opt-out phase:</u> 20,280/26,757 (75.8%) offered screening; 6273/20,280 (30.9%) accepted screening	11/21(52.4%) false-positive preliminary rapid tests; all occurred during first 2 months of study (opt-in phase); cause unknown	75% of opt-in and 77% of opt-out newly diagnosed cases linked to care within 90 days of diagnosis	Universal opt-in screening offered by ED triage nurses and providers vs. universal opt-out screening offered by ED front desk registration staff: mean CD4 count of 0.415 x 10 <sup>9</sup> cells/L (SD, 0.237) in 8 new confirmed HIV infections (0.2% prevalence) vs. 0.307 x 10 <sup>9</sup> cells/L (SD, 0.274) in 21 new confirmed HIV infections (0.4% prevalence) 25% of opt-in and 48% of opt-out newly diagnosed patients had CD4 count <0.200 x 10 <sup>9</sup> cells/L	Fair	CDC

AHRQ = Agency for Healthcare Research and Quality; CDC = Centers for Disease Control and Prevention; CI = confidence interval; ED = emergency department; IQR = interquartile range; PPV = positive predictive value.

**Appendix B6. Key Question 2e: Quality Assessment of Cohort Studies**

<b>Author, Year</b>	<b>Did the study attempt to enroll all (or a random sample of) patients meeting inclusion criteria, or a random sample (inception cohort)?</b>	<b>Were the groups comparable at baseline on key prognostic factors (by restriction or matching)?</b>	<b>Did the study maintain comparable groups through the study period?</b>	<b>Did the study use accurate methods for ascertaining exposures and potential confounders?</b>	<b>Were outcome assessors and/or data analysts blinded to the exposure being studied?</b>	<b>Did the article report attrition?</b>	<b>Did the study perform appropriate statistical analyses on potential confounders?</b>	<b>Is there important differential loss to followup or overall high loss to followup?</b>	<b>Were outcomes prespecified, defined, and ascertained using accurate methods?</b>	<b>Quality rating</b>
Haukoos et al, 2010 <sup>68</sup>	Yes	Yes	Not applicable	Yes	Unclear	Not applicable	Yes	Not applicable	Yes	Fair
White et al, 2011 <sup>73</sup>	Yes	Yes; differ only on acuity rating	Not applicable	Yes	Yes	Not applicable	Unclear; states bivariate analysis completed but not shown	Not applicable	Yes	Fair

**Appendix B7. Key Question 2f: Evidence Table of Studies Reporting Linkage to Care Following HIV Testing**

Author, Year	Type of study/location/ setting/high or low prevalence population (based on 0.1% prevalence rate)	Study timeframe	Comparison groups	Baseline population characteristics	Eligibility criteria	Exclusion criteria
Haukoos et al, 2010 <sup>68</sup>	Quasi-experiment with sequential time samples in large urban ED (Denver) where rapid HIV testing (Uni-Gold Recombigen) performed as opt-out x 3 months vs. diagnostic (physician-directed) testing x 4 months over 2 years (3 cycles each); local estimated HIV prevalence, 0.7%	April 15, 2007 to April 15, 2009	Opt-out vs. diagnostic (physician-directed) timeframes	During opt-out phase: mean age, 36 years; 56% male, 40% white, 37% Hispanic, 14% black During diagnostic phase: mean age, 36 yrs; 57% male, 41% white, 37% Hispanic, 14% black	All ED patients ages ≥16 years and capable of providing consent for emergency mediare care	If unable to provide consent for HIV testing; detainees/ prisoners; seeking care after sexual assault; seeking care after occupational exposure; self-identified as HIV-infected; left ED prior to being placed in treatment room
Myers et al, 2009 <sup>76</sup>	Pre-post testing intervention in FQHCs in North Carolina, South Carolina, and Mississippi; 0.16% HIV prevalence	2007 to 2008 (13 months)	HIV testing rate before/after routine rapid HIV test staff training intervention	66% female; 30% African American, 37% Latino, 26% white; 45% uninsured	Patients ages 13–64 years seen at 6 participating FQHCs	Excluded previously diagnosed HIV-positive patients
White et al, 2011 <sup>73</sup>	Pre-post evaluation of opt-in vs. opt-out testing implementation on screening rates and acceptance of rapid oral HIV screening in an ED in Oakland, California	February 1, 2007 to January 31, 2008	Opt-in period: screening offered by providers (February 1, 2007–July 31, 2007; n=23,236) vs. opt-out period: screening offered by registration staff (August 1, 2007– January 31, 2007; n=26,757)	Demographic data available only for patients offered testing: opt-in phase (n=6479): mean age, 39 years (SD, 13); 53% male; 43% black, 27% Hispanic, 15% white Opt-out phase: mean age, 42 years (SD, 14); 45% female; 45% black, 26% Hispanic, 15% white	Ages ≥15 years; medically stable; able to consent for HIV testing (opt-in phase) or complete general consent (opt-in and opt-out phase)	Patients requiring immediate medical evaluation or if staff deemed patient "too ill"

Author, Year	Number screened/ Acceptability	Clinical outcomes	Adverse events	Linkage to care	CD4 count at HIV diagnosis	Quality Rating	Funding Source
Haukoos et al, 2010 <sup>68</sup>	During opt-out phase: 6762/28,043 eligible patients (24%) screened; during diagnostic phase: 243/29,925 eligible patients (0.8%) tested	During opt-out phase: 16 confirmed HIV infections diagnosed (0.24% of tests); during diagnostic phase: 5 confirmed HIV infections diagnosed (2.1% of tests)	Across both phases, 6/7656 tests performed were false-positive tests (0.08%). PPV, 82.4%	During opt-out phase: 30/31 (96.8%) of preliminary positives attended at least 1 appt in HIV clinic; during diagnostic phase: 5/5 (100%) preliminary positives attended initial HIV clinic visit	During opt-out phase: median CD4 count was 0.069 x 10 <sup>9</sup> cells/L (IQR, 0.017–0.430 x 10 <sup>9</sup> ); during diagnostic phase: median CD4 count was 0.013 x 10 <sup>9</sup> cells/L (IQR, 0.011–0.015 x 10 <sup>9</sup> ; p=0.02)	Fair	CDC, AHRQ
Myers et al, 2009 <sup>76</sup>	16,148/58,619 eligible patients (28%) offered screening; 10,769/16,148 (67%) offered screening	HIV testing rates increased from 3% in year preceding intervention to 18% of those eligible during intervention year; preliminary positive: 39/10,769 (0.36%); confirmed newly diagnosed HIV infection: 17/10,769 (0.16%)	19/36 (52.8%) who received confirmatory testing were confirmed or probable false-positive rapid HIV tests	14/17 (82%) confirmed positives linked to care	No data presented	Uncontrolled study; not rated	CDC; Gilead Sciences, Inc.

**Appendix B7. Key Question 2f: Evidence Table of Studies Reporting Linkage to Care Following HIV Testing**

Author, Year	Number screened/ Acceptability	Clinical outcomes	Adverse events	Linkage to care	CD4 count at HIV diagnosis	Quality Rating	Funding Source
White et al, 2011 <sup>73</sup>	Opt-in phase: 6479/23,236 eligible (62.9%) offered screening; 4061/6479 (62.7%) accepted screening; opt-out phase: 20,280/26,757 (75.8%) offered screening; 6273/20,280 (30.9%) accepted screening	Opt-in phase: 21/4053 preliminary positive rapid tests; 10/4053 confirmed positive (0.25% prevalence); opt-out phase: 28/4679 preliminary positive; 28/4679 confirmed positive (0.60%). When previously known HIV-positive subjects excluded, opt-in identified 8 new cases (0.2% of tested) and opt-out identified 21 new cases (0.4%); p=0.04	11/21(52.4%) false-positive preliminary rapid tests; all occurred during first 2 months of study (opt-in phase); cause unknown	75% of opt-in and 77% of opt-out newly diagnosed cases linked to care within 90 days of diagnosis	Mean CD4 count (opt-in): 0.415 x 10 <sup>9</sup> cells/L (SD, 0.237 x 10 <sup>9</sup> ); mean CD4 count (opt-out ): 0.307 x 10 <sup>9</sup> cells/L (SD, 0.274 x 10 <sup>9</sup> ); 25% of opt-in and 48% of opt-out newly diagnosed patients had CD4 count <0.200 x 10 <sup>9</sup> cells/L	Analyzed as uncontrolled study for this key question; not rated	CDC

AHRQ = Agency for Healthcare Research and Quality; CDC = Centers for Disease Control and Prevention; ED = emergency department; FQHC = Federally Qualified Health Center; IQR = interquartile range; PPV = positive predictive value; SD = standard deviation.

**Appendix B8. Key Question 2f: Quality Assessment of a Cohort Study**

<b>Author, Year</b>	<b>Did the study attempt to enroll all (or a random sample of) patients meeting inclusion criteria, or a random sample (inception cohort)?</b>	<b>Were the groups comparable at baseline on key prognostic factors (by restriction or matching)?</b>	<b>Did the study maintain comparable groups through the study period?</b>	<b>Did the study use accurate methods for ascertaining exposures and potential confounders?</b>	<b>Were outcome assessors and/or data analysts blinded to the exposure being studied?</b>	<b>Did the article report attrition?</b>	<b>Did the study perform appropriate statistical analyses on potential confounders?</b>	<b>Is there important differential loss to followup or overall high loss to followup?</b>	<b>Were outcomes prespecified, defined, and ascertained using accurate methods?</b>	<b>Quality rating</b>
Haukoos et al, 2010 <sup>68</sup>	Yes	Yes	Not applicable	Yes	Unclear	Not applicable	Yes	Not applicable	Yes	Fair

**Appendix B9. Key Question 3a: Evidence Table of Studies of Effect of Knowledge of HIV-Positive Status or Use of Highly Active Antiretroviral Therapy on Risky Behaviors**

Author, year	Type of study	Location/setting/ high or low prevalence population (based on 0.1% prevalence rate)	Study duration/ followup	Comparison groups	Demographics/baseline disease
Amaro et al, 2005 <sup>84</sup>	Before-after observational	Massachusetts; HIV counseling and testing sites; high-risk sites (seroprevalence ≥2%), low risk sites (seroprevalence <2%)	May 1996 to February 1997; 3 months	Before HIV test vs. after HIV test (3 months after testing)	48.9% male <b>Males:</b> mean age, 35.9 years (SD, 9.74); 38.7% white, 31.7% black, 24.5% Hispanic, 5% other; 12.8% married, 4.0% same sex partner, 38.3% different sex partner, 44.2% not in special relationship; 55.1% history of partner HIV risk (sex partner in last 5 years who was IDU, had sex outside the relationship, was HIV positive, or had an STD); 2.9% exchanged sex for drugs (35% unknown); 32.5% history of IDU; 61.3% previous HIV test; 4.7% positive HIV test result <b>Females:</b> mean age, 31.5 years (SD, 9.23); 53.2% white, 16.4% black, 22.0% Hispanic, 8% other; 11.5% married, 3.1% same sex partner, 47.9% different sex partner, 36.4% not in special relationship; 62.2% history of partner HIV risk (sex partner in last 5 years who was IDU, had sex outside the relationship, was HIV positive, or had an STD); 7.7% exchanged sex for drugs (35% unknown); 17.8% history of IDU; 64.0% previous HIV test; 1.0% positive HIV test result
Brogly et al, 2002 <sup>85</sup> ; Bruneau et al, 2001 <sup>88</sup>	Before-after observational	Montreal, Canada; self-referral, hospital detoxification unit, IDU centers; high; prevalence in original study cohort 11.1% (Bruneau, 2001)	January 1996 to July 1999 (source cohort recruiting began 1988 [Bruneau, 2001]); first followup visit planned at 3 months, subsequent every 6 months (although participants did not adhere to this schedule and eligibility changed to minimum of 1 month between time of HIV-positive notification and next study visit)	Before HIV diagnosis vs. after HIV diagnosis (at least 1 month after diagnosis)  Also had HIV-positive vs. HIV-negative group	93% male; 79% French speaking; mean and median age, 38 years <u>Comparing IDU who test positive for HIV vs. those who test negative:</u> Currently have no stable home: 56/2% vs. 36.5%; p=0.003 In drug treatment since last visit: 32.9% vs. 47.9%; p=0.025 Perceived current health status >6 (1=very bad, 9=perfect): 43.8% vs. 62.1%; p=0.006 Mean (SD) number of cocaine injections per day in past 4 weeks: 7.9 (8.8) vs. 4.2 (6.3); p<0.001 Mean (SD) number of heroin injections per day in the past 4 weeks: 0.2 (0.5) vs. 0.6 (1.3); p=0.040 Lent needles in past 4 weeks: 35.6% vs. 22.8%; p=0.031 Borrowed needles in past 4 weeks: 50.7% vs. 32.0%; p=0.004 Shared needles with an HIV-positive partner since last visit: 45.2% vs. 13.2%; p<0.0111 Used needle exchange program to obtain clean needles in the past 3 months: 61.6% vs. 45.7%; p=0.018
Camoni et al, 2009 <sup>86</sup>	Before-after observational (retrospective)	5 large cities in Italy; infectious disease and sexually transmitted infection clinics; not reported	2006; not applicable	Before HIV diagnosis vs. after HIV diagnosis (at least 2 years after diagnosis)	65.5% male; median age, 40 years (range, 34–45); 85.2% Italian; HIV exposure category: 43.4% heterosexual contact, 27.2% homosexual contact, 20.6% IDU; 52.5% clinical stage A upon enrollment; n=138/253 IDU
Fox et al, 2009 <sup>87</sup>	Before-after observational	London, UK; HIV clinic; not reported	January 2002 to January 2004; 3 months	Before HIV diagnosis vs. after HIV diagnosis (at 12 weeks ± 5 days after diagnosis)	96% Caucasian, 1% black Caribbean, 2% Asian, 1% other; median age, 33 years (range, 20–59); 88% had seroconversion symptoms; 26% had STD at HIV diagnosis; 51% had unprotected insertive anal sex with casual partner, 64% had unprotected receptive anal sex with casual partner, 38% ever received payment for sex, 10% had no casual sex partner in past 3 months, 38% had 1–5 casual sex partners in past 3 months, 17% had 6–10 casual sex partners in past 3 months, 35% had >10 casual sex partners in past 3 months



**Appendix B9. Key Question 3a: Evidence Table of Studies of Effect of Knowledge of HIV-Positive Status or Use of Highly Active Antiretroviral Therapy on Risky Behaviors**

Author, year	Eligibility criteria	Exclusion criteria	Number screened/ eligible/enrolled/ withdrawals/% analyzed	Virologic response	CD4 count response	Adjusted variables for statistical analysis
Amaro et al, 2005 <sup>84</sup>	Ages ≥18 years, speaker of English or Spanish, ability to give informed consent, attending 1 of 13 study sites	Exclusively homosexual behavior	1286 eligible; 939 (73%) enrolled, completed pretest questionnaire; 672 completed posttest questionnaire (72% followup rate); 560 analyzed overall; 16 HIV-positive	Not reported	Not reported	Multinomial logistic regression analysis used to examine effects of HIV serostatus and counseling services, sociodemographic, behavioral predictors, on post-HIV test stage of change for condom use with main partners, stratified by stage of change and condom use at pretest
Brogly et al, 2002 <sup>85</sup> ; Bruneau et al, 2001 <sup>88</sup>	Cohort eligibility: ages ≥14 years, residing in Montreal, having injected drugs in past 6 months, having provided informed consent Current investigation: injected drugs in past 6 months, unaware of HIV-positive status at enrollment Current analysis: aware of HIV diagnosis for at least 1 month before study visit for those testing positive	For particular behavior change analysis, only participants that were aware of their status for relevant amount of time were included (e.g., those who knew of status for past 3 months) and individuals had to be aware of HIV seropositivity for a minimum of 70% of time period over which behavior change was assessed; only those who could augment or diminish behavior as measured by questionnaire were included; changes in sexual behavior assessed in male subjects only due to small number of females	103 HIV-positive eligible; 73 HIV-positive analyzed, 219 HIV-negative analyzed	Not reported	Not reported	No adjustments
Camoni et al, 2009 <sup>86</sup>	Ages ≥18 years, diagnosed at least 2 years prior to study	Not reported	497 eligible; 487 enrolled; 487 analyzed for sexual behavior, 253 analyzed for drug use behavior	Not reported	Not reported	No adjustments
Fox et al, 2009 <sup>87</sup>	Men who have sex with men, diagnosed with primary HIV infection	Not reported	104 eligible; 98 analyzed (100% followup)	Not reported	Not reported	No adjustments

Author, year	Outcomes	Adverse events	Funding source and role	Quality rating
Amaro et al, 2005 <sup>84</sup>	All HIV-positive participants adopted safer behavior with main and nonmain partners at posttest, indicating that HIV status was the most significant factor determining stage of change for condom use at posttest. Posttest questionnaire given at 3 month followup visit (statistics for this group not reported)	Not reported	Centers for Disease Control and Prevention	Fair
Brogly et al, 2002 <sup>85</sup> ; Bruneau et al, 2001 <sup>88</sup>	Behavior change in IDUs who received positive test result: 26.2% (11/42) stopped injecting, 49.3% (36/73) decreased number of injections by 20%, 62.5% (5/8) decreased injection heroin use, 73.1% (19/26) stopped lending needles, 62.2% (23/37) stopped borrowing needles, 70.6% (12/17) stopped sharing needles with HIV-positive partner, 34.2% (25/73) increased number of needles from needle exchange program by 25%, 37.5% (27/72) increased use of needle exchange program, 50.0% (9/18) of males stopped sexual realtions, 100% (5/5) of men stopped sex work. For majority of behaviors examined, significantly higher proportion of HIV-positive IDUs adopted protective vs. risky behaviors (data not shown). Considering behavior change among HIV-positive individuals only, substantial number of IDUs responded to HIV diagnosis by engaging in lower risk behaviors.	Not reported	National Health Research and Development Program of Health Canada; National Institute of Drug Abuse	Fair

**Appendix B9. Key Question 3a: Evidence Table of Studies of Effect of Knowledge of HIV-Positive Status or Use of Highly Active Antiretroviral Therapy on Risky Behaviors**

Author, year	Outcomes	Adverse events	Funding source and role	Quality rating
Camoni et al, 2009 <sup>66</sup>	<p><u>Comparing drug use before HIV diagnosis vs. after HIV diagnosis</u>                      Injecting drug use: yes, n=138 (54.5%) vs. n=82 (32.4%); no, n=114 (45.1%) vs. n=164 (64.8%); no answer, n=1 (0.4%) vs. n=7 (2.8%); McNemar chi=42.9; p&lt;0.0005                      Syringe exchange: yes, n=113 (44.7%) vs. n=40 (15.8%); no, n=104 (41.1%) vs. n=160 (63.3%); no answer, n=36 (14.2%) vs. n=53 (20.9%); McNemar chi=53.7; p&lt;0.0005</p> <p><u>Comparing sexual behavior before HIV diagnosis vs. after HIV diagnosis</u>                      Number of sex partners: &lt;2, n=81 (16.6%) vs. n=219 (45.0%); &gt;2, n=405 (83.2%) vs. n=264 (54.2%); no answer, n=1 (0.2%) vs. n=4 (0.8%); McNemar chi=113.47; p&lt;0.0005                      Sex for money or drugs: yes, n=64 (13.1%) vs. n=33 (6.8%); no, n=413 (84.8%) vs. n=433 (88.9%); no answer, n=10 (2.1%) vs. n=21 (4.3%); McNemar chi=16.68; p&lt;0.0005                      Sex with sex workers: yes, n=78 (16.0%) vs. n=35 (7.2%); no, n=381 (78.25%) vs. n=416 (85.4%); no answer, n=28 (5.8%) vs. n=36 (7.4%); McNemar chi=22.37; p&lt;0.0005</p> <p><u>Comparing sexual behavior with stable partner and occasional partner before HIV diagnosis vs. after HIV diagnosis</u>                      Stable partner: yes, n=434 (89.1%) vs. n=377 (77.4%); no, n=53 (10.9%) vs. n=110 (22.6%); McNemar chi=27.75; p&lt;0.0005                      Condom use, vaginal sex: always, n=24 (5.5%) vs. n=150 (39.8%); not always/never, n=323 (74.5%) vs. n=122 (32.4%); no answer, n=87 (20.0%) vs. n=105 (27.8%); McNemar chi=118.07; p&lt;0.0005                      Condom use, anal sex: always, n=18 (4.1%) vs. n=120 (31.8%); not always/never, n=292 (67.3%) vs. n=126 (33.5%); no answer, n=124 (28.6%) vs. n=131 (34.7%); McNemar chi=86.49; p&lt;0.0005                      Condom use, oral-genital sex: always, n=4 (0.9%) vs. n=34 (9.0%); not always/never, n=372 (85.7%) vs. n=273 (72.4%); no answer, n=58 (13.4%) vs. n=70 (18.6%); McNemar chi=26.03; p&lt;0.0005                      Occasional partners: yes, n=400 (82.1%) vs. n=283 (58.1%); no, n=87 (17.9%) vs. n=204 (41.9%); McNemar chi=89.11; p&lt;0.0005                      Condom use, vaginal sex: always, n=41 (10.3%) vs. n=107 (37.8%); not always/never, n=254 (63.5%) vs. n=65 (23.0%); no answer, n=105 (26.2%) vs. n=111 (39.2%); McNemar chi=65.33; p&lt;0.0005                      Condom use, anal sex: always, n=42 (10.5%) vs. n=115 (40.6%); not always/never, n=267 (66.8%) vs. n=91 (32.2%); no answer, n=91 (22.7%) vs. n=77 (27.2%); McNemar chi=68.36; p&lt;0.0005                      Condom use, oral-genital sex: always, n=11 (2.7%) vs. n=49 (17.3%); not always/never, n=329 (82.3%) vs. n=188 (66.4%); no answer, n=60 (15.0%) vs. n=46 (16.3%), McNemar chi=31.24, p&lt;0.0005</p>	Not reported	VI Programma Nazionale di Ricerca sull'AIDS 2005	Fair
Fox et al, 2009 <sup>67</sup>	<p>Risk for onward transmission: unprotected anal intercourse with regular partner of unknown or negative HIV status, unprotected anal intercourse with casual male partners, or incident sexually transmitted infection                      Significant changes in risk behavior in the 12 weeks following HIV diagnosis, n=74/98 (76%) posing no risk for onward transmission during that period. Overall shift to fewer sex partners in cohort with 65 men decreasing number of partners, 26 staying same, 7 increasing number (Wilcoxon test Z, -6.302; p&lt;0.001) (visual representation).                      Proportion always using condoms during receptive anal intercourse with casual partners increased from n=13/76 (17%) to 29/45 (64%) (p&lt;0.001) and for insertive anal intercourse from n=22/72 (31%) to 28/46 (61%) (p&lt;0.01).                      Paired analysis for receptive anal intercourse showed 23 men increased condom use, 16 stayed the same, 2 used condoms less (Wilcoxon test Z, -4.097; p&lt;0.001). Paired analysis for insertive anal intercourse showed 15 men increased condom use, 19 stayed the same, 5 reduced use (Wilcoxon test Z, -2.294; p=0.024). 24 men reported behaviors that posed a continuing risk for transmission to others post-HIV diagnosis, although this group significantly decreased their numbers of sex partners post-diagnosis (14/24 reduced number of partners, 8/24 stayed the same, 2/24 increased number; Wilcoxon test Z, -2.610; p&lt;0.009)</p>	Not reported	United Kingdom Medical Research Council, UNAIDS	Good

IDU = injection drug user; SD = standard deviation; STD = sexually transmitted disease.

**Appendix B10. Key Question 3a: Quality Assessment of Cohort Studies**

Author, Year	Did the study attempt to enroll all (or a random sample of) patients meeting inclusion criteria, or a random sample (inception cohort)?	Were the groups comparable at baseline on key prognostic factors (by restriction or matching)?	Did the study maintain comparable groups through the study period?	Did the study use accurate methods for ascertaining exposures and potential confounders?	Were outcome assessors and/or data analysts blinded to the exposure being studied?	Did the article report attrition?	Did the study perform appropriate statistical analyses on potential confounders?	Is there important differential loss to followup or overall high loss to followup?	Were outcomes prespecified, defined, and ascertained using accurate methods?	Quality rating
Amaro et al, 2005 <sup>84</sup>	Yes	Not relevant; pre-post design, one group	Not relevant; pre-post design	Yes	Unclear	Yes	Yes	Yes; 72% followup	Yes	Fair
Brogly et al, 2002 <sup>85</sup> , Bruneau et al, 2001 <sup>88</sup>	Yes	Not relevant; pre-post design, one group	Not relevant; pre-post design	Yes	Unclear	No	Yes	Unclear; no followup proportion given	Yes	Fair
Camoni et al, 2009 <sup>86</sup>	Yes	Not relevant; pre-post design, one group	Not relevant; pre-post design	Yes	Unclear	Not relevant; retrospective	Yes	Not relevant; retrospective	Yes	Fair
Fox et al, 2009 <sup>87</sup>	Yes	Not relevant; pre-post design, one group	Not relevant; pre-post design	Yes	Unclear	Yes	Yes	No	Yes	Good

**Appendix B11. Key Question 3b: Evidence Table of Studies of Effect of Knowledge of HIV-Positive Status or Use of Highly Active Antiretroviral Therapy on Risky Behaviors**

Author, year	Type of study	Location/setting/high or low prevalence population (based on 0.1% prevalence rate)	Study duration/followup	Comparison groups	Demographics/baseline disease
Del Romero et al, 2010 <sup>93</sup>	Cross sectional and prospective cohort	Madrid, Spain; HIV clinic; high; no ART 9.2%, ART 8.7%; 9% HIV prevalence among partners whose index partner was not on ART, 0% in those on ART	1989–2008; 1355 couple-years accrued in prospective cohort	ART vs. no ART	Index cases 83% male; female median age, 29 years; male median age, 32 years; median CD4 count, 500 x 10 <sup>9</sup> cells/L (IQR, 295–700); median plasma HIV RNA, 200 copies/mL (IQR, nondetectable to 8876); 54% detectable viral load; median known duration of HIV infection, 29 months (IQR, 3–94)
Diamond et al, 2005 <sup>94</sup>	Cross sectional of patients randomly selected for clinic trial	California; HIV clinic; not reported	October 1998 to September 1999; baseline visit data	ART vs. no ART	45% ages <37 years; 88% male; 39% white, 37% Latino, 16% black, 8% Asian/Pacific Islander/American Indian/Alaska native/other; HIV exposure: 62% homosexual sex, 16% heterosexual sex, 10% injection drug use, 9% both homosexual sex and injection drug use, 3% transfusion/other/don't know; 22% current CD4 count 0–199 x 10 <sup>9</sup> cells/L, 45% current CD4 count 200–499 x 10 <sup>9</sup> cells/L, 32% current CD4 count ≥500 x 10 <sup>9</sup> cells/L; 42% recent undetectable viral load; 65% with 1 sex partner in past 3 months, 13% with 2 sex partners in past 3 months, 22% with ≥3 sex partners in past 3 months; 48% sex with main partner only in past 3 months, 46% sex with casual exchange partner in past 3 months, 6% sex with exchange partner in past 3 months; 34% unprotected anal/vaginal intercourse in past 3 months; 79% using ART; 74% taking ≥95% of medication; median time from diagnosis of HIV infection, 6 years (range, 0–18)
Elford et al, 2007 <sup>95</sup> ; Elford et al, 2006 <sup>100</sup>	Cross sectional	London, UK; HIV clinic; 17,000 gay men, 13,000 black African heterosexual men and women with HIV (Elford 2006)	4–6 month period in 2004–2005; once only data	ART use vs. no ART use	<u>Gay men</u> : median age, 39 years (range, 18–72); 85% white; 70.7% on ART; 61.2% undetectable viral load; median CD4 count, 350 x 10 <sup>9</sup> cells/L (range, 0–999); 42.5% recreational drug use; median time since diagnosis, 6 years (range, 0–21) <u>Black African heterosexual</u> : median age, 39 years (range, 18–69); 85.5% on ART; 59.2% undetectable viral load; median CD4 count, 150 x 10 <sup>9</sup> cells/L (range, 0–999); 0% recreational drug use; median time since diagnosis, 3 years (range, 0–18) <u>Black African heterosexual women</u> : median age, 36 years (range, 18–67); 75% on ART; 62.3% undetectable viral load; median CD4 count, 200 x 10 <sup>9</sup> cells/L (range, 0–999); 0.2% recreational drug use; median time since diagnosis, 3 years (range, 0–20) **Significant differences between groups on age, use of ART, CD4 count, years since diagnosis, employment status, education, birth in the U.K., number of years in the U.K., relationship status, knowledge of partner's HIV status, partner's knowledge of index case's HIV status, access to the Internet, use of Internet to look for sexual partners, HIV treatment optimism
Miguez-Burbano et al, 2002 <sup>96</sup>	Cross sectional embedded in RCT	Miami; community health and research clinic; not reported	RCT 1998–2001; behavioral questionnaire approved in 2000; RCT cohort followed 1998–2001	ART use vs. no ART use	Mean age, 39.1 years (SD, 6); 57.6% male; 78% African American, 4% Caucasian, 17% Hispanic, 1% other (Haitian); 67% drug use (65% past use of injecting heroin, 46% past use of injecting cocaine); 65% heterosexual, 11% homosexual, 24% bisexual; 91% single, 9% stable partner; 31% not on ART, 47% on ART, 22% on ART but not taking it; 68% diagnosed before 1995, 8% diagnosed after 1999 (range, 1981–2000 [questionnaire approved in 2000])

**Appendix B11. Key Question 3b: Evidence Table of Studies of Effect of Knowledge of HIV-Positive Status or Use of Highly Active Antiretroviral Therapy on Risky Behaviors**

Author, year	Type of study	Location/setting/high or low prevalence population (based on 0.1% prevalence rate)	Study duration/ followup	Comparison groups	Demographics/baseline disease
Morin et al, 2007 <sup>97</sup>	Cross sectional	Various clinics throughout U.S.; Ryan White-funded clinics; not reported	April 2004 to December 2006; baseline interview data	ART vs. no ART	<p><b>MSM:</b> 51% white, 29% black/African American, 15% Hispanic/Latino, 5% other; 84% homosexual, 13% bisexual, 1% heterosexual, 2% unknown/no answer; 41% ages &lt;39 years, 59% ages &gt;40 years; 15% CD4 count &lt;200 x 10<sup>9</sup> cells/L, 66% CD4 count ≥200 x 10<sup>9</sup> cells/L, 18% unknown CD4 count; 57% most recent viral load undetectable, 33% most recent viral load detectable, 10% most recent viral load unknown/no answer; 14% not currently on ART, 69% currently on ART, 18% unknown/no answer; 40% unprotected anal or vaginal sex in last 6 months; 4% injected any drug in last 30 days</p> <p><b>Women:</b> 16% white, 68% black/African American, 11% Hispanic/Latino, 4% other; 3% homosexual, 5% bisexual, 89% heterosexual, 3% unknown/no answer; 41% ages &lt;39 years, 59% ages &gt;40 years; 14% CD4 count &lt;200 x 10<sup>9</sup> cells/L, 57% CD4 count ≥200 x 10<sup>9</sup> cells/L, 29% unknown CD4 count; 52% most recent viral load undetectable, 34% most recent viral load detectable, 14% most recent viral load unknown/no answer; 18% not currently on ART, 60% currently on ART, 22% unknown/no answer; 27% unprotected anal or vaginal sex in last 6 months; 3% injected any drug in past 30 days</p> <p><b>MSW:</b> 15% white, 68% black/African American, 15% Hispanic/Latino, 2% other; &lt;1% homosexual, 2% bisexual, 96% heterosexual, 1% unknown/no answer; 20% ages &lt;39 years, 80% ages &gt;40 years; 19% CD4 count &lt;200 x 10<sup>9</sup> cells/L, 52% CD4 count ≥200 x 10<sup>9</sup> cells/L, 29% unknown CD4 count; 53% most recent viral load undetectable, 36% most recent viral load detectable, 11% most recent viral load unknown/no answer; 11% not currently on ART, 71% currently on ART, 18% unknown/no answer; 20% unprotected anal or vaginal sex in last 6 months; 7% injected any drug in last 30 days; no data on duration of HIV infection</p>
Smit et al, 2006 <sup>98</sup> ; van Haastrecht et al, 1991 <sup>101</sup>	Prospective cohort	Amsterdam; methadone maintenance outposts, sexually transmitted diseases clinic, word of mouth; assumed high prevalence (homosexual drug users in Amsterdam); high; adjusted prevalence rate was 34.1% among IDUs participating in study 1986–1989 (van Haastrecht, 1991)	December 1985 to ongoing Treatment, 8.08 years (range, 4.6–10.2) Control: 7.98 years (range, 4.2–10.0)	ART use vs. no ART use	<p>Treatment: 73% male; mean age, 40 years; 87% methadone users; 51% naive; median CD4 count, 185 x 10<sup>9</sup> cells/L</p> <p>Control: 71% male; mean age, 38 years; 95% methadone users; 58% naive; median CD4 count, 0.200 x 10<sup>9</sup> cells/L; no data on duration of HIV diagnosis</p>
Tun et al, 2004 <sup>99</sup> ; Vlahov et al, 1991 <sup>102</sup> ; Vlahov et al, 2001 <sup>103</sup>	Before-after derived from prospective cohort	Baltimore; community outreach recruitment; high; 24% in population enrolled from 1988–1989 (Vlahov, 2001)	ALIVE cohort recruitment 1988–1989 and 1994 Present analysis: enrolled July 1996 to November 2000; followup to August 2001, occurrence of behavioral outcome or last study visit (variable durations)	ART vs. no ART	70.5% male; 95.3% African American; median age at ART initiation, 44 years (IQR, 40–47); median CD4 count, 0.260 x 10 <sup>9</sup> cells/L (IQR, 0.129–0.358 x 10 <sup>9</sup> ); median HIV RNA level for 64% of sample, 23,709 copies/mL (2,184–10,4544); 20.0% with AIDS diagnosis prior to ART; 66.3% engaged in any sex 1 year prior to ART; 22.1% engaged in unprotected sex 1 year prior to ART; 52.6% injected drugs 1 year prior to ART; 20% shared needles 1 year prior to ART; no data on duration of HIV diagnosis

**Appendix B11. Key Question 3b: Evidence Table of Studies of Effect of Knowledge of HIV-Positive Status or Use of Highly Active Antiretroviral Therapy on Risky Behaviors**

Author, year	Eligibility criteria	Exclusion criteria	Number screened/ eligible/enrolled/ withdrawals/% analyzed	Virologic response	CD4 count response
Del Romero et al, 2010 <sup>93</sup>	All heterosexual couples who had an ongoing sexual relationship over the preceding 6 months, were serodiscordant for HIV, and returned for at least 1 followup visit	Non-index partner with previous HIV diagnosis or known risk exposures other than relationship with index partner	648 eligible; 602 serodiscordant at first visit; 625 analyzed (first visit data); 424 with followup	Detectable viral load in 111/120 (93%) not taking ART vs. 30/145 (21%) taking ART (p<0.001)	Not reported
Diamond et al, 2005 <sup>94</sup>	Patients enrolled in trial of clinic-based safer sex interventions at 6 public HIV clinics, ages ≥18 years, HIV infection diagnosed for at least 3 months, sexually active during past 3 months, English or Spanish speaking, and expecting to continue care at clinic for next year	Missing information on unprotected sex (n=1), women who had sex with women only (n=11)	2027 approached; 1840 screened; 1278 eligible; 886 enrolled (69% of patients screened and eligible); 874 analyzed	Not reported	Not reported
Elford et al, 2007 <sup>95</sup> ; Elford et al, 2006 <sup>100</sup>	People ages ≥18 years diagnosed with HIV infection and receiving treatment and care in 6 East London public hospitals. Ineligible = limited command of English, too ill or too distressed to complete questionnaire	Bisexual women, lesbians; analysis included only gay or bisexual men, black African heterosexual men and women (87% of respondents), other groups excluded due to small sample size	2680 screened; 2299 eligible; 1687 completed questionnaire (gay men, n=758; black African heterosexual men, n=224; black African heterosexual women, n=480; response rate, 73% eligible attenders)	Not reported	Not reported
Miguez-Burbano et al, 2002 <sup>96</sup>	RCT enrolled HIV-1 infected drug abusers at University of Miami clinic	Not reported	87 screened; 85 enrolled, participated	Among those on ART, men were 7 times less likely to achieve positive virological response (undetectable viral loads after 6 months of treatment) compared with HIV-infected women (95% CI, 1–12.4; p=0.03). No gender differences in viral load for those not on ART	Not reported
Morin et al, 2007 <sup>97</sup>	HIV-infected status, receipt of primary care at clinic, ages ≥18 years, ability to provide informed consent.	Transgendered individuals	# screened not reported; # eligible not reported; 4016 enrolled: n=2109 (52.5%) MSM; n=1104 (27.5%) women; n=803 (20.0%) MSW	Not reported	Not reported

**Appendix B11. Key Question 3b: Evidence Table of Studies of Effect of Knowledge of HIV-Positive Status or Use of Highly Active Antiretroviral Therapy on Risky Behaviors**

Author, year	Eligibility criteria	Exclusion criteria	Number screened/ eligible/enrolled/ withdrawals/% analyzed	Virologic response	CD4 count response
Smit et al, 2006 <sup>98</sup> ; van Haastrecht et al, 1991 <sup>101</sup>	HIV-positive homosexual drug users Treatment: use of ART regimen, including a combination of ≥2 antiretrovirals with ≥1 protease inhibitor or nonnucleoside reverse transcriptase inhibitor	Not reported	202 screened; 68 eligible; 67 enrolled on ART, 130 not on ART	During first 1.5 months after ART initiation, strong decline seen in HIV RNA levels among IDUs on ART and homosexual men on ART. Differed significantly from IDUs not on ART. After 1.5 months, decrease in HIV RNA was not significant in either ART group and increased nonsignificantly in IDUs on ART.	In first 3 months after therapy initiation, CD4 cell counts increased significantly in both ART- treated IDUs and homosexual men. After 3 months, CD4 cell counts continued to increase significantly among ART-treated homosexual men, remained stable among IDUs. CD4 cell counts continued to decrease significantly with IDUs on ART were insignificant.
Tun et al, 2004 <sup>99</sup> ; Vlahov et al, 1991 <sup>102</sup> ; Vlahov et al, 2001 <sup>103</sup>	ALIVE cohort participants had to be ages >18 years, report history of illicit drug injection within previous 11 years, and be AIDS-free at time of enrollment Present analysis: Initiated ART between July 1996 and November 2000, had CD4 count obtained at visit immediately prior to ART initiation, had at ≥1 semiannual visit after ART initiation	Present analysis included those starting ART between July 1996 and November 2000 with CD4 count data for visit prior to ART initiation and 1 visit after ART initiation, others excluded	3360 enrolled in cohort; 693 HIV-positive enrolled 1996–2000; 276 initiated ART during study period; 190 analyzed	Not reported	Not reported

Author, year	Adjusted variables for statistical analysis	Outcomes	Adverse events	Funding source and role	Quality rating
Del Romero et al, 2010 <sup>93</sup>	No adjustments	<p><u>Proportion engaging in unprotected sexual intercourse in past 6 months, no ART vs. ART</u> 273/476 (57%) vs. 69/149 (46%); p=0.019</p> <p><u>Proportion of couples with previous pregnancies, no ART vs. ART</u> 226/476 (47%) vs. 53/149 (36%); p=0.011</p> <p><u>Characteristics of couples and events during followup based on ART of index partner, no treatment vs. mono/dual therapy vs. combined treatment</u> Couples with unprotected sexual contacts: n=187 (55%) vs. n=24 (51%) vs. n=101 (70%) Couples with unprotected penile-anal contacts: n=13 vs. n=4 vs. n=11 Estimated number of risky sexual exposures: 11,000 vs. 1600 vs. 7400 **Sexual risk exposures include penile-vaginal or penile-anal contacts without a condom and condoms breaking or slipping during intercourse</p>	Not reported	Grant from FIPSE (foundation formed by Spanish Ministry of Health and Consumer Affairs and multiple pharmaceutical companies), and Spanish Network for Research on AIDS	Fair

**Appendix B11. Key Question 3b: Evidence Table of Studies of Effect of Knowledge of HIV-Positive Status or Use of Highly Active Antiretroviral Therapy on Risky Behaviors**

Author, year	Adjusted variables for statistical analysis	Outcomes	Adverse events	Funding source and role	Quality rating
Diamond et al, 2005 <sup>94</sup>	Age, sex, race, HIV exposure category, years since HIV diagnosis, current CD4 count, number of sex partners in past 3 months, type of sex partners in past 3 months, use of illicit drugs or alcohol in past 3 months, depression and health beliefs, clinical site, frequency of missed appointments, duration of clinic attendance	<u>Unprotected anal or vaginal sex:</u> anal or vaginal intercourse without a condom within past 3 months. Amphetamine use variable included any route, including injection. <u>Proportion engaging in unprotected sexual intercourse, ART vs. no ART</u> 215/689 (31%) vs. 86/185 (46%); OR, 0.5 (95% CI, 0.4–0.7), p<0.001 <u>Proportion engaging in unprotected sexual intercourse with ART adherence data, &gt;95% ART adherence vs. &lt;95% ART adherence</u> 142/683 (28%) vs. 72/175 (41%); OR, 0.6 (95% CI, 0.4–0.8); p<0.001 <u>Stratified analysis results:</u> ART was significantly associated with decreased unprotected anal and vaginal intercourse across ages and sexes in whites, Latinos, MSM, and injection drug users, those diagnosed with HIV for <4 or >8 years, those with CD4 counts >200 x 10 <sup>9</sup> cells/L, those with detectable viral loads, 1 sexual partner in past 3 months, main and casual sex partners in past 3 months, no use of marijuana, amphetamines, or nitrates (OR and CI available for these associations, more variables described in Table 3) **Among those with exchange partners, unprotected intercourse was higher in those on ART than not on ART, only such group but nonsignificant result <u>Multivariate analysis:</u> negative relationship between ART use and unprotected intercourse remained after adjusting for race/ethnicity, marijuana use, alcohol use, symptomatic depression, clinic site, duration of clinic attendance (adjusted OR, 0.70 [95% CI, 0.50–1.0] p<0.04)	Not reported	Supported by National Institute of Mental Health grant, California Collaborative Treatment Group funded by universitywide AIDS research program of State of California, CDC, NCI grant	Fair
Elford et al, 2007 <sup>95</sup> ; Elford et al, 2006 <sup>100</sup>	Age, number of years since diagnosis, CD4 count, employment, education, relationship, ART use, viral load, recreational drug use, seeking sex through Internet, HIV optimism (no significant differences found between black African heterosexual men and women on any sexual behavior outcomes [p>0.3], so combined for analysis)	Alpha=0.01. <u>Unprotected intercourse:</u> vaginal or anal intercourse without a condom in previous 3 months. In multivariate analysis, no significant association found between being on ART and unprotected intercourse with a casual partner of unknown or negative HIV status among gay men (p>0.01); in multivariate model, no variables other than seeking sex through Internet and recreational drug use were associated with unprotected intercourse with a casual partner who was HIV-positive among gay men (p>0.1); in multivariate analysis, no variables associated with unprotected intercourse with main partner of unknown or negative HIV status among gay men (p>0.1); in multivariate analysis there was no significant association between any variables and unprotected intercourse with main partner who was HIV-positive, -negative, or unknown for African men and women (p>0.05); abstract: neither viral load nor being on ART were significantly associated with unprotected intercourse among gay men or black African heterosexual men and women (p>0.05)	Not reported	Sponsorship: St. Bartholomew's and the Royal London Charitable Foundation Research Advisory Board, City University London, Institute of Health Sciences, St. Bartholomew School of Nursing and Midwifery	Fair
Miguez-Burbano et al, 2002 <sup>96</sup>	Unclear; states that multivariate analysis was performed but no details	<u>Risk-taking behavior and HIV treatment</u> Contaminated needles used by 18 participants; 85% of this group was receiving ART Men receiving ART tended to have unprotected anal sex compared with those not on ART; OR, 2 (95% CI, 0.47–11.73; p=0.067)	Not reported	NIDA, NIH-Fogarty	Fair



**Appendix B11. Key Question 3b: Evidence Table of Studies of Effect of Knowledge of HIV-Positive Status or Use of Highly Active Antiretroviral Therapy on Risky Behaviors**

Author, year	Adjusted variables for statistical analysis	Outcomes	Adverse events	Funding source and role	Quality rating
Morin et al, 2007 <sup>97</sup>	For transmission risk acts: sexual identity, education, age, employment, alcohol use, stimulant use, ART use, race Results separated by sex (CD4 count and viral load were not associated with risk in univariate analysis, so not used in multivariate)	<u>Sexual behavior over 6-month period</u> Unprotected sex: any act of insertive or receptive anal or vaginal intercourse in which a participant did not use a condom <u>Predictors of transmission risk sex, ART vs. no ART</u> MSM: transmission rate, 19% vs. 28%; adjusted OR, 0.73 (95% CI, 0.54–1.00); p=0.05 Women: transmission rate, 14% vs. 21%; adjusted OR, 0.75 (95% CI, 0.49–1.16); p=0.19 MSW: transmission rate, 10% vs. 12%; adjusted OR, 0.81 (95% CI, 0.39–1.67); p=0.56	Mathematical modeling analyses among 4016 participants with HIV: total infections, 36.6; mean infections per participant, 0.009; infections per sexually active participant, 0.012	Health Resources and Services Administration Special Projects of National Significance Program grant	Fair
Smit et al, 2006 <sup>98</sup> ; van Haastrecht et al, 1991 <sup>101</sup>	No adjustments	At reference visit, 42% of ART users had injected drugs since previous visit, declining to 30% by third visit. At reference visit, 61% of nonART users had injected drugs since previous visit, declining to 44% by third visit. The proportion of IDUs that reported injecting drugs was significantly lower among ART users than nonART users at all visits (p<0.05), except the last 2. Modelled piecewise, ART users and nonART users showed nonsignificant declines in injecting drugs over time, which did not change after ART initiation. At reference visit, 15% of ART users and 13% of nonART users had engaged in unprotected sex. Significant differences between ART users and nonusers were seen at every visit (p<0.05). ART users reported significantly more unprotected sex than nonART users at reference visit, visit prior, and visit after reference visit (p<0.05). Modelled piecewise, sexual risk behavior nonsignificantly increased before ART initiation (OR, 1.67 per year [95% CI, 0.98–2.83]; p=0.06), and changed after initiation, nonsignificantly (OR, 0.33 per year [95% CI, 0.10–1.08]; p=0.07). Sexual risk behavior did not change over time for nonART users.	Not reported	Netherlands Organization for Health Research and Development; Ministry of Health, Welfare, and Sport; and the Dutch AIDS Fund	Fair
Tun et al, 2004 <sup>99</sup> ; Vlahov et al, 1991 <sup>102</sup> ; Vlahov et al, 2001 <sup>103</sup>	Change in CD4 count from baseline, baseline CD4 count at visit prior to ART initiation, AIDS diagnosis prior to ART initiation, engaging in relevant risk behavior in the year prior to ART initiation or year of ART initiation, age at ART initiation, biological sex. Some analyses adjusted for past behavior	<u>Unprotected sexual intercourse</u> : engaging in vaginal or anal sex without using a condom (assessed in preceding 6 months of each semiannual visit). Proportion of participants who engaged in any sexual intercourse (66.3%–71.6%), unprotected sex (22.9%–26.2%), any drug injection (52.7%–49.0%), and/or needle sharing (20%–26.3%) remained stable or increased slightly from before to after ART initiation, not significant (figure shows proportion who initiated, discontinued, or continued each behavior); at individual level, about 6%–11% discontinued any 1 of the behaviors and about 7%–14% initiated any 1 of the behaviors after starting ART, about 80% continued same behaviors before and after ART <u>Unprotected sex</u> : 26.3% had engaged in unprotected sex after ART initiation, 48% of whom had not engaged in unprotected sex in year prior to ART initiation <u>Drug injection</u> : after followup, 48.9% reported injecting drugs, 15.1% of whom had not injected drugs in year prior to ART initiation; 26.3% shared needles after ART, 52% of whom had not shared needles in year prior to ART	Not reported	National Institute on Drug Abuse grants and National Research Service Award from National Institute of Mental Hygiene	Fair

ART = antiretroviral therapy; CDC = Centers for Disease Control and Prevention; CI = confidence interval; IDU = injection drug user; IQR = interquartile range; MSM = men who have sex with men; MSW = men who have sex with women; NCI = National Cancer Institute; NIDA = National Institute on Drug Abuse; NIH = National Institutes of Health; OR = odds ratio; RCT = randomized, controlled trial; SD = standard deviation.

**Appendix B12. Key Question 3b: Quality Assessment of Cohort Studies**

Author, Year	Did the study attempt to enroll all (or a random sample of) patients meeting inclusion criteria, or a random sample (inception cohort)?	Were the groups comparable at baseline on key prognostic factors (by restriction or matching)?	Did the study maintain comparable groups through the study period?	Did the study use accurate methods for ascertaining exposures and potential confounders?	Were outcome assessors and/or data analysts blinded to the exposure being studied?	Did the article report attrition?	Did the study perform appropriate statistical analyses on potential confounders?	Was there important differential loss to followup or overall high loss to followup?	Were outcomes prespecified, defined, and ascertained using accurate methods?	Quality rating
Del Romero et al, 2010 <sup>93</sup>	Yes	No	Not relevant, cross sectional	Yes	Unclear	Not relevant, cross sectional	No	Not relevant, cross sectional	Yes	Fair
Diamond et al, 2005 <sup>94</sup>	Yes	Unclear	Not reported	Yes	Unclear	Not reported	Yes	No	Yes	Fair
Elford et al, 2007 <sup>95</sup>	Yes	Unclear	Not reported	Yes	Unclear	Not reported	Partially	No	Yes	Fair
Miguez-Burbano et al, 2002 <sup>96</sup>	Yes	Unclear	Not relevant, cross sectional	Yes	Unclear	Not relevant, cross sectional	Unclear, states multivariate analysis was performed but no details	Not relevant, cross sectional	Yes	Fair
Morin et al, 2007 <sup>97</sup>	Yes	Unclear	Not reported	Yes	Unclear	Not reported	Yes	No	Yes	Fair
Smit et al, 2005 <sup>98</sup>	Yes	Yes	Yes	Yes	Unclear	No	Partially	Unclear	Yes	Fair
Tun et al, 2004 <sup>99</sup>	Yes	Not reported	Not reported	Yes	Unclear	No	Yes	Unclear	Yes	Fair

**Appendix B13. Key Question 4a: Evidence Table of a Systematic Review of Effects of Counseling or Antiretroviral Therapy Use on HIV Transmission**

Author, Year	Purpose of study	Databases searched, date of last search	Number of studies	Types of studies included/ limitations of primary studies	Methods for rating methodological quality of primary studies	Methods for synthesizing results of primary studies	Number of patients (treatment and control)	Interventions	Results	Adverse events	Quality rating
Anglemyer et al, 2011 <sup>108</sup>	To determine if ART use by the HIV-infected partner in a serodiscordant relationship is associated with lower risk for transmission to the uninfected partner	PubMed, EMBASE, Cochrane Central Register of Controlled Trials, Web of Science, LILACS, Aegis archive of conference abstracts, CROI, International AIDS Society Web site Last search: February 1, 2011	8	1 RCT and 7 cohorts; limited by small numbers of transmissions; only 3 included studies adjusted odds ratios for age, sex, or frequency of sex; only 4 studies described loss to followup	Quality rating assessed randomization, allocation concealment, blinding, incomplete outcome data, selective reporting, and other biases	Data pooled using fixed and random-effects models. Heterogeneity assessed using subgroup analyses, and sensitivity analysis performed to identify outlying studies	11,478 serodiscordant couples	Use of antiretroviral drugs in HIV-infected members of serodiscordant couples	<u>ART vs. no ART</u> Total seroconversions: 71 vs. 365; pooled HR, 0.34 (95% CI, 0.13–0.92); adjusted HRs, 0.16 (95% CI, 0.07–0.35) after removing studies responsible for statistical heterogeneity, 0.06 (95% CI, 0.01–0.54) after restricting analysis to couples in which HIV-infected partner had CD4 count <200 x 10 <sup>9</sup> cells/L, 0.02 (95% CI, 0.00–0.89) in couples in which index case was male, 0.24 (95% CI, 0.06–1.03) in couples residing in low-/middle-income countries	Not reported	Good

ART = antiretroviral therapy; HR = hazard rate; RCT = randomized, controlled trial.

**Appendix B14. Key Question 4a: Quality Assessment of a Systematic Review**

<b>Study, Year</b>	<b>A priori design provided?</b>	<b>Duplicate study selection and data extraction?</b>	<b>Comprehensive literature search performed?</b>	<b>Status of publication used as an inclusion criteria?</b>	<b>List of studies (included and excluded) provided?</b>	<b>Characteristics of included studies provided?</b>	<b>Scientific quality of included studies assessed and documented?</b>	<b>Scientific quality of included studies used appropriately in formulating conclusions?</b>	<b>Methods used to synthesize the findings of studies appropriate?</b>	<b>Likelihood of publication bias assessed?</b>	<b>Conflict of interest stated?</b>	<b>Quality rating</b>
Anglemyer et al, 2011 <sup>108</sup>	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Systematic review: yes Individual studies: no	Good

**Appendix B15. Key Question 4a: Evidence Table of Studies of Effects of Counseling or Antiretroviral Therapy Use on HIV Transmission**

Author, Year	Type of study	Location/setting/ high or low prevalence population (based on 0.1% prevalence rate)	Study duration/ followup	Treatment groups (or comparison groups if observational study)	Demographics/ baseline disease	Eligibility criteria	Exclusion criteria	Number screened/eligible/enrolled/withdrawals/ % analyzed
Cohen et al, 2011 <sup>109</sup>	RCT	Botswana, Kenya, Malawi, South Africa, Zimbabwe, India, Brazil, Thailand, and United States	Median followup, 42 months	Treatment: immediate ART Comparison: delayed ART initiated after decline in CD4 count to $\leq 250 \times 10^9$ cells/mL or onset of AIDS-related illness	61% of participants ages 26 to 40 years Median CD4 count: $0.442 \times 10^9$ cells/L for early-therapy group, $0.428 \times 10^9$ cells/L for delayed therapy group	Couples in which 1 partner was HIV-1 positive and the other negative; CD4 counts $0.350\text{--}0.550 \times 10^9$ cells/L; in a stable relationship for $\geq 3$ months; reported $\geq 3$ instances of vaginal or anal intercourse; willing to disclose serostatus to partner	HIV-positive participants who had previously received ART (with exception of short-term prevention of mother-to-child transmission)	10,838 screened; 1763 couples enrolled
Del Romero et al, 2010 <sup>95</sup>	Prospective cohort	Madrid, Spain; HIV clinic; high prevalence (no ART: 9.2%, ART: 8.7%)	1355 couple-years	ART vs. no ART	Index cases 83% male; women median age, 29 years; men median age, 32 years; median CD4 count, $0.500 \times 10^9$ cells/L (IQR, $0.295\text{--}0.700 \times 10^9$ ); median plasma HIV RNA, 200 copies/mL (IQR, ND to 8876); 54% detectable viral load	All heterosexual couples who had an ongoing sexual relationship over preceding 6 months, were serodiscordant for HIV, and returned for $\geq 1$ followup visit	Nonindex partner with previous HIV diagnosis or known risk exposures other than relationship with index partner	648 eligible; 602 serodiscordant at first visit; 424 with followup
Donnell et al, 2010 <sup>110</sup>	Pre-post analysis of prospective cohort data	14 sites in 7 African countries (Botswana, Kenya, Rwanda, South Africa, Tanzania, Uganda, and Zambia)	Median study duration at ART initiation, 13 months	PreART transmission vs. postART transmission	<u>HIV-infected partner vs. HIV-susceptible partner</u> Mean age: 32 vs. 33 years Female sex: 68% vs. 32% HSV-2 positive: 100% vs. 68%	HIV-1 and HSV-2 serodiscordant couples reporting $\geq 3$ episodes of vaginal intercourse during previous 3 months, with seropositive partner ages $\geq 18$ years, CD4 count $\geq 0.250 \times 10^9$ cells/L	History of AIDS-defining condition, receiving ART	3408 enrolled; 3381 analyzed  Note: 27 couples' baseline serology did not confirm HIV-1 and HSV-2
Goncalves Melo et al, 2008 <sup>111</sup>	Retrospective cohort	Urban HIV/AIDS referral center in Porto Alegre, Brazil; assumed high prevalence	<u>Median followup</u> transmitters: 25.5 months nontransmitters: 22.3 months	Transmitters vs. nontransmitters	72% women (index cases); 57.7% IDUs; 91% unprotected sex; 23.6% STD diagnosis	ART-naive HIV-1 infected people with uninfected, steady, opposite-sex partners	None	4500 screened retrospectively; 56 enrolled retrospectively and 37 enrolled prospectively (93 total enrolled)
Musicco et al, 1994 <sup>107</sup>	Prospective cohort	Multicenter; Italy; assumed high prevalence (high risk)	Mean followup, 2 years (740 person-years)	Zidovudine vs. no zidovudine	Mean age, 26 years; 100% female; median duration of relationship with HIV-positive partner, 3 years; 56% consistent condom use; 53% regular sexual intercourse; 15% anal sex; 48% oral sex	Serodiscordant women identified through partner's attendance at specialty clinic with $\geq 1$ followup visit	None	Not reported; 525 eligible; 436 enrolled; unclear; unclear  Data from 103 person-years excluded

**Appendix B15. Key Question 4a: Evidence Table of Studies of Effects of Counseling or Antiretroviral Therapy Use on HIV Transmission**

Author, Year	Type of study	Location/setting/ high or low prevalence population (based on 0.1% prevalence rate)	Study duration/ followup	Treatment groups (or comparison groups if observational study)	Demographics/ baseline disease	Eligibility criteria	Exclusion criteria	Number screened/eligible/enrolled/withdrawals/ % analyzed
Reynolds et al, 2011 <sup>112</sup>	Retrospective cohort	Multicenter; Rakai, Uganda; high prevalence	Median followup Before ART initiation: 1.57 years After ART initiation: 1.54 years	PreART transmission vs. postART transmission	Male index partner: 58% (142/250) Consistent condom use: 4% Polygamous husbands: 20%	HIV-1 discordant married couples	None	15,000 screened; 250 eligible; 250 enrolled
Sullivan et al, 2009 <sup>113</sup>	Retrospective cohort	Rwanda and Zambia	Median followup, 512 days (1.4 years)	ART vs. no ART	Not reported	HIV-serodiscordant couples	Not reported	2993 enrolled
Wang et al, 2010 <sup>114</sup>	Retrospective cohort	Multicenter, community-based in Henan Province, China; assumed high prevalence (high risk)	Median followup, 2.8 years	ART vs. no ART	Mean age, 44 years; 43% female; 84% regular sexual intercourse; 78% condom use; 99% monogamous	Serodiscordant couples; stable marriage with no separation or divorce; voluntary participation and provided informed consent	None	4348 screened; 4301 eligible; 1927 enrolled; no withdrawals; 100% analyzed

Author, Year	Virologic response	CD4 count response	Outcomes	Adverse events	Funding source and role	Quality rating
Cohen et al, 2011 <sup>109</sup>	<u>Virologic failure, treatment vs. comparison</u> 45/886 (5%) vs. 5/184 (3%); p=0.23	Treatment: 0.442 x 10 <sup>9</sup> cells/L at enrollment to 0.603 x 10 <sup>9</sup> cells/L at 12 months Comparison: 0.428 x 10 <sup>9</sup> cells/L at enrollment to 0.399 x 10 <sup>9</sup> cells/L at 12 months	<u>Transmission events, treatment vs. comparison</u> 4 events (IR, 0.3 per 100 person-years [95% CI, 0.1–0.6]) vs. 35 events (IR, 2.2 per 100 person-years [95% CI, 1.6–3.1]); HR, 0.11 (95% CI, 0.04–0.32); p<0.001 <u>Total clinical events, treatment vs. comparison</u> HR, 0.59 (95% CI, 0.40–0.88) <u>Linked transmission, treatment vs. comparison</u> HR, 0.04 (95% CI, 0.01–0.28); p<0.001	<u>Severe or life-threatening adverse events, treatment vs. comparison</u> 127/886 (14%) vs. 119/877 (14%); NS Most frequent adverse events: infections, psychiatric and nervous system disorders, and gastrointestinal disorders <u>Grade 3 or 4 laboratory abnormalities, treatment vs. comparison</u> 242/886 (27%) vs. 161/877 (18%); p<0.001 Most frequent laboratory abnormalities: neutropenia, abnormal phosphate levels, bilirubin elevations	National Institute of Allergy and Infectious Diseases	Good
Del Romero et al, 2010 <sup>93</sup>	Detectable viral load in 111/120 (93%) not taking ART vs. 30/145 (21%) on ART; p<0.001	Not reported	<u>Proportion engaging in unprotected sexual intercourse, no ART vs. ART</u> 273/476 (57%) vs. 69/149 (46%); p=0.019 <u>Proportion of couples with previous pregnancies, no ART vs. ART</u> 226/476 (47%) vs. 53/149 (36%); p=0.011 <u>Transmission, no ART vs. ART</u> 5 instances vs. 0 instances <u>Rate per 100 couple-years, no ART vs. ART</u> 0.4 (95% CI, 0.2–1.4) vs. 0 (95% CI, 0–1.1)	Not reported	Grant from FIPSE (foundation formed by Spanish Ministry of Health and Consumer Affairs and multiple pharmaceutical companies) and Spanish Network for Research on AIDS	Fair

Appendix B15. Key Question 4a: Evidence Table of Studies of Effects of Counseling or Antiretroviral Therapy Use on HIV Transmission

Author, Year	Virologic response	CD4 count response	Outcomes	Adverse events	Funding source and role	Quality rating
Donnell et al, 2010 <sup>110</sup>	Not reported	Not reported	<u>PreART vs. postART transmission</u> Overall: 102/4558 person-years (IR, 2.24 [95% CI, 1.84–2.72]) vs. 1/273 person-years (IR, 0.37 [95% CI, 0.09–2.04]) Overall adjusted incidence RR: 0.08 (95% CI, 0.00–0.57); p=0.004	Not reported	Bill & Melinda Gates Foundation; University of Washington Center for AIDS Research; University of Washington AIDS Clinical Trials Group Virology Support Laboratory; US National Institutes of Health	Good
Goncalves Melo et al, 2008 <sup>111</sup>	Not reported	Not reported	<u>Transmissions, ART vs. no ART</u> 0/41 vs. 6/52 <u>Median viral load, transmitters vs. nontransmitters</u> 24,082 (range, 1479–100,539) vs. 4583 (range, 78–47,974); p=0.042	Not reported	Not reported	Fair
Musicco et al, 1994 <sup>107</sup>	Not reported	Not reported	<u>Seroconversions, zidovudine vs. no zidovudine</u> 6/64 (3.8/100 person-years) vs. 21/? (4.4/100 person-years); adjusted RR, 0.5 (95% CI, 0.1–0.9)	Not reported	Ministry of Health, Italy; National Research Council of Italy	Fair
Reynolds et al, 2011 <sup>112</sup>	6 months: 71.4% (20/28) below detectable limit and remaining 28.6% (8/28) below 2000 copies/mL 12 months: 85.2% (23/27) below 400 copies/mL, 14.8% (4/27) ranging from 2293 to 672,513 copies/mL 24 months: 100% (28/28) below 400 copies/mL	Not reported	<u>Transmission</u> PreART: 9.2/100 person-years (95% CI, 6.59–12.36) PostART: 0/53.6 person-years (95% CI, -1.91 to 16.38); p=0.0097	Not reported	Division of Intramural Research, National Institute of Allergy and Infectious Diseases; Eunice Kennedy Shriver National Institute of Child Health and Human Development	Fair
Sullivan et al, 2009 <sup>113</sup>	Not reported	Not reported	<u>Transmissions, ART vs. no ART</u> 4/175 vs. 171/175 <u>Incidence density, ART vs. no ART</u> 0.7%/100 person-years vs. 3.4%/100 person-years (RR, 0.21 [95% CI, 0.08–0.59]) <u>Hazard of infection, ART vs. no ART</u> HR, 0.21 (95% CI, 0.09–0.52)	Not reported	Not reported	NA

**Appendix B15. Key Question 4a: Evidence Table of Studies of Effects of Counseling or Antiretroviral Therapy Use on HIV Transmission**

Author, Year	Virologic response	CD4 count response	Outcomes	Adverse events	Funding source and role	Quality rating
Wang et al, 2010 <sup>14</sup>	Not reported	Not reported	<u>Seroconversions, ART vs. no ART</u> 66/1369 (4.8%) vs 18/558 (3.2%); univariate RR, 0.76 (95% CI, 0.45–1.28)	Not reported	China and Fogarty International Center; National Institutes of Health, Office of the Director, Office of AIDS Research; National Cancer Center; National Eye Institute; National Heart, Blood, and Lung Institute; National Institute of Dental and Craniofacial Research; National Institute on Drug Abuse; National Institute of Mental Health; National Institute of Allergy and Infectious Diseases Health	Fair

ART = antiretroviral therapy; CI = confidence interval; HR = hazard rate; HSV-2 = herpes simplex virus 2; IDU = injection drug user; IR = incidence rate; IQR = interquartile range; NA = not applicable; RCT = randomized, controlled trial; RR = relative risk; STD = sexually transmitted disease.



**Appendix B16. Key Question 4a: Quality Assessment of a Randomized, Controlled Trial**

Author, Year	Randomization adequate?	Allocation concealment adequate?	Groups similar at baseline?	Eligibility criteria specified?	Outcome assessors masked?	Care provider masked?	Patient masked?	Attrition and withdrawals reported?	Loss to followup differential or high?	Intention-to-treat analysis?	Quality rating	Funding
Cohen et al, 2011 <sup>109</sup>	Yes	Unclear	Yes	Yes	Yes	Unclear	Unclear	Yes	Differential: no High: no	Yes	Good	National Institute of Allergy and Infectious Diseases

**Appendix B17. Key Question 4a: Quality Assessment of Cohort Studies**

<b>Author, Year</b>	<b>Did the study attempt to enroll all (or a random sample of) patients meeting inclusion criteria, or a random sample (inception cohort)?</b>	<b>Were the groups comparable at baseline on key prognostic factors (by restriction or matching)?</b>	<b>Did the study maintain comparable groups through the study period?</b>	<b>Did the study use accurate methods for ascertaining exposures and potential confounders?</b>	<b>Were outcome assessors and/or data analysts blinded to the exposure being studied?</b>	<b>Did the article report attrition?</b>	<b>Did the study perform appropriate statistical analyses on potential confounders?</b>	<b>Is there important differential loss to followup or overall high loss to followup?</b>	<b>Were outcomes prespecified, defined, and ascertained using accurate methods?</b>	<b>Quality rating</b>
Del Romero et al, 2010 <sup>93</sup>	Yes	No	Yes	Yes; questionnaire, blood draw	Unclear	No	No	No	Yes	Fair
Donnell et al, 2010 <sup>110</sup>	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Good
Goncalves Melo et al, 2008 <sup>111</sup>	Unclear	No	Yes	Yes	Unclear	No	Yes	Unclear	Yes	Fair
Musicco et al, 1994 <sup>107</sup>	Yes	No; zidovudine patients had more advanced disease	Unclear	Yes	Unclear	Yes	Yes	Yes	Yes	Fair
Reynolds et al, 2011 <sup>112</sup>	Unclear	No; condom use	Not relevant; retrospective	Yes	Unclear	Not relevant; retrospective	Yes	Not relevant; retrospective	Yes	Fair
Wang et al, 2010 <sup>114</sup>	Unclear	Unclear	Yes	Yes	Unclear	Yes	Yes	No	Yes	Fair

Note: Sullivan et al, 2009<sup>113</sup> is omitted from this table because it is only available as an abstract.

**Appendix B18. Key Question 4b: Evidence Table of Studies of Effects of Counseling or Antiretroviral Therapy Use on HIV Transmission**

Author, year, study name	Type of study	Location/setting/high or low prevalence population (based on 0.1% prevalence rate)	Study duration/followup	Treatment groups (or comparison groups if observational study)	Demographics/ baseline disease	Eligibility criteria
El-Bassel et al, 2010 <sup>117</sup> ; NIMH Multisite HIV/STD Prevention Trial for African American Couples Group, 2008 <sup>116</sup>	Cluster RCT	Not reported	8 week duration; 12 month followup	Treatment: 8 weekly 2-hour sessions of couple-focused counseling intervention incorporating traditional African concepts with social cognitive theory and other elements of interventions found to be efficacious Comparison: individual-focused health promotion intervention	Mean age, 43.4 years Mean CD4 count, 0.526 x 10 <sup>9</sup> cells/L % viral load >50 copies/mL, 29%	Couples in which both partners were age 18 or older, in a relationship for 6 months, intended to remain together for at least 12 months, ≥1 instance of unprotected intercourse in previous 90 days, no plans to relocate from study site, ≥1 partner African American or black, not planning pregnancy within 18 months, aware of each other's serostatus, 1 partner is HIV+ and has known for at least 3 months
Hernando et al, 2009 <sup>118</sup>	Prospective cohort of serodiscordant dyads	Multidisciplinary clinic providing HIV/STD counseling, diagnosis, and treatment in Madrid, Spain	1989–2007, 1279 couple-years; mean followup, 3.2 years, median followup, 2.1 years	Pre-post study of counseling intervention including comprehensive medical consultation, HIV and STD testing, free condoms, risk counseling	56.7% with CD4 count >0.350 x 10 <sup>9</sup> cells/L Median viral load, 405 copies/mL 82.3% of index cases were male Mean age of index case, 29.4 years for women and 32.9 years for men 30.3% receiving antiretrovirals	Heterosexual couples in an uninterrupted relationship for at least 6 months, in which 1 member was diagnosed with HIV and the nonindex partner was HIV-negative, who returned for at least 1 followup visit

Author, year, study name	Exclusion criteria	Number screened/eligible/enrolled/withdrawals/ % analyzed	Virologic response	CD4 count response	Outcomes	Adverse events	Funding source and role
El-Bassel et al, 2010 <sup>117</sup> ; NIMH Multisite HIV/STD Prevention Trial for African American Couples Group, 2008 <sup>116</sup>	No mailing address; clinically significant psychiatric, physical, or neurological impairment; victim of severe intimate partner violence; unwilling to complete study; not fluent in English; or participated in a couples-based HIV/STD risk-reduction intervention in the past year	589 couples eligible; 535 couples randomized	Not reported	Not reported	<u>HIV risk behaviors, adjusted for baseline response, over entire followup</u> Proportion of condom-protected sex: RR, 1.24 (95% CI, 1.09–1.41; p=0.006) Consistent condom use: RR, 1.45 (95% CI, 1.24–1.7; p<0.001) Mean difference in number of (log) unprotected intercourse acts: -1.52 (95% CI, -2.07 to -0.98; p<0.001) <u>HIV transmissions</u> Treatment: 2 seroconversions Comparison: 3 seroconversions	Not reported	National Institute of Mental Health
Hernando et al, 2009 <sup>118</sup>	Index partner with other sexual partners	564 eligible; 399 returned for followup	Not reported	Not reported	Total number of coital relations: IQR, 24–84 vs. 24–72 (p=0.001) Median sexual risk practices: 2.6 (IQR, 0–31.7) vs. 0 (IQR, 0–11.1) (p<0.001) Systematic condom use: 49.4% vs. 68.9% (p<0.0001) Transmission: 5/399 (1.3%), HIV seroconversion rate 3.9 per 1000 couple-years (95% CI, 1.4–9.7). None took place in couples where index case was on antiretroviral therapy	Not reported	Grant from FIPSE (foundation formed by Spanish Ministry of Health and Consumer Affairs and multiple pharmaceutical companies) and Spanish Network for Research on AIDS

RCT = randomized, controlled trial; STD = sexually transmitted disease.

**Appendix B19. Key Question 4b: Quality Assessment of a Randomized Controlled Trial**

Author, Year	Randomization adequate?	Allocation concealment adequate?	Groups similar at baseline?	Eligibility criteria specified?	Outcome assessors masked?	Care provider masked?	Patient masked?	Attrition and withdrawals reported?	Loss to followup differential or high?	Intention -to-treat analysis	Quality rating	Funding
El-Bassel et al, 2010 <sup>117</sup>	Yes	Yes	Yes	Yes	Unclear	No (not possible)	No (not possible)	Yes	Differential: no High: no	Yes	Good	National Institute of Mental Health

**Appendix B20. Key Question 4b: Quality Assessment of a Cohort Study**

<b>Author, Year</b>	<b>Did study attempt to enroll all (or a random sample of) patients meeting inclusion criteria, or a random sample (inception cohort)?</b>	<b>Were groups comparable at baseline on key prognostic factors (by restriction or matching)?</b>	<b>Did study maintain comparable groups through the study period?</b>	<b>Did study use accurate methods for ascertaining exposures and potential confounders?</b>	<b>Were outcome assessors and/or data analysts blinded to the exposure being studied?</b>	<b>Did article report attrition?</b>	<b>Did study perform appropriate statistical analyses on potential confounders?</b>	<b>Is there important differential loss to followup or overall high loss to followup?</b>	<b>Were outcomes prespecified, defined, and ascertained using accurate methods?</b>	<b>Quality rating</b>
Hernando et al, 2009 <sup>118</sup>	Yes	Yes	No; participants who didn't return for second visit older, in longer relationships, used condoms less, fewer noninjection drug users, more ART use	Yes	Unclear	Not relevant	Yes	Not relevant	Yes	Fair

**Appendix B21. Key Question 4c: Evidence Table of Trials of Effect of Initiating Highly Active Antiretroviral Therapy at Different CD4 Counts or Viral Load Thresholds on Clinical Outcomes**

Author, Year	Study name	Type of study	Location/setting	Duration of followup	Treatment groups	Population characteristics	Inclusion criteria
Cohen et al, 2011 <sup>109</sup>	HIV Prevention Trials Network study 052	RCT	Botswana, Kenya, Malawi, South Africa, Zimbabwe, India, Brazil, Thailand, and United States	Median, 42 months	Delayed treatment: initiation after 2 consecutive measures of CD4 count of $\leq 0.250 \times 10^9$ cells/mL or at onset of AIDS-related illness (n=877) Early treatment: immediate initiation of ART at CD4 count of $0.350$ to $0.550 \times 10^9$ cells/mL (n=886)	n=1763 serodiscordant couples (HIV+ participants: n=886 early treatment, 877 delayed treatment) Mean age not reported; 61% of participants ages 26 to 40 years Median CD4 count, $0.442 \times 10^9$ cells/L for early-therapy group, $0.428 \times 10^9$ cells/L for delayed therapy group	Couples in which 1 partner is HIV-1 positive and other is negative; CD4 counts of $0.350$ to $0.550 \times 10^9$ cells/L; in a stable relationship for at least 3 months; reported 3 or more instances of vaginal or anal intercourse; willing to disclose serostatus to partner
Severe et al, 2010 <sup>130</sup>	Study not named	Open-label RCT	Haiti; single specialty clinic (Haitian Group for the Study of Karposi's Sarcoma and Opportunistic Infections [GHESKIO])	Mean, 21 months (range, 1–44 months)	Early treatment (CD4 count $0.201$ – $0.350 \times 10^9$ cells/L) (n=408): lamivudine 150 mg + zidovudine 300 mg bid, efavirenz 600 mg qd Standard treatment (n=408): same intervention as early treatment group, started when CD4 count $\leq 0.200 \times 10^9$ cells/L	n=816 Mean age not reported, median age 40 years 58% female Median CD4 count, $0.281 \times 10^9$ cells/L	Age >18 years, HIV-infected, confirmed CD4 count $>0.200 \times 10^9$ cells/L and $<0.350 \times 10^9$ cells/L within 45 days before enrollment
SMART Study Group, 2008 <sup>131</sup> Other publication: SMART Study Group, 2006 <sup>138</sup>	Strategies for Management of Antiretroviral Therapy Study Group (SMART Study)	RCT (subgroup analysis)	United States/Europe; multicenter	Mean, 18 months (median, 15 months)	Intermittent ART-drug conservation group: CD4 count $<0.250 \times 10^9$ cells/L or CD4 percentage $<15\%$ or symptomatic (n=131 ART naive) Continuous ART-viral suppression group: CD4 count $>0.350 \times 10^9$ cells/L (n=118 ART naive)	n=477 (249 ART naive; 228 no ART) Median age, 41 years 26% female 49% white, 36% black, 15% other Median CD4 count, $0.447 \times 10^9$ cells/L (range, $0.385$ – $0.536 \times 10^9$ )	ART naive or no use of ART for a minimum of 6 months prior to study entry; at least 1 HIV RNA measure and level at least $>10,000$ copies/mL

Author, Year	Exclusion criteria	Number screened/eligible/enrolled/withdrawals/% analyzed	Clinical outcomes	Adverse events	Funding source and role	Quality rating
Cohen et al, 2011 <sup>109</sup>	Previous ART (with the exception of short-term prevention of mother-to-child transmission)	10,838 screened; 1763 couples enrolled	<u>Mortality</u> Delayed treatment, 13/877 (2%) vs. early treatment, 10/886 (1%); HR, 1.3 (95% CI, 0.57 to 3.0) <u>Clinical event (death, WHO Stage 4 event, severe bacterial infection, pulmonary infection)</u> Delayed treatment, 65/877 (7%) vs. early treatment, 40/886 (5%); adjusted HR, 1.7 (95% CI, 1.1 to 2.5) <u>Extrapulmonary tuberculosis</u> Delayed treatment, 17/877 (2%) vs. early treatment, 3/886 (0.3%); RR, 5.6 (95% CI, 1.7 to 20) <u>Pulmonary tuberculosis</u> Delayed treatment, 15/877 (2%) vs. early treatment, 13/886 (2%); RR, 1.2 (95% CI, 0.56 to 2.4)	<u>Severe or life-threatening adverse events</u> Early treatment, 127/886 (14%) vs. delayed treatment, 119/877 (14%)	National Institute of Allergy and Infectious Diseases	Good

**Appendix B21. Key Question 4c: Evidence Table of Trials of Effect of Initiating Highly Active Antiretroviral Therapy at Different CD4 Counts or Viral Load Thresholds on Clinical Outcomes**

Author, Year	Exclusion criteria	Number screened/eligible/enrolled/withdrawals/% analyzed	Clinical outcomes	Adverse events	Funding source and role	Quality rating
Severe et al, 2010 <sup>130</sup>	History of AIDS-defining illness (WHO Stage 4) or previously used ART	816/816; unclear	<p><u>Mortality</u> Standard treatment, 23/408 (6%) vs. early treatment, 6/408 (2%); unadjusted HR, 4 (95% CI, 1.6 to 9.8)</p> <p><u>Incident tuberculosis</u> Standard treatment, 36/408 (9%) vs. early treatment, 18/408 (4%); unadjusted HR, 2 (95% CI, 1.2 to 3.6)</p>	<p><u>Any severe or life-threatening drug reaction</u> Standard treatment, 18/160* (11%) vs. early treatment, 32/408 (8%)</p> <p><u>Anemia</u> Standard treatment, 13/160 (8%) vs. early treatment, 14/408 (3%) *160/408 standard treatment patients received ART once CD4 counts reached <math>\leq 200 \times 10^9</math> cells/L</p>	National Institute of Allergy and Infectious Disease; Fogarty International Center; Global Fund to Fight AIDS, Tuberculosis and Malaria; GlaxoSmithKline; Abbot Laboratory; Fondation Merieux	Good
SMART Study Group, 2008 <sup>131</sup> Other publication: SMART Study Group, 2006 <sup>138</sup>	No use of ART for <6 months before randomization	SMART subgroup analysis: 477 screened; 477 eligible; 477 enrolled	<p><u>Opportunistic disease or death*</u> DC, 4/131 (event rate, 2.7/100 person-years) vs. 1/118 (event rate, 0.5/100 person-years); HR, 5.3; p=0.13</p> <p><u>Fatal or nonfatal opportunistic disease*</u> DC, 3/131 (event rate, 2/100 person-years) vs. 1/118 (event rate, 0.5/100 person-years); HR, 4.1; p=0.22</p> <p><u>Serious nonAIDS events, including death due to nonopportunistic disease*</u> DC, 4/131 (event rate, 2.8/100 person-years) vs. VS, 1/118 (event rate, 0.5/100 person-years); HR, 5.1; p=0.15</p> <p><u>Fatal or nonfatal opportunistic disease or serious nonAIDS event including death due to nonopportunistic disease*</u> DC, 7/131 (event rate, 4.9/100 person-years) vs. VS, 2/118 (event rate, 1/100 person-years); HR, 4.6; p=0.06</p> <p>*ART naive only</p>	Not reported	National Institute of Allergy and Infectious Diseases	Good

ART = antiretroviral therapy; DC = drug conservative; HR = hazard rate; RCT = randomized, controlled trial; VS = viral suppression; WHO = World Health Organization.

**Appendix B22. Key Question 4c: Quality Assessment of Randomized, Controlled Trials**

Author, year	Randomization adequate?	Allocation concealment adequate?	Groups similar at baseline?	Eligibility criteria specified?	Outcome assessors masked?	Care provider masked?	Patient masked?	Attrition and withdrawals reported?	Loss to followup differential or high overall?	Intention-to-treat analysis	Quality rating	Funding
Severe et al, 2010 <sup>130</sup>	Yes	Unclear	Yes	Yes	Yes	No	No	Yes	Differential: no High overall: no	Yes	Good	National Institute of Allergy and Infectious Disease; Fogarty International Center; Global Fund to Fight AIDS, Tuberculosis and Malaria; Glaxo Smith Kline; Abbot Laboratory; Fondation Merieux
SMART Study Group, 2008 <sup>131</sup> Other publication: SMART Study Group, 2006 <sup>138</sup>	Yes	Unclear	Yes	Yes	Yes	No	No	No (post-hoc subgroup analysis)	Differential: no High overall: no	Yes	Good	National Institute of Allergy and Infectious Diseases



**Appendix B23. Key Question 4c: Evidence Table of Cohort Studies of Effects of Initiating Highly Active Antiretroviral Therapy at Different CD4 Counts or Viral Load Thresholds on Clinical Outcomes**

Author, Year	Study name	Study design	Setting/data source	Cohorts	Duration of followup
HIV-CAUSAL Collaboration, 2011 <sup>133</sup> Other publication: HIV-CAUSAL Collaboration 2010 <sup>134</sup>	HIV-CAUSAL Collaboration	Retrospective cohort	Pooled national health care data from 12 European cohorts	UK CHIC; ATHENA; French Hospital Database on HIV (FHDH ANRS CO4); Swiss HIV Cohort Study; PICIS Cohort Study; CoRIS; Veterans Aging Cohort Study Virtual Cohort (VACS-VC); UK Register of Seroconverters; ANRS PRIMO; ANRS SEROCO; Spanish Multicenter Study Group of Seroconverters	Median, 12 months (interquartile range, 5–26 months)
HIV-CAUSAL Collaboration, 2010 <sup>134</sup> Other publication: HIV-CAUSAL Collaboration 2011 <sup>133</sup>	HIV-CAUSAL Collaboration	Retrospective cohort	Pooled national health care data from 12 European cohorts	UK CHIC; ATHENA; French Hospital Database on HIV (FHDH ANRS CO4); Swiss HIV Cohort Study; PICIS Cohort Study; CoRIS; Veterans Aging Cohort Study Virtual Cohort (VACS-VC); UK Register of Seroconverters; ANRS PRIMO; ANRS SEROCO; Spanish Multicenter Study Group of Seroconverters	Mean duration, 3 years
Kitahata et al, 2009 <sup>135</sup>	North American AIDS Cohort Collaboration (NA-ACCORD)	Retrospective cohort	Pooled data from 22 cohorts in North America	AIDS Link to the IntraVenous Experience; AACTG Longitudinal Linked Randomized Trials; Case Western Reserve University Immunology Unit Patient Care and Research Database; Fenway Community Health Center; HIV Research Network; ART Observational Medical Evaluation and Research; HIV Outpatient Study; Johns Hopkins HIV Clinical Cohort; Kaiser Permanente Northern California; Longitudinal Study of Ocular Complications of AIDS; Multicenter AIDS Cohort Study; Second Multicenter Hemophilia Cohort Study; Montreal Chest Institute Immunodeficiency Service Cohort; Ontario HIV Treatment Network Cohort Study; Retrovirus Research Center; Southern Alberta Clinic Cohort; SCOPE (Study of the Consequences of the Protease Inhibitor); EraSUN (Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy); University of Alabama at Birmingham 1917 Clinic Cohort; University of North Carolina, Chapel Hill HIV Clinic; University of Washington HIV Cohort; VACS (Veterans Aging Cohort Study and Virtual Cohort); Vanderbilt-Meharry CFAR Cohort; Women's Interagency HIV Study	Mean duration not reported; data for 23,977 person-years for CD4 counts 0.351–0.500 x 10 <sup>9</sup> cells/L, 26,439 person-years for CD4 counts >0.500 x 10 <sup>9</sup> cells/L
May et al, 2007 <sup>136</sup> Other publications: Lanoy et al, 2009 <sup>139</sup> ; Moore et al, 2009 <sup>140</sup>	Antiretroviral Therapy Cohort Collaboration (ART)	Retrospective cohort	Pooled data from 12 cohorts in Europe and North America	Italian Cohort of Antiretroviral-Naive Patients (ICONA); Swiss HIV Cohort Study (SHCS); AIDS Therapy Evaluation Project Netherlands (ATHENA); Multicenter Study Group on EuroSIDA; Collaborations in HIV Outcomes Research US (CHORUS); Frankfurt HIV Cohort; Aquitaine Cohort ANRS CO3; ART Observational Medical Evaluation and Research (HOMER), British Columbia Center for Excellence in HIV/AIDS; Royal Free Hospital Cohort; South Alberta Clinic; Koln/Bonn Cohort	Mean duration not reported; 34% had <2 years, 49% had 2–5 years, 17% had 5 years; 61,798 patient-years
When to Start Consortium, 2009 <sup>137</sup>	When to Start Consortium	Retrospective cohort	Pooled data from 18 cohorts in Europe and North America	Multicenter AIDS Cohort Study (MACS); Swiss HIV Cohort Study (SHCS); ANRS CO4 French Hospital Database on HIV (FHDH); ANRS CO3 Aquitaine Cohort; Amsterdam Cohort Studies; South Alberta Clinic; Concerted Action on Seroconversion to AIDS and Death in Europe (CASCADE); ATHENA; ICONA; CHORUS; VACS; PISCIS; EuroSIDA	Mean duration, 3 years
Writing Committee for the CASCADE Collaboration, 2011 <sup>132</sup>	CASCADE Collaboration	Retrospective cohort	Pooled data from 23 clinical cohorts in Europe, Australia, and Canada	Austrian HIV Cohort Study; PHAEDRA cohort; Southern Alberta Clinic Cohort; Aquitaine Cohort; French Hospital Database; Lyon Primary Infection Cohort; SEROCO Cohort; French PRIMO Cohort; German Cohort; AMACS; Greek Haemophilia Cohort; Italian Seroconversion Study; ICONA cohort; Amsterdam Cohort Studies in Homosexual Men and IDUs; Oslo and Ullevål Hospital Cohorts; Badalona IDU Hospital Cohort; Barcelona IDU Cohort; CoRIS-scv; Madrid Cohort; Valencia IDU Cohort; Swiss HIV Cohort Study; Early Infection Cohorts; Genital Shedding Study Cohort; Edinburgh Hospital Cohort; UK Register of HIV Seroconverters; Royal Free Haemophilia Cohort	Median, 4.7 years (range, 2–9 years; 52,268 person-years)

**Appendix B23. Key Question 4c: Evidence Table of Cohort Studies of Effects of Initiating Highly Active Antiretroviral Therapy at Different CD4 Counts or Viral Load Thresholds on Clinical Outcomes**

Author, year	Population characteristics	Inclusion criteria	Exclusion criteria	Number eligible/enrolled/analyzed	Comparison groups
HIV-CAUSAL Collaboration, 2011 <sup>133</sup> Other publication: HIV-CAUSAL Collaboration 2010 <sup>134</sup>	N=20,971 Mean age not reported; 48% <35 years, 44% 35–49 years, 8% ≥50 years Race not reported 44% homosexual or bisexual 30% heterosexual 11% injection drug users 15% other/unknown Median CD4 count, 0.660 x 10 <sup>9</sup> cells/L	Age >18 years; HIV-1 infection; ART naive; no history of CD4 count <0.500 x 10 <sup>9</sup> cells/L; CD4 count and HIV RNA measurements within 6 months of each other	Pregnancy; history of AIDS-defining illness	Not reported; not reported; 20,971	CD4 count: 0.200 x 10 <sup>9</sup> (n=8066*) 0.250 x 10 <sup>9</sup> (n=8078) 0.300 x 10 <sup>9</sup> (n=8101) 0.350 x 10 <sup>9</sup> (n=8144) 0.400 x 10 <sup>9</sup> (n=8201) 0.450 x 10 <sup>9</sup> (n=8281) 0.500 x 10 <sup>9</sup> (n=8392) *Patient-level data may cross CD4 thresholds
HIV-CAUSAL Collaboration, 2010 <sup>134</sup> Other publication: HIV-CAUSAL Collaboration 2011 <sup>133</sup>	N=62,760 Mean age not reported 26% female Race not reported 13% injection drug users Median CD4 count, 0.390 x 10 <sup>9</sup> cells/L Median HIV RNA, 29,700/mL	Age >18 years; HIV-1 infection; ART naive; HIV RNA >500 copies/mL; CD4 count and HIV RNA measurements within 6 months of each other	Pregnancy; history of category C AIDS-defining illness	Not reported; not reported; 62,760	CD4 count: <0.100 x 10 <sup>9</sup> (n=5319) 0.100 to <0.200 x 10 <sup>9</sup> (n=6521) 0.200 to <0.350 x 10 <sup>9</sup> (n=14,886) 0.350 to <0.500 x 10 <sup>9</sup> (n=15,360) ≥0.500 x 10 <sup>9</sup> (n=20,674)
Kitahata et al, 2009 <sup>135</sup>	N=17,517 Mean age not reported; median, 38 years 24% female 43% white 42% black 15% other <u>Median CD4 count</u> Total cohort: 0.401 x 10 <sup>9</sup> cells/L Among patients 0.351–0.500 x 10 <sup>9</sup> : 0.422 x 10 <sup>9</sup> (early-therapy group) and 0.286 x 10 <sup>9</sup> (deferred therapy group) Among patients >0.500 x 10 <sup>9</sup> cells/L: 0.679 x 10 <sup>9</sup> (early-therapy group) and 0.410 x 10 <sup>9</sup> (deferred therapy group)	Patients receiving medical care between January 1996 and December 2005, no previous AIDS-defining illness or ART, stratified between baseline CD4 counts of 0.351–0.500 x 10 <sup>9</sup> and >0.500 x 10 <sup>9</sup> cells/L	None reported	Not reported; not reported; 17,517	CD4 count 0.351–0.500 x 10 <sup>9</sup> : Early therapy (n=2084) Deferred therapy (n=6278) CD4 count >0.500 x 10 <sup>9</sup> : Early therapy (n=2220) Deferred therapy (n=6936)
May et al, 2007 <sup>136</sup> Other publications: Lanoy et al, 2009 <sup>139</sup> , Moore et al, 2009 <sup>140</sup>	N=20,379 Median age, 36 years 24% female Race not reported 40% MSM 35% heterosexual 16% injection drug users 9% other <u>CD4 count</u> 10% <0.025 x 10 <sup>9</sup> 6% 0.025–0.049 x 10 <sup>9</sup> 10% 0.050–0.099 x 10 <sup>9</sup> 18% 0.100–0.199 x 10 <sup>9</sup> 27% 0.200–0.349 x 10 <sup>9</sup> 28% ≥0.350 x 10 <sup>9</sup>	Age ≥16 years, no previous ART and started ART with a combination of at least 3 drugs, median duration of followup at least 1 year	Baseline HIV-1 RNA <1000 copies/mL (possibly not treatment-naive)	20,379; 20,379; 20,379	CD4 count: <0.025 x 10 <sup>9</sup> (n=2034) 0.025–0.049 x 10 <sup>9</sup> (n=1295) 0.050–0.099 x 10 <sup>9</sup> (n=2059) 0.100–0.199 x 10 <sup>9</sup> (n=3782) 0.200–0.349 x 10 <sup>9</sup> (n=5550) ≥0.350 x 10 <sup>9</sup> (n=5659) HIV-RNA: ≥5 log copies/mL (n=9734) 4.99 log copies/mL (n=8391) 3–3.99 log copies/mL (n=2254)

**Appendix B23. Key Question 4c: Evidence Table of Cohort Studies of Effects of Initiating Highly Active Antiretroviral Therapy at Different CD4 Counts or Viral Load Thresholds on Clinical Outcomes**

Author, year	Population characteristics	Inclusion criteria	Exclusion criteria	Number eligible/enrolled/analyzed	Comparison groups
When to Start Consortium, 2009 <sup>137</sup>	N=45,691 (24,444 received ART) Mean age, 36 years 26% female Race not reported 47% MSM 42% heterosexual 11% other/unknown Mean CD4 count, $0.288 \times 10^9$ cells/L (range, $0.130-0.448 \times 10^9$ )	For cohorts: age >16 years with no previous ART, started treatment with at least 3 drugs, and median duration of followup of at least 1 year	Commencement of combination therapy prior to January 1, 1996; presumed HIV transmission due to injecting drug use	Not reported; not reported; 24,444	CD4 count: $<0.051 \times 10^9$ (n=2594) $0.051-0.150 \times 10^9$ (n=4638) $0.151-0.250 \times 10^9$ (n=6406) $0.251-0.350 \times 10^9$ (n=5753) $0.351-0.400 \times 10^9$ (n=3260) $0.451-0.500 \times 10^9$ (n=1793)
Writing Committee for the CASCADE Collaboration, 2011 <sup>132</sup>	N=9455 Median age at seroconversion, 30 years 22% female 57% MSM	Age $\geq 13$ years; ART-naive as of first month of trial; no end point of interest (AIDS or death) as of end of the month; no more than 21 days of cumulative monotherapy or dual therapy; CD4 count $<0.800 \times 10^9$ cells/L; $\geq 180$ after seroconversion and in previous 365 days	Not reported	18,347; 9455; 9455	CD4 count, unique individuals (numbers overlap): $0-0.049 \times 10^9$ (n=183) $0.050-0.199 \times 10^9$ (n=1521) $0.200-0.349 \times 10^9$ (n=4459) $0.350-0.499 \times 10^9$ (n=5527) $0.500-0.799 \times 10^9$ (n=5162)

Author, year	Adjusted variables for statistical analysis	Clinical outcomes	Quality rating	Funding source
HIV-CAUSAL Collaboration, 2011 <sup>133</sup> Other publication: HIV-CAUSAL Collaboration 2010 <sup>134</sup>	Sex, age, race, geographic origin, method of transmission, CD4 count, HIV-1 RNA level, calendar year, cohort, months from baseline to first CD4 count $<0.500 \times 10^9$ cells/L	<p><u>Mortality, initiation of ART at CD4 count <math>0.500 \times 10^9</math> (n=65/8392) vs:</u>  <math>0.200 \times 10^9</math> (n=99/8066): HR, 0.83 (CI, 0.68 to 1.03)  <math>0.250 \times 10^9</math> (n=95/8078): HR, 0.92 (CI, 0.78 to 1.09)  <math>0.300 \times 10^9</math> (n=97/8101): HR, 0.99 (CI, 0.84 to 1.18)  <math>0.350 \times 10^9</math> (n=94/8144): HR, 0.99 (CI, 0.82 to 1.19)  <math>0.400 \times 10^9</math> (n=89/8201): HR, 0.95 (CI, 0.79 to 1.16)  <math>0.450 \times 10^9</math> (n=81/8281): HR, 0.97 (CI, 0.88 to 1.09)</p> <p><u>Mortality, initiation of ART at CD4 count <math>0.350 \times 10^9</math> (n=94/8144) vs:</u>  <math>0.200 \times 10^9</math> (n=99/8066): HR, 0.85 (CI, 0.68 to 1.05)  <math>0.250 \times 10^9</math> (n=95/8078): HR, 0.93 (CI, 0.75 to 1.16)  <math>0.300 \times 10^9</math> (n=97/8101): HR, 1.01 (CI, 0.79 to 1.28)  <math>0.400 \times 10^9</math> (n=89/8201): HR, 0.97 (CI, 0.85 to 1.10)  <math>0.450 \times 10^9</math> (n=81/8281): HR, 0.99 (CI, 0.79 to 1.22)  <math>0.500 \times 10^9</math> (n=65/8392): HR, 1.01 (CI, 0.74 to 1.41)</p> <p><u>AIDS-defining illness or death, initiation of ART at CD4 count <math>0.500 \times 10^9</math> (n=158/8392) vs:</u>  <math>0.200 \times 10^9</math> (n=330/8066): HR, 0.53 (CI, 0.47 to 0.60)  <math>0.250 \times 10^9</math> (n=329/8078): HR, 0.60 (CI, 0.54 to 0.67)  <math>0.300 \times 10^9</math> (n=317/8101): HR, 0.68 (CI, 0.61 to 0.75)  <math>0.350 \times 10^9</math> (n=296/8144): HR, 0.72 (CI, 0.64 to 0.81)  <math>0.400 \times 10^9</math> (n=256/8201): HR, 0.78 (CI, 0.68 to 0.87)  <math>0.450 \times 10^9</math> (n=209/8281): HR, 0.88 (CI, 0.82 to 0.93)</p> <p><u>AIDS-defining illness or death, initiation of ART at CD4 count <math>0.350 \times 10^9</math> (n=296/8144) vs:</u>  <math>0.200 \times 10^9</math> (n=330/8066): HR, 0.73 (CI, 0.64 to 0.83)  <math>0.250 \times 10^9</math> (n=329/8078): HR, 0.83 (CI, 0.72 to 0.95)  <math>0.300 \times 10^9</math> (n=317/8101): HR, 0.93 (CI, 0.81 to 1.09)  <math>0.400 \times 10^9</math> (n=256/8201): HR, 1.06 (CI, 0.99 to 1.16)  <math>0.450 \times 10^9</math> (n=209/8281): HR, 1.20 (CI, 1.05 to 1.39)  <math>0.500 \times 10^9</math> (n=158/8392): HR, 1.39 (CI, 1.14 to 1.69)</p>	Fair	Not reported

**Appendix B23. Key Question 4c: Evidence Table of Cohort Studies of Effects of Initiating Highly Active Antiretroviral Therapy at Different CD4 Counts or Viral Load Thresholds on Clinical Outcomes**

Author, year	Adjusted variables for statistical analysis	Clinical outcomes	Quality rating	Funding source
HIV-CAUSAL Collaboration, 2010 <sup>134</sup> Other publication: HIV-CAUSAL Collaboration 2011 <sup>133</sup>	Ever use of ART, month of followup, CD4 count, HIV RNA level, gender, transmission group, calendar year, age, geographic origin, race, years since HIV diagnosis, cohort	<u>Mortality, initiation of ART vs. no initiation of ART, by CD4 count:</u> $<0.100 \times 10^9$ : HR, 0.29 (CI, 0.22 to 0.37) $0.100$ to $<0.200 \times 10^9$ : HR, 0.33 (CI, 0.25 to 0.44) $0.200$ to $<0.350 \times 10^9$ : HR, 0.38 (CI, 0.28 to 0.52) $0.350$ to $<0.500 \times 10^9$ : HR, 0.55 (CI, 0.41 to 0.74) $\geq 0.500 \times 10^9$ : HR, 0.77 (CI, 0.58 to 1.01) <u>Mortality, initiation of ART vs. no initiation of ART, by HIV RNA:</u> $<10,000$ : HR, 0.82 (CI, 0.64 to 1.05) $10,000$ – $100,000$ : HR, 0.46 (CI, 0.36 to 0.60) $>100,000$ : HR, 0.36 (CI, 0.28 to 0.45)	Fair	National Institutes of Health
Kitahata et al, 2009 <sup>135</sup>	Sex, age, CD4 count at baseline and HIV RNA level, history of injection drug use, HCV infection when known (unknown status analyzed separately)	<u>Mortality, initiation of ART at CD4 count <math>0.351</math>–<math>0.500 \times 10^9</math> vs. <math>\leq 0.350 \times 10^9</math></u> Early therapy vs. deferred therapy, adjusted for age, sex, and HIV RNA level: RR, 0.61 (CI, 0.46 to 0.83) Early therapy vs. deferred therapy, adjusted for history of injection drug use: RR, 0.78 (CI, 0.52 to 1.18) Early therapy vs. deferred therapy, adjusted for presence of HCV infection: RR, 0.58 (CI, 0.41 to 0.83) <u>Mortality, CD4 count <math>&gt;0.500 \times 10^9</math> vs. <math>\leq 0.500 \times 10^9</math></u> Early therapy vs. deferred therapy, adjusted for age, sex, and HIV RNA level: RR, 0.54 (CI, 0.35 to 0.83) Early therapy vs. deferred therapy, excluding patients with history of injection drug use: RR, 0.5 (CI, 0.29 to 0.87) Early therapy vs. deferred therapy, excluding patients with HCV infection: RR, 0.52 (CI, 0.31 to 0.88)	Fair	National Institutes of Health; AHRQ
May et al, 2007 <sup>136</sup> Other publications: Lanoy et al, 2009 <sup>139</sup> , Moore et al, 2009 <sup>140</sup>	HIV-1 RNA level, age, assumed transmission group, clinical AIDs	<u>Mortality, initiation of ART at varying CD4 counts vs. CD4 count <math>&lt;0.025 \times 10^9</math></u> $0.025$ – $0.049 \times 10^9$ : 111/1295 vs. 222/2034; HR, 0.82 (CI, 0.66 to 1.04) $0.050$ – $0.099 \times 10^9$ : 162/2059 vs. 222/2034; HR, 0.77 (CI, 0.63 to 0.95) $0.100$ – $0.199 \times 10^9$ : 202/3782 vs. 222/2034; HR, 0.67 (CI, 0.55 to 0.82) $0.200$ – $0.349 \times 10^9$ : 178/5550 vs. 222/2034; HR, 0.48 (CI, 0.39 to 0.60) $\geq 0.350 \times 10^9$ : 130/5659 vs. 222/2034; HR, 0.34 (CI, 0.27 to 0.44) <u>AIDS or death from start of ART, initiation of ART at varying CD4 counts vs. CD4 count <math>&lt;0.025 \times 10^9</math></u> $0.025$ – $0.049 \times 10^9$ : 277/1295 vs. 519/2034; HR, 0.85 (CI, 0.73 to 0.98) $0.050$ – $0.099 \times 10^9$ : 408/2059 vs. 519/2034; HR, 0.76 (CI, 0.66 to 0.87) $0.100$ – $0.199 \times 10^9$ : 445/3782 vs. 519/2034; HR, 0.49 (CI, 0.43 to 0.56) $0.200$ – $0.349 \times 10^9$ : 361/5550 vs. 519/2034; HR, 0.29 (CI, 0.25 to 0.33) $\geq 0.350 \times 10^9$ : 298/5659 vs. 519/2034; HR, 0.23 (CI, 0.19 to 0.27) <u>Mortality, initiation of ART at varying HIV-1 RNA viral loads vs. HIV-1 RNA <math>\geq 100,000</math> copies/mL</u> $10,000$ to $<100,000$ : 305/8391 vs. 607/9734; HR, 0.89 (CI, 0.77 to 1.02) $1000$ to $<10,000$ : 93/2254 vs. 607/9734; HR, 1.11 (CI, 0.89 to 1.39) <u>AIDS or death, initiation of ART at varying HIV-1 RNA viral loads vs. HIV-1 RNA <math>\geq 100,000</math> copies/mL</u> $10,000$ to $<100,000$ : 701/8391 vs. 1449/9734; HR, 0.80 (CI, 0.73 to 0.88) $1000$ to $<10,000$ : 158/2254 vs. 1449/9734; HR, 0.80 (CI, 0.68 to 0.95)	Fair	UK Medical Research Grant; Glaxo Smith Kline
When to Start Consortium, 2009 <sup>137</sup>	Age, gender, CD4 count, method of transmission, year of enrollment, lead time, unseen events	<u>Mortality, initiation of ART at varying CD4 counts vs. <math>0.351</math>–<math>0.450 \times 10^9</math></u> $0.451$ – $0.550 \times 10^9$ : HR, 0.93 (CI, 0.6 to 1.4) $0.251$ – $0.350 \times 10^9$ : HR, 0.83 (CI, 0.59 to 1.25) $0.151$ – $0.250 \times 10^9$ : HR, 0.67 (CI, 0.51 to 0.99) <u>Progression to AIDS or death, initiation of ART at varying CD4 counts vs. <math>0.351</math>–<math>0.450 \times 10^9</math></u> $0.451$ – $0.550 \times 10^9$ : HR, 0.90 (CI, 0.76 to 1.29) $0.251$ – $0.350 \times 10^9$ : HR, 0.74 (CI, 0.59 to 0.95) $0.151$ – $0.250 \times 10^9$ : HR, 0.45 (CI, 0.37 to 0.53)	Fair	United Kingdom Medical Research Council

**Appendix B23. Key Question 4c: Evidence Table of Cohort Studies of Effects of Initiating Highly Active Antiretroviral Therapy at Different CD4 Counts or Viral Load Thresholds on Clinical Outcomes**

Author, year	Adjusted variables for statistical analysis	Clinical outcomes	Quality rating	Funding source
Writing Committee for the CASCADE Collaboration, 2011 <sup>132</sup>	Injection drug use, HIV test interval <30 days, gender, time since seroconversion, age, calendar year, HCV, HBV, CD4 count, days between last CD4 count and start of followup, number of previous CD4 measures, most recent viral load, days between last viral load and start of followup, peak viral load, number of previous viral load measures	<u>Mortality, treatment vs. no treatment initiation during index month, by CD4 count</u> 0–0.049 x 10 <sup>9</sup> : HR, 0.37 (CI, 0.14 to 0.95); RD, -18.2 (CI, -32 to -4.4); NNT, 6 (CI, 3 to 23) 0.050–0.199 x 10 <sup>9</sup> : HR, 0.55 (CI, 0.28 to 1.07); RD, -7.2 (CI, -10.1 to -4.4); NNT, 14 (CI, 10. to 23) 0.200–0.349 x 10 <sup>9</sup> : HR, 0.71 (CI, 0.44 to 1.15); RD, -1.4 (CI, 0.3 to 0.3); NNT, 74 (CI, 33 to ∞) 0.350–0.499 x 10 <sup>9</sup> : HR, 0.51 (CI, 0.33 to 0.80); RD, -1.4 (CI, -2.2 to -0.6); NNT, 71 (45 to 165) 0.500–0.799 x 10 <sup>9</sup> : HR, 1.02 (CI, 0.49 to 2.12); RD, -0.4 (CI, -2 to 1.2); NNT, 239 (49 to ∞) <u>Progression to AIDS or death, treatment vs. no treatment initiation during index month, by CD4 count</u> 0–0.049 x 10 <sup>9</sup> : HR, 0.32 (CI, 0.17 to 0.59); RD, -30 (CI, -45.1 to -15); NNT, 2 (CI, 2 to 7) 0.050–0.199 x 10 <sup>9</sup> : HR, 0.48 (CI, 0.31 to 0.74); RD, -15 (CI, -19.7 to -10.3); NNT, 7 (CI, 5 to 10) 0.200–0.349 x 10 <sup>9</sup> : HR, 0.59 (CI, 0.43 to 0.81); RD, -4.8 (CI, -7 to -2.6); NNT, 21 (CI, 14 to 38) 0.350–0.499 x 10 <sup>9</sup> : HR, 0.75 (CI, 0.49 to 1.14); RD, -2.9 (CI, -5 to -0.9); NNT, 34 (CI, 20 to 115) 0.500–0.799 x 10 <sup>9</sup> : HR, 1.10 (CI, 0.67 to 1.79); RD, 0.3 (CI, -3.7 to 4.2); NNT, ∞	Fair	National Institute of Allergy and Infections Diseases, National Institutes of Health

AHRQ = Agency for Healthcare Research and Quality; ART = antiretroviral therapy; CI = confidence interval; HBV = hepatitis B virus; HCV = hepatitis C virus; HR = hazard rate; MSM = men who have sex with men; NR = not reported; RR = relative risk.

**Appendix B24. Key Question 4c: Quality Assessment of Cohort Studies**

Author, Year	Did study attempt to enroll all (or a random sample of) patients meeting inclusion criteria, or a random sample (inception cohort)?	Were groups comparable at baseline on key prognostic factors (by restriction or matching)?	Did study use accurate methods for ascertaining exposures and potential confounders?	Were outcome assessors and/or data analysts blinded to the exposure being studied?	Did article report attrition?	Did study perform appropriate statistical analyses on potential confounders?	Is there important differential loss to followup or overall high loss to followup?	Were outcomes prespecified, defined, and ascertained using accurate methods?	Quality rating
HIV-CAUSAL Collaboration, 2010 <sup>134</sup> Other publication: HIV-CAUSAL Collaboration 2011 <sup>133</sup>	Yes	No	Yes	Unclear	No	Yes	Differential: unclear High overall: unclear	Yes	Fair
Kitahata et al, 2009 <sup>135</sup>	Yes	Unclear	Yes	Unclear	No	Yes	Differential: unclear High overall: unclear	Yes	Fair
May et al, 2007 <sup>136</sup> Other publications: Lanoy et al, 2009 <sup>139</sup> , Moore et al, 2009 <sup>140</sup>	Yes	Unclear	Yes	Unclear	Yes	Yes	Differential: unclear High overall: yes (19%)	Yes	Fair
When to Start Consortium, 2009 <sup>137</sup>	Yes	Unclear	Yes	Unclear	No	Yes	Differential: unclear High overall: unclear	Yes	Fair
Writing Committee for the CASCADE Collaboration, 2011 <sup>132</sup>	Yes	Unclear	Yes	Unclear	Yes	Yes	Differential: unclear High overall: no	Yes	Fair

**Appendix B25. Key Question 5: Evidence Table of Studies of Longer-Term Harms of Highly Active Antiretroviral Therapy Use**

Author, Year	Study design	Setting/data source	Duration of followup	Population characteristics	Inclusion criteria	Exclusion criteria	Number eligible/enrolled/analyzed
Bedimo et al, 2011 <sup>145</sup>	Retrospective observational study	Veteran's Health Administration (VHA) Clinical Case Registry (CCR)	Median, 4 years	n=19,424 Median age, 46 years 2% female 29% smokers 13% diabetes 38% hypertension 26% hypercholesterolemia 8% chronic kidney disease 32% HCV infection	HIV infected; enrolled in VHA facility between 1996 and 2004 and entered into CCR	Not reported	Not reported; 19,424; 19,424
DAD Study Group, 2010 <sup>144</sup>	Prospective observational study	11 North American, European, and Australian cohorts	Median, 6 years	n=33,308 Median age, 44 years 26% female Race not reported Framingham risk, total population: -53% low risk; -15% moderate risk; -4% high risk Framingham risk, patients with MI: -26% low risk; -30% moderate risk; -18% high risk Framingham risk, patients without MI: -54% low risk; -15% moderate risk; -4% high risk	HIV infected; enrolled in 1 of 11 cohorts	Not reported	33,308; 33,308; 33,308
DAD Study Group, 2008 <sup>143</sup>	Prospective observational study	11 North American, European, and Australian cohorts	Median, 5 years	n=33,347 Mean age, 43 years 26% female Race not reported Framingham risk, patients with MI: -22% (113/517) low risk; -26% (134/517) moderate risk; -23% (120/517) high risk; -29% (150/517) unknown risk	HIV infected; enrolled in 1 of 11 cohorts	Not reported	33,347; 33,347; 33,347
DAD Study Group, 2007 <sup>142</sup> Other publication: Friis-Moller et al, 2003 <sup>141</sup>	Prospective observational study	11 North American, European, and Australian cohorts	Median, 5 years (range, <1 to >7 years)	n=23,437 Median age, 39 years 24% female 78% white* 17% black 3% Hispanic 2% Asian 27% AIDS 61% current/former smokers 14% hypertension 42% dyslipidemia (*61% of patients had data on race)	HIV infected; enrolled in 1 of 11 cohorts	Not reported	23,437; 23,437; 23,437
Danish HIV Cohort Study, Obel et al, 2010 <sup>146</sup> Other publications: Obel et al, 2008 <sup>148</sup> ; Lohse et al, 2006 <sup>149</sup>	Prospective observational study	Danish National Hospital Registry	Mean, 6 years (19,124 person-years)	n=2952 Median age, 39 years 76% male 82% white (other races not reported) Median CD4 count not reported CVD risk factors not reported	Age >15 years; HIV-infected with diagnosis prior to January 1, 2005; treated with HAART; treated in 1 of 8 specialized treatment centers	MI prior to HAART initiation	2952; 2952; 2952

**Appendix B25. Key Question 5: Evidence Table of Studies of Longer-Term Harms of Highly Active Antiretroviral Therapy Use**

Author, Year	Study design	Setting/data source	Duration of followup	Population characteristics	Inclusion criteria	Exclusion criteria	Number eligible/enrolled/analyzed
Ribaudo et al, 2011 <sup>147</sup>	Retrospective observational analyses of clinical trial data	AIDS Clinical Trials Group (ACTG) Logitudinal linked randomized trials	Median, 3 years	n=5056 (1122 with 6-year data) Median age, 37 years 18% female 40% white 36% black 21% Hispanic 10% prior IV drug user 15% 2 or more CVD risk factors 5% CVD 10-year risk score ≥10	HIV-infected; prospectively randomized to receive ART within ACTG trials between June 1998 and November 2007; ART naive	Not reported	5056; 5056; 4640 (1-year data); 1122 (6-year data)

Author, Year	Interventions	Adjusted variables for statistical analysis	Clinical outcomes	Quality rating	Funding source
Bedimo et al, 2011 <sup>145</sup>	Any HAART (n=14,063)	Age, diabetes, hypertension, hypercholesterolemia, smoking	<u>MI, cumulative exposure</u> Abacavir: adjusted HR, 1.18 (95% CI, 0.92 to 1.5); p=0.19 Other NRTIs: adjusted HR, 0.99 (CI, 0.87 to 1.11); p=0.87 Mono- or dual-therapy ART: adjusted HR, 1.29 (CI, 1.10 to 1.52); p=0.002 <u>Cerebrovascular event, cumulative exposure</u> Abacavir: adjusted HR, 1.15 (CI, 0.97 to 1.37); p=0.1 Other NRTIs: adjusted HR, 0.93 (CI, 0.86 to 1.0); p=0.48 Mono- or dual-therapy ART: adjusted HR, 1.11 (CI, 0.98 to 1.25); p=0.1	Fair	Not reported
DAD Study Group, 2010 <sup>144</sup>	Protease inhibitors: Nelfinavir (n=10,370) Indinavir (n=11,985) Lopinavir-ritonavir (n=9,995) Saquinavir (n=8070) NRTIs: Zidovudine (n=25,754) Didanosine (n=13,851) Zalcitabine (n=4951) Stavudine (n=16,840) Lamivudine (n=28,835) Abacavir (n=12,511) Tenofovir (n=13,100) NNRTIs: Nevirapine (n=12,194) Efavirenz (n=13,522)	Age, sex, HIV transmission group, race, calendar year, cohort, smoking, family history of CVD, previous CV event, BMI, exposure to other ART	<u>MI, all patients</u> Incidence: 3.2/1000 person-years Absolute rate, any MI: 1.7% (580/33,308) Absolute rate, fatal MI: 0.4% (148/33,308) <u>MI, with cumulative PI use (relative rate)</u> Nelfinavir: 1.04 (CI, 0.98 to 1.11) Indinavir: 1.12 (CI, 1.07 to 1.18) Lopinavir-ritonavir: 1.13 (CI, 1.05 to 1.21) Saquinavir: 1.04 (CI, 0.98 to 1.11) <u>MI, per year of PI exposure (relative rate)</u> Indinavir: 1.11 (CI, 1.05 to 1.18) Indinavir + ritonavir: 1.18 (CI, 1.07 to 1.30) Saquinavir: 1.07 (CI, 0.97 to 1.20) Saquinavir + ritonavir: 1.06 (CI, 0.97 to 1.14) <u>MI, with cumulative NRTI use (relative rate)</u> Zidovudine: not significant (data not reported) Didanosine: 1.41 (CI, 1.09 to 1.82) Zalcitabine: not significant (data not reported) Stavudine: not significant (data not reported) Lamivudine: not significant (data not reported) Abacavir: 1.07 (CI, 1.00 to 1.14) Tenofovir: 1.04 (CI, 0.91 to 1.18) <u>MI, recent NRTI use (relative rate)</u> Abacavir: 1.7 (CI, 1.17 to 2.47) Tenofovir: 1.14 (CI, 0.85 to 1.53) <u>MI, with cumulative NNRTI use (relative rate)</u> Nevirapine: 0.97 (CI, 0.92 to 1.03) Efavirenz: 1.02 (CI, 0.96 to 1.08)	Good	HAART Oversight Committee; Health Insurance Fund Council; Agence Nationale de Recherches sur le SIDA; Australian Department of Health and Ageing; National Institutes of Health; Fondo de Investigación Sanitaria; Fundación para la Investigación y la Prevención del SIDA en Españã; European Commission BIOMED 1, BIOMED 2, the 5th and 6th Framework; Bristol-Myers Squibb; GlaxoSmithKline; Roche; Gilead; Pfizer; Merck; Tibotec; Boehringer-Ingelheim



**Appendix B25. Key Question 5: Evidence Table of Studies of Longer-Term Harms of Highly Active Antiretroviral Therapy Use**

Author, Year	Interventions	Adjusted variables for statistical analysis	Clinical outcomes	Quality rating	Funding source
DAD Study Group, 2008 <sup>143</sup>	NRTIs (n not reported): Zidovudine Didanosine Stavudine Lamivudine Abacavir	Age, sex, risk group, race, cohort, BMI, family history of CVD, smoking, previous CV event, year, cumulative exposure to other ART	<p><u>MI, cumulative exposure (relative rate)</u>                      Zidovudine: 1.04 (CI, 0.99 to 1.09); p=0.15                      Didanosine: 1.00 (CI, 0.93 to 1.07); p=0.91                      Stavudine: 1.02 (CI, 0.95 to 1.09); p=0.6                      Lamivudine: 0.99 (CI, 0.93 to 1.06); p=0.8                      Abacavir: 1.00 (CI, 0.92 to 1.08); p=0.91</p> <p><u>MI, recent exposure (relative rate)</u>                      Zidovudine: 1.22 (CI, 0.82 to 1.81)                      Didanosine: 1.53 (CI, 1.10 to 2.13)                      Stavudine: 1.22 (CI, 0.84 to 1.77)                      Lamivudine: 1.69 (CI, 1.02 to 2.8)                      Abacavir: 1.94 (CI, 1.48 to 2.55)</p> <p><u>MI, past exposure (relative rate)</u>                      Zidovudine: 1.29 (CI, 0.89 to 1.85)                      Didanosine: 1.08 (CI, 0.84 to 1.39)                      Stavudine: 1.24 (CI, 0.93 to 1.66)                      Lamivudine: 1.45 (CI, 0.88 to 2.4)                      Abacavir: 1.29 (CI, 0.94 to 1.77)</p> <p><u>MI, CV death, or invasive CV procedure, cumulative exposure (relative rate)</u>                      Zidovudine: 1.04 (CI, 1.00 to 1.08); p=0.06                      Didanosine: 0.99 (CI, 0.94 to 1.05); p=0.84                      Stavudine: 1.04 (CI, 0.99 to 1.10); p=0.13                      Lamivudine: 1.01 (CI, 0.96 to 1.06); p=0.74                      Abacavir: 1.03 (CI, 0.96 to 1.10); p=0.38</p> <p><u>MI, CV death, or invasive CV procedure, any recent exposure (relative rate)</u>                      Zidovudine: 0.98 (CI, 0.79 to 1.21); p=0.83                      Didanosine: 1.40 (1.11 to 1.77); p=0.005                      Stavudine: 0.99 (CI, 0.78 to 1.25); p=0.9                      Lamivudine: 1.15 (CI, 0.91 to 1.44); p=0.23                      Abacavir: 1.63 (CI, 1.3 to 2.04); p=0.0001</p> <p><u>Possible or definite stroke, cumulative exposure (relative rate)</u>                      Zidovudine: 1.07 (CI, 0.99 to 1.19); p=0.1                      Didanosine: 0.9 (CI, 0.8 to 1.02); p=0.09                      Stavudine: 1.04 (CI, 0.94 to 1.16); p=0.47                      Lamivudine: 0.99 (CI, 0.89 to 1.10); p=0.89                      Abacavir: 1.06 (CI, 0.93 to 1.21); p=0.40</p> <p><u>Possible or definite stroke, any recent exposure (relative rate)</u>                      Zidovudine: 0.85 (CI, 0.55 to 1.29); p=0.44                      Didanosine: 1.09 (CI, 0.67 to 1.77); p=0.74                      Stavudine: 0.91 (CI, 0.56 to 1.46); p=0.69                      Lamivudine: 1.04 (CI, 0.67 to 1.62); p=0.86                      Abacavir: 1.05 (CI, 0.66 to 1.67); p=0.84</p>	Good	See above

**Appendix B25. Key Question 5: Evidence Table of Studies of Longer-Term Harms of Highly Active Antiretroviral Therapy Use**

Author, Year	Interventions	Adjusted variables for statistical analysis	Clinical outcomes	Quality rating	Funding source
DAD Study Group, 2007 <sup>142</sup> Other publication: Friis-Moller et al, 2003 <sup>141</sup>	Any HAART (n=21,921) Protease inhibitors (n=18,919) NNRTI (n=15,142)	Model 1: age, sex, cohort, HIV transmission group, race, age, BMI, family history of CVD, smoking, previous CV event, calendar year Model 2: all from Model 1 plus total cholesterol, HDL, hypertension, diabetes	<u>MI, all patients</u> Incidence: 3.65/1000 person-years Absolute rate: 1.5% (345/23,347) <u>MI with HAART use (relative rate)</u> Incidence: 97/16,805 person-years; 5.77/1000 person-years Model 1: 1.16 (CI, 1.09 to 1.23) <u>MI with PI use (relative rate)</u> Model 1: 1.16 (CI, 1.10 to 1.23); p<0.001 Model 2: 1.10 (CI, 1.04 to 1.18); p=0.002 Excluding patients exposed to NRTIs: 1.15 (CI, 1.06 to 1.25) <u>MI with NRTI use (relative rate)</u> Model 1: 1.05 (CI, 0.98 to 1.13); p=0.17 Model 2: 1.00 (CI, 0.93 to 1.09); p=0.92 Excluding patients exposed to PIs: 0.94 (CI, 0.74 to 1.19)	Good	See above
Danish HIV Cohort Study, Obel et al, 2010 <sup>146</sup> Other publications: Obel et al, 2008 <sup>148</sup> ; Lohse et al, 2006 <sup>149</sup>	Triple NRTI regimen including abacavir NNRTI or PI regimen including abacavir Specific drugs: Abacavir (n=1761) Zidovudine (n=2711) Lamivudine (n=2867) Stavudine (n=1031) Didanosine (n=813)	Age, gender, year of diagnosis, year of HAART initiation, CD4 count, viral load, race, injecting drug use, use of other antiretrovirals, comorbidities	<u>MI, abacavir use vs. nonuse</u> Any abacavir exposure: incidence 2.4/1000 (CI, 1.7 to 3.4) vs. 5.7/1000 (CI, 4.1 to 7.9); adjusted RR, 2.0 (CI, 1.1 to 3.6) Actual abacavir use: RR, 1.95 (CI, 1.05 to 3.6) Early abacavir use: RR, 2.37 (CI, 0.88 to 6.36) Abacavir as part of triple NRTI: RR, 1.91 (CI, 0.88 to 4.17) Abacavir with NNRTI or PI: RR, 2.06 (CI, 1.06 to 4.01) Abacavir initiated within 2 years of HAART: RR, 1.77 (CI, 0.82 to 3.82) Abacavir initiated >2 years of HAART: RR, 2.66 (CI, 1.31 to 5.39)	Good	No outside funding
Ribaudo et al, 2011 <sup>147</sup>	Abacavir (n=1704) No abacavir (n=3352)	Age, sex, race, CVD risk factors, smoking, family history of CVD	<u>MI, abacavir use vs. nonuse</u> 1 year: adjusted HR, 0.7 (CI, 0.2 to 2.6) 6 years: adjusted HR, 0.6 (CI, 0.3 to 1.4) <u>Serious CVD events, abacavir use vs. nonuse</u> 1 year: adjusted HR, 1.1 (CI, 0.5 to 2.1) 6 years: adjusted HR, 0.9 (CI, 0.5 to 1.3)	Good	National Institute of Allergy and Infectious Diseases

ART = antiretroviral therapy; BMI = body mass index; CI = confidence interval; CV = cardiovascular; CVD = cardiovascular disease; HAART = highly active antiretroviral therapy; HDL = high-density lipoprotein; MI = myocardial infarction; NNRTI = nonnucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; RR = relative risk.

**Appendix B26. Key Question 5: Quality Assessment of Cohort Studies**

Author, Year	Did study attempt to enroll all (or a random sample of) patients meeting inclusion criteria, or a random sample (inception cohort)?	Were groups comparable at baseline on key prognostic factors?	Did study use accurate methods for ascertaining exposures and potential confounders?	Were outcome assessors and/or data analysts blinded to the exposure being studied?	Did article report attrition?	Did study perform appropriate statistical analyses on potential confounders?	Is there important differential loss to followup or overall high loss to followup?	Were outcomes prespecified, defined, and ascertained using accurate methods?	Quality rating
Bedimo et al, 2011 <sup>145</sup>	Yes	No	Yes	Unclear	Yes	Yes	Differential: unclear High overall: no	Yes	Fair
DAD Study Group, 2010 <sup>144</sup>	Yes	Yes	Yes	Yes	Yes	Yes	Differential: unclear High overall: no	Yes	Good
DAD Study Group, 2008 <sup>143</sup>	Yes	Yes. A slightly higher proportion of patients with recent use of abacavir had a moderate to high CHD risk profile compared with recent use of other NRTIs (20% vs. 16–18%)	Yes	Yes	Yes	Yes	Differential: unclear High overall: no	Yes	Good
DAD Study Group, 2007 <sup>142</sup> Other publication: Friis-Moller et al, 2003 <sup>141</sup>	Yes	Yes	Yes	Yes	Yes	Yes	Differential: unclear High overall: no	Yes	Good
Danish HIV Cohort Study, Obel et al, 2010 <sup>146</sup> Other publications: Obel et al, 2008 <sup>148</sup> , Lohse et al, 2006 <sup>149</sup>	Yes	Yes	Yes	Unclear	Yes	Yes	Differential: unclear High overall: no	Yes	Good
Ribaudo et al, 2011 <sup>147</sup>	Yes	Unclear	Yes	Yes	Yes	Yes	Differential: unclear High overall: no	Yes	Good

**Appendix B27. Key Question 6a: Evidence Table of Studies of Effect of Viremia on HIV Transmission Rates**

Author, Year	Type of study	Location/setting/high or low prevalence population (based on 0.1% prevalence rate)	Study duration/followup	Comparison groups	Demographics/baseline disease	Eligibility criteria
<b>Studies examining individual patients</b>						
Donnell et al, 2010 <sup>105</sup>	Pre-post analysis of prospective cohort data	14 sites in 7 African countries (Botswana, Kenya, Rwanda, South Africa, Tanzania, Uganda, and Zambia)	Median study duration at ART initiation: 13 months	Pre-ART transmission vs. post-ART transmission	HIV-infected partner vs. HIV-susceptible partner Mean age: 32 vs. 33 years Female sex: 68% vs. 32% HSV-2 positive: 100% vs. 68%	HIV-1 and HSV-2 serodiscordant couples reporting ≥3 episodes of vaginal intercourse during previous 3 months, with seropositive partner age ≥18 years, CD4 count ≥0.250 x 10 <sup>9</sup> cells/L
Fideli et al, 2001 <sup>155</sup>	Case-control	HIV testing and counseling center; Lusaka, Zambia; assumed high prevalence	Mean followup: 22 months	Transmitters vs. nontransmitters	Mean age, years Male transmitters: 33 Female transmitters: 26 Male nontransmitters: 36 Female nontransmitters: 27 Viral load, copies/mL <10,000: 5/63 male transmitters, 3/41 female transmitters, 16/114 male nontransmitters, 32/93 female nontransmitters 10,001–99,999: 22/63 male transmitters, 16/41 female transmitters, 46/114 male nontransmitters, 38/93 female nontransmitters >100,000: 36/63 male transmitters, 22/41 female transmitters, 52/114 male nontransmitters, 23/93 female nontransmitters	Discordant HIV status, cohabitating for at least 6 months, women younger than age 48 years and men younger than age 65 years
Fisher et al, 2010 <sup>156</sup>	Retrospective and prospective cohort	HIV treatment clinic, Brighton and Sussex University Hospital, United Kingdom	2000–2006	1 cohort, stratified by viral load	Not reported	HIV-infected men who have sex with men attending an HIV treatment clinic
<b>Community viral load studies</b>						
Das et al, 2010 <sup>157</sup>	Retrospective cohort (using cross-sectional community viral load data)	San Francisco, CA	2004–2008	None (analyzes association between community viral load and demographics or treatments)	Mean community viral load: 23,348 copies/mL Female sex: 6% (786/12,512)	Reported HIV-positive diagnosis
Montaner et al, 2010 <sup>158</sup>	Retrospective cohort	British Columbia, Canada	1996–2009	None	Not reported	Reported HIV-positive diagnosis
Wood et al, 2009 <sup>159</sup>	Prospective cohort	Inner city Vancouver, Canada	1996–2007	HIV-positive vs. HIV-negative	HIV-positive vs. HIV-negative Median age: 36.6 vs. 36.1 years Female sex: 40.2% vs. 32.5% White: 43.4% vs. 37.1%	Injection drug users

**Appendix B27. Key Question 6a: Evidence Table of Studies of Effect of Viremia on HIV Transmission Rates**

Author, Year	Exclusion criteria	Number screened/eligible/enrolled/withdrawals/% analyzed	Outcomes	Adverse events	Funding source and role	Quality rating
<b>Studies examining individual patients</b>						
Donnell et al, 2010 <sup>105</sup>	History of AIDS-defining condition, receiving ART	3408 enrolled; 3381 analyzed Note: 27 couples' baseline serology did not confirm HIV-1 and HSV-2	<u>Pre-ART vs. post-ART transmission</u> Overall: 102/4558 person-years (incidence rate, 2.24 [95% CI, 1.84–2.72]) vs. 1/273 person-years (incidence rate, 0.37 [95% CI, 0.09–2.04]) Overall adjusted incidence rate ratio: 0.08 (95% CI, 0.00–0.57); p=0.004	Not reported	Bill & Melinda Gates Foundation; University of Washington Center for AIDS Research; UW AIDS Clinical Trials Group Virology Support Laboratory; United States National Institutes of Health	Good
Fideli et al, 2001 <sup>155</sup>	None	1022 enrolled; 129 linked transmission pairs; 109 (84.5%) analyzed compared with 208 consecutive controls	<u>Median viral load, transmitters vs. nontransmitters</u> 123,507 vs. 51,310 (p<0.001)	Not reported	National Institutes of Health	Fair
Fisher et al, 2010 <sup>156</sup>	None	1144 eligible; 859 enrolled	Adjusted rate ratio of transmission risk per log <sub>10</sub> higher viral load: RR, 1.61 (95% CI, 1.15–2.25); p=0.005	Not reported	University College London Hospitals/ University College London National Institute for Health Research Comprehensive Biomedical Research Center; European Community's Seventh Framework Programme	Fair
<b>Community viral load studies</b>						
Das et al, 2010 <sup>157</sup>	None	12,512 seroconversions	<u>Association between decreasing community viral load and decreasing new HIV diagnoses</u> Mean community viral load: p=0.003 Total community viral load: p=0.002	Not reported	California HIV/AIDS Research Program	Fair
Montaner et al, 2010 <sup>158</sup>	None	Active ART users: 5413	Association between number of individuals on ART and number of new HIV diagnoses: 0.89 (p<0.0001) Estimated number of new HIV cases per log <sub>10</sub> decrease in viral load: 0.86 (95% CI, 0.75–0.98)	Not reported	US National Institutes of Health; Canadian Institutes of Health Research; Michael Smith Foundation for Health Research; Merck; Gilead; ViiV Healthcare	Fair
Wood et al, 2009 <sup>159</sup>	Not reported	Not reported; not reported; 2051 Of 1796 eligible HIV-negative individuals, 20.4% (367/1796) were lost to followup	Time to seroconversion according to plasma HIV RNA (per log <sub>10</sub> increase): HR, 3.32 (95% CI, 1.82–6.08); p<0.001	Not reported	US National Institutes of Health, Canadian Institutes of Health Research	Fair

ART = antiretroviral therapy; HSV-2 = herpes simplex virus 2.

**Appendix B28. Key Question 6a: Quality Assessment of Cohort Studies**

<b>Author, Year</b>	<b>Did study attempt to enroll all (or a random sample of) patients meeting inclusion criteria, or a random sample (inception cohort)?</b>	<b>Were groups comparable at baseline on key prognostic factors (by restriction or matching)?</b>	<b>Did study maintain comparable groups through the study period?</b>	<b>Did study use accurate methods for ascertaining exposures and potential confounders?</b>	<b>Were outcome assessors and/or data analysts blinded to the exposure being studied?</b>	<b>Did the article report attrition?</b>	<b>Did study perform appropriate statistical analyses on potential confounders?</b>	<b>Is there important differential loss to followup or overall high loss to followup?</b>	<b>Were outcomes prespecified, defined, and ascertained using accurate methods?</b>	<b>Quality rating</b>
Das et al, 2010 <sup>157</sup>	Yes; all attempted	NR	NR	Yes	Unclear	No	Yes	NR	Yes	Fair
Donnell et al, 2010 <sup>105</sup>	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Good
Fideli et al, 2001 <sup>155</sup>	No	Yes; not age and STDs	Yes	Yes	Unclear	Yes	Yes	No	Yes	Fair
Fisher et al, 2010 <sup>156</sup>	Unclear	NR	NR	Yes	Unclear	Yes	Yes	Yes; 25% loss	Yes	Fair
Montaner et al, 2010 <sup>158</sup>	Yes; all attempted	NR	NR	Yes	Unclear	No	Yes	NR	Yes	Fair
Wood et al, 2009 <sup>159</sup>	No; chain-referral (snowball) sampling	Yes; not sex and ethnicity	Yes	Yes	Unclear	Yes	Yes	Yes; 20.4% loss in HIV-negative group	Yes	Fair

NR = not reported; STD = sexually transmitted disease.

## Appendix B29. Key Question 6b: Evidence Table of Studies of Effects of Risky Behaviors on HIV Transmission Rates

Author, Year	Type of study	Location/setting/high or low prevalence population (based on 0.1% prevalence rate)	Study duration/followup	Treatment groups (or comparison groups if observational study)	Demographics/baseline disease	Eligibility criteria	Exclusion criteria
Del Romero et al, 2010 <sup>93</sup>	Prospective cohort	Madrid, Spain; HIV clinic; high prevalence (no ART: 9.2%, ART: 8.7%)	1355 couple-years	ART vs. no ART	Index cases 83% male Female median age, 29 years Male median age, 32 years Median CD4 count, 0.500 x 10 <sup>9</sup> cells/L (IQR, 0.295–0.700 x 10 <sup>9</sup> ) Median plasma HIV RNA, 200 copies/mL (IQR, not detectable–8876) 54% detectable viral load	All heterosexual couples who had an ongoing sexual relationship over preceding 6 months, were serodiscordant for HIV, and returned for ≥1 followup visit	Nonindex partner with previous HIV diagnosis or known risk exposures other than relationship with index partner
Wang et al, 2010 <sup>14</sup>	Prospective cohort	County hospitals, community health centers, and home residences in Zhumadian City, Henan Province, China	Median followup: 2.84 years	Converters vs. nonconverters	Sex: 43.3% (835/1927) female Mean age: 44.2 years Race/ethnicity: 99.6% Han, 0.4% Hui	HIV-negative persons living with HIV-positive partner, in a stable marriage, and providing informed consent	None

Author, Year	Number screened/eligible/enrolled/withdrawals/% analyzed	Outcomes	Adverse events	Funding source and role	Quality rating
Del Romero et al, 2010 <sup>93</sup>	648 eligible; 602 serodiscordant at first visit; 424 with followup	Proportion engaging in unprotected sexual intercourse, no ART vs. ART: 273/476 (57%) vs. 69/149 (46%); p=0.019 Proportion of couples with previous pregnancies, no ART vs. ART: 226/476 (47%) vs. 53/149 (36%); p=0.011 Transmission, no ART vs. ART: 5 instances vs. 0 instances Rate per 100 couple-years, no ART vs. ART: 0.4 (95% CI, 0.2–1.4) vs. 0 (95% CI, 0–1.1)	Not reported	Grant from FIPSE (foundation formed by Spanish Ministry of Health and Consumer Affairs and multiple pharmaceutical companies), and by Spanish Network for Research on AIDS	Fair
Wang et al, 2010 <sup>14</sup>	4301 eligible; 1927 enrolled	Transmission rate: 1.71/100 person-years ART vs. no ART: 4.8% vs. 3.2%; p=0.12 Never switched ART regimen vs. switched ART regimen: RR, 2.66 (95% CI, 1.15–6.15); p=0.11 with multivariate analysis	<u>Reasons for switching ART regimens</u> Severe gastrointestinal symptoms: 31.8% (74/233) Skin rash: 8.6% (20/233) Anemia: 5.6% (13/233) Abnormal liver function test: 4.7% (11/233) Bone marrow suppression: 3.9% (9/233)	11th 5-year plan of China; International Clinical Research Fellows Program at Vanderbilt	Fair

ART = antiretroviral therapy; IQR = interquartile range.

**Appendix B30. Key Question 6b: Quality Assessment of Cohort Studies**

<b>Author, Year</b>	<b>Did study attempt to enroll all (or a random sample of) patients meeting inclusion criteria, or a random sample (inception cohort)?</b>	<b>Were groups comparable at baseline on key prognostic factors (by restriction or matching)?</b>	<b>Did study maintain comparable groups through the study period?</b>	<b>Did study use accurate methods for ascertaining exposures and potential confounders?</b>	<b>Were outcome assessors and/or data analysts blinded to the exposure being studied?</b>	<b>Did article report attrition?</b>	<b>Did study perform appropriate statistical analyses on potential confounders?</b>	<b>Is there important differential loss to followup or overall high loss to followup?</b>	<b>Were outcomes prespecified, defined, and ascertained using accurate methods?</b>	<b>Quality rating</b>
Del Romero et al, 2010 <sup>93</sup>	Yes	No; differ on many factors	Yes	Yes; questionnaire, blood draw	Unclear	No	No	No	Yes	Fair
Wang et al, 2010 <sup>14</sup>	Unclear	Yes	Yes	Yes	Unclear	Yes	Yes	Yes; only 44.8% of sample completed surveys	Yes	Fair